
<html lang="en"     class="pb-page"  data-request-id="89f5bd73-81c5-4164-9327-3ba3bb801aae"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/acs.jmedchem.6b00306;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2016.59.issue-10;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase" /></meta><meta name="dc.Creator" content="Wei-Sheng  Huang" /></meta><meta name="dc.Creator" content="Shuangying  Liu" /></meta><meta name="dc.Creator" content="Dong  Zou" /></meta><meta name="dc.Creator" content="Mathew  Thomas" /></meta><meta name="dc.Creator" content="Yihan  Wang" /></meta><meta name="dc.Creator" content="Tianjun  Zhou" /></meta><meta name="dc.Creator" content="Jan  Romero" /></meta><meta name="dc.Creator" content="Anna  Kohlmann" /></meta><meta name="dc.Creator" content="Feng  Li" /></meta><meta name="dc.Creator" content="Jiwei  Qi" /></meta><meta name="dc.Creator" content="Lisi  Cai" /></meta><meta name="dc.Creator" content="Timothy A.  Dwight" /></meta><meta name="dc.Creator" content="Yongjin  Xu" /></meta><meta name="dc.Creator" content="Rongsong  Xu" /></meta><meta name="dc.Creator" content="Rory  Dodd" /></meta><meta name="dc.Creator" content="Angela  Toms" /></meta><meta name="dc.Creator" content="Lois  Parillon" /></meta><meta name="dc.Creator" content="Xiaohui  Lu" /></meta><meta name="dc.Creator" content="Rana  Anjum" /></meta><meta name="dc.Creator" content="Sen  Zhang" /></meta><meta name="dc.Creator" content="Frank  Wang" /></meta><meta name="dc.Creator" content="Jeffrey  Keats" /></meta><meta name="dc.Creator" content="Scott D.  Wardwell" /></meta><meta name="dc.Creator" content="Yaoyu  Ning" /></meta><meta name="dc.Creator" content="Qihong  Xu" /></meta><meta name="dc.Creator" content="Lauren E.  Moran" /></meta><meta name="dc.Creator" content="Qurish K.  Mohemmad" /></meta><meta name="dc.Creator" content="Hyun Gyung  Jang" /></meta><meta name="dc.Creator" content="Tim  Clackson" /></meta><meta name="dc.Creator" content="Narayana I.  Narasimhan" /></meta><meta name="dc.Creator" content="Victor M.  Rivera" /></meta><meta name="dc.Creator" content="Xiaotian  Zhu" /></meta><meta name="dc.Creator" content="David  Dalgarno" /></meta><meta name="dc.Creator" content="William C.  Shakespeare" /></meta><meta name="dc.Description" content="In the treatment of echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase positive (ALK+) non-small-cell lung cancer (NSCLC), secondary mutations within the ALK kinase ..." /></meta><meta name="Description" content="In the treatment of echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase positive (ALK+) non-small-cell lung cancer (NSCLC), secondary mutations within the ALK kinase ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="May 12, 2016" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.6b00306" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2016 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00306" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.6b00306" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00306" /></link>
        
    
    

<title>Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.6b00306" /></meta><meta property="og:title" content="Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.6b00306/20160520/images/large/jm-2016-00306u_0005.jpeg" /></meta><meta property="og:description" content="In the treatment of echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase positive (ALK+) non-small-cell lung cancer (NSCLC), secondary mutations within the ALK kinase domain have emerged as a major resistance mechanism to both first- and second-generation ALK inhibitors. This report describes the design and synthesis of a series of 2,4-diarylaminopyrimidine-based potent and selective ALK inhibitors culminating in identification of the investigational clinical candidate brigatinib. A unique structural feature of brigatinib is a phosphine oxide, an overlooked but novel hydrogen-bond acceptor that drives potency and selectivity in addition to favorable ADME properties. Brigatinib displayed low nanomolar IC50s against native ALK and all tested clinically relevant ALK mutants in both enzyme-based biochemical and cell-based viability assays and demonstrated efficacy in multiple ALK+ xenografts in mice, including Karpas-299 (anaplastic large-cell lymphomas [ALCL]) and H3122 (NSCLC). Brigatinib represents the most clinically advanced phosphine oxide-containing drug candidate to date and is currently being evaluated in a global phase 2 registration trial." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.6b00306"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b00306">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.6b00306&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.6b00306&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.6b00306&amp;href=/doi/10.1021/acs.jmedchem.6b00306" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2016</span><span class="cit-fg-volume">, 59</span><span class="cit-fg-issue">, 10</span><span class="cit-fg-pageRange">, 4948-4964</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/59/10" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.6b00287" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.6b00238" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wei-Sheng++Huang">Wei-Sheng Huang</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shuangying++Liu">Shuangying Liu</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dong++Zou">Dong Zou</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mathew++Thomas">Mathew Thomas</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yihan++Wang">Yihan Wang</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tianjun++Zhou">Tianjun Zhou</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jan++Romero">Jan Romero</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Anna++Kohlmann">Anna Kohlmann</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Feng++Li">Feng Li</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jiwei++Qi">Jiwei Qi</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lisi++Cai">Lisi Cai</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Timothy+A.++Dwight">Timothy A. Dwight</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yongjin++Xu">Yongjin Xu</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Rongsong++Xu">Rongsong Xu</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Rory++Dodd">Rory Dodd</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Angela++Toms">Angela Toms</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lois++Parillon">Lois Parillon</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xiaohui++Lu">Xiaohui Lu</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Rana++Anjum">Rana Anjum</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sen++Zhang">Sen Zhang</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Frank++Wang">Frank Wang</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jeffrey++Keats">Jeffrey Keats</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Scott+D.++Wardwell">Scott D. Wardwell</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yaoyu++Ning">Yaoyu Ning</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Qihong++Xu">Qihong Xu</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lauren+E.++Moran">Lauren E. Moran</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Qurish+K.++Mohemmad">Qurish K. Mohemmad</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hyun+Gyung++Jang">Hyun Gyung Jang</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tim++Clackson">Tim Clackson</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Narayana+I.++Narasimhan">Narayana I. Narasimhan</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Victor+M.++Rivera">Victor M. Rivera</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xiaotian++Zhu">Xiaotian Zhu</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=David++Dalgarno">David Dalgarno</a></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=William+C.++Shakespeare">William C. Shakespeare</a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div><div class="corresp-info"><strong>*</strong>Phone: +1-617-621-2341. E-mail: <a href="/cdn-cgi/l/email-protection#d98ebcb0f48ab1bcb7bef791acb8b7be99b8abb0b8bdf7bab6b4"><span class="__cf_email__" data-cfemail="f0a79599dda398959e97deb885919e97b09182999194de939f9d">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00306&amp;href=/doi/10.1021%2Facs.jmedchem.6b00306" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2016</span></span><span class="cit-volume">, 59</span><span class="cit-issue">, 10</span><span class="cit-pageRange">, 4948–4964</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">May 4, 2016</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>26 February 2016</li><li><span class="item_label"><b>Published</b> online</span>12 May 2016</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 26 May 2016</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.6b00306" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00306</a></div><div class="article_header-article-copyright"><strong>Copyright © 2016 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D4948%26pageCount%3D17%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DWei-Sheng%2BHuang%252C%2BShuangying%2BLiu%252C%2BDong%2BZou%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D59%26issueNum%3D10%26contentID%3Dacs.jmedchem.6b00306%26title%3DDiscovery%2Bof%2BBrigatinib%2B%2528AP26113%2529%252C%2Ba%2BPhosphine%2BOxide-Containing%252C%2BPotent%252C%2BOrally%2BActive%2BInhibitor%2Bof%2BAnaplastic%2BLymphoma%2BKinase%26numPages%3D17%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D4964%26publicationDate%3DMay%2B2016">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.6b00306"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">9107</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">155</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.6b00306" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Wei-Sheng&quot;,&quot;last_name&quot;:&quot;Huang&quot;},{&quot;first_name&quot;:&quot;Shuangying&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Dong&quot;,&quot;last_name&quot;:&quot;Zou&quot;},{&quot;first_name&quot;:&quot;Mathew&quot;,&quot;last_name&quot;:&quot;Thomas&quot;},{&quot;first_name&quot;:&quot;Yihan&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Tianjun&quot;,&quot;last_name&quot;:&quot;Zhou&quot;},{&quot;first_name&quot;:&quot;Jan&quot;,&quot;last_name&quot;:&quot;Romero&quot;},{&quot;first_name&quot;:&quot;Anna&quot;,&quot;last_name&quot;:&quot;Kohlmann&quot;},{&quot;first_name&quot;:&quot;Feng&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Jiwei&quot;,&quot;last_name&quot;:&quot;Qi&quot;},{&quot;first_name&quot;:&quot;Lisi&quot;,&quot;last_name&quot;:&quot;Cai&quot;},{&quot;first_name&quot;:&quot;Timothy&quot;,&quot;last_name&quot;:&quot;A. Dwight&quot;},{&quot;first_name&quot;:&quot;Yongjin&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Rongsong&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Rory&quot;,&quot;last_name&quot;:&quot;Dodd&quot;},{&quot;first_name&quot;:&quot;Angela&quot;,&quot;last_name&quot;:&quot;Toms&quot;},{&quot;first_name&quot;:&quot;Lois&quot;,&quot;last_name&quot;:&quot;Parillon&quot;},{&quot;first_name&quot;:&quot;Xiaohui&quot;,&quot;last_name&quot;:&quot;Lu&quot;},{&quot;first_name&quot;:&quot;Rana&quot;,&quot;last_name&quot;:&quot;Anjum&quot;},{&quot;first_name&quot;:&quot;Sen&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Frank&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Jeffrey&quot;,&quot;last_name&quot;:&quot;Keats&quot;},{&quot;first_name&quot;:&quot;Scott&quot;,&quot;last_name&quot;:&quot;D. Wardwell&quot;},{&quot;first_name&quot;:&quot;Yaoyu&quot;,&quot;last_name&quot;:&quot;Ning&quot;},{&quot;first_name&quot;:&quot;Qihong&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Lauren&quot;,&quot;last_name&quot;:&quot;E. Moran&quot;},{&quot;first_name&quot;:&quot;Qurish&quot;,&quot;last_name&quot;:&quot;K. Mohemmad&quot;},{&quot;first_name&quot;:&quot;Hyun&quot;,&quot;last_name&quot;:&quot;Gyung Jang&quot;},{&quot;first_name&quot;:&quot;Tim&quot;,&quot;last_name&quot;:&quot;Clackson&quot;},{&quot;first_name&quot;:&quot;Narayana&quot;,&quot;last_name&quot;:&quot;I. Narasimhan&quot;},{&quot;first_name&quot;:&quot;Victor&quot;,&quot;last_name&quot;:&quot;M. Rivera&quot;},{&quot;first_name&quot;:&quot;Xiaotian&quot;,&quot;last_name&quot;:&quot;Zhu&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;Dalgarno&quot;},{&quot;first_name&quot;:&quot;William&quot;,&quot;last_name&quot;:&quot;C. Shakespeare&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2016&quot;,&quot;month&quot;:&quot;05&quot;,&quot;day&quot;:&quot;12&quot;,&quot;issue&quot;:&quot;10&quot;,&quot;volume&quot;:&quot;59&quot;,&quot;pages&quot;:&quot;4948-4964&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.6b00306&quot;},&quot;abstract&quot;:&quot;In the treatment of echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase positive (ALK+) non-small-cell lung cancer (NSCLC), secondary mutations within the ALK kinase domain have emerged as a major resistance mechanism to both first- and second-generation ALK inhibitors. This report describes the design and synthesis of a series of 2,4-diarylaminopyrimidine-based potent and selective ALK inhibitors culminating in identification of the investigational clinical candidate brigatinib. A unique structural feature of brigatinib is a phosphine oxide, an overlooked but novel hydrogen-bond acceptor that drives potency and selectivity in addition to favorable ADME properties. Brigatinib displayed low nanomolar IC50s against native ALK and all tested clinically relevant ALK mutants in both enzyme-based biochemical and cell-based viability assays and demonstrated efficacy in multiple ALK+ xenografts in mice, including Karpas-299 (anaplastic large-cell lymphomas [ALCL]) and H3122 (NSCLC). Bri&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00306&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00306" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00306&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00306" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00306&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00306" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00306&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00306&amp;href=/doi/10.1021/acs.jmedchem.6b00306" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.6b00306" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.6b00306" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.6b00306%26sid%3Dliteratum%253Aachs%26pmid%3D27144831%26genre%3Darticle%26aulast%3DHuang%26date%3D2016%26atitle%3DDiscovery%2Bof%2BBrigatinib%2B%2528AP26113%2529%252C%2Ba%2BPhosphine%2BOxide-Containing%252C%2BPotent%252C%2BOrally%2BActive%2BInhibitor%2Bof%2BAnaplastic%2BLymphoma%2BKinase%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D59%26issue%3D10%26spage%3D4948%26epage%3D4964%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/59/10" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/jmcmar.2016.59.issue-10/20160526/jmcmar.2016.59.issue-10.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.6b00306/20160520/images/medium/jm-2016-00306u_0005.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.6b00306/20160520/images/large/jm-2016-00306u_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00306&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">In the treatment of echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase positive (ALK+) non-small-cell lung cancer (NSCLC), secondary mutations within the ALK kinase domain have emerged as a major resistance mechanism to both first- and second-generation ALK inhibitors. This report describes the design and synthesis of a series of 2,4-diarylaminopyrimidine-based potent and selective ALK inhibitors culminating in identification of the investigational clinical candidate brigatinib. A unique structural feature of brigatinib is a phosphine oxide, an overlooked but novel hydrogen-bond acceptor that drives potency and selectivity in addition to favorable ADME properties. Brigatinib displayed low nanomolar IC<sub>50</sub>s against native ALK and all tested clinically relevant ALK mutants in both enzyme-based biochemical and cell-based viability assays and demonstrated efficacy in multiple ALK+ xenografts in mice, including Karpas-299 (anaplastic large-cell lymphomas [ALCL]) and H3122 (NSCLC). Brigatinib represents the most clinically advanced phosphine oxide-containing drug candidate to date and is currently being evaluated in a global phase 2 registration trial.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50301" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50301" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase of the insulin receptor family, was originally identified as a part of the fusion protein NPM–ALK resulting from a reciprocal translocation between chromosomes 2 and 5 in anaplastic large-cell lymphomas (ALCL).<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> NPM–ALK has been detected in approximately 75% of ALK+ ALCL patients, and its constitutive activation drives disease pathogenesis.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Subsequently, alternate ALK fusion genes were discovered as drivers of inflammatory myofibroblastic tumors and diffuse large B-cell lymphoma.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3, 4)</a> Despite these early findings, the significance of ALK as a valid oncogenic drug target was not fully recognized until 2007, when the EML4–ALK fusion protein was identified in approximately 5% of non-small-cell lung cancer (NSCLC).<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Given the large NSCLC patient population, new cases of ALK+ lung cancer are estimated to exceed 8000 per year in the US, representing an important unmet medical need. Interestingly, patient populations harboring the <i>EML4–ALK</i> gene rarely overlap with those carrying epidermal growth factor receptor (<i>EGFR</i>) or kirsten rat sarcoma virus (<i>KRAS</i>) mutations,<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> making EML4–ALK a distinct molecular target for a subset of NSCLC patients. More recently, amplification or activating point mutations of the <i>ALK</i> gene have been reported in neuroblastoma,<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> anaplastic thyroid cancer,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> and ovarian cancer.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a></div><div class="NLM_p">The first-generation inhibitor crizotinib<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(10, 11)</a> was approved for clinical use in 2011 and has demonstrated clear clinical benefit, with responses observed in 60–74% of ALK+ NSCLC patients (median progression-free survival of 8–11 months).<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12, 13)</a> Despite early effectiveness of crizotinib treatment, a majority of patients develop disease relapse within 1 year post-treatment. Various resistance mechanisms have been identified, including amplification of the ALK fusion gene, activation of bypass signaling pathways, inadequate exposure in the central nervous system, and, as observed with other targeted therapies, emergence of secondary ALK kinase domain mutations.<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14, 15)</a> Roughly one-third of crizotinib-resistant patients develop secondary mutations, and ∼40% of ALK-positive patients never have an objective response while on crizotinib therapy.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Recently, several more potent second-generation inhibitors, including ceritinib<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17, 18)</a> and alectinib,<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19, 20)</a> have been identified to combat disease resistance. Although these second-generation inhibitors have demonstrated efficacy against the majority of crizotinib-resistant mutants, they remain inactive against several mutations, including I1171N/T/S for alectinib, F1174C/V for ceritinib, and G1202R for both agents.<a onclick="showRef(event, 'ref18 ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref18 ref21 ref22">(18, 21, 22)</a> Development of next generation ALK inhibitors capable of potently inhibiting all acquired ALK mutants is therefore highly desirable. Continued search has advanced several compounds to clinical trials including <b>1</b> (ASP3026),<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a><b>2</b> (ensartinib, X-396),<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> CEP-37440 (structure undisclosed, series exemplified as compound <b>3</b>),<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> TSR-011 (structure undisclosed),<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a><b>4</b> (lorlatinib, PF-06463922),<a onclick="showRef(event, 'ref27 ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref27 ref28 ref29">(27-29)</a><b>5</b> (entrectinib, RXDX-101, NMS-E628),<a onclick="showRef(event, 'ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref30 ref31">(30, 31)</a> and <b>11q</b> (brigatinib) (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). In addition, a number of ALK inhibitors derived from a variety of diversified chemical classes have been evaluated at preclinical stages.<a onclick="showRef(event, 'ref32 ref33 ref34 ref35 ref36 ref37 ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref32 ref33 ref34 ref35 ref36 ref37 ref38 ref39">(32-39)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.6b00306/20160520/images/medium/jm-2016-00306u_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.6b00306/20160520/images/large/jm-2016-00306u_0007.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of select ALK inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.6b00306/20160520/images/large/jm-2016-00306u_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00306&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Phosphorus, despite its abundance in the human body, is rarely found in drug molecules, with its clinical utility limited to a few phosphonic or bisphosponic acid-based medicines, acting as phosphate mimics, as well as several phosphonate, phosphinate, or phosphate-containing prodrugs.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Concerns about poor cell penetration, low oral bioavailability, or biological instability have limited broader application of these functional classes in drug design. In our efforts to discover pharmaceuticals with novel functionality, we have previously explored the potential wider utilization of phosphorus in drug design. For example, dimethylphosphorylation at the C43-OH of rapamycin led to discovery of ridaforolimus, a chemically stable mTOR inhibitor that advanced to late-stage clinical trials in oncology and is currently being investigated as a component of drug-eluting stents.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Introduction of a bone-targeting arylphosphinylmethylphosphonic acid (PMP) functionality onto multiple templates generated several series of SRC kinase inhibitors as potential antiresorptive agents.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> More recently, we have explored whether the P═O bond can be exploited as a hydrogen-bond acceptor in kinase inhibitor design. In this regard, incorporation of a dimethylphosphine oxide (DMPO) moiety in <b>6</b> (AP23464) (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>) led to a 70-fold increase in SRC potency (IC<sub>50</sub> = 0.45 nM) relative to the unsubstituted analog.<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43, 44)</a> To further explore the potential of this functionality, we have incorporated the DMPO in our design of ALK inhibitors leading to the discovery of the potent, orally active ALK inhibitor brigatinib. Detailed biological characterization of brigatinib as an inhibitor of native ALK and clinically relevant ALK mutants will be reported in a separate publication.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Herein we present our medicinal chemistry work leading to the discovery of brigatinib.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.6b00306/20160520/images/medium/jm-2016-00306u_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.6b00306/20160520/images/large/jm-2016-00306u_0008.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Chemical structures of SRC inhibitor <b>6</b> and ALK inhibitors <b>10a</b>–<b>g</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.6b00306/20160520/images/large/jm-2016-00306u_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00306&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05465" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05465" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Early ALK Inhibitor Design and Exploration</h3><div class="NLM_p">Prior to launching an ALK inhibitor program, inhibitors based on an array of different structural scaffolds,<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> including crizotinib (then known as PF-2341066) and <b>7</b> (TAE684, <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>),<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> had been reported. Further optimization of <b>7</b> to address selectivity and potential idiosyncratic toxicity issues led to the eventual discovery of ceritinib a few years later.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></div><div class="NLM_p">Initially, we explored several parallel paths with the goal to identify ALK inhibitors with multiple distinct chemotypes. Among others, one early chemotype was based on morphing the crizotinib scaffold into a bicyclic tetrahydropyrazino[2,3,<i>b</i>]-pyrazine template.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> An alternative, parallel approach focused on constructing and testing a library of substituted 2-anilinopyrimidine compounds. This design strategy stemmed from our observation that numerous kinase inhibitors evaluated clinically or at preclinical stages were derived from this scaffold. We anticipated that introduction of diversified functional groups at C2, C4, and C5 on the pyrimidine core might favorably alter kinase selectivity of 2-anilinopyrimidine-based ALK inhibitors. Particularly, we monitored new inhibitor activity toward the insulin receptor kinase (InsR) and insulin-like growth factor receptor (IGF1R), because both kinases bear high sequence homology with ALK and are important for maintaining glucose homeostasis.</div><div class="NLM_p">To incorporate the DMPO onto the 2-anilinopyrimidine template, our initial efforts, by analogy to <b>6</b>, targeted the 4′ position of the 2′-methoxyaniline group at C2 adjacent to the hinge region of the kinase. Incorporation of the 2′-methoxy group was intended to prevent general kinase promiscuity through interaction with a small hydrophobic pocket adjacent to the hinge that is unique to certain protein kinases including ALK protein.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Gratifyingly, DMPO incorporation at C4′ was found to increase ALK activity by approximately 7-fold relative to the unsubstituted analog (<b>10a</b> and <b>10g</b>, <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>) when investigated in the context of a small focused library at C4. Several C4 <i>ortho</i>-substituted aniline analogs <b>10a</b>–<b>e</b> exhibited potent ALK inhibition with IC<sub>50</sub>’s in the sub-nanomolar range in biochemical assays. Most compounds also effectively inhibited viability of the Karpas-299 ALCL cell line with an IC<sub>50</sub> range of 20–740 nM and with ∼4–240-fold decreased activity against the ALK-negative U937 histolytic lymphoma cell line. In this series, the isopropylsulfonyl analog <b>10a</b>, despite displaying the most favorable cellular potency, did not confer desirable selectivity over IGF1R.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Activity Profiles of Inhibitors <b>10a</b>–<b>g</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">enzyme-based kinase activity (IC<sub>50</sub>, nM)</th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">viability of cell lines (IC<sub>50</sub>, nM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center" char=".">ALK</th><th class="colsep0 rowsep0" align="center" char=".">IGF1R</th><th class="colsep0 rowsep0" align="center" char=".">InsR</th><th class="colsep0 rowsep0" align="center" char=".">Karpas-299 (ALK+)</th><th class="colsep0 rowsep0" align="center" char=".">U937 (ALK−)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">crizotinib</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">0.64</td><td class="colsep0 rowsep0" align="char" char=".">143</td><td class="colsep0 rowsep0" align="char" char=".">201</td><td class="colsep0 rowsep0" align="char" char=".">365</td><td class="colsep0 rowsep0" align="char" char=".">2286</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10a</b></td><td class="colsep0 rowsep0" align="left">SO<sub>2</sub>–CHMe<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">0.31</td><td class="colsep0 rowsep0" align="char" char=".">1.9</td><td class="colsep0 rowsep0" align="char" char=".">9.9</td><td class="colsep0 rowsep0" align="char" char=".">20</td><td class="colsep0 rowsep0" align="char" char=".">4838</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10b</b></td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="char" char=".">0.96</td><td class="colsep0 rowsep0" align="char" char=".">22.1</td><td class="colsep0 rowsep0" align="char" char=".">55.2</td><td class="colsep0 rowsep0" align="char" char=".">278</td><td class="colsep0 rowsep0" align="char" char=".">2908</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10c</b></td><td class="colsep0 rowsep0" align="left">C(═O)–Me</td><td class="colsep0 rowsep0" align="char" char=".">0.79</td><td class="colsep0 rowsep0" align="char" char=".">0.47</td><td class="colsep0 rowsep0" align="char" char=".">0.88</td><td class="colsep0 rowsep0" align="char" char=".">251</td><td class="colsep0 rowsep0" align="char" char=".">1423</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10d</b></td><td class="colsep0 rowsep0" align="left">C(═O)–NH<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">0.68</td><td class="colsep0 rowsep0" align="char" char=".">0.11</td><td class="colsep0 rowsep0" align="char" char=".">14.1</td><td class="colsep0 rowsep0" align="char" char=".">613</td><td class="colsep0 rowsep0" align="char" char=".">2368</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10e</b></td><td class="colsep0 rowsep0" align="left">SO<sub>2</sub>–Me</td><td class="colsep0 rowsep0" align="char" char=".">0.33</td><td class="colsep0 rowsep0" align="char" char=".">0.40</td><td class="colsep0 rowsep0" align="char" char=".">4.7</td><td class="colsep0 rowsep0" align="char" char=".">405</td><td class="colsep0 rowsep0" align="char" char=".">4813</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10f</b></td><td class="colsep0 rowsep0" align="left">P(═O)Me<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">1.06</td><td class="colsep0 rowsep0" align="char" char=".">139</td><td class="colsep0 rowsep0" align="char" char=".">726</td><td class="colsep0 rowsep0" align="char" char=".">738</td><td class="colsep0 rowsep0" align="char" char=".">13193</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10g</b></td><td class="colsep0 rowsep0" align="left"><a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char=".">2.1</td><td class="colsep0 rowsep0" align="char" char="."><a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="."><a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">349</td><td class="colsep0 rowsep0" align="char" char=".">20824</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">Not applicable.</p></div><div class="footnote" id="t1fn2"><sup>b</sup><p class="last">Not determined.</p></div></div></div><div class="NLM_p">In addition to exploring DMPO substitution on the aniline near the kinase region, homology-based molecular modeling (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>) revealed that <i>ortho</i>-substituents on the C4 anilines of <b>10a</b>–<b>e</b> can potentially form an intramolecular hydrogen bond to the aniline NH or hydrogen bond with the Lys-NH (K1150) on the protein. This prompted us to explore the H-bonding potential of the DMPO functionality beyond that noted near the hinge; therefore, a double-phosphorylated analog <b>10f</b> was synthesized and tested. Although <b>10f</b> did not exhibit increased ALK activity relative to <b>10a</b>–<b>e</b>, its improved selectivity over both IGF1R and InsR was remarkable and unanticipated. Given this finding, to further explore SAR, we retained the <i>ortho</i>-DMPO-substituted aniline at C4 to maintain selectivity while optimizing C2 and C5 substitutions to improve both potency and the overall drug metabolism and pharmacokinetics (DMPK) profile.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.6b00306/20160520/images/medium/jm-2016-00306u_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.6b00306/20160520/images/large/jm-2016-00306u_0009.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Homology model of <b>10f</b> bound to ALK. Dotted lines indicate hydrogen bond interactions.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.6b00306/20160520/images/large/jm-2016-00306u_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00306&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Development of Structure–Activity Relationship (SAR)</h3><div class="NLM_p">Given the hydrophilic nature of the bis-DMPO inhibitor <b>10f</b> (cLogP = 0.4, ChemBioDraw Ultra 14.0), we examined how substitution of the C2-DMPO with basic amine side chains might influence ALK activity, particularly the cellular potency. Based on the <i>para</i>-substitution vector directed at the solvent front, a large focused library of diverse basic amine-containing solubilizing groups was designed and synthesized, including N-, O-, and C-linked derivatives. As shown in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>, these new analogs were potent ALK inhibitors, and their activities were nearly indistinguishable in biochemical assays because of their high potency under assay conditions (1 h and 10 μM ATP). Fortunately, potency separation was more clearly delineated in cell-based viability assays following inhibitor treatment for 72 h. The discrepancy between enzymatic and cellular potencies may be explained by the higher ATP concentrations in the physiological cellular system or the structural difference between truncated enzyme and full-length receptor. Interestingly, this potency mismatch was also observed on structurally similar inhibitors such as ceritinib and <b>7</b>.<a onclick="showRef(event, 'ref17 ref48'); return false;" href="javascript:void(0);" class="ref ref17 ref48">(17, 48)</a> In our chemical series, compounds bearing a piperazine (<b>11e</b>, <b>11i</b>) or piperidine ring (<b>11l</b>, <b>11m</b>, <b>11n</b>, <b>11q</b>) directly attached to C2 phenyl displayed excellent cell potency. A basic nitrogen atom appeared critical for driving cell-based activity. Substitution of the terminal piperazinyl nitrogen in <b>11e</b> by oxygen or carbon atoms (<b>11d</b>, <b>11g</b>) or removal or attenuation of nitrogen basicity (<b>11f</b>, <b>11h</b>) led to reduced ALK potency. Seven-membered homopiperazine or five-membered pyrrolidine analogs were less active than corresponding six-membered inhibitors (<b>11j</b> vs <b>11e</b>, <b>11k</b> vs <b>11l</b>, <b>11s</b> vs <b>11n</b>) despite possessing equivalently basic nitrogens, highlighting the importance of ring size. The basic nitrogen can be incorporated into a second ring; however, its basicity (<b>11p</b> vs <b>11q</b>) and size (<b>11q</b> vs <b>11r</b>) influenced activity similar to that observed with the monoring analogs (<b>11d</b>, <b>11e</b>, <b>11j</b>, <b>11l</b>). Installation of the solubilizing group identical to crizotinib (<b>11t</b>) resulted in significant potency loss, presumably due to suboptimal location of the basic nitrogen atom or unfavorable aromatic ring attachment and vectors or both. An alternate C-linked basic amine-containing inhibitor (<b>11u</b>), designed for the purpose of mitigating potential idiosyncratic bioactivation associated with the 1,4-diaminophenyl motif, demonstrated equipotent ALK activity relative to its N-linked counterpart (<b>11e</b>). Relative to other inhibitors, compounds <b>11i</b> and <b>11u</b> exhibited slightly compromised selectivity over InsR. The moderately increased activity toward InsR could be rationalized by interaction of the hydroxylethyl group in <b>11i</b> with Ser1063 of helix D or interaction of the stronger basic amine in <b>11u</b> with the negatively charged patch in the ATP ribose binding pocket of InsR. Overall, this solubilizing group screening campaign identified several amines (<b>11e</b>, <b>11m</b>, <b>11n</b>, <b>11q</b>, <b>11u</b>) with favorable potency and selectivity profiles.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Activity Profiles of Inhibitors <b>11a</b>–<b>u</b> Bearing a Variety of Basic Amines</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.6b00306/20160520/images/medium/jm-2016-00306u_0015.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.6b00306/20160520/images/medium/jm-2016-00306u_0001.gif" alt="" id="fx2" /></img><div></div></div><div class="NLM_p">For further lead optimization, we next chose to maintain the C2 amine group of compound <b>11q</b> while exploring the SAR at other positions on the inhibitor core (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). A chloro substituent at C5 on the pyrimidine ring appears optimal; analogs with a variety of R<sup>1</sup> groups at C5 (<b>12a</b>–<b>d</b>) exhibited reduced cellular viability despite having similar biochemical enzymatic activity. An acetyl substituent at C5 (<b>12e</b>) largely ablated activity in the biochemical and viability assays. Increasing the alkyl group size on phosphorus from methyl to ethyl (<b>12f</b>) led to 5-fold potency loss in Karpas-299 cells. Similarly, fluoro group introduction <i>para</i> to the methoxy substituent on the 2-substituted aniline (<b>12g</b>) furnished a less active inhibitor. Interestingly, analog <b>12h</b> bearing a methyl group at the same position was equipotent to <b>11q</b> in cellular settings, despite exhibiting moderate enzymatic potency loss. Finally, substitution of the methoxy group by either ethoxy (<b>12i</b>) or isopropoxy analogs (<b>12j</b>) demonstrated enhanced selectivity over both IGF1R and InsR; however, both inhibitors exhibited reduced (∼50%) ALK potency.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. SAR at C5 of Pyrimidine Core and Phenyl Rings at C2 and C4</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.6b00306/20160520/images/medium/jm-2016-00306u_0002.gif" alt="" id="fx3" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="​" /></col><col align="char" char="​" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">enzyme-based kinase activity (IC<sub>50</sub>, nM)</th><th class="rowsep1 colsep0" colspan="2" align="center" char="​">viability of cell lines (IC<sub>50</sub>, nM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">R<sup>1</sup></th><th class="colsep0 rowsep0" align="center">R<sup>2</sup></th><th class="colsep0 rowsep0" align="center">R<sup>3</sup></th><th class="colsep0 rowsep0" align="center">R<sup>4</sup></th><th class="colsep0 rowsep0" align="center" char=".">ALK</th><th class="colsep0 rowsep0" align="center" char=".">IGF1R</th><th class="colsep0 rowsep0" align="center" char=".">InsR</th><th class="colsep0 rowsep0" align="center" char="​">Karpas 299 (ALK+)</th><th class="colsep0 rowsep0" align="center" char="​">U937 (ALK−)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">crizotinib</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">0.64</td><td class="colsep0 rowsep0" align="char" char=".">143</td><td class="colsep0 rowsep0" align="char" char=".">201</td><td class="colsep0 rowsep0" align="char" char="​">365</td><td class="colsep0 rowsep0" align="char" char="​">2286</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11q</b></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char=".">0.37</td><td class="colsep0 rowsep0" align="char" char=".">24.9</td><td class="colsep0 rowsep0" align="char" char=".">196</td><td class="colsep0 rowsep0" align="char" char="​">29</td><td class="colsep0 rowsep0" align="char" char="​">3194</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12a</b></td><td class="colsep0 rowsep0" align="left">c-Pr</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char=".">3.23</td><td class="colsep0 rowsep0" align="char" char=".">434</td><td class="colsep0 rowsep0" align="char" char=".">367</td><td class="colsep0 rowsep0" align="char" char="​">278</td><td class="colsep0 rowsep0" align="char" char="​">10630</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12b</b></td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char=".">1.19</td><td class="colsep0 rowsep0" align="char" char=".">117</td><td class="colsep0 rowsep0" align="char" char=".">1684</td><td class="colsep0 rowsep0" align="char" char="​">429</td><td class="colsep0 rowsep0" align="char" char="​">13863</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12c</b></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char=".">0.39</td><td class="colsep0 rowsep0" align="char" char=".">143</td><td class="colsep0 rowsep0" align="char" char=".">1683</td><td class="colsep0 rowsep0" align="char" char="​">147</td><td class="colsep0 rowsep0" align="char" char="​">24166</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12d</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char=".">0.42</td><td class="colsep0 rowsep0" align="char" char=".">128</td><td class="colsep0 rowsep0" align="char" char=".">483</td><td class="colsep0 rowsep0" align="char" char="​">46.9</td><td class="colsep0 rowsep0" align="char" char="​">5307</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12e</b></td><td class="colsep0 rowsep0" align="left">C(═O)Me</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char=".">291</td><td class="colsep0 rowsep0" align="char" char="."><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char="."><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char="​"><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char="​"><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12f</b></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char=".">0.12</td><td class="colsep0 rowsep0" align="char" char=".">45.1</td><td class="colsep0 rowsep0" align="char" char=".">314</td><td class="colsep0 rowsep0" align="char" char="​">169</td><td class="colsep0 rowsep0" align="char" char="​">3465</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12g</b></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char=".">1.03</td><td class="colsep0 rowsep0" align="char" char=".">59.5</td><td class="colsep0 rowsep0" align="char" char=".">1179</td><td class="colsep0 rowsep0" align="char" char="​">162</td><td class="colsep0 rowsep0" align="char" char="​">1231</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12h</b></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char=".">0.86</td><td class="colsep0 rowsep0" align="char" char=".">27</td><td class="colsep0 rowsep0" align="char" char=".">171</td><td class="colsep0 rowsep0" align="char" char="​">16<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="​">1282<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12i</b></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="char" char=".">0.75</td><td class="colsep0 rowsep0" align="char" char=".">103</td><td class="colsep0 rowsep0" align="char" char=".">253</td><td class="colsep0 rowsep0" align="char" char="​">58.9</td><td class="colsep0 rowsep0" align="char" char="​">22398</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12j</b></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">i-Pr</td><td class="colsep0 rowsep0" align="char" char=".">0.68</td><td class="colsep0 rowsep0" align="char" char=".">203</td><td class="colsep0 rowsep0" align="char" char=".">700</td><td class="colsep0 rowsep0" align="char" char="​">54.6</td><td class="colsep0 rowsep0" align="char" char="​">21475</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">NT = not tested.</p></div><div class="footnote" id="t3fn2"><sup>b</sup><p class="last">GI<sub>50</sub>’s (concentrations required to inhibit growth by 50%); for comparison, <b>11q</b> had GI<sub>50</sub> of 10 and 3194 nM toward Karpas 299 and U937, respectively.</p></div></div></div><div class="NLM_p">To confirm and extend our observations regarding the critical role of the C4 DMPO moiety on both potency and selectivity (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>), analogs of <b>11q</b> where the DMPO was systematically modified (mostly with H-bond acceptors) were synthesized and tested (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). While compounds <b>13c</b> and <b>13i</b> conferred reasonable selectivity over IGF1R and InsR kinases, both inhibitors were 5- or 3-fold less active toward ALK relative to <b>11q</b>. Interestingly, acetyl inhibitor <b>13h</b>, while potent against ALK, was completely nonselective over IGFR and InsR relative to its reduced analog <b>13i</b>, suggesting that sp<sup>3</sup> hybridization at this position may be differentiating these kinases. Compound <b>7</b>, a 2-fold more potent inhibitor than <b>11q</b>, displayed a narrow selectivity window, and its sulfonamide analog <b>13g</b> was also poorly selective and exhibited 5-fold reduced ALK activity. To assess whether the bulkier isopropyl group of <b>7</b> was leading to poor selectivity, analog <b>13j</b> bearing a methylsulfone group, more closely resembling the DMPO in size, was tested. Compound <b>13j</b> demonstrated similar selectivity but reduced activity relative to <b>7</b>, indicating no correlation between alkyl substituent size and kinase selectivity. Taken together, independent of the C2 substituents directed at the kinase solvent front, the C4 DMPO functionality was an essential structural feature necessary to achieve the proper balance between potency and selectivity with this inhibitor core.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. SAR of DMPO Replacements at C4 (IC<sub>50</sub>, nM)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.6b00306/20160520/images/medium/jm-2016-00306u_0003.gif" alt="" id="fx4" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.6b00306/20160520/images/medium/jm-2016-00306u_0004.gif" alt="" id="fx5" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>Table a</sup><p class="last">Not determined.</p></div></div><div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Structural Analysis of Brigatinib Binding and Selectivity</h3><div class="NLM_p">Elsewhere, we have reported detailed structural characteristics of the ALK–brigatinib complex (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5J7H">5J7H</a>).<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Briefly, the structure shows that brigatinib binds to ALK in the ATP-binding site by adopting a U-shaped ligand conformation. While the pyrimidine core of brigatinib binds in the adenosine site, its methoxy group and DMPO aniline bind in the vicinity of the hinge and DFG sites, respectively (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>A). As revealed in the structure, the potency of brigatinib against ALK can be largely attributed to the chemical substituents installed on the bisanilinopyrimidine scaffold. These include the molecular interactions of the methoxy group with the hinge residue L1198, of the C5-chlorine atom with the gatekeeper residue L1196, and of the DMPO moiety with the GDFG motif (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>A). In addition, the DMPO moiety fosters intramolecular interactions and stabilizes the U-shaped conformation of brigatinib through an O···NH hydrogen bond (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>A). Interestingly, the DMPO aniline in brigatinib is rotated significantly toward the lower lobe of ALK compared with the moiety in compound <b>7</b> (in which the DMPO is replaced by isopropylsulfone) (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>B). As a result, the DMPO aniline stays further away from the P-loop relative to the isopropylsulfone aniline in compound <b>7</b>, which may have led brigatinib to rely less on P-loop interactions for potency. The observed conformational differences between brigatinib and compound <b>7</b> in this region are likely driven by distinct binding interactions between the inhibitors and ALK. Apart from the phenyl groups, which both bind underneath the P-loop, one of the methyl groups from the DMPO or the isopropylsulfone occupies a very similar position such that each methyl makes a strong hydrophobic interaction with the side chain of L1256 (from the adenine binding pocket) (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>B). The solubilizing group, particularly the methyl piperazine, is largely disordered likely due to lack of strong binding interactions. Of interest, the catalytic lysine (K1150) is also partially disordered despite being proximal to the DMPO moiety. No cocrystal structures of brigatinib or <b>7</b> bound to insulin kinase are available; however, by analogy, brigatinib may also interact with this part of insulin kinase differently than the other analogs indicated in <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>, resulting in the different selectivity profile.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.6b00306/20160520/images/medium/jm-2016-00306u_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.6b00306/20160520/images/large/jm-2016-00306u_0010.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) X-ray crystal structure of ALK in complex with investigational brigatinib. Dotted lines indicate hydrogen bond interactions. (B) Comparison of brigatinib (pink) and compound <b>7</b> (orange) bound to wild-type ALK. Certain residues in the brigatinib–ALK complex are shown in gray; residue L1256 (green) in the <b>7</b>–ALK complex is also displayed.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.6b00306/20160520/images/large/jm-2016-00306u_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00306&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Pharmacokinetic (PK) and Pharmacodynamic (PD) Properties of Selected Inhibitors</h3><div class="NLM_p">During this program, potent ALK inhibitors were evaluated for their PK properties in rats and mice immediately following assessment of their <i>in vitro</i> activity. A number of inhibitors with diverse solubilizing groups on the C2 aniline exhibited high levels of oral absorption in both species (<a class="ref internalNav" href="#tbl5" aria-label="Tables 5">Tables 5</a> and <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>). Upon dosing intravenously (iv) in rats, <i>N</i><sup>4</sup>-(2-hydroxyethyl)piperazine inhibitor <b>11i</b> exhibited faster clearance than <i>N</i><sup>4</sup>-methyl piperazine analog <b>11e</b>. Similarly, pyrrolidinylpiperidine analog <b>11n</b> showed higher clearance relative to the piperazinylpiperdine analog <b>11q</b>. Both <b>11i</b> and <b>11n</b> displayed lower oral exposures suggesting relatively poor bioavailability. Interestingly, the more basic piperidine analog <b>11u</b>, despite displaying higher iv clearance than piperazine inhibitor <b>11e</b>, had higher systemic exposure when dosed orally in both rats and mice. To the contrary, the O-linked inhibitor <b>11c</b>, despite exhibiting low iv clearance and excellent oral exposure in rats, possessed lower oral exposure in mice relative to other analogs.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Mean PK Parameters Following Intravenous (iv) or Oral (po) Dosing in CD Rats<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center" char=".">iv<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="rowsep1 colsep0" colspan="5" align="center" char=".">po<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>0–∞</sub> (ng·h/mL)</th><th class="colsep0 rowsep0" align="center" char=".">CL (L/(h·kg))</th><th class="colsep0 rowsep0" align="center" char="."><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>V</i>ss (L/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub> (ng/mL)</th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>0–∞</sub> (ng·h/mL)</th><th class="colsep0 rowsep0" align="center" char="."><i>t</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11e</b></td><td class="colsep0 rowsep0" align="char" char=".">3092</td><td class="colsep0 rowsep0" align="char" char=".">0.91</td><td class="colsep0 rowsep0" align="char" char=".">6.6</td><td class="colsep0 rowsep0" align="char" char=".">6.12</td><td class="colsep0 rowsep0" align="char" char=".">254.0</td><td class="colsep0 rowsep0" align="char" char=".">4056</td><td class="colsep0 rowsep0" align="char" char=".">6.0</td><td class="colsep0 rowsep0" align="char" char=".">12.5</td><td class="colsep0 rowsep0" align="char" char=".">39</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11i</b></td><td class="colsep0 rowsep0" align="char" char=".">1326</td><td class="colsep0 rowsep0" align="char" char=".">2.15</td><td class="colsep0 rowsep0" align="char" char=".">8.4</td><td class="colsep0 rowsep0" align="char" char=".">9.51</td><td class="colsep0 rowsep0" align="char" char=".">75.7</td><td class="colsep0 rowsep0" align="char" char=".">777</td><td class="colsep0 rowsep0" align="char" char=".">4.0</td><td class="colsep0 rowsep0" align="char" char=".">2.9</td><td class="colsep0 rowsep0" align="char" char=".">18</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11g</b></td><td class="colsep0 rowsep0" align="char" char=".">4546</td><td class="colsep0 rowsep0" align="char" char=".">0.64</td><td class="colsep0 rowsep0" align="char" char=".">5.6</td><td class="colsep0 rowsep0" align="char" char=".">2.74</td><td class="colsep0 rowsep0" align="char" char=".">772.3</td><td class="colsep0 rowsep0" align="char" char=".">9725</td><td class="colsep0 rowsep0" align="char" char=".">0.25</td><td class="colsep0 rowsep0" align="char" char=".">2.7</td><td class="colsep0 rowsep0" align="char" char=".">64</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11n</b></td><td class="colsep0 rowsep0" align="char" char=".">2170</td><td class="colsep0 rowsep0" align="char" char=".">1.36</td><td class="colsep0 rowsep0" align="char" char=".">4.7</td><td class="colsep0 rowsep0" align="char" char=".">6.61</td><td class="colsep0 rowsep0" align="char" char=".">109.0</td><td class="colsep0 rowsep0" align="char" char=".">1353</td><td class="colsep0 rowsep0" align="char" char=".">4.0</td><td class="colsep0 rowsep0" align="char" char=".">3.7</td><td class="colsep0 rowsep0" align="char" char=".">19</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11c</b></td><td class="colsep0 rowsep0" align="char" char=".">5035</td><td class="colsep0 rowsep0" align="char" char=".">0.59</td><td class="colsep0 rowsep0" align="char" char=".">3.6</td><td class="colsep0 rowsep0" align="char" char=".">2.89</td><td class="colsep0 rowsep0" align="char" char=".">658.7</td><td class="colsep0 rowsep0" align="char" char=".">9221</td><td class="colsep0 rowsep0" align="char" char=".">4.0</td><td class="colsep0 rowsep0" align="char" char=".">3.9</td><td class="colsep0 rowsep0" align="char" char=".">55</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11p</b></td><td class="colsep0 rowsep0" align="char" char=".">17889</td><td class="colsep0 rowsep0" align="char" char=".">0.17</td><td class="colsep0 rowsep0" align="char" char=".">3.9</td><td class="colsep0 rowsep0" align="char" char=".">0.78</td><td class="colsep0 rowsep0" align="char" char=".">2836.7</td><td class="colsep0 rowsep0" align="char" char=".">43643</td><td class="colsep0 rowsep0" align="char" char=".">2.0</td><td class="colsep0 rowsep0" align="char" char=".">6.8</td><td class="colsep0 rowsep0" align="char" char=".">73</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11u</b></td><td class="colsep0 rowsep0" align="char" char=".">1550</td><td class="colsep0 rowsep0" align="char" char=".">1.91</td><td class="colsep0 rowsep0" align="char" char=".">4.0</td><td class="colsep0 rowsep0" align="char" char=".">8.55</td><td class="colsep0 rowsep0" align="char" char=".">601.3</td><td class="colsep0 rowsep0" align="char" char=".">5670</td><td class="colsep0 rowsep0" align="char" char=".">4.0</td><td class="colsep0 rowsep0" align="char" char=".">2.5</td><td class="colsep0 rowsep0" align="char" char=".">110</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11m</b></td><td class="colsep0 rowsep0" align="char" char=".">8619</td><td class="colsep0 rowsep0" align="char" char=".">0.35</td><td class="colsep0 rowsep0" align="char" char=".">3.6</td><td class="colsep0 rowsep0" align="char" char=".">1.46</td><td class="colsep0 rowsep0" align="char" char=".">353.0</td><td class="colsep0 rowsep0" align="char" char=".">4572</td><td class="colsep0 rowsep0" align="char" char=".">6.0</td><td class="colsep0 rowsep0" align="char" char=".">3.4</td><td class="colsep0 rowsep0" align="char" char=".">16</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11q</b></td><td class="colsep0 rowsep0" align="char" char=".">2268</td><td class="colsep0 rowsep0" align="char" char=".">0.46</td><td class="colsep0 rowsep0" align="char" char=".">4.8</td><td class="colsep0 rowsep0" align="char" char=".">7.80</td><td class="colsep0 rowsep0" align="char" char=".">305.0</td><td class="colsep0 rowsep0" align="char" char=".">3954</td><td class="colsep0 rowsep0" align="char" char=".">4.0</td><td class="colsep0 rowsep0" align="char" char=".">3.4</td><td class="colsep0 rowsep0" align="char" char=".">52</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last"><i>n</i> = 3 animals per study.</p></div><div class="footnote" id="t5fn2"><sup>b</sup><p class="last">Dosed at 3 mg/kg.</p></div><div class="footnote" id="t5fn3"><sup>c</sup><p class="last">Dosed at 10 mg/kg.</p></div></div></div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Mouse PK Parameters Following Oral Dosing<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub> (ng/mL)</th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>0–24h</sub> (ng·h/mL)</th><th class="colsep0 rowsep0" align="center" char="."><i>t</i><sub>1/2</sub> (h)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11e</b></td><td class="colsep0 rowsep0" align="char" char=".">418</td><td class="colsep0 rowsep0" align="char" char=".">5184</td><td class="colsep0 rowsep0" align="char" char=".">2.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11g</b></td><td class="colsep0 rowsep0" align="char" char=".">2943</td><td class="colsep0 rowsep0" align="char" char=".">13262</td><td class="colsep0 rowsep0" align="char" char=".">2.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11n</b></td><td class="colsep0 rowsep0" align="char" char=".">411</td><td class="colsep0 rowsep0" align="char" char=".">3231</td><td class="colsep0 rowsep0" align="char" char=".">3.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11c</b></td><td class="colsep0 rowsep0" align="char" char=".">184</td><td class="colsep0 rowsep0" align="char" char=".">951</td><td class="colsep0 rowsep0" align="char" char=".">1.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11u</b></td><td class="colsep0 rowsep0" align="char" char=".">421</td><td class="colsep0 rowsep0" align="char" char=".">3451</td><td class="colsep0 rowsep0" align="char" char=".">5.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11m</b></td><td class="colsep0 rowsep0" align="char" char=".">498</td><td class="colsep0 rowsep0" align="char" char=".">6494</td><td class="colsep0 rowsep0" align="char" char=".">3.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11q</b></td><td class="colsep0 rowsep0" align="char" char=".">448</td><td class="colsep0 rowsep0" align="char" char=".">5772</td><td class="colsep0 rowsep0" align="char" char=".">5.8</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>a</sup><p class="last">Three animals for each of seven time points; dose level = 10 mg/kg.</p></div></div></div><div class="NLM_p">Several potent inhibitors (<b>11g</b>, <b>11q</b>, <b>11c</b>, <b>11p</b>, <b>11u</b>, <b>11e</b>, <b>11m</b>, and <b>11n</b>) bearing diverse solubilizing groups and exhibiting desirable PK profiles were selected for a single oral (po) dose (25 mg/kg) PK/PD study in a mouse Karpas-299 model. Although most inhibitors demonstrated strong inhibition of ALK phosphorylation (p-ALK) for 10 h (<a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>), several (e.g., <b>11e</b> and <b>11q</b>) exhibited more sustained signal suppression (up to 16 h), with <b>11q</b> (brigatinib) offering the most durable inhibition (p-ALK = 7% and 39% at 16 and 24 h, respectively). These data suggested that once-daily po dosing would likely be appropriate for efficacy studies. Overall, the PK/PD experiments were found to be highly predictive of <i>in vivo</i> efficacy (<i>vide infra</i>).</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Single-Dose (25 mg/kg, po) PD: Percentage of p-ALK at 10, 16, and 24 h<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="​" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="."><b>11c</b></th><th class="colsep0 rowsep0" align="center" char="."><b>11e</b></th><th class="colsep0 rowsep0" align="center" char="​"><b>11g</b></th><th class="colsep0 rowsep0" align="center" char="."><b>11m</b></th><th class="colsep0 rowsep0" align="center" char="."><b>11n</b></th><th class="colsep0 rowsep0" align="center" char="."><b>11p</b></th><th class="colsep0 rowsep0" align="center" char="."><b>11q</b></th><th class="colsep0 rowsep0" align="center" char="."><b>11u</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">10 h</td><td class="colsep0 rowsep0" align="char" char=".">23</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char="​">41<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">13</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">16 h</td><td class="colsep0 rowsep0" align="char" char=".">125</td><td class="colsep0 rowsep0" align="char" char=".">14</td><td class="colsep0 rowsep0" align="char" char="​">25</td><td class="colsep0 rowsep0" align="char" char=".">60</td><td class="colsep0 rowsep0" align="char" char=".">39</td><td class="colsep0 rowsep0" align="char" char=".">52</td><td class="colsep0 rowsep0" align="char" char=".">7</td><td class="colsep0 rowsep0" align="char" char=".">69</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">24 h</td><td class="colsep0 rowsep0" align="char" char=".">160</td><td class="colsep0 rowsep0" align="char" char=".">94</td><td class="colsep0 rowsep0" align="char" char="​">168</td><td class="colsep0 rowsep0" align="char" char=".">104</td><td class="colsep0 rowsep0" align="char" char=".">51</td><td class="colsep0 rowsep0" align="char" char=".">50</td><td class="colsep0 rowsep0" align="char" char=".">39</td><td class="colsep0 rowsep0" align="char" char=".">118</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup>a</sup><p class="last">Data presented are percent ALK phosphorylation (p-ALK) relative to the p-ALK levels in vehicle-treated tumors at 2 h post dosing; all p-ALK levels were normalized to the corresponding total ALK levels.</p></div><div class="footnote" id="t7fn2"><sup>b</sup><p class="last">8 h value.</p></div></div></div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> <i>In Vivo</i> Efficacy of Selected Inhibitors</h3><div class="NLM_p">Potent inhibitors possessing favorable PK profiles and displaying a strong correlation between PK and inhibition of ALK phosphorylation were evaluated for their antitumor activity in a Karpas-299 xenograft mouse model expressing the NPM–ALK fusion. Animals were treated orally with inhibitors at selected doses, once daily for 13 consecutive days. Tumor growth inhibition of treated (T) mice relative to untreated control (C) was used to assess efficacy and was reported as % T/C in <a class="ref internalNav" href="#tbl8" aria-label="Table 8">Table 8</a>. Compound <b>11g</b> was essentially inactive up to 50 mg/kg, whereas <b>11n</b> displayed limited but dose-responsive efficacy. Inhibitors <b>11e</b> and <b>11q</b> demonstrated dose-dependent antitumor activity, with the latter being more efficacious at each dose level. While a 50 mg/kg dose of <b>11e</b> led to tumor stasis, an equivalent dose of <b>11q</b> resulted in tumor regression with no signs of overt toxicity.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. <i>In Vivo</i> Anti-tumor Activity in a Karpas-299 Mouse Model<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="​" /></col><col align="char" char="​" /></col><col align="char" char="​" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="​"><b>11e</b></th><th class="colsep0 rowsep0" align="center" char="​"><b>11g</b></th><th class="colsep0 rowsep0" align="center" char="​"><b>11n</b></th><th class="colsep0 rowsep0" align="center" char="."><b>11q</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">10 mg/kg</td><td class="colsep0 rowsep0" align="char" char="​">81<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="​">96<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="​">76<a class="ref internalNav" href="#t8fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char=".">50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">25 mg/kg</td><td class="colsep0 rowsep0" align="char" char="​">41</td><td class="colsep0 rowsep0" align="char" char="​">85<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="​">52</td><td class="colsep0 rowsep0" align="char" char=".">12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">50 mg/kg</td><td class="colsep0 rowsep0" align="char" char="​">1.4</td><td class="colsep0 rowsep0" align="char" char="​">67<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="​">26</td><td class="colsep0 rowsep0" align="char" char=".">–11</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup>a</sup><p class="last">Reported as % T/C. Unless otherwise indicated, <i>p</i> < 0.01. Negative value indicates tumor regression; all other values represent tumor growth inhibition.</p></div><div class="footnote" id="t8fn2"><sup>b</sup><p class="last"><i>p</i> > 0.05.</p></div><div class="footnote" id="t8fn3"><sup>c</sup><p class="last"><i>p</i> < 0.05.</p></div></div></div><div class="NLM_p">Next, we evaluated the activity of <b>11q</b> in a mouse model of NSCLC (H3122 cells expressing the EML4–ALK fusion). In this model, once-daily oral administration (for 19 days) of <b>11q</b> resulted in dose-dependent antitumor activity, with tumor regressions observed at all doses tested (including the lowest 10 mg/kg dose) (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>). By comparison, animals treated daily with 100 mg/kg crizotinib exhibited 97% tumor growth inhibition (data not shown). Consistent with the favorable safety profile demonstrated in the Karpas-299 model, no clinical signs of gross toxicity or body weight loss were observed at any brigatinib dose level tested, relative to vehicle control-treated animals.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.6b00306/20160520/images/medium/jm-2016-00306u_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.6b00306/20160520/images/large/jm-2016-00306u_0011.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. <i>In vivo</i> efficacy of <b>11q</b> (brigatinib) in a H3122 NSCLC model.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.6b00306/20160520/images/large/jm-2016-00306u_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00306&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Kinase Selectivity and Mutant Profile</h3><div class="NLM_p">To assess the kinase selectivity profile of <b>11q</b> (brigatinib) beyond ALK, IGF1R, and InsR, it was screened against a broad panel of 289 kinases and mutants and isoforms, and the results were reported elsewhere.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> In brief, ∼4% (11 out of 289) of the kinases in this panel were inhibited with IC<sub>50</sub>’s of <10 nM, indicating a relatively high degree of selectivity. Among them, brigatinib potently inhibited FLT3 and ROS1 with IC<sub>50</sub> values of 2.1 and 1.9 nM, respectively. Unlike crizotinib, which is characterized as a dual c-Met/ALK inhibitor that also potently inhibits Ron, <b>11q</b> did not show significant activity toward c-Met or Ron up to 1 μM.</div><div class="NLM_p last">Kinase domain mutations have been identified as one of the major mechanisms for crizotinib resistance. Elsewhere, we have reported the cellular activity of brigatinib against a broad panel of clinically relevant EML4–ALK mutants.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Briefly, brigatinib was active against 17 clinically and preclinically identified resistant mutants; these include F1174C/V, I1171N, and G120R mutations, which have been reported in patients failing crizotinib or the second-generation inhibitors (ceritinib and alectinib). Additionally, in an accelerated cell-based ENU mutagenesis screen, brigatinib completely suppressed the outgrowth of all mutants at a concentration of 500 nM indicating its potential as a pan-ALK inhibitor.</div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> DMPO and Its Impact on the Properties of Brigatinib</h3><div class="NLM_p">Brigatinib represents the most clinically advanced phosphine oxide-containing molecule currently in development. The reason that this functionality has been overlooked by medicinal chemists is unclear; it is easily synthesized using conventional methods and largely inert once installed. Unlike carbonyls and alcohols, the PO bond does not undergo redox chemistry and its ability to act as a H-bond acceptor makes it an important complement to existing more conventional H-bond acceptors such as carbonyls and sulfones. Moreover, phosphine oxides are tetrahedral, and there are very few H-bond acceptors that allow for three points of chemical derivatization. In a study to determine hydrogen-bond basicity, the equilibrium constants for a series of bases to form 1:1 complexes with 4-fluorophenol were measured by infrared spectroscopy.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> Trimethylphosphine oxide was found to possess a pKBHX of 3.53, which indicates that its oxygen should be a strong hydrogen-bond acceptor. By comparison, dimethyl sulfoxide, <i>N</i>,<i>N</i>-dimethylacetamide, <i>N</i>,<i>N</i>-dimethylmethanesulfonamide, acetone, and dimethylsulfone have pKBHXs of 2.54, 2.44, 1.3, 1.2, and 1.1, respectively. Interestingly, brigatinib analogs incorporating some of these weaker hydrogen-bond acceptors were all less potent against ALK and also displayed narrower selectivity over IGF1R and InsR (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>).</div><div class="NLM_p last">Experimental ESR and NMR data,<a onclick="showRef(event, 'ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref52 ref53">(52, 53)</a><i>ab initio</i> NMR calculation, and atoms-in-molecules (AIM) study, all suggest that the PO bond in a phosphine oxide is highly ionic and that its Lewis structure is better represented as R<sub>3</sub>P<sup>+</sup>–O<sup>–</sup> in a manner directly analogous to N-oxides.<a onclick="showRef(event, 'ref54 ref55 ref56'); return false;" href="javascript:void(0);" class="ref ref54 ref55 ref56">(54-56)</a> This dative, and therefore polarizable, PO bond imparts a number of important drug-like properties to the DMPO-containing molecules. For example, the increased polarity relative to the isopropyl sulfone derivative <b>7</b> has a direct effect on lipophilicity where the measured log <i>D</i> (pH 7.0) was reduced by more than a log unit relative to <b>7</b> (3.02 vs 4.12). Since lipophilicity and protein binding are positively correlated, it was notable that <b>11q</b> is moderately protein bound, with plasma binding being 66%, 73%, and 64% in human, rat, and mouse, respectively. In contrast, <b>7</b> is highly protein bound, exhibiting binding levels of 99% or higher in all three species. Finally, <b>11q</b> demonstrated a marked increase in aqueous solubility relative to <b>7</b> at physiological pH (337 vs 14.6 μg/mL) such that the compound can be formulated as the free base for human clinical evaluation.</div></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Chemical Synthesis</h3><div class="NLM_p">The inhibitors reported herein were synthesized via a general method in which both chlorines of the 2,4-dichloropyrimidine core were sequentially displaced by a variety of substituted anilines (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). While the first chlorine displacement at C4 was a typical base-mediated S<sub>N</sub>Ar process, subsequent substitution at C2 was realized via an acid-promoted S<sub>N</sub>Ar or a Pd-catalyzed N-arylation method. Syntheses of the requisite substituted aniline intermediates were often key to making these ALK inhibitors.</div><figure id="sch1" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.6b00306/20160520/images/medium/jm-2016-00306u_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.6b00306/20160520/images/large/jm-2016-00306u_0012.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.6b00306/20160520/images/large/jm-2016-00306u_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00306&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) K<sub>2</sub>CO<sub>3</sub>, NaH or LiHMDS, DMF, 65 °C; (ii) for <b>11t</b> and <b>11u</b>, Pd(OAc)<sub>2</sub>, Xantphos, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 110 °C; for other inhibitors, 2.5 M HCl in EtOH, dioxane, 2-methoxyethanol, or 2-butanol.</p></p></figure><div class="NLM_p">The syntheses of certain requisite C2 anilines are depicted in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. Aniline <b>15</b> is the common precursor for inhibitors <b>10a</b>–<b>f</b> compiled in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>; it can be prepared from 2-nitro-5-chloroanisole and dimethylphosphine oxide via Pd-catalyzed C–P bond formation<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> followed by reduction of the nitro group under hydrogenation. The synthesis of aniline <b>16</b> represents a general protocol for making all C2 anilines required for compounds <b>11d</b>–<b>s</b>. S<sub>N</sub>Ar fluoro displacement of 2-nitro-5-fluoroanisole by secondary amines with K<sub>2</sub>CO<sub>3</sub> as the base, followed by nitro reduction, routinely furnished anilines in high yields. The required O-linked anilines for compounds <b>11a</b>–<b>c</b> can be accessed similarly except that NaH was employed as the base. C-Linked aniline <b>17</b> was obtained by Suzuki coupling of 4-iodo-2-methoxyaniline with corresponding requisite boronate. Finally, C-linked aniline <b>18</b> was prepared by a similar Suzuki coupling followed by hydrogenation of the azacyclohexenyl derivative and exhaustive reduction of the Boc protecting group by lithium aluminum hydride.</div><figure id="sch2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.6b00306/20160520/images/medium/jm-2016-00306u_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.6b00306/20160520/images/large/jm-2016-00306u_0013.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.6b00306/20160520/images/large/jm-2016-00306u_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00306&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) Pd(OAc)<sub>2</sub>, xantphos, K<sub>3</sub>PO<sub>4</sub>, DMF, 120 °C; (ii) Pd on carbon, 30 psi H<sub>2</sub>, EtOH, rt; (iii) K<sub>2</sub>CO<sub>3</sub>, MeCN, 80 °C; (iv) 2.5 M HCl in EtOH, 2-methoxyethanol, 120 °C; (v) Pd(OAc)<sub>2</sub>, PPh<sub>3</sub>, K<sub>2</sub>CO<sub>3</sub>, DMF/H<sub>2</sub>O, reflux; (vi) lithium aluminum hydride, THF, reflux.</p></p></figure><div class="NLM_p">Many required substituted anilines at C4 were commercially available with the exception that phosphorus-containing aniline <b>19</b> was made directly from iodoaniline and dimethylphosphine oxide via a Pd-catalyzed P-arylation method (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). In this C–P bond-forming reaction, no competing N-arylation was observed. It represents the first example of specific P-arylation of aryl halides with dialkyl- or diaryl-phosphine oxide in the presence of reactive anilino NH<sub>2</sub> despite similar P-arylation with more nucleophilic dialkylphosphonate (also termed as dialkoxy-phosphine oxide) being known.<a onclick="showRef(event, 'ref58 ref59'); return false;" href="javascript:void(0);" class="ref ref58 ref59">(58, 59)</a> S<sub>N</sub>Ar reaction of <b>19</b> with trichloropyrimidine under basic conditions provided a common intermediate <b>20</b>, which underwent subsequent acid-promoted chlorine displacement with a range of amines like <b>16</b> to afford inhibitors summarized in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>. Similarly, reaction of <b>20</b> and 2-methoxy-4-bromo-5-fluoroaniline generated intermediate <b>21</b> and subsequent Cu-catalyzed N-arylation of the bromide with 1-methyl-4-(4-piperidinyl)piperazine furnished analog <b>12g</b>.</div><figure id="sch3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.6b00306/20160520/images/medium/jm-2016-00306u_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.6b00306/20160520/images/large/jm-2016-00306u_0014.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.6b00306/20160520/images/large/jm-2016-00306u_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00306&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) dimethylphosphine oxide, Pd(OAc)<sub>2</sub>, xantphos, K<sub>3</sub>PO<sub>4</sub>, DMF, 120 °C; (ii) 2,4,5-trichloropyrimidine, K<sub>2</sub>CO<sub>3</sub>, <i>n</i>-Bu<sub>4</sub>NHSO<sub>4</sub>, DMF, 65 °C; (iii) 2.5 M HCl in EtOH, 2-methoxyethanol, 120 °C; (iv) 1-methyl-4-(piperidin-4-yl)piperazine, CuI, <span class="smallcaps smallerCapital">l</span>-proline, K<sub>3</sub>PO<sub>4</sub>, DMSO, 100 °C; (v) trimethylsilylacetylene, Pd(PPh<sub>3</sub>)<sub>4</sub>, CuI, Et<sub>3</sub>N, DMF, 50 °C.</p></p></figure><div class="NLM_p last">Most inhibitors in <a class="ref internalNav" href="#tbl3" aria-label="Tables 3">Tables 3</a> and <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a> were synthesized according to these general procedures except compounds <b>12e</b> and <b>13i</b>. For <b>12e</b>, Sonagashira coupling of bromide <b>22</b> with (trimethylsilyl)acetylene yielded intermediate <b>23</b>. Installation of the aniline at C2 under acid conditions concomitantly hydrolyzed the alkyne moiety generating the C5 acetyl compound <b>12e</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). Reduction of ketone analog <b>13h</b> with NaBH<sub>4</sub> provided inhibitor <b>13i</b>.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04523" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04523" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Starting from our interest to develop next-generation ALK inhibitors and motivated to further explore stable phosphorus functionality in drug design, we synthesized and tested a library of phosphine oxide-containing compounds based on the 2-aminopyrimidine scaffold. Extensive medicinal chemistry efforts led to the identification of investigational brigatinib, a potent inhibitor of native ALK and a broad panel of clinically relevant crizotinib-resistant mutations. Brigatinib demonstrated oral efficacy in multiple ALK+ mouse models, including Karpas-299 (ALCL) and H3122 (NSCLC), while demonstrating no signs of toxicity, including weight loss. A unique structural feature of brigatinib is the dimethylphosphine oxide, a novel hydrogen bond acceptor that was critical for balancing ALK potency and selectivity over the highly homologous IGF1R and InsR kinases. When compared with other hydrogen-bond acceptors, the highly ionic P═O bond imparts a number of important drug-like properties, including decreased lipophilicity, increased aqueous solubility, reduced protein binding, and robust metabolic stability. Phosphine oxides belong to a chemical class seldom employed in drug design; the discovery of brigatinib and its clinical activity may further inspire application of this unique functional group more broadly in the field of medicinal chemistry.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13180" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13180" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> General Chemistry</h3><div class="NLM_p last">All reagents and solvents were used as received. <sup>1</sup>H NMR spectra were recorded on a Bruker AVANCE400 spectrometer using TMS as internal standard. MS spectra were recorded on a Waters Micromass ZQ spectrometer. Elemental analyses were performed by Robertson Microlit Laboratories in Madison, NJ. HPLC was performed on an Agilent 1100 or an Agilent 1200 HPLC system. The purity of all SAR compounds was determined to be ≥95% by reverse phase HPLC (C-18 column, MeCN/H<sub>2</sub>O with 0.1% CF<sub>3</sub>CO<sub>2</sub>H as the mobile phase). Certain compounds, such as <b>12a</b>, <b>12b</b>, <b>12f</b>, and <b>13d</b>, were made in a focused library synthesis via standard general procedures and passed purity and mass check by LC-MS; these inhibitors were not described in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>.</div></div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> (3-Methoxy-4-nitrophenyl)dimethylphosphine Oxide (<b>14</b>)</h3><div class="NLM_p last">To a solution of 5-chloro-2-nitroanisole (0.5 g, 2.67 mmol) in 5 mL of DMF was added dimethylphosphine oxide (0.229 g, 2.93 mmol), palladium acetate (30 mg, 0.13 mmol), xantphos (0.092 g, 0.16 mmol), and potassium phosphate (0.623 g, 2.93 mmol). The mixture was purged with argon, and heated at 120 °C for 18 h. The reaction mixture was basified with saturated sodium bicarbonate solution and extracted with ethyl acetate. The organic layer was concentrated and purified by silica gel column chromatography to give the final product (0.16 g, 30% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.98 (dd, <i>J</i> = 2.76, 8.03 Hz, 1H), 7.64 (dd, <i>J</i> = 1.13, 12.17 Hz, 1H), 7.50 (ddd, <i>J</i> = 1.25, 8.03, 10.54 Hz, 1H), 3.98 (s, 3H), 1.71 (d, <i>J</i> = 13.55 Hz, 6H). MS/ES+: <i>m</i>/<i>z</i> = 230.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> (4-Amino-3-methoxyphenyl)dimethylphosphine Oxide (<b>15</b>)</h3><div class="NLM_p last">To a solution of <b>14</b> (0.1 g, 0.44 mmol) in 5 mL of EtOH was added 10 wt % palladium on carbon (0.2 g). The mixture was purged with argon and hydrogenated under 30 psi H<sub>2</sub> for 2 h. The mixture was passed through Celite, and the filtrates were concentrated to give the final product (0.088 g, 86% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 6.94–7.14 (m, 2H), 6.67 (dd, <i>J</i> = 3.26, 7.78 Hz, 1H), 5.24 (s, 2H), 3.79 (s, 3H), 1.53 (d, <i>J</i> = 13.05 Hz, 6H). MS/ES+: <i>m</i>/<i>z</i> = 200.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> 2-Methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)aniline (<b>16</b>)</h3><div class="NLM_p last">A suspension of 5-fluoro-2-nitroanisole (85.6 g, 0.5 mol), 1-methyl-4-(piperidin-4-yl)piperazine (91.7 g, 0.5 mol), and potassium carbonate (138.5 g, 1.0 mol) in MeCN (500 mL) was stirred at 80 °C for 13 h. After cooling, the upper clear layer was decanted, and the residue was taken into DCM (1 L). The resulting suspension was filtered, and the solid was washed with DCM (500 mL). The combined organic layers were washed with water (400 mL), dried, and concentrated to give the nitro intermediate as a yellow solid (163 g, 97%). This nitro compound (78 g, 0.23 mol), after dissolution in EtOH (800 mL), was subjected to hydrogenation (20 psi H<sub>2</sub>) on palladium-activated carbon (4 g, 10%, wet) in a shaker for 2.5 h. The mixture was filtered through Celite, and the filtrate was concentrated to give a purple solid (69.8 g, 98% yield).</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> <i>tert</i>-Butyl 4-(4-(4-amino-3-methoxyphenyl)-1<i>H</i>-pyrazol-1-yl)piperidine-1-carboxylate (<b>17</b>)</h3><div class="NLM_p last">A sealed tube was charged with 4-iodo-2-methoxyaniline (0.25 g, 1 mmol), <i>tert</i>-butyl 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazol-1-yl)piperidine-1-carboxylate (0.50 g, 1.4 mmol), palladium acetate (0.012 g, 0.05 mmol), triphenylphosphine (0.026 g, 0.10 mmol), and potassium carbonate (0.18 g, 1.3 mmol). After being purged with N<sub>2</sub>, the tube was sealed and degassed DMF (1.5 mL) and H<sub>2</sub>O (2.0 mL) were added. The resulting solution was refluxed for 10 min, followed by cooling to rt. The top layer was separated and concentrated; the resulting residue was purified by prep-TLC furnishing the desired product (95 mg, 26%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.71 (d, <i>J</i> = 0.63 Hz, 1H), 7.58 (d, <i>J</i> = 0.63 Hz, 1H), 6.86–6.96 (m, 2H), 6.73 (d, <i>J</i> = 7.78 Hz, 1H), 4.29 (tdd, <i>J</i> = 4.02, 7.64, 15.32 Hz, 3H), 3.91 (s, 3H), 3.66–3.88 (m, 2H), 2.92 (t, <i>J</i> = 12.42 Hz, 2H), 2.12–2.25 (m, 2H), 1.96 (dq, <i>J</i> = 4.39, 12.21 Hz, 2H), 1.50 (s, 9H).</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> (2-Aminophenyl)dimethylphosphine Oxide (<b>19</b>)</h3><div class="NLM_p last">To a solution of 2-iodoaniline (8.6 g, 39.3 mmol) and dimethylphosphine oxide (3.6 g, 46.6 mmol) in DMF (70 mL) were added potassium phosphate (9.2 g, 42.3 mmol), palladium acetate (0.46 g, 2 mmol), and xantphos (1.2 g, 2 mmol). The reaction mixture was purged with nitrogen and then stirred at 120 °C for 6 h. Upon cooling, the resulting mixture was filtered through a pad of Celite (5 g), and the solid was washed with ethyl acetate (2 × 25 mL). The combined organics were evaporated to give crude product, which was purified by silica gel column chromatography with MeOH/DCM (5:95) as eluents furnishing an off-white solid (9.2 g, 64% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.10–7.24 (m, 2H), 6.59–6.67 (m, 1H), 6.50–6.57 (m, 1H), 6.14 (s, 2H), 1.63 (d, <i>J</i> = 13.30 Hz, 6H).</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> General Procedure A for C4 Chlorine Substitution: (2-((2,5-Dichloropyrimidin-4-yl)amino)phenyl)dimethylphosphine Oxide (<b>20</b>)</h3><div class="NLM_p">A suspension of 2,4,5-trichloropyrimidine (5.4 g, 30 mmol), aniline <b>19</b> (5.0 g, 30 mmol), potassium carbonate (4.9 g, 35.5 mmol), and nBu<sub>4</sub>NHSO<sub>4</sub> (1.0 g, 3 mmol) in DMF(100 mL) was stirred at 65 °C for 8 h. Upon cooling, the reaction mixture was filtered, and the filtrates were evaporated. The residue was purified on silica gel column with MeOH/DCM (2/98) as eluents furnishing the desired product as an off-white solid (7.3 g, 78% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.82 (s, 1H), 8.45 (s, 1H), 8.42 (dd, <i>J</i> = 4.14, 8.28 Hz, 1H), 7.47–7.81 (m, 2H), 7.24 (t, <i>J</i> = 7.22 Hz, 1H), 1.80 (d, <i>J</i> = 13.68 Hz, 6H).</div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> (2-((2-((4-Bromo-5-fluoro-2-methoxyphenyl)amino)-5-chloropyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide (<b>21</b>)</h4><div class="NLM_p last">General procedure B (<i>vide infra</i>) was followed. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.18 (s, 1H), 8.41 (dd, <i>J</i> = 4.14, 8.28 Hz, 1H), 8.25 (s, 1H), 8.16 (s, 1H), 8.10 (d, <i>J</i> = 11.29 Hz, 1H), 7.58–7.67 (m, 1H), 7.50 (t, <i>J</i> = 7.65 Hz, 1H), 7.30 (d, <i>J</i> = 6.53 Hz, 1H), 7.22 (t, <i>J</i> = 6.71 Hz, 1H), 3.87 (s, 3H), 1.78 (d, <i>J</i> = 13.55 Hz, 6H).</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> (2-((5-Bromo-2-chloropyrimidin-4-yl)amino)phenyl)dimethylphosphine Oxide (<b>22</b>)</h4><div class="NLM_p last">General procedure A (<i>vide supra</i>) was followed. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.52 (br. s., 1H), 8.53 (s, 1H), 8.31 (dd, <i>J</i> = 4.08, 7.97 Hz, 1H), 7.56–7.72 (m, 2H), 7.21–7.35 (m, 1H), 1.81 (d, <i>J</i> = 13.55 Hz, 6H).</div></div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> (2-((2-Chloro-5-((trimethylsilyl)ethynyl)pyrimidin-4-yl)amino)phenyl)dimethylphosphine Oxide (<b>23</b>)</h3><div class="NLM_p last">A mixture of bromide <b>22</b> (0.2 g, 0.56 mmmol), Pd(PPh<sub>3</sub>)<sub>4</sub> (32 mg, 0.03 mmol), and CuI (8 mg, 0.04 mmol) was placed in a sealed tube and was purged with N<sub>2</sub>. Degassed trimethylsilylacetylene (0.16 mL, 1.1 mmol), Et<sub>3</sub>N (0.09 mL, 0.6 mmol), and DMF (2 mL) were added through a septum. The resulting solution was heated at 50 °C for 18 h under stirring. Volatile components were removed on a rotavap, and the residue was purified on silica gel column with MeOH/DCM (2/98) as eluents furnishing the desired product (0.1 g, 48% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.45 (s, 1H), 8.39 (s, 1H), 8.33 (dd, <i>J</i> = 3.70, 8.09 Hz, 1H), 7.55–7.70 (m, 2H), 7.24 (t, <i>J</i> = 7.53 Hz, 1H), 1.78 (d, <i>J</i> = 13.55 Hz, 6H), 0.22–0.32 (m, 9H).</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> General Procedure B for C2 Chlorine Substitution to Synthesize Inhibitors <b>10</b>–<b>13</b>: (2-((5-Chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-pyrimidin-4-yl)amino)phenyl)dimethylphosphine Oxide (<b>11q</b>)</h3><div class="NLM_p">To a solution of <b>20</b> (5.5 g, 17.4 mmol) and <b>16</b> (7.4 g, 24.4 mmol) in 2-methoxyethanol (75 mL) was added 2.5 M HCl in ethanol (18 mL). The resulting mixture was heated at 120 °C for 6 h in a sealed tube under stirring. Upon cooling, volatile components were removed on a rotavap, and the resulting semisolid was dissolved in water (50 mL). After washing with EtOAc (50 mL), the aqueous layer was basified with 20% NaOH until pH value reached 12. Extraction with DCM (3 × 50 mL) followed by concentration of combined organics furnished a dark residue. This was purified on silica gel column with MeOH/DCM (10/90) as eluents to give the desired product as an off-white solid (12.7 g, 65% yield). Mp 215 °C. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.33 (dd, <i>J</i> = 4.52, 8.03 Hz, 1H), 8.02 (s, 1H), 7.66 (d, <i>J</i> = 8.78 Hz, 1H), 7.59 (ddd, <i>J</i> = 1.51, 7.78, 14.05 Hz, 1H), 7.47–7.54 (m, 1H), 7.25 (ddt, <i>J</i> = 1.00, 2.26, 7.53 Hz, 1H), 6.65 (d, <i>J</i> = 2.51 Hz, 1H), 6.45 (dd, <i>J</i> = 2.51, 8.78 Hz, 1H), 3.84 (s, 3H), 3.69 (d, <i>J</i> = 12.30 Hz, 2H), 2.62–2.86 (m, 6H), 2.43–2.62 (m, 4H), 2.33–2.42 (m, 1H), 2.29 (s, 3H), 1.97–2.08 (m, 2H), 1.83 (d, <i>J</i> = 13.30 Hz, 6H), 1.66 (dq, <i>J</i> = 3.89, 12.09 Hz, 2H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) δ 18.57 (d, <i>J</i> = 71.53 Hz), 28.28 (s), 46.02 (s), 49.01 (s), 50.52 (s), 55.46 (s), 55.65 (s), 61.79 (s), 101.07 (s), 106.01 (s), 108.41 (s), 120.25 (d, <i>J</i> = 95.73 Hz), 120.68 (s), 122.09 (s), 122.41 (d, <i>J</i> = 12.10 Hz), 123.13 (br d, <i>J</i> = 6.60 Hz), 129.48 (d, <i>J</i> = 11.00 Hz), 132.36 (s), 143.91 (d, <i>J</i> = 2.20 Hz), 147.59 (s), 149.38 (s), 154.97 (s), 155.91 (s), 157.82 (s). <sup>31</sup>P NMR (162 MHz, CDCl<sub>3</sub>) δ 43.55. MS/ES+: <i>m</i>/<i>z</i> = 584.3 [M + H]<sup>+</sup>. Anal. Calcd for C<sub>29</sub>H<sub>39</sub>ClN<sub>7</sub>O<sub>2</sub>P: C, 59.63; H, 6.73; Cl, 6.07; N, 16.79; O, 5.48; P, 5.30. Found: C, 59.26; H, 6.52; Cl, 6.58; N, 16.80.</div><div id="sec4_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> (4-((5-Chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)dimethylphosphine Oxide (<b>10a</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.53 (s, 1H), 8.51 (d, <i>J</i> = 8.28 Hz, 1H), 8.38 (s, 1H), 8.31 (s, 1H), 8.01 (dd, <i>J</i> = 3.07, 8.09 Hz, 1H), 7.85 (dd, <i>J</i> = 1.51, 7.91 Hz, 1H), 7.73 (t, <i>J</i> = 7.87 Hz, 1H), 7.31–7.46 (m, 2H), 7.26 (ddd, <i>J</i> = 1.44, 8.13, 11.26 Hz, 1H), 3.89 (s, 3H), 3.39–3.51 (m, 1H), 1.65 (d, <i>J</i> = 13.30 Hz, 6H), 1.16 (d, <i>J</i> = 6.78 Hz, 6H). MS/ES+: <i>m</i>/<i>z</i> = 509.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> (4-((5-Chloro-4-((2-methoxyphenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)dimethyl-phosphine Oxide (<b>10b</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.39 (s, 1H), 8.16 (s, 1H), 8.00–8.04 (m, 1H), 7.97 (dd, <i>J</i> = 3.01, 8.16 Hz, 1H), 7.81 (d, <i>J</i> = 6.65 Hz, 1H), 7.28 (dd, <i>J</i> = 1.51, 12.17 Hz, 1H), 7.19–7.25 (m, 1H), 7.08–7.16 (m, 2H), 6.97 (dt, <i>J</i> = 1.32, 7.62 Hz, 1H), 3.87 (s, 3H), 3.81 (s, 3H), 1.62 (d, <i>J</i> = 13.30 Hz, 6H). MS/ES+: <i>m</i>/<i>z</i> = 433.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 1-(2-((5-Chloro-2-((4-(dimethylphosphoryl)-2-methoxyphenyl)amino)pyrimidin-4-yl)amino)-phenyl)ethan-1-one (<b>10c</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.86 (s, 1H), 8.84 (d, <i>J</i> = 8.41 Hz, 1H), 8.55 (s, 1H), 8.35 (s, 1H), 8.16 (dd, <i>J</i> = 1.51, 8.03 Hz, 1H), 8.08 (dd, <i>J</i> = 3.01, 8.03 Hz, 1H), 7.56–7.66 (m, 1H), 7.33–7.46 (m, 2H), 7.21–7.29 (m, 1H), 3.94 (s, 3H), 2.74 (s, 3H), 1.71 (d, <i>J</i> = 13.30 Hz, 6H). MS/ES+: <i>m</i>/<i>z</i> = 445.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 2-((5-Chloro-2-((4-(dimethylphosphoryl)-2-methoxyphenyl)amino)pyrimidin-4-yl)amino)-benzamide (<b>10d</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.89 (s, 1H), 8.64 (d, <i>J</i> = 8.41 Hz, 1H), 8.28–8.38 (m, 2H), 8.25 (s, 1H), 8.11 (dd, <i>J</i> = 3.01, 8.03 Hz, 1H), 7.82 (dd, <i>J</i> = 1.32, 7.84 Hz, 1H), 7.76 (br. s., 1H), 7.43–7.52 (m, 1H), 7.27–7.40 (m, 2H), 7.10–7.17 (m, 1H), 3.90 (s, 3H), 1.66 (d, <i>J</i> = 13.30 Hz, 6H). MS/ES+: <i>m</i>/<i>z</i> = 446.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> (4-((5-Chloro-4-((2-(methylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)dimethylphosphine Oxide (<b>10e</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.59 (s, 1H), 9.38 (s, 1H), 8.41 (d, <i>J</i> = 8.03 Hz, 1H), 8.30 (s, 2H), 7.98 (dd, <i>J</i> = 3.01, 8.16 Hz, 1H), 7.92 (dd, <i>J</i> = 1.51, 7.91 Hz, 1H), 7.68–7.75 (m, 1H), 7.38–7.44 (m, 1H), 7.33 (dd, <i>J</i> = 1.51, 12.17 Hz, 1H), 7.22 (ddd, <i>J</i> = 1.44, 8.16, 11.36 Hz, 1H), 3.89 (s, 3H), 3.25 (s, 3H), 1.64 (d, <i>J</i> = 13.30 Hz, 6H). MS/ES+: <i>m</i>/<i>z</i> = 481.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> (2-((5-Chloro-2-((4-(dimethylphosphoryl)-2-methoxyphenyl)amino)pyrimidin-4-yl)amino)phenyl)-dimethylphosphine oxide (<b>10f</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.23 (s, 1H), 8.44 (dd, <i>J</i> = 4.20, 8.34 Hz, 1H), 8.26 (s, 1H), 8.22 (s, 1H), 8.08 (dd, <i>J</i> = 3.07, 8.09 Hz, 1H), 7.59 (ddd, <i>J</i> = 1.38, 7.65, 13.80 Hz, 1H), 7.49 (t, <i>J</i> = 7.91 Hz, 1H), 7.34 (dd, <i>J</i> = 1.44, 12.11 Hz, 1H), 7.27 (ddd, <i>J</i> = 1.51, 8.16, 11.29 Hz, 1H), 7.16–7.21 (m, 1H), 3.89 (s, 3H), 1.77 (d, <i>J</i> = 13.55 Hz, 6H), 1.64 (d, <i>J</i> = 13.30 Hz, 6H). MS/ES+: <i>m</i>/<i>z</i> = 479.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 5-Chloro-<i>N</i><sup>4</sup>-(2-(isopropylsulfonyl)phenyl)-<i>N</i><sup>2</sup>-(2-methoxyphenyl)pyrimidine-2,4-diamine (<b>10g</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.51 (s, 1H), 8.51 (d, J = 8.53 Hz, 1H), 8.31 (s, 1H), 8.24 (s, 1H), 7.81 (dd, J = 1.63, 7.91 Hz, 1H), 7.72 (d, J = 7.53 Hz, 1H), 7.57–7.67 (m, 1H), 7.27–7.41 (m, 1H), 7.01–7.16 (m, 2H), 6.79–6.99 (m, 1H), 3.79 (s, 3H), 3.43 (quin, J = 6.78 Hz, 1H), 1.15 (d, J = 6.78 Hz, 6H). MS/ES+: <i>m</i>/<i>z</i> = 434.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> (2-((5-Chloro-2-((2-methoxy-4-(3-(pyrrolidin-1-yl)propoxy)phenyl)amino)pyrimidin-4-yl)amino)-phenyl)dimethylphosphine Oxide (<b>11a</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.74 (s, 1H), 8.54 (dd, <i>J</i> = 7.8, 8.0 Hz, 1H), 8.02 (d, <i>J</i> = 6.8 Hz, 1H), 8.01 (s, 1H), 7.38–7.49 (m, 1H), 7.28 (dd, <i>J</i> = 7.8, 1.5 Hz, 1H), 7.19 (dd, <i>J</i> = 7.7, 1.6 Hz, 1H), 7.14 (s, 1H), 7.05 (ddt, <i>J</i> = 1.2, 2.2, 7.5 Hz, 1H), 6.44 (d, <i>J</i> = 2.5 Hz, 1H), 6.37 (dd, <i>J</i> = 8.8, 2.5 Hz, 1H), 3.96 (t, <i>J</i> = 6.4 Hz, 2H), 3.79 (s, 3H), 2.48–2.73 (m, 2H), 2.58 (br, 2H), 1.95–2.06 (m, 2H), 1.75–1.82 (m, 2H), 1.76 (d, <i>J</i> = 13.1 Hz, 6H), 1.15–1.27 (m, 2H), 0.81 (t, <i>J</i> = 6.7 Hz, 2H). MS/ES+: <i>m</i>/<i>z</i> = 530.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> (2-((5-Chloro-2-((2-methoxy-4-((1-methylpyrrolidin-3-yl)oxy)phenyl)amino)pyrimidin-4-yl)amino)-phenyl)dimethylphosphine Oxide (<b>11b</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.18 (s, 1H), 8.46 (br, s, 1H), 8.11 (s, 1H), 8.08 (s, 1H),7.54 (ddd, <i>J</i> = 1.5, 7.8, 14.0 Hz, 1H), 7.44 (d, <i>J</i> = 8.8 Hz, 1H), 7.35 (dd, <i>J</i> = 7.6, 7.9 Hz, 1H), 7.08–7.14 (m, 1H), 6.59 (d, <i>J</i> = 2.7 Hz, 1H), 6.44 (dd, <i>J</i> = 2.6, 8.7 Hz, 1H), 4.86–4.93 (m, 1H), 3.76 (s, 2H), 2.51 (m, 4H), 2.28 (s, 3H), 1.77 (d, <i>J</i> = 13.7 Hz, 6H). MS/ES+: <i>m</i>/<i>z</i> = 502.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> (2-((5-Chloro-2-((2-methoxy-4-((1-methylpiperidin-4-yl)oxy)phenyl)amino)pyrimidin-4-yl)amino)-phenyl)dimethylphosphine Oxide (<b>11c</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.17 (s, 1H), 8.44 (d, <i>J</i> = 4.52 Hz, 1H), 8.10 (s, 1H), 8.07 (s, 1H), 7.53 (ddd, <i>J</i> = 1.38, 7.72, 13.99 Hz, 1H), 7.43 (d, <i>J</i> = 8.53 Hz, 1H), 7.32 (t, <i>J</i> = 7.78 Hz, 1H), 7.06–7.13 (m, 1H), 6.64 (d, <i>J</i> = 2.51 Hz, 1H), 6.52 (dd, <i>J</i> = 2.64, 8.66 Hz, 1H), 4.32–4.40 (m, 1H), 3.75 (s, 3H), 2.56–2.71 (m, 2H), 2.19 (s, 3H), 2.09–2.26 (m, 2H), 1.89–1.97 (m, 2H), 1.76 (d, <i>J</i> = 13.55 Hz, 6H), 1.56–1.71 (m, 2H). MS/ES+: <i>m</i>/<i>z</i> = 516.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> (2-((5-Chloro-2-((2-methoxy-4-morpholinophenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethyl-phosphine Oxide (<b>11d</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.93 (br. s., 1H), 8.52–8.75 (m, 1H), 8.08 (s, 1H), 7.41–7.59 (m, 1H), 7.25–7.34 (m, 3H), 7.11–7.18 (m, 1H), 6.51–6.61 (m, 1H), 6.49 (dd, <i>J</i> = 2.26, 8.78 Hz, 1H), 3.87–3.92 (m, 4H), 3.88 (s, 3H), 3.04–3.25 (m, 4H), 1.85 (d, <i>J</i> = 13.05 Hz, 6H). MS/ES+: <i>m</i>/<i>z</i> = 488.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> (2-((5-Chloro-2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)-phenyl)dimethylphosphine Oxide (<b>11e</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.74 (s, 1H), 8.55 (dd, <i>J</i> = 4.52, 8.03 Hz, 1H), 8.03 (d, <i>J</i> = 8.78 Hz, 1H), 8.01 (s, 1H), 7.36–7.46 (m, 1H), 7.14–7.25 (m, 2H), 7.00–7.09 (m, 1H), 6.48 (d, <i>J</i> = 2.51 Hz, 1H), 6.42 (dd, <i>J</i> = 2.51, 8.78 Hz, 1H), 3.80 (s, 3H), 3.06–3.19 (m, 4H), 2.51–2.59 (m, 4H), 2.32 (s, 3H), 1.76 (d, <i>J</i> = 13.05 Hz, 6H). MS/ES+: <i>m</i>/<i>z</i> = 501.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 1-(4-(4-((5-Chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxy-phenyl)piperazin-1-yl)ethan-1-one (<b>11f</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.78 (s, 1H), 8.58 (dd, <i>J</i> = 4.27, 8.28 Hz, 1H), 8.12 (d, <i>J</i> = 8.78 Hz, 1H), 8.06 (s, 1H), 7.39–7.54 (m, 1H), 7.19–7.34 (m, 2H), 7.07–7.18 (m, 1H), 6.52 (d, <i>J</i> = 2.51 Hz, 1H), 6.46 (dd, <i>J</i> = 2.51, 8.53 Hz, 1H), 3.85 (s, 3H), 3.73–3.79 (m, 2H), 3.56–3.64 (m, 2H), 3.09 (td, <i>J</i> = 5.27, 12.55 Hz, 4H), 2.12 (s, 3H), 1.81 (d, <i>J</i> = 13.05 Hz, 6H). MS/ES+: <i>m</i>/<i>z</i> = 529.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> (2-((5-Chloro-2-((4-(4-hydroxypiperidin-1-yl)-2-methoxyphenyl)amino)pyrimidin-4-yl)amino)-phenyl)dimethylphosphine Oxide (<b>11g</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.78 (s, 1H), 8.62 (dd, <i>J</i> = 4.39, 7.91 Hz, 1H), 8.06–8.10 (m, 2H), 7.50 (t, <i>J</i> = 7.86 Hz, 1H), 7.22–7.34 (m, 2H), 7.12 (ddt, <i>J</i> = 1.00, 2.26, 7.53 Hz, 1H), 6.57 (d, <i>J</i> = 2.51 Hz, 1H), 6.50 (dd, <i>J</i> = 2.51, 8.78 Hz, 1H), 3.87 (s, 3H), 3.80–3.94 (m, 1H), 3.41–3.56 (m, 2H), 2.82–2.97 (m, 2H), 1.95–2.11 (m, 2H), 1.83 (d, <i>J</i> = 13.05 Hz, 6H), 1.65–1.80 (m, 2H). MS/ES+: <i>m</i>/<i>z</i> = 502.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 2-(4-(4-((5-Chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxy-phenyl)piperazin-1-yl)-<i>N</i>-methylacetamide (<b>11h</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.75 (s, 1H), 8.55 (dd, <i>J</i> = 4.27, 8.03 Hz, 1H), 8.04 (d, <i>J</i> = 8.78 Hz, 1H), 8.01 (s, 1H), 7.17–7.25 (m, 2H), 7.01–7.09 (m, 2H), 6.46 (d, <i>J</i> = 2.51 Hz, 1H), 6.40 (dd, <i>J</i> = 2.51, 8.78 Hz, 1H), 3.79 (s, 3H), 3.07–3.11 (m, 4H), 3.02 (s, 2H), 2.80 (d, <i>J</i> = 5.02 Hz, 3H), 2.62–2.67 (m, 4H), 1.75 (d, <i>J</i> = 13.05 Hz, 6H). MS/ES+: <i>m</i>/<i>z</i> = 558.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> (2-((5-Chloro-2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methoxyphenyl)amino)pyrimidin-4-yl)-amino)phenyl)dimethylphosphine Oxide (<b>11i</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.81 (s, 1H), 8.63 (dd, <i>J</i> = 4.27, 8.03 Hz, 1H), 8.12 (d, <i>J</i> = 8.53 Hz, 1H), 8.10 (s, 1H), 7.50 (dd, <i>J</i> = 7.28, 8.53 Hz, 1H), 7.25–7.33 (m, 2H), 7.13 (ddt, <i>J</i> = 1.00, 2.32, 7.50 Hz, 1H), 6.56 (d, <i>J</i> = 2.51 Hz, 1H), 6.50 (dd, <i>J</i> = 2.51, 8.78 Hz, 1H), 3.88 (s, 3H), 3.70 (t, <i>J</i> = 5.27 Hz, 2H), 3.17–3.23 (m, 4H), 2.72–2.77 (m, 4H), 2.63–2.69 (m, 2H), 1.84 (d, <i>J</i> = 13.30 Hz, 6H). MS/ES+: <i>m</i>/<i>z</i> = 531.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> (2-((5-Chloro-2-((2-methoxy-4-(4-methyl-1,4-diazepan-1-yl)phenyl)amino)pyrimidin-4-yl)amino)-phenyl)dimethylphosphine Oxide (<b>11j</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.83 (s, 1H), 8.68 (dd, <i>J</i> = 4.14, 8.16 Hz, 1H), 8.06 (s, 1H), 7.92 (d, <i>J</i> = 8.53 Hz, 1H), 7.38–7.54 (m, 1H), 7.18–7.34 (m, 1H), 7.03–7.15 (m, 2H), 6.15–6.35 (m, 2H), 3.85 (s, 3H), 3.55–3.62 (m, 2H), 3.50 (t, <i>J</i> = 6.27 Hz, 2H), 2.72–2.79 (m, 2H), 2.58–2.66 (m, 2H), 2.41 (s, 3H), 2.00–2.11 (m, 2H), 1.82 (d, <i>J</i> = 13.05 Hz, 6H). MS/ES+: <i>m</i>/<i>z</i> = 515.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> (<i>R</i>)-(2-((5-Chloro-2-((4-(3-(dimethylamino)pyrrolidin-1-yl)-2-methoxyphenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine Oxide (<b>11k</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.80 (s, 1H), 8.63–8.70 (m, 1H), 8.05 (s, 1H), 7.92 (d, <i>J</i> = 8.53 Hz, 1H), 7.45 (dt, <i>J</i> = 1.25, 7.91 Hz, 1H), 7.20–7.29 (m, 1H), 7.03–7.12 (m, 2H), 6.09–6.17 (m, 2H), 3.86 (s, 3H), 3.39–3.53 (m, 2H), 3.34 (dt, <i>J</i> = 7.03, 9.29 Hz, 1H), 3.17 (t, <i>J</i> = 8.28 Hz, 1H), 2.84–2.95 (m, 1H), 2.33 (s, 6H), 2.16–2.26 (m, 1H), 1.88–2.01 (m, 1H), 1.81 (d, <i>J</i> = 13.05 Hz, 6H). MS/ES+: <i>m</i>/<i>z</i> = 515.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> (2-((5-Chloro-2-((4-(4-(dimethylamino)piperidin-1-yl)-2-methoxyphenyl)amino)pyrimidin-4-yl)-amino)phenyl)dimethylphosphine Oxide (<b>11l</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.81 (s, 1H), 8.63 (dd, <i>J</i> = 4.52, 8.03 Hz, 1H), 8.10 (d, <i>J</i> = 8.26 Hz, 1H), 8.09 (s, 1H), 7.44–7.55 (m, 1H), 7.22–7.34 (m, 2H), 7.08–7.18 (m, 1H), 6.57 (d, <i>J</i> = 2.51 Hz, 1H), 6.50 (dd, <i>J</i> = 2.51, 8.78 Hz, 1H), 3.88 (s, 3H), 3.66 (d, <i>J</i> = 12.55 Hz, 2H), 2.72 (dt, <i>J</i> = 2.26, 12.17 Hz, 3H), 2.41 (s, 6H), 1.99 (d, <i>J</i> = 12.30 Hz, 2H), 1.84 (d, <i>J</i> = 13.05 Hz, 6H), 1.66–1.79 (m, 2H). MS/ES+: <i>m</i>/<i>z</i> = 529.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> (2-((2-((4-(4-(Azetidin-1-ylmethyl)piperidin-1-yl)-2-methoxyphenyl)amino)-5-chloropyrimidin-4-yl)amino)phenyl)dimethylphosphine Oxide (<b>11m</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.82 (s, 1H), 8.65 (dd, <i>J</i> = 4.52, 8.28 Hz, 1H), 8.10 (s, 1H), 8.09 (d, <i>J</i> = 8.78 Hz, 1H), 7.47–7.57 (m, 1H), 7.31 (dd, <i>J</i> = 1.51, 7.53 Hz, 1H), 7.26 (s, 1H), 7.11–7.17 (m, 1H), 6.57 (d, <i>J</i> = 2.51 Hz, 1H), 6.51 (dd, <i>J</i> = 2.51, 8.78 Hz, 1H), 3.88 (s, 3H), 3.59 (d, <i>J</i> = 12.30 Hz, 2H), 3.23–3.34 (m, 4H), 2.61–2.74 (m, 2H), 2.40 (d, <i>J</i> = 6.27 Hz, 2H), 2.06–2.21 (m, 3H), 1.85 (d, <i>J</i> = 13.05 Hz, 6H), 1.32–1.54 (m, 4H). MS/ES+: <i>m</i>/<i>z</i> = 555.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> (2-((5-Chloro-2-((2-methoxy-4-(4-(pyrrolidin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)-amino)phenyl)dimethylphosphine Oxide (<b>11n</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.81 (s, 1H), 8.65 (dd, <i>J</i> = 4.52, 8.03 Hz, 1H), 8.10 (s, 1H), 8.08 (s, 1H), 7.48–7.56 (m, 1H), 7.24–7.34 (m, 2H), 7.14 (ddt, <i>J</i> = 1.00, 2.38, 7.47 Hz, 1H), 6.58 (d, <i>J</i> = 2.51 Hz, 1H), 6.51 (dd, <i>J</i> = 2.51, 8.78 Hz, 1H), 3.88 (s, 3H), 3.58–3.67 (m, 2H), 2.75 (dt, <i>J</i> = 2.38, 12.11 Hz, 2H), 2.64–2.69 (m, 4H), 2.19 (tt, <i>J</i> = 3.70, 10.73 Hz, 1H), 2.00–2.09 (m, 2H), 1.81–1.89 (m, 2H), 1.86 (d, <i>J</i> = 13.05 Hz, 6H), 1.69–1.80 (m, 2H). MS/ES+: <i>m</i>/<i>z</i> = 555.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> (2-((5-Chloro-2-((2-methoxy-4-(4-(1-methylpiperidin-4-yl)piperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine Oxide (<b>11o</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.16 (s, 1H), 8.48 (d, <i>J</i> = 3.76 Hz, 1H), 8.06 (s, 1H), 8.03 (s, 1H), 7.53 (ddd, <i>J</i> = 1.51, 7.78, 14.05 Hz, 1H), 7.40 (d, <i>J</i> = 8.78 Hz, 1H), 7.34 (t, <i>J</i> = 7.78 Hz, 1H), 7.05–7.14 (m, 1H), 6.62 (d, <i>J</i> = 2.51 Hz, 1H), 6.45 (dd, <i>J</i> = 2.51, 8.78 Hz, 1H), 3.76 (s, 3H), 3.08–3.16 (m, 4H), 2.80 (d, <i>J</i> = 11.54 Hz, 2H), 2.58–2.66 (m, 4H), 2.11–2.21 (m, 1H), 2.14 (s, 3H), 1.81–1.88 (m, 2H), 1.72–1.80 (m, 2H), 1.76 (d, <i>J</i> = 13.55 Hz, 6H), 1.44 (dq, <i>J</i> = 3.51, 11.88 Hz, 2H). MS/ES+: <i>m</i>/<i>z</i> = 584.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> (2-((5-Chloro-2-((2-methoxy-4-(4-morpholinopiperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)-phenyl)dimethylphosphine Oxide (<b>11p</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.73 (s, 1H), 8.55 (dd, <i>J</i> = 4.39, 7.91 Hz, 1H), 8.01 (s, 1H), 8.01 (d, <i>J</i> = 8.78 Hz, 1H), 7.42 (dt, <i>J</i> = 1.25, 7.91 Hz, 1H), 7.22 (dd, <i>J</i> = 1.51, 7.78 Hz, 1H), 7.16–7.20 (m, 1H), 7.04 (ddt, <i>J</i> = 1.00, 2.32, 7.50 Hz, 1H), 6.48 (d, <i>J</i> = 2.51 Hz, 1H), 6.42 (dd, <i>J</i> = 2.51, 8.78 Hz, 1H), 3.79 (s, 3H), 3.66–3.70 (m, 4H), 3.58 (d, <i>J</i> = 12.55 Hz, 2H), 2.63 (dt, <i>J</i> = 2.26, 12.17 Hz, 2H), 2.52–2.58 (m, 4H), 2.29 (t, <i>J</i> = 11.17 Hz, 1H), 1.89 (d, <i>J</i> = 12.30 Hz, 2H), 1.75 (d, <i>J</i> = 13.05 Hz, 6H), 1.56–1.70 (m, 2H). MS/ES+: <i>m</i>/<i>z</i> = 571.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> (2-((5-Chloro-2-((2-methoxy-4-(4-(4-methyl-1,4-diazepan-1-yl)piperidin-1-yl)phenyl)amino)-pyrimidin-4-yl)amino)phenyl)dimethylphosphine Oxide (<b>11r</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.73 (s, 1H), 8.56 (dd, <i>J</i> = 4.39, 7.91 Hz, 1H), 8.01 (s, 1H), 8.01 (d, <i>J</i> = 8.53 Hz, 1H), 7.37–7.46 (m, 1H), 7.13–7.26 (m, 4H), 7.05 (ddt, <i>J</i> = 1.00, 2.32, 7.50 Hz, 1H), 6.48 (d, <i>J</i> = 2.51 Hz, 1H), 6.42 (dd, <i>J</i> = 2.51, 8.78 Hz, 1H), 3.79 (s, 3H), 3.57 (d, <i>J</i> = 12.05 Hz, 2H), 2.72–2.84 (m, 4H), 2.61 (dd, <i>J</i> = 9.79, 12.05 Hz, 6H), 2.48–2.55 (m, 1H), 2.34 (s, 3H), 1.73–1.85 (m, 4H), 1.76 (d, <i>J</i> = 13.30 Hz, 6H), 1.57–1.70 (m, 2H). MS/ES+: <i>m</i>/<i>z</i> = 598.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> (2-((5-Chloro-2-((2-methoxy-4-(3-(piperidin-1-yl)pyrrolidin-1-yl)phenyl)amino)pyrimidin-4-yl)-amino)phenyl)dimethylphosphine Oxide (<b>11s</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.24 (s, 1H), 8.50–8.64 (m, 1H), 8.11 (s, 1H), 8.08 (s, 1H), 7.56–7.65 (m, 1H), 7.30–7.43 (m, 2H), 7.16 (t, <i>J</i> = 8.03 Hz, 1H), 6.31 (d, <i>J</i> = 2.51 Hz, 1H), 6.18 (dd, <i>J</i> = 2.38, 8.66 Hz, 1H), 3.84 (s, 3H), 3.53–3.63 (m, 1H), 3.40–3.50 (m, 1H), 3.28–3.36 (m, 1H), 3.16 (t, <i>J</i> = 8.66 Hz, 1H), 2.95–3.06 (m, 1H), 2.44–2.56 (m, 3H), 2.22–2.33 (m, 1H), 1.82–1.89 (m, 2H), 1.84 (d, <i>J</i> = 13.55 Hz, 6H), 1.57–1.67 (m, 4H), 1.45–1.53 (m, 2H). MS/ES+: <i>m</i>/<i>z</i> = 555.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> (2-((5-Chloro-2-((2-methoxy-4-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)phenyl)amino)pyrimidin-4-yl)-amino)phenyl)dimethylphosphine Oxide (<b>11t</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.82 (s, 1H), 8.63 (dd, <i>J</i> = 4.27, 7.78 Hz, 1H), 8.36 (d, <i>J</i> = 8.53 Hz, 1H), 8.15 (s, 1H), 7.77 (d, <i>J</i> = 0.75 Hz, 1H), 7.69 (s, 1H), 7.53–7.60 (m, 2H), 7.33 (ddd, <i>J</i> = 1.51, 7.65, 13.93 Hz, 1H), 7.14–7.22 (m, 1H), 7.03 (dd, <i>J</i> = 2.01, 8.28 Hz, 1H), 6.99 (d, <i>J</i> = 1.76 Hz, 1H), 4.42–4.53 (m, 1H), 3.97 (s, 3H), 3.51–3.66 (m, 2H), 3.04–3.18 (m, 2H), 2.29–2.51 (m, 4H), 1.86 (d, <i>J</i> = 13.05 Hz, 6H). MS/ES+: <i>m</i>/<i>z</i> = 552.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> (2-((5-Chloro-2-((2-methoxy-4-(1-methylpiperidin-4-yl)phenyl)amino)pyrimidin-4-yl)amino)-phenyl)dimethylphosphine Oxide (<b>11u</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.81 (s, 1H), 8.57–8.63 (m, 1H), 8.22 (d, <i>J</i> = 8.03 Hz, 1H), 8.11 (s, 1H), 7.47–7.53 (m, 1H), 7.45 (s, 1H), 7.29 (ddd, <i>J</i> = 1.51, 7.78, 14.05 Hz, 1H), 7.13 (ddt, <i>J</i> = 1.00, 2.38, 7.47 Hz, 1H), 6.76–6.81 (m, 2H), 3.87 (s, 3H), 2.99 (d, <i>J</i> = 11.80 Hz, 2H), 2.39–2.55 (m, 1H), 2.34 (s, 3H), 1.99–2.14 (m, 2H), 1.82–1.85 (m, 4H), 1.83 (d, <i>J</i> = 13.50 Hz, 6H). MS/ES+: <i>m</i>/<i>z</i> = 500.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> (2-((5-Fluoro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine Oxide (<b>12c</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.47 (s, 1H), 8.62 (dd, <i>J</i> = 4.02, 8.41 Hz, 1H), 8.03 (d, <i>J</i> = 3.51 Hz, 1H), 7.82 (s, 1H), 7.55 (dd, <i>J</i> = 7.65, 14.18 Hz, 1H), 7.50 (d, <i>J</i> = 8.66 Hz, 1H), 7.39 (t, <i>J</i> = 7.91 Hz, 1H), 7.06–7.13 (m, 1H), 6.63 (d, <i>J</i> = 2.51 Hz, 1H), 6.49 (dd, <i>J</i> = 2.45, 8.72 Hz, 1H), 3.78 (s, 3H), 3.71 (d, <i>J</i> = 12.67 Hz, 2H), 2.62–2.73 (m, 2H), 2.49–2.53 (m, 4H), 2.22–2.41 (m, 5H), 2.15 (s, 3H), 1.86 (d, <i>J</i> = 10.92 Hz, 2H), 1.79 (d, <i>J</i> = 13.55 Hz, 6H), 1.47–1.60 (m, 2H). MS/ES+: <i>m</i>/<i>z</i> = 568.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> (2-((2-((2-Methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-methylpyrimidin-4-yl)amino)phenyl)dimethylphosphine Oxide (<b>12d</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.80 (s, 1H), 8.64 (dd, <i>J</i> = 4.27, 8.41 Hz, 1H), 7.86 (s, 1H), 7.65 (d, <i>J</i> = 8.66 Hz, 1H), 7.47–7.57 (m, 2H), 7.39 (t, <i>J</i> = 7.84 Hz, 1H), 7.02–7.10 (m, 1H), 6.63 (d, <i>J</i> = 2.51 Hz, 1H), 6.47 (dd, <i>J</i> = 2.51, 8.78 Hz, 1H), 3.79 (s, 3H), 3.68 (d, <i>J</i> = 12.30 Hz, 2H), 3.29–3.38 (m, 1H), 2.59–2.71 (m, 2H), 2.49–2.51 (m, 3H), 2.21–2.40 (m, 5H), 2.15 (s, 3H), 2.06 (s, 3H), 1.81–1.90 (m, 2H), 1.78 (d, <i>J</i> = 13.55 Hz, 6H), 1.53 (dq, <i>J</i> = 3.83, 11.86 Hz, 2H). MS/ES+: <i>m</i>/<i>z</i> = 564.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> 1-(4-((2-(Dimethylphosphoryl)phenyl)amino)-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperi-din-1-yl)phenyl)amino)pyrimidin-5-yl)ethan-1-one (<b>12e</b>)</h4><div class="NLM_p last">General procedure B was applied to the S<sub>N</sub>Ar reaction of chloride <b>23</b> and 2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)aniline. Concomitant hydrolysis of the C5 alkyne moiety furnished the desired product. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 11.08 (s, 1H), 8.64 (br. s., 1H), 8.19 (s, 2H), 7.90–8.03 (m, 1H), 7.62 (br. s., 2H), 7.52 (t, <i>J</i> = 7.72 Hz, 1H), 7.40 (d, <i>J</i> = 5.52 Hz, 1H), 6.39 (d, <i>J</i> = 2.13 Hz, 1H), 3.78 (s, 3H), 3.48–3.62 (m, 2H), 2.72–3.14 (m, 7H), 2.55–2.67 (m, 4H), 2.53 (s, 3H), 2.49 (s, 3H), 1.84–1.98 (m, 2H), 1.70 (d, <i>J</i> = 13.30 Hz, 6H), 1.55–1.67 (m, 2H). MS/ES+: <i>m</i>/<i>z</i> = 592.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> (2-((5-Chloro-2-((5-fluoro-2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-pyrimidin-4-yl)amino)phenyl)dimethylphosphine Oxide (<b>12g</b>)</h4><div class="NLM_p last">A mixture of bromide <b>21</b> (125 mg, 0.25 mmmol), 1-methyl-4-(piperidin-4-yl)piperazine (91 mg, 0.50 mmol), <span class="smallcaps smallerCapital">l</span>-proline (17 mg, 0.15 mmol), CuI (14 mg, 0.075 mmol), and K<sub>3</sub>PO<sub>4</sub> (132 mg, 0.62 mmol) was placed in a vial and purged with N<sub>2</sub>. Degassed DMSO (1.5 mL) was added through a septum. The resulting solution was heated at 100 °C for 16 h under stirring. Upon cooling, the reaction mixture was taken up in DCM/H<sub>2</sub>O (8/2 mL). Evaporation of the organic layer gave a solid residue, which was purified on a reverse phase HPLC furnishing the desired product. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.73 (s, 1H), 8.47 (dd, <i>J</i> = 4.27, 8.16 Hz, 1H), 8.09 (d, <i>J</i> = 14.56 Hz, 1H), 8.04 (br. s., 1H), 7.52 (t, <i>J</i> = 7.91 Hz, 1H), 7.34 (br. s., 1H), 7.20–7.27 (m, 1H), 7.04–7.14 (m, 1H), 6.46 (d, <i>J</i> = 7.78 Hz, 1H), 3.78 (s, 3H), 3.37 (d, <i>J</i> = 11.80 Hz, 2H), 2.56–2.71 (m, 6H), 2.46 (br. s., 4H), 2.34 (t, <i>J</i> = 11.54 Hz, 1H), 2.25 (s, 3H), 1.81–1.90 (m, 2H), 1.76 (d, <i>J</i> = 13.05 Hz, 6H), 1.63–1.73 (m, 2H). MS/ES+: <i>m</i>/<i>z</i> = 602.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> (2-((5-Chloro-2-((2-methoxy-5-methyl-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)-amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine Oxide (<b>12h</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.15 (s, 1H), 8.45 (dd, <i>J</i> = 3.95, 8.34 Hz, 1H), 8.10 (s, 1H), 8.02 (s, 1H), 7.55 (ddd, <i>J</i> = 1.38, 7.75, 13.96 Hz, 1H), 7.44 (s, 1H), 7.35 (t, <i>J</i> = 7.78 Hz, 1H), 7.08–7.17 (m, 1H), 6.71 (s, 1H), 3.76 (s, 3H), 3.08 (d, <i>J</i> = 11.80 Hz, 2H), 2.64 (t, <i>J</i> = 10.98 Hz, 3H), 2.51–2.57 (m, 4H), 2.32 (d, <i>J</i> = 10.67 Hz, 4H), 2.16 (s, 3H), 2.13 (s, 3H), 1.86 (d, <i>J</i> = 11.04 Hz, 2H), 1.77 (d, <i>J</i> = 13.55 Hz, 6H), 1.50–1.67 (m, 2H). MS/ES+: <i>m</i>/<i>z</i> = 598.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> (2-((5-Chloro-2-((2-ethoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine Oxide (<b>12i</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.15 (s, 1H), 8.46 (d, <i>J</i> = 4.64 Hz, 1H), 8.07 (s, 1H), 7.94 (s, 1H), 7.53 (dd, <i>J</i> = 6.96, 13.24 Hz, 1H), 7.44 (d, <i>J</i> = 8.78 Hz, 1H), 7.34 (t, <i>J</i> = 7.84 Hz, 1H), 7.10 (t, <i>J</i> = 7.59 Hz, 1H), 6.60 (d, <i>J</i> = 2.51 Hz, 1H), 6.46 (dd, <i>J</i> = 2.38, 8.78 Hz, 1H), 4.02 (q, <i>J</i> = 6.99 Hz, 2H), 3.61–3.76 (m, 2H), 2.59–2.73 (m, 2H), 2.46–2.54 (m, 4H), 2.31 (dd, <i>J</i> = 2.76, 7.03 Hz, 5H), 2.14 (s, 3H), 1.84 (d, <i>J</i> = 11.04 Hz, 2H), 1.76 (d, <i>J</i> = 13.55 Hz, 6H), 1.43–1.60 (m, 2H), 1.25 (t, <i>J</i> = 6.96 Hz, 3H). MS/ES+: <i>m</i>/<i>z</i> = 598.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> (2-((5-Chloro-2-((2-isopropoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-pyrimidin-4-yl)amino)phenyl)dimethylphosphine Oxide (<b>12j</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.72 (s, 1H), 8.56 (dd, <i>J</i> = 4.33, 8.22 Hz, 1H), 8.05 (d, <i>J</i> = 8.78 Hz, 1H), 8.01 (s, 1H), 7.38–7.46 (m, 1H), 7.16–7.27 (m, 2H), 7.02–7.10 (m, 1H), 6.49 (d, <i>J</i> = 2.38 Hz, 1H), 6.41 (dd, <i>J</i> = 2.51, 8.78 Hz, 1H), 4.48 (spt, <i>J</i> = 6.09 Hz, 1H), 3.55 (d, <i>J</i> = 12.30 Hz, 2H), 2.54–2.70 (m, 6H), 2.39–2.52 (m, 4H), 2.28–2.38 (m, 1H), 2.26 (s, 3H), 1.87 (d, <i>J</i> = 12.17 Hz, 2H), 1.76 (d, <i>J</i> = 13.18 Hz, 6H), 1.57–1.71 (m, 2H), 1.29 (d, <i>J</i> = 6.15 Hz, 6H). MS/ES+: <i>m</i>/<i>z</i> = 612.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> 5-Chloro-<i>N</i><sup>2</sup>-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)-<i>N</i><sup>4</sup>-phenylpyrimidine-2,4-diamine (<b>13a</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.86 (s, 1H), 7.67 (d, <i>J</i> = 8.78 Hz, 1H), 7.41–7.52 (m, 2H), 7.24 (t, <i>J</i> = 7.97 Hz, 2H), 7.06 (d, <i>J</i> = 7.40 Hz, 1H), 6.54 (d, <i>J</i> = 2.51 Hz, 1H), 6.31 (dd, <i>J</i> = 2.51, 8.78 Hz, 1H), 4.14–4.28 (m, 1H), 3.75 (s, 3H), 3.50–3.64 (m, 3H), 3.18 (d, <i>J</i> = 2.89 Hz, 1H), 3.10 (d, <i>J</i> = 3.89 Hz, 1H), 2.53–2.75 (m, 9H), 2.32 (s, 3H), 1.92 (d, <i>J</i> = 11.92 Hz, 2H). MS/ES+: <i>m</i>/<i>z</i> = 508.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> 5-Chloro-<i>N</i><sup>4</sup>-(2-iodophenyl)-<i>N</i><sup>2</sup>-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)-pyrimidine-2,4-diamine (<b>13b</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.27 (dd, <i>J</i> = 1.44, 8.22 Hz, 1H), 8.00–8.05 (m, 1H), 7.92 (d, <i>J</i> = 8.78 Hz, 1H), 7.78 (dd, <i>J</i> = 1.44, 7.97 Hz, 1H), 7.38 (s, 1H), 7.25–7.32 (m, 1H), 6.75–6.83 (m, 1H), 6.47 (d, <i>J</i> = 2.51 Hz, 1H), 6.38 (dd, <i>J</i> = 2.51, 8.91 Hz, 1H), 3.79 (s, 3H), 3.64–3.70 (m, 1H), 3.58 (d, <i>J</i> = 12.30 Hz, 2H), 3.37–3.48 (m, 1H), 2.53–2.71 (m, 6H), 2.44 (br. s., 3H), 2.24 (s, 3H), 1.88 (d, <i>J</i> = 12.17 Hz, 2H), 1.64 (dq, <i>J</i> = 3.76, 12.00 Hz, 2H). MS/ES+: <i>m</i>/<i>z</i> = 634.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> 2-((5-Chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)benzonitrile (<b>13c</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.17 (s, 1H), 8.09 (s, 1H), 7.86 (dd, <i>J</i> = 1.13, 7.78 Hz, 1H), 7.80 (dt, <i>J</i> = 1.51, 7.84 Hz, 1H), 7.66 (dd, <i>J</i> = 0.63, 8.16 Hz, 1H), 7.56 (dt, <i>J</i> = 1.13, 7.65 Hz, 1H), 7.49 (d, <i>J</i> = 8.78 Hz, 1H), 6.96 (s, 1H), 6.69 (d, <i>J</i> = 8.41 Hz, 1H), 3.90 (s, 3H), 3.78–3.86 (m, 2H), 3.41–3.53 (m, 4H), 3.05–3.31 (m, 7H), 2.95 (s, 3H), 2.22 (d, <i>J</i> = 12.42 Hz, 2H), 1.89–2.06 (m, 2H). MS/ES+: <i>m</i>/<i>z</i> = 533.2[M + H]<sup>+</sup>.</div></div><div id="sec4_3_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> 2-((5-Chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)benzamide (<b>13e</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.63 (d, <i>J</i> = 8.28 Hz, 1H), 8.37 (br. s., 2H), 8.00 (s, 1H), 7.99–8.00 (m, 1H), 7.69–7.78 (m, 2H), 7.36–7.43 (m, 1H), 7.04–7.13 (m, 1H), 6.65–6.71 (m, 1H), 6.51–6.57 (m, 1H), 3.78–3.89 (m, 4H), 3.73 (d, <i>J</i> = 12.67 Hz, 2H), 2.89–3.10 (m, 7H), 2.70–2.80 (m, 2H), 2.66–2.69 (m, 4H), 1.94–2.12 (m, 2H), 1.64–1.81 (m, 2H). MS/ES+: <i>m</i>/<i>z</i> = 551.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> 2-((5-Chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)-N,N-dimethylbenzamide (<b>13f</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.85–7.92 (m, 1H), 7.63 (dd, <i>J</i> = 0.75, 8.16 Hz, 1H), 7.28–7.41 (m, 3H), 7.21–7.27 (m, 1H), 6.74 (d, <i>J</i> = 2.26 Hz, 1H), 6.52 (dd, <i>J</i> = 2.45, 8.85 Hz, 1H), 3.71 (s, 3H), 3.61–3.69 (m, 2H), 3.23–3.35 (m, 4H), 2.92–3.03 (m, 3H), 2.88 (br. s., 3H), 2.71–2.81 (m, 6H), 2.02 (d, <i>J</i> = 12.30 Hz, 2H), 1.68–1.83 (m, 2H), 1.68–1.83 (m, 2H). MS/ES+: <i>m</i>/<i>z</i> = 579.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> 2-((5-Chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)-N,N-dimethylbenzenesulfonamide (<b>13g</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.33 (d, <i>J</i> = 8.28 Hz, 1H), 8.19 (s, 1H), 8.09 (s, 1H), 7.94 (dd, <i>J</i> = 1.44, 7.97 Hz, 1H), 7.67–7.78 (m, 2H), 7.44–7.52 (m, 1H), 7.03 (d, <i>J</i> = 2.26 Hz, 1H), 3.93 (s, 3H), 3.86 (d, <i>J</i> = 12.42 Hz, 2H), 3.39–3.52 (m, 5H), 3.17–3.31 (m, 6H), 2.94 (s, 3H), 2.74 (s, 6H), 2.23 (d, <i>J</i> = 12.92 Hz, 2H), 1.93–2.03 (m, 2H). MS/ES+: <i>m</i>/<i>z</i> = 615.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> 1-(2-((5-Chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)ethan-1-one (<b>13h</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.72 (d, <i>J</i> = 8.16 Hz, 1H), 8.17 (dd, <i>J</i> = 1.51, 8.03 Hz, 1H), 8.14 (s, 1H), 7.54–7.64 (m, 2H), 7.32–7.39 (m, 1H), 6.98 (d, <i>J</i> = 2.51 Hz, 1H), 6.87 (dd, <i>J</i> = 2.51, 8.78 Hz, 1H), 3.88–4.01 (m, 5H), 3.48–3.62 (m, 4H), 3.36–3.46 (m, 4H), 3.13–3.24 (m, 3H), 2.97 (s, 3H), 2.70–2.77 (m, 3H), 2.26 (d, <i>J</i> = 13.05 Hz, 2H), 1.91–2.08 (m, 2H). MS/ES+: <i>m</i>/<i>z</i> = 550.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> 1-(2-((5-Chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)ethan-1-ol (<b>13i</b>)</h4><div class="NLM_p last">To a solution of compound <b>13h</b> (40 mg) in MeOH (4 mL) was added NaBH<sub>4</sub> (20 mg) at 0 °C. After stirring at rt for 4 h, a few drops of aq HCl (2.0 M) was added at 0 °C to quench the reaction. Volatile components were evaporated and the residue was taken up in DCM and saturated aq Na<sub>2</sub>CO<sub>3</sub>. Extraction followed by concentration of combined organic layers gave a residue, which was purified on a reverse phase HPLC furnishing the desired product as an off-white solid (16 mg, 40% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.94–7.99 (m, 2H), 7.77–7.82 (m, 1H), 7.39–7.47 (m, 1H), 7.42 (d, <i>J</i> = 8.66 Hz, 1H), 7.29 (dd, <i>J</i> = 2.07, 7.22 Hz, 1H), 7.18 (dquin, <i>J</i> = 1.76, 7.50 Hz, 2H), 6.79 (d, <i>J</i> = 1.76 Hz, 1H), 6.58 (dd, <i>J</i> = 2.20, 8.72 Hz, 1H), 4.89 (q, <i>J</i> = 6.61 Hz, 1H), 3.77 (s, 3H), 3.73 (d, <i>J</i> = 12.55 Hz, 2H), 3.23–3.34 (m, 4H), 2.84–3.15 (m, 7H), 2.78 (s, 3H), 2.05 (d, <i>J</i> = 13.05 Hz, 2H), 1.71–1.86 (m, 2H), 1.37 (d, <i>J</i> = 6.53 Hz, 3H). MS/ES+: <i>m</i>/<i>z</i> = 552.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> 5-Chloro-<i>N</i><sup>2</sup>-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)-<i>N</i><sup>4</sup>-(2-(methylsulfonyl)phenyl)pyrimidine-2,4-diamine (<b>13j</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CD<sub>2</sub>Cl<sub>2</sub>) δ 9.26 (s, 1H), 8.57 (d, <i>J</i> = 7.65 Hz, 1H), 8.14 (s, 1H), 7.96 (td, <i>J</i> = 1.87, 8.19 Hz, 2H), 7.57–7.73 (m, 1H), 7.19–7.35 (m, 2H), 6.55 (d, <i>J</i> = 2.51 Hz, 1H), 6.46 (dd, <i>J</i> = 2.51, 8.78 Hz, 1H), 3.86 (s, 3H), 3.65 (d, <i>J</i> = 12.55 Hz, 2H), 3.06 (s, 3H), 2.70 (dt, <i>J</i> = 2.45, 12.14 Hz, 2H), 2.60 (br. s., 2H), 2.28–2.49 (m, 3H), 2.23 (s, 3H), 1.93 (d, <i>J</i> = 12.17 Hz, 2H), 1.42–1.74 (m, 6H). MS/ES+: <i>m</i>/<i>z</i> = 586.2 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> Model of Inhibitors Bound to ALK</h3><div class="NLM_p last">Before the ALK crystal structure was available, a homology model of ALK was built based on the crystal structure of activated insulin kinase (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1ir3">1ir3</a>) using Prime (Schrodinger software package). Inhibitors such as <b>10f</b> were docked into ALK by using Glide SP with postdocking minimization (Schrodinger). The top scoring pose was chosen after manual inspection for further analysis.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> Kinase Assay</h3><div class="NLM_p last"><i>In vitro</i> kinase assays were performed at Reaction Biology Corp (Malvern, PA). The assay was conducted in the presence of 10 μM [<sup>33</sup>P]-ATP.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> Cell Lines and <i>in Vitro</i> Cellular Assays</h3><div class="NLM_p last">U937 cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA), Karpas-299 cells were from the Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH (DSMZ, Germany), and H3122 cells were from the National Cancer Institute (Bethesda, MD). All cell lines were used within 20 passages of the initial thaw. Following inhibitor treatment for 72 h, cell growth was assessed using CellTiter 96 AQueous One solution (Promega, Madison, WI) to determine the concentration that causes 50% inhibition of cell viability (IC<sub>50</sub>).</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> Pharmacokinetics (PK), Pharmacodynamics (PD), and <i>in Vivo</i> Efficacy</h3><div class="NLM_p">All <i>in vivo</i> experiments were conducted in accordance with ARIAD Pharmaceuticals, Inc., Institutional Animal Care and Use Committee (IACUC) guidelines. Unless otherwise stated, all animals were obtained from Charles River Laboratories (Wilmington, MA). Rats were housed two per cage and mice were housed five per cage, in microisolator caging, and were offered food and water <i>ad libitum</i> unless otherwise stated.</div><div id="sec4_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> PK Studies</h4><div class="NLM_p last">Oral and iv PK testing was performed on 6–8 week old female CD rats. For oral dosing, the rats were fasted overnight and received food 2 h post-dosing. The dosing levels and volumes were set at 10 mg/kg and 4 mL/kg for po administration and 3 mg/kg and 2 mL/kg for iv administration (compound <b>11q</b> was tested at 10 mg/kg po and 2 mg/kg iv). At prescribed time points, whole blood was collected from the retro orbital plexus (serial bleeds, <i>N</i> = 3) into microcentrifuge tubes containing 50 μL of 0.5 mM EDTA for plasma isolation. PK testing in mice was performed only by the oral route of administration. The dosing level was set at 10 mg/kg and 10 mL/kg. At prescribed time points, whole blood samples were collected from the heart of anesthetized mice into microcentrifuge tubes containing 50 μL of 0.5 mM EDTA (<i>N</i> = 3 per time point). Compound concentrations in mouse or rat plasma were assessed by measuring the concentrations of the indicated compound using LC/MS/MS. Plasma samples were deproteinized before analysis and were analyzed in the presence of internal standards.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> <i>In Vivo</i> Efficacy</h4><div class="NLM_p last">(1) Eight- to 10-week-old female SCID/beige mice were injected intravenously with 5 × 10<sup>6</sup> H3122 cells per mouse and were randomly selected into treatment groups (<i>n</i> = 10) when the average tumor size reached ∼300 mm<sup>3</sup> (day zero). Treatments were administered orally for up to 21 consecutive days at a 10 mL/kg dose volume. Subcutaneous tumors were measured two or three times weekly. Tumor volume (in mm<sup>3</sup>) was calculated using the formula (<i>L</i> × <i>W</i><sup>2</sup>)/2. When a tumor reached 10% of the body weight of the host, the animal was euthanized via CO<sub>2</sub> asphyxiation. (2) Eight- to 10-week old female SCID/beige mice were injected subcutaneously with 2.5 × 10<sup>6</sup> Karpas-299 cells per mouse and were randomly selected into treatment groups (<i>n</i> = 10) when the average tumor size reached ∼180 mm<sup>3</sup> (day zero). Treatments were administered orally for 14 consecutive days at a 10 mL/kg dose volume. Tumor volume was measured and calculated as described for the H3122 model.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> PK/PD Analyses</h4><div class="NLM_p last">Eight- to 10-week old female SCID/beige mice were injected subcutaneously with 2.5 × 10<sup>6</sup> Karpas-299 cells per mouse and, approximately 22 days after inoculation, were randomly selected into 25 mg/kg single oral dose treatment groups for each compound tested. At prescribed time points after oral administration, three mice from each treatment group for each compound were asphyxiated for whole blood and tumor collection. Blood samples were collected from the heart of anesthetized mice into microcentrifuge tubes containing 50 μL of 0.5 mM EDTA (<i>N</i> = 3 per time point). After plasma samples were deproteinized, inhibitor concentrations in plasma were assessed by measuring the concentrations of the indicated compound using LC/MS/MS in the presence of internal standards. Tumors were collected by blunt dissection; the samples were lysed in RIPA buffer and subjected to ELISA or immunoblotting to evaluate PD effects.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.6b00306" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76136" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76136" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wei-Sheng Huang</span> - <span class="hlFld-Affiliation affiliation">ARIAD
Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#2d7a4844007e4548434a0365584c434a6d4c5f444c49034e4240"><span class="__cf_email__" data-cfemail="5601333f7b053e333831781e233738311637243f37327835393b">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shuangying Liu</span> - <span class="hlFld-Affiliation affiliation">ARIAD
Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dong Zou</span> - <span class="hlFld-Affiliation affiliation">ARIAD
Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mathew Thomas</span> - <span class="hlFld-Affiliation affiliation">ARIAD
Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yihan Wang</span> - <span class="hlFld-Affiliation affiliation">ARIAD
Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tianjun Zhou</span> - <span class="hlFld-Affiliation affiliation">ARIAD
Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jan Romero</span> - <span class="hlFld-Affiliation affiliation">ARIAD
Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anna Kohlmann</span> - <span class="hlFld-Affiliation affiliation">ARIAD
Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Feng Li</span> - <span class="hlFld-Affiliation affiliation">ARIAD
Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jiwei Qi</span> - <span class="hlFld-Affiliation affiliation">ARIAD
Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lisi Cai</span> - <span class="hlFld-Affiliation affiliation">ARIAD
Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Timothy A. Dwight</span> - <span class="hlFld-Affiliation affiliation">ARIAD
Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yongjin Xu</span> - <span class="hlFld-Affiliation affiliation">ARIAD
Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rongsong Xu</span> - <span class="hlFld-Affiliation affiliation">ARIAD
Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rory Dodd</span> - <span class="hlFld-Affiliation affiliation">ARIAD
Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Angela Toms</span> - <span class="hlFld-Affiliation affiliation">ARIAD
Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lois Parillon</span> - <span class="hlFld-Affiliation affiliation">ARIAD
Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaohui Lu</span> - <span class="hlFld-Affiliation affiliation">ARIAD
Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rana Anjum</span> - <span class="hlFld-Affiliation affiliation">ARIAD
Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sen Zhang</span> - <span class="hlFld-Affiliation affiliation">ARIAD
Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Frank Wang</span> - <span class="hlFld-Affiliation affiliation">ARIAD
Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeffrey Keats</span> - <span class="hlFld-Affiliation affiliation">ARIAD
Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Scott D. Wardwell</span> - <span class="hlFld-Affiliation affiliation">ARIAD
Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yaoyu Ning</span> - <span class="hlFld-Affiliation affiliation">ARIAD
Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qihong Xu</span> - <span class="hlFld-Affiliation affiliation">ARIAD
Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lauren E. Moran</span> - <span class="hlFld-Affiliation affiliation">ARIAD
Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qurish K. Mohemmad</span> - <span class="hlFld-Affiliation affiliation">ARIAD
Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hyun Gyung Jang</span> - <span class="hlFld-Affiliation affiliation">ARIAD
Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tim Clackson</span> - <span class="hlFld-Affiliation affiliation">ARIAD
Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Narayana I. Narasimhan</span> - <span class="hlFld-Affiliation affiliation">ARIAD
Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Victor M. Rivera</span> - <span class="hlFld-Affiliation affiliation">ARIAD
Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaotian Zhu</span> - <span class="hlFld-Affiliation affiliation">ARIAD
Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David Dalgarno</span> - <span class="hlFld-Affiliation affiliation">ARIAD
Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">William C. Shakespeare</span> - <span class="hlFld-Affiliation affiliation">ARIAD
Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): All authors are (or were) employees and equity holders of ARIAD at the time that this study was conducted.<br /></br></div></li></ul></div><div class="ack" id="ACK-d113e5595-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i82">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88282" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88282" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank T. Padukkavidana and H. Gu for critical reading of the manuscript.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i84" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i84"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i85" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i85"> Abbreviations</h2><tr><td class="NLM_term">ALCL</td><td class="NLM_def"><p class="first last">anaplastic large-cell lymphoma</p></td></tr><tr><td class="NLM_term">c-MET</td><td class="NLM_def"><p class="first last">mesenchymal epithelial transition factor</p></td></tr><tr><td class="NLM_term">DFG</td><td class="NLM_def"><p class="first last">aspartic acid–phenylalanine–glycine</p></td></tr><tr><td class="NLM_term">DMPO</td><td class="NLM_def"><p class="first last">dimethylphosphine oxide</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">EML4</td><td class="NLM_def"><p class="first last">echinoderm microtubule-associated protein-like 4</p></td></tr><tr><td class="NLM_term">ENU</td><td class="NLM_def"><p class="first last"><i>N</i>-ethyl-<i>N</i>-nitrosourea</p></td></tr><tr><td class="NLM_term">FLT3</td><td class="NLM_def"><p class="first last">feline McDonough sarcoma (FMS)-like tyrosine kinase 3</p></td></tr><tr><td class="NLM_term">IGF1R</td><td class="NLM_def"><p class="first last">insulin-like growth factor receptor</p></td></tr><tr><td class="NLM_term">InsR</td><td class="NLM_def"><p class="first last">insulin receptor kinase</p></td></tr><tr><td class="NLM_term">KRAS</td><td class="NLM_def"><p class="first last">kirsten rat sarcoma virus</p></td></tr><tr><td class="NLM_term">NPM</td><td class="NLM_def"><p class="first last">nucleophosmin</p></td></tr><tr><td class="NLM_term">ROS1</td><td class="NLM_def"><p class="first last">c-ros oncogene 1</p></td></tr><tr><td class="NLM_term">S<sub>N</sub>Ar</td><td class="NLM_def"><p class="first last">aromatic nucleophilic substitution</p></td></tr><tr><td class="NLM_term">SRC</td><td class="NLM_def"><p class="first last">sarcoma</p></td></tr><tr><td class="NLM_term">T/C</td><td class="NLM_def"><p class="first last">treatment/control</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i86">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85441" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85441" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 59 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Morris, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirstein, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valentine, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dittmer, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saltman, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Look, A. T.</span><span> </span><span class="NLM_article-title">Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">263</span><span class="NLM_x">, </span> <span class="NLM_fpage">1281</span><span class="NLM_x">–</span> <span class="NLM_lpage">1284</span><span class="refDoi"> DOI: 10.1126/science.8122112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1126%2Fscience.8122112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=8122112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADyaK2cXis1aks7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=263&publication_year=1994&pages=1281-1284&author=S.+W.+Morrisauthor=M.+N.+Kirsteinauthor=M.+B.+Valentineauthor=K.+G.+Dittmerauthor=D.+N.+Shapiroauthor=D.+L.+Saltmanauthor=A.+T.+Look&title=Fusion+of+a+kinase+gene%2C+ALK%2C+to+a+nucleolar+protein+gene%2C+NPM%2C+in+non-Hodgkin%E2%80%99s+lymphoma&doi=10.1126%2Fscience.8122112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma</span></div><div class="casAuthors">Morris, Stephan, W.; Kirstein, Mark, N.; Valentine, Marcus B.; Dittmer, Kristopher G.; Shapiro, David N.; Saltman, David L.; Look, A. Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">263</span>
        (<span class="NLM_cas:issue">5151</span>),
    <span class="NLM_cas:pages">1281-4</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">The 2;5 chromosomal translocation occurs in most anaplastic large-cell non-Hodgkin's lymphomas arising from activated T lymphocytes.  This rearrangement was shown to fuse the NPM nucleolar phosphoprotein gene on chromosome 5q35 to a previously unidentified protein tyrosine kinase gene, ALK, on chromosome 2p23.  In the predicted hybrid protein, the amino terminus of nucleophosmin (NPM) is linked to the catalytic domain of anaplastic lymphoma kinase (ALK).  Expressed in the small intestine, testis, and brain but not in normal lymphoid cells, ALK shows greatest sequence similarity to the insulin receptor subfamily of kinases.  Unscheduled expression of the truncated ALK may contribute to malignant transformation in these lymphomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGox3KZnxLYaerVg90H21EOLACvtfcHk0lg5UnDZQYHZuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXis1aks7Y%253D&md5=219ee9615e613be456a05f8f1ded6066</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1126%2Fscience.8122112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.8122112%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DS.%2BW.%26aulast%3DKirstein%26aufirst%3DM.%2BN.%26aulast%3DValentine%26aufirst%3DM.%2BB.%26aulast%3DDittmer%26aufirst%3DK.%2BG.%26aulast%3DShapiro%26aufirst%3DD.%2BN.%26aulast%3DSaltman%26aufirst%3DD.%2BL.%26aulast%3DLook%26aufirst%3DA.%2BT.%26atitle%3DFusion%2520of%2520a%2520kinase%2520gene%252C%2520ALK%252C%2520to%2520a%2520nucleolar%2520protein%2520gene%252C%2520NPM%252C%2520in%2520non-Hodgkin%25E2%2580%2599s%2520lymphoma%26jtitle%3DScience%26date%3D1994%26volume%3D263%26spage%3D1281%26epage%3D1284%26doi%3D10.1126%2Fscience.8122112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Chiarle, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voena, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ambrogio, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piva, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inghirami, G.</span><span> </span><span class="NLM_article-title">The anaplastic lymphoma kinase in the pathogenesis of cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">11</span><span class="NLM_x">–</span> <span class="NLM_lpage">23</span><span class="refDoi"> DOI: 10.1038/nrc2291</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1038%2Fnrc2291" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=18097461" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVKku73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=11-23&author=R.+Chiarleauthor=C.+Voenaauthor=C.+Ambrogioauthor=R.+Pivaauthor=G.+Inghirami&title=The+anaplastic+lymphoma+kinase+in+the+pathogenesis+of+cancer&doi=10.1038%2Fnrc2291"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The anaplastic lymphoma kinase in the pathogenesis of cancer</span></div><div class="casAuthors">Chiarle, Roberto; Voena, Claudia; Ambrogio, Chiara; Piva, Roberto; Inghirami, Giorgio</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-23</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The receptor tyrosine kinase anaplastic lymphoma kinase (ALK) was first identified as part of a chromosomal translocation assocd. with some anaplastic large cell lymphomas (ALCLs).  Now data are emerging that indicate that ALK might be a valid therapeutic target in ALCL and that it could also be involved in other cancers.  Tyrosine kinases are involved in the pathogenesis of most cancers.  However, few tyrosine kinases have been shown to have a well-defined pathogenetic role in lymphomas.  The anaplastic lymphoma kinase (ALK) is the oncogene of most anaplastic large cell lymphomas (ALCL), driving transformation through many mol. mechanisms.  In this review, we will analyze how translocations or deregulated expression of ALK contribute to oncogenesis and how recent genetic or pharmacol. tools, aimed at neutralizing its activity, can represent the basis for the design of powerful combination therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5HoaZPQUiUrVg90H21EOLACvtfcHk0lg5UnDZQYHZuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVKku73P&md5=a57d7ab61be51664ca9f5b804c3e2910</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrc2291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2291%26sid%3Dliteratum%253Aachs%26aulast%3DChiarle%26aufirst%3DR.%26aulast%3DVoena%26aufirst%3DC.%26aulast%3DAmbrogio%26aufirst%3DC.%26aulast%3DPiva%26aufirst%3DR.%26aulast%3DInghirami%26aufirst%3DG.%26atitle%3DThe%2520anaplastic%2520lymphoma%2520kinase%2520in%2520the%2520pathogenesis%2520of%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2008%26volume%3D8%26spage%3D11%26epage%3D23%26doi%3D10.1038%2Fnrc2291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Griffin, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawkins, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dvorak, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henkle, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellingham, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perlman, E. J.</span><span> </span><span class="NLM_article-title">Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">2776</span><span class="NLM_x">–</span> <span class="NLM_lpage">2780</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10383129" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADyaK1MXktVOktbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1999&pages=2776-2780&author=C.+A.+Griffinauthor=A.+L.+Hawkinsauthor=C.+Dvorakauthor=C.+Henkleauthor=T.+Ellinghamauthor=E.+J.+Perlman&title=Recurrent+involvement+of+2p23+in+inflammatory+myofibroblastic+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors</span></div><div class="casAuthors">Griffin, Constance A.; Hawkins, Anita L.; Dvorak, Cecily; Henkle, Carol; Ellingham, Tara; Perlman, Elizabeth J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2776-2780</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">AACR Subscription Office</span>)
        </div><div class="casAbstract">Inflammatory myofibroblastic tumor (IMT) is a relatively rare soft tissue tumor.  The reactive vs. neoplastic pathogenesis of this tumor is unresolved.  We found clonal chromosome aberrations involving 2p23 upon metaphase anal. of two IMTs.  Fluorescence in situ hybridization with a probe flanking the ALK gene at 2p23 demonstrated rearrangement of the probe in both of these cases and in a third case, and immunohistochem. revealed ALK expression in all three cases.  A 2p22-24 involvement has been reported previously in four addnl. cases of IMT.  We suggest that chromosomal rearrangements involving 2p23 near or within ALK are recurrent alterations in IMT and that ALK may have a novel role outside its previously recognized realm of lymphoid neoplasms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocvXV2ukz3crVg90H21EOLACvtfcHk0lgTBHZ43xgQug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXktVOktbk%253D&md5=8054eeaaf0cb85ee85afff461797c84c</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGriffin%26aufirst%3DC.%2BA.%26aulast%3DHawkins%26aufirst%3DA.%2BL.%26aulast%3DDvorak%26aufirst%3DC.%26aulast%3DHenkle%26aufirst%3DC.%26aulast%3DEllingham%26aufirst%3DT.%26aulast%3DPerlman%26aufirst%3DE.%2BJ.%26atitle%3DRecurrent%2520involvement%2520of%25202p23%2520in%2520inflammatory%2520myofibroblastic%2520tumors%26jtitle%3DCancer%2520Res.%26date%3D1999%26volume%3D59%26spage%3D2776%26epage%3D2780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Gascoyne, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamant, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin-Subero, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lestou, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, N. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller-Hermelink, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seymour, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horsman, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Auvigne, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Espinos, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siebert, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delsol, G.</span><span> </span><span class="NLM_article-title">ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">2568</span><span class="NLM_x">–</span> <span class="NLM_lpage">2573</span><span class="refDoi"> DOI: 10.1182/blood-2003-03-0786</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1182%2Fblood-2003-03-0786" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=12763927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnslykurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2003&pages=2568-2573&author=R.+D.+Gascoyneauthor=L.+Lamantauthor=J.+I.+Martin-Suberoauthor=V.+S.+Lestouauthor=N.+L.+Harrisauthor=H.+K.+Muller-Hermelinkauthor=J.+F.+Seymourauthor=L.+J.+Campbellauthor=D.+E.+Horsmanauthor=I.+Auvigneauthor=E.+Espinosauthor=R.+Siebertauthor=G.+Delsol&title=ALK-positive+diffuse+large+B-cell+lymphoma+is+associated+with+Clathrin-ALK+rearrangements%3A+report+of+6+cases&doi=10.1182%2Fblood-2003-03-0786"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">ALK-positive diffuse large B-cell lymphoma is associated with clathrin-ALK rearrangements: Report of 6 cases</span></div><div class="casAuthors">Gascoyne, Randy D.; Lamant, Laurence; Martin-Subero, Jose I.; Lestou, Valia S.; Harris, Nancy Lee; Mueller-Hermelink, Hans-Konrad; Seymour, John F.; Campbell, Lynda J.; Horsman, Douglas E.; Auvigne, Isabelle; Espinos, Estelle; Siebert, Reiner; Delsol, Georges</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2568-2573</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Expression of ALK protein by lymphoid cells and the description of variant anaplastic lymphoma kinase (ALK) translocations have typically been restricted to cases of T-cell and null anaplastic large-cell lymphoma (ALCL).  All such cases result from a novel fusion created by the ALK gene on chromosome 2p23 and NPM on 5q35 or other variant translocation partners.  A rare variant of diffuse large B-cell lymphoma (DLBCL), originally described in 1997, was thought to overexpress full-length ALK in contrast to a chimeric protein characteristic of ALCL.  However, full-length ALK protein lacks tyrosine kinase activity and thus the mechanism of oncogenesis has remained elusive.  We describe 6 cases of ALK+ DLBCL characterized by a simple or complex t(2;17)(p23;q23) involving the clathrin gene (CLTC) at chromosome band 17q23 and the ALK gene at chromosome band 2p23.  All cases were studied using fluorescence in situ hybridization (FISH), complemented in one case with std. cytogenetic anal., multicolor karyotyping (M-FISH), and reverse transcriptase-polymerase chain reaction.  These results clearly demonstrate that most cases of ALK+ DLBCL share the same mechanism of deregulated ALK expression.  Moreover, these results demonstrate the presence of CLTC-ALK fusions in these tumors and extend the list of diseases assocd. with this genetic abnormality to include classical T-cell or null ALCL, ALK+ DLBCL, and inflammatory myofibroblastic tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3UcmsuahiXLVg90H21EOLACvtfcHk0lgTBHZ43xgQug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnslykurw%253D&md5=9eedc8c22c580dbadee982b4d3da35a8</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1182%2Fblood-2003-03-0786&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2003-03-0786%26sid%3Dliteratum%253Aachs%26aulast%3DGascoyne%26aufirst%3DR.%2BD.%26aulast%3DLamant%26aufirst%3DL.%26aulast%3DMartin-Subero%26aufirst%3DJ.%2BI.%26aulast%3DLestou%26aufirst%3DV.%2BS.%26aulast%3DHarris%26aufirst%3DN.%2BL.%26aulast%3DMuller-Hermelink%26aufirst%3DH.%2BK.%26aulast%3DSeymour%26aufirst%3DJ.%2BF.%26aulast%3DCampbell%26aufirst%3DL.%2BJ.%26aulast%3DHorsman%26aufirst%3DD.%2BE.%26aulast%3DAuvigne%26aufirst%3DI.%26aulast%3DEspinos%26aufirst%3DE.%26aulast%3DSiebert%26aufirst%3DR.%26aulast%3DDelsol%26aufirst%3DG.%26atitle%3DALK-positive%2520diffuse%2520large%2520B-cell%2520lymphoma%2520is%2520associated%2520with%2520Clathrin-ALK%2520rearrangements%253A%2520report%2520of%25206%2520cases%26jtitle%3DBlood%26date%3D2003%26volume%3D102%26spage%3D2568%26epage%3D2573%26doi%3D10.1182%2Fblood-2003-03-0786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Soda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Enomoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takada, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamashita, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujiwara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurashina, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatanaka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bando, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohno, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aburatani, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sohara, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugiyama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mano, H.</span><span> </span><span class="NLM_article-title">Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">448</span><span class="NLM_x">, </span> <span class="NLM_fpage">561</span><span class="NLM_x">–</span> <span class="NLM_lpage">566</span><span class="refDoi"> DOI: 10.1038/nature05945</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1038%2Fnature05945" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=17625570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BD2sXosVSrtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=448&publication_year=2007&pages=561-566&author=M.+Sodaauthor=Y.+L.+Choiauthor=M.+Enomotoauthor=S.+Takadaauthor=Y.+Yamashitaauthor=S.+Ishikawaauthor=S.+Fujiwaraauthor=H.+Watanabeauthor=K.+Kurashinaauthor=H.+Hatanakaauthor=M.+Bandoauthor=S.+Ohnoauthor=Y.+Ishikawaauthor=H.+Aburataniauthor=T.+Nikiauthor=Y.+Soharaauthor=Y.+Sugiyamaauthor=H.+Mano&title=Identification+of+the+transforming+EML4-ALK+fusion+gene+in+non-small-cell+lung+cancer&doi=10.1038%2Fnature05945"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer</span></div><div class="casAuthors">Soda, Manabu; Choi, Young Lim; Enomoto, Munehiro; Takada, Shuji; Yamashita, Yoshihiro; Ishikawa, Shunpei; Fujiwara, Shin-ichiro; Watanabe, Hideki; Kurashina, Kentaro; Hatanaka, Hisashi; Bando, Masashi; Ohno, Shoji; Ishikawa, Yuichi; Aburatani, Hiroyuki; Niki, Toshiro; Sohara, Yasunori; Sugiyama, Yukihiko; Mano, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">448</span>
        (<span class="NLM_cas:issue">7153</span>),
    <span class="NLM_cas:pages">561-566</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Improvement in the clin. outcome of lung cancer is likely to be achieved by identification of the mol. events that underlie its pathogenesis.  Here we show that a small inversion within chromosome 2p results in the formation of a fusion gene comprising portions of the echinoderm microtubule-assocd. protein-like 4 (EML4) gene and the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer (NSCLC) cells.  Mouse 3T3 fibroblasts forced to express this human fusion tyrosine kinase generated transformed foci in culture and s.c. tumors in nude mice.  The EML4-ALK fusion transcript was detected in 6.7% (5 out of 75) of NSCLC patients examd.; these individuals were distinct from those harboring mutations in the epidermal growth factor receptor gene.  Our data demonstrate that a subset of NSCLC patients may express a transforming fusion kinase that is a promising candidate for a therapeutic target as well as for a diagnostic mol. marker in NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomhAXuLtrJ6rVg90H21EOLACvtfcHk0lgTBHZ43xgQug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXosVSrtrs%253D&md5=7f567e80814b9ccc87e5bceeebb467a7</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnature05945&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature05945%26sid%3Dliteratum%253Aachs%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DEnomoto%26aufirst%3DM.%26aulast%3DTakada%26aufirst%3DS.%26aulast%3DYamashita%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DS.%26aulast%3DFujiwara%26aufirst%3DS.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DKurashina%26aufirst%3DK.%26aulast%3DHatanaka%26aufirst%3DH.%26aulast%3DBando%26aufirst%3DM.%26aulast%3DOhno%26aufirst%3DS.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DAburatani%26aufirst%3DH.%26aulast%3DNiki%26aufirst%3DT.%26aulast%3DSohara%26aufirst%3DY.%26aulast%3DSugiyama%26aufirst%3DY.%26aulast%3DMano%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520the%2520transforming%2520EML4-ALK%2520fusion%2520gene%2520in%2520non-small-cell%2520lung%2520cancer%26jtitle%3DNature%26date%3D2007%26volume%3D448%26spage%3D561%26epage%3D566%26doi%3D10.1038%2Fnature05945" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Gainor, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varghese, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kabraji, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Awad, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katayama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawlak, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mino-Kenudson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeap, B. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arcila, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladanyi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dias-Santagata, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span> </span><span class="NLM_article-title">ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">4273</span><span class="NLM_x">–</span> <span class="NLM_lpage">4281</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-0318</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1158%2F1078-0432.CCR-13-0318" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=23729361" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1amt7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=4273-4281&author=J.+F.+Gainorauthor=A.+M.+Vargheseauthor=S.+H.+Ouauthor=S.+Kabrajiauthor=M.+M.+Awadauthor=R.+Katayamaauthor=A.+Pawlakauthor=M.+Mino-Kenudsonauthor=B.+Y.+Yeapauthor=G.+J.+Rielyauthor=A.+J.+Iafrateauthor=M.+E.+Arcilaauthor=M.+Ladanyiauthor=J.+A.+Engelmanauthor=D.+Dias-Santagataauthor=A.+T.+Shaw&title=ALK+rearrangements+are+mutually+exclusive+with+mutations+in+EGFR+or+KRAS%3A+an+analysis+of+1%2C683+patients+with+non-small+cell+lung+cancer&doi=10.1158%2F1078-0432.CCR-13-0318"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Gainor, Justin F.; Varghese, Anna M.; Ou, Sai-Hong Ignatius; Kabraji, Sheheryar; Awad, Mark M.; Katayama, Ryohei; Pawlak, Amanda; Mino-Kenudson, Mari; Yeap, Beow Y.; Riely, Gregory J.; Iafrate, A. John; Arcila, Maria E.; Ladanyi, Marc; Engelman, Jeffrey A.; Dias-Santagata, Dora; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4273-4281</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Anaplastic lymphoma kinase (ALK) gene rearrangements define a distinct mol. subset of non-small cell lung cancer (NSCLC).  Recently, several case reports and small series have reported that ALK rearrangements can overlap with other oncogenic drivers in NSCLC in crizotinib-naive and crizotinib-resistant cancers.  Exptl. Design: We reviewed clin. genotyping data from 1,683 patients with NSCLC and investigated the prevalence of concomitant EGFR or KRAS mutations among patients with ALK-pos. NSCLC.  We also examd. biopsy specimens from 34 patients with ALK-pos. NSCLC after the development of resistance to crizotinib.  Results: Screening identified 301 (17.8%) EGFR mutations, 465 (27.6%) KRAS mutations, and 75 (4.4%) ALK rearrangements.  EGFR mutations and ALK rearrangements were mutually exclusive.  Four patients with KRAS mutations were found to have abnormal ALK FISH patterns, most commonly involving isolated 5' green probes.  Sufficient tissue was available for confirmatory ALK immunohistochem. in 3 cases, all of which were neg. for ALK expression.  Among patients with ALK-pos. NSCLC who acquired resistance to crizotinib, repeat biopsy specimens were ALK FISH pos. in 29 of 29 (100%) cases.  Secondary mutations in the ALK kinase domain and ALK gene amplification were obsd. in 7 of 34 (20.6%) and 3 of 29 (10.3%) cases, resp.  No EGFR or KRAS mutations were identified among any of the 25 crizotinib-resistant, ALK-pos. patients with sufficient tissue for testing.  Conclusions: Functional ALK rearrangements were mutually exclusive with EGFR and KRAS mutations in a large Western patient population.  This lack of overlap was also obsd. in ALK-pos. cancers with acquired resistance to crizotinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnuDecyNaYQrVg90H21EOLACvtfcHk0lhw0-D2yITPOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1amt7zI&md5=6355f3f634ef5b7ba06a497d0bf71a1a</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-0318&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-0318%26sid%3Dliteratum%253Aachs%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DVarghese%26aufirst%3DA.%2BM.%26aulast%3DOu%26aufirst%3DS.%2BH.%26aulast%3DKabraji%26aufirst%3DS.%26aulast%3DAwad%26aufirst%3DM.%2BM.%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DPawlak%26aufirst%3DA.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DYeap%26aufirst%3DB.%2BY.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DDias-Santagata%26aufirst%3DD.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DALK%2520rearrangements%2520are%2520mutually%2520exclusive%2520with%2520mutations%2520in%2520EGFR%2520or%2520KRAS%253A%2520an%2520analysis%2520of%25201%252C683%2520patients%2520with%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D4273%26epage%3D4281%26doi%3D10.1158%2F1078-0432.CCR-13-0318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Mosse, Y. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laudenslager, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Longo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Attiyeh, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laquaglia, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sennett, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laureys, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Speleman, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hakonarson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torkamani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schork, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brodeur, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonini, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rappaport, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maris, J. M.</span><span> </span><span class="NLM_article-title">Identification of ALK as a major familial neuroblastoma predisposition gene</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">455</span><span class="NLM_x">, </span> <span class="NLM_fpage">930</span><span class="NLM_x">–</span> <span class="NLM_lpage">935</span><span class="refDoi"> DOI: 10.1038/nature07261</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1038%2Fnature07261" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=18724359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Ggur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=930-935&author=Y.+P.+Mosseauthor=M.+Laudenslagerauthor=L.+Longoauthor=K.+A.+Coleauthor=A.+Woodauthor=E.+F.+Attiyehauthor=M.+J.+Laquagliaauthor=R.+Sennettauthor=J.+E.+Lynchauthor=P.+Perriauthor=G.+Laureysauthor=F.+Spelemanauthor=C.+Kimauthor=C.+Houauthor=H.+Hakonarsonauthor=A.+Torkamaniauthor=N.+J.+Schorkauthor=G.+M.+Brodeurauthor=G.+P.+Toniniauthor=E.+Rappaportauthor=M.+Devotoauthor=J.+M.+Maris&title=Identification+of+ALK+as+a+major+familial+neuroblastoma+predisposition+gene&doi=10.1038%2Fnature07261"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of ALK as a major familial neuroblastoma predisposition gene</span></div><div class="casAuthors">Mosse, Yael P.; Laudenslager, Marci; Longo, Luca; Cole, Kristina A.; Wood, Andrew; Attiyeh, Edward F.; Laquaglia, Michael J.; Sennett, Rachel; Lynch, Jill E.; Perri, Patrizia; Laureys, Genevieve; Speleman, Frank; Kim, Cecilia; Hou, Cuiping; Hakonarson, Hakon; Torkamani, Ali; Schork, Nicholas J.; Brodeur, Garrett M.; Tonini, Gian P.; Rappaport, Eric; Devoto, Marcella; Maris, John M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">455</span>
        (<span class="NLM_cas:issue">7215</span>),
    <span class="NLM_cas:pages">930-935</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Neuroblastoma is a childhood cancer that can be inherited, but the genetic etiol. is largely unknown.  Here we show that germline mutations in the anaplastic lymphoma kinase (ALK) gene explain most hereditary neuroblastomas, and that activating mutations can also be somatically acquired.  We first identified a significant linkage signal at chromosome bands 2p23-24 using a whole-genome scan in neuroblastoma pedigrees.  Re-sequencing of regional candidate genes identified three sep. germline missense mutations in the tyrosine kinase domain of ALK that segregated with the disease in eight sep. families.  Re-sequencing in 194 high-risk neuroblastoma samples showed somatically acquired mutations in the tyrosine kinase domain in 12.4% of samples.  Nine of the ten mutations map to crit. regions of the kinase domain and were predicted, with high probability, to be oncogenic drivers.  Mutations resulted in constitutive phosphorylation, and targeted knockdown of ALK mRNA resulted in profound inhibition of growth in all cell lines harboring mutant or amplified ALK, as well as in two out of six wild-type cell lines for ALK.  Our results demonstrate that heritable mutations of ALK are the main cause of familial neuroblastoma, and that germline or acquired activation of this cell-surface kinase is a tractable therapeutic target for this lethal pediatric malignancy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMNOcIFf5xjbVg90H21EOLACvtfcHk0lhw0-D2yITPOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Ggur%252FP&md5=bb998ef8f6bfbd85f928263e13954ce4</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnature07261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07261%26sid%3Dliteratum%253Aachs%26aulast%3DMosse%26aufirst%3DY.%2BP.%26aulast%3DLaudenslager%26aufirst%3DM.%26aulast%3DLongo%26aufirst%3DL.%26aulast%3DCole%26aufirst%3DK.%2BA.%26aulast%3DWood%26aufirst%3DA.%26aulast%3DAttiyeh%26aufirst%3DE.%2BF.%26aulast%3DLaquaglia%26aufirst%3DM.%2BJ.%26aulast%3DSennett%26aufirst%3DR.%26aulast%3DLynch%26aufirst%3DJ.%2BE.%26aulast%3DPerri%26aufirst%3DP.%26aulast%3DLaureys%26aufirst%3DG.%26aulast%3DSpeleman%26aufirst%3DF.%26aulast%3DKim%26aufirst%3DC.%26aulast%3DHou%26aufirst%3DC.%26aulast%3DHakonarson%26aufirst%3DH.%26aulast%3DTorkamani%26aufirst%3DA.%26aulast%3DSchork%26aufirst%3DN.%2BJ.%26aulast%3DBrodeur%26aufirst%3DG.%2BM.%26aulast%3DTonini%26aufirst%3DG.%2BP.%26aulast%3DRappaport%26aufirst%3DE.%26aulast%3DDevoto%26aufirst%3DM.%26aulast%3DMaris%26aufirst%3DJ.%2BM.%26atitle%3DIdentification%2520of%2520ALK%2520as%2520a%2520major%2520familial%2520neuroblastoma%2520predisposition%2520gene%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D930%26epage%3D935%26doi%3D10.1038%2Fnature07261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Murugan, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xing, M.</span><span> </span><span class="NLM_article-title">Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">4403</span><span class="NLM_x">–</span> <span class="NLM_lpage">4411</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-4041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1158%2F0008-5472.CAN-10-4041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=21596819" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotlersb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=4403-4411&author=A.+K.+Muruganauthor=M.+Xing&title=Anaplastic+thyroid+cancers+harbor+novel+oncogenic+mutations+of+the+ALK+gene&doi=10.1158%2F0008-5472.CAN-10-4041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic Thyroid Cancers Harbor Novel Oncogenic Mutations of the ALK Gene</span></div><div class="casAuthors">Murugan, Avaniyapuram Kannan; Xing, Mingzhao</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4403-4411</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Thyroid cancer is the most common endocrine cancer, and targeted approaches to treat it pose considerable interest.  In this study, the authors report the discovery of ALK gene mutations in thyroid cancer that may rationalize clin. evaluation of anaplastic lymphoma kinase (ALK) inhibitors in this setting.  In undifferentiated anaplastic thyroid cancer (ATC), the authors identified 2 novel point mutations, C3592T and G3602A, in exon 23 of the ALK gene, with a prevalence of 11.11%, but found no mutations in the matched normal tissues or in well-differentiated thyroid cancers.  These 2 mutations, resulting in L1198F and G1201E amino acid changes, resp., both reside within the ALK tyrosine kinase domain where they dramatically increased tyrosine kinase activities.  Similarly, these mutations heightened the ability of ALK to activate the phosphatidylinositol 3-kinase (PI3K)/Akt and mitogen-activated protein (MAP) kinase pathways in established mouse cells.  Further investigations showed that these 2 ALK mutants strongly promoted cell focus formation, anchorage-independent growth, and cell invasion.  Similar oncogenic properties were obsd. in the neuroblastoma-assocd. ALK mutants K1062M and F1174L but not in wild-type ALK.  Overall, the authors' results reveal 2 novel gain-of-function mutations of ALK in certain ATCs, and they suggest efforts to clin. evaluate the use of ALK kinase inhibitors to treat patients who harbor ATCs with these mutations.  Cancer Res; 71(13); 4403-11.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLyuBgJ52gn7Vg90H21EOLACvtfcHk0li3273ZG5cDZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotlersb4%253D&md5=0316be9945baab3a8d08b6c75e2cd90f</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-4041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-4041%26sid%3Dliteratum%253Aachs%26aulast%3DMurugan%26aufirst%3DA.%2BK.%26aulast%3DXing%26aufirst%3DM.%26atitle%3DAnaplastic%2520thyroid%2520cancers%2520harbor%2520novel%2520oncogenic%2520mutations%2520of%2520the%2520ALK%2520gene%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D4403%26epage%3D4411%26doi%3D10.1158%2F0008-5472.CAN-10-4041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Ren, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, Z. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crosby, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haack, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beausoleil, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moritz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Innocenti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rush, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, X. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comb, M. J.</span><span> </span><span class="NLM_article-title">Identification of anaplastic lymphoma kinase as a potential therapeutic target in ovarian cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">3312</span><span class="NLM_x">–</span> <span class="NLM_lpage">3323</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-11-3931</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1158%2F0008-5472.CAN-11-3931" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=22570254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsFKku7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=3312-3323&author=H.+Renauthor=Z.+P.+Tanauthor=X.+Zhuauthor=K.+Crosbyauthor=H.+Haackauthor=J.+M.+Renauthor=S.+Beausoleilauthor=A.+Moritzauthor=G.+Innocentiauthor=J.+Rushauthor=Y.+Zhangauthor=X.+M.+Zhouauthor=T.+L.+Guauthor=Y.+F.+Yangauthor=M.+J.+Comb&title=Identification+of+anaplastic+lymphoma+kinase+as+a+potential+therapeutic+target+in+ovarian+cancer&doi=10.1158%2F0008-5472.CAN-11-3931"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Anaplastic Lymphoma Kinase as a Potential Therapeutic Target in Ovarian Cancer</span></div><div class="casAuthors">Ren, Hong; Tan, Zhi-Ping; Zhu, Xin; Crosby, Katherine; Haack, Herbert; Ren, Jian-Min; Beausoleil, Sean; Moritz, Albrecht; Innocenti, Gregory; Rush, John; Zhang, Yi; Zhou, Xin-Min; Gu, Ting-Lei; Yang, Yi-Feng; Comb, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3312-3323</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Findings suggest the use of ALK kinase inhibitors now in clin. development as potential agents for treatment of some patients with serous ovarian carcinoma or stromal sarcoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoi924EZXGeJ7Vg90H21EOLACvtfcHk0li3273ZG5cDZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsFKku7w%253D&md5=a263a135244b307b864c098769d10a7a</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-3931&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-3931%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DH.%26aulast%3DTan%26aufirst%3DZ.%2BP.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DCrosby%26aufirst%3DK.%26aulast%3DHaack%26aufirst%3DH.%26aulast%3DRen%26aufirst%3DJ.%2BM.%26aulast%3DBeausoleil%26aufirst%3DS.%26aulast%3DMoritz%26aufirst%3DA.%26aulast%3DInnocenti%26aufirst%3DG.%26aulast%3DRush%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DX.%2BM.%26aulast%3DGu%26aufirst%3DT.%2BL.%26aulast%3DYang%26aufirst%3DY.%2BF.%26aulast%3DComb%26aufirst%3DM.%2BJ.%26atitle%3DIdentification%2520of%2520anaplastic%2520lymphoma%2520kinase%2520as%2520a%2520potential%2520therapeutic%2520target%2520in%2520ovarian%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D3312%26epage%3D3323%26doi%3D10.1158%2F0008-5472.CAN-11-3931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran-Dube, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pairish, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funk, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botrous, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grodsky, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padrique, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timofeevski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mroczkowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kania, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. P.</span><span> </span><span class="NLM_article-title">Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">6342</span><span class="NLM_x">–</span> <span class="NLM_lpage">6363</span><span class="refDoi"> DOI: 10.1021/jm2007613</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2007613" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVegtLrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6342-6363&author=J.+J.+Cuiauthor=M.+Tran-Dubeauthor=H.+Shenauthor=M.+Nambuauthor=P.+P.+Kungauthor=M.+Pairishauthor=L.+Jiaauthor=J.+Mengauthor=L.+Funkauthor=I.+Botrousauthor=M.+McTigueauthor=N.+Grodskyauthor=K.+Ryanauthor=E.+Padriqueauthor=G.+Altonauthor=S.+Timofeevskiauthor=S.+Yamazakiauthor=Q.+Liauthor=H.+Zouauthor=J.+Christensenauthor=B.+Mroczkowskiauthor=S.+Benderauthor=R.+S.+Kaniaauthor=M.+P.+Edwards&title=Structure+based+drug+design+of+crizotinib+%28PF-02341066%29%2C+a+potent+and+selective+dual+inhibitor+of+mesenchymal-epithelial+transition+factor+%28c-MET%29+kinase+and+anaplastic+lymphoma+kinase+%28ALK%29&doi=10.1021%2Fjm2007613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)</span></div><div class="casAuthors">Cui, J. Jean; Tran-Dube, Michelle; Shen, Hong; Nambu, Mitchell; Kung, Pei-Pei; Pairish, Mason; Jia, Lei; Meng, Jerry; Funk, Lee; Botrous, Iriny; McTigue, Michele; Grodsky, Neil; Ryan, Kevin; Padrique, Ellen; Alton, Gordon; Timofeevski, Sergei; Yamazaki, Shinji; Li, Qiuhua; Zou, Helen; Christensen, James; Mroczkowski, Barbara; Bender, Steve; Kania, Robert S.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6342-6363</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Because of the crit. roles of aberrant signaling in cancer, both c-MET and ALK receptor tyrosine kinases are attractive oncol. targets for therapeutic intervention.  The cocrystal structure of 3 (PHA-665752), bound to c-MET kinase domain, revealed a novel ATP site environment, which served as the target to guide parallel, multiattribute drug design.  A novel 2-amino-5-aryl-3-benzyloxypyridine series was created to more effectively make the key interactions achieved with 3.  In the novel series, the 2-aminopyridine core allowed a 3-benzyloxy group to reach into the same pocket as the 2,6-dichlorophenyl group of 3 via a more direct vector and thus with a better ligand efficiency (LE).  Further optimization of the lead series generated the clin. candidate crizotinib (PF-02341066), which demonstrated potent in vitro and in vivo c-MET kinase and ALK inhibition, effective tumor growth inhibition, and good pharmaceutical properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHs_cKJ-U3t7Vg90H21EOLACvtfcHk0lgHethOMcGrmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVegtLrN&md5=dbab4c1b3e7c76180dbad04be2b6a474</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fjm2007613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2007613%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DTran-Dube%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DNambu%26aufirst%3DM.%26aulast%3DKung%26aufirst%3DP.%2BP.%26aulast%3DPairish%26aufirst%3DM.%26aulast%3DJia%26aufirst%3DL.%26aulast%3DMeng%26aufirst%3DJ.%26aulast%3DFunk%26aufirst%3DL.%26aulast%3DBotrous%26aufirst%3DI.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DGrodsky%26aufirst%3DN.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DPadrique%26aufirst%3DE.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DStructure%2520based%2520drug%2520design%2520of%2520crizotinib%2520%2528PF-02341066%2529%252C%2520a%2520potent%2520and%2520selective%2520dual%2520inhibitor%2520of%2520mesenchymal-epithelial%2520transition%2520factor%2520%2528c-MET%2529%2520kinase%2520and%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6342%26epage%3D6363%26doi%3D10.1021%2Fjm2007613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arango, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonnell, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koudriakova, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambu, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Los, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mroczkowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span> </span><span class="NLM_article-title">An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">4408</span><span class="NLM_x">–</span> <span class="NLM_lpage">4417</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-06-4443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1158%2F0008-5472.CAN-06-4443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=17483355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltVyrsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=4408-4417&author=H.+Y.+Zouauthor=Q.+Liauthor=J.+H.+Leeauthor=M.+E.+Arangoauthor=S.+R.+McDonnellauthor=S.+Yamazakiauthor=T.+B.+Koudriakovaauthor=G.+Altonauthor=J.+J.+Cuiauthor=P.+P.+Kungauthor=M.+D.+Nambuauthor=G.+Losauthor=S.+L.+Benderauthor=B.+Mroczkowskiauthor=J.+G.+Christensen&title=An+orally+available+small-molecule+inhibitor+of+c-Met%2C+PF-2341066%2C+exhibits+cytoreductive+antitumor+efficacy+through+antiproliferative+and+antiangiogenic+mechanisms&doi=10.1158%2F0008-5472.CAN-06-4443"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms</span></div><div class="casAuthors">Zou, Helen Y.; Li, Qiuhua; Lee, Joseph H.; Arango, Maria E.; McDonnell, Scott R.; Yamazaki, Shinji; Koudriakova, Tatiana B.; Alton, Gordon; Cui, Jingrong J.; Kung, Pei-Pei; Nambu, Mitchell D.; Los, Gerrit; Bender, Steven L.; Mroczkowski, Barbara; Christensen, James G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4408-4417</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The c-Met receptor tyrosine kinase and its ligand, hepatocyte growth factor (HGF), have been implicated in the progression of several human cancers and are attractive therapeutic targets.  PF-2341066 was identified as a potent, orally bioavailable, ATP-competitive small-mol. inhibitor of the catalytic activity of c-Met kinase.  PF-2341066 was selective for c-Met (and anaplastic lymphoma kinase) compared with a panel of >120 diverse tyrosine and serine-threonine kinases.  PF-2341066 potently inhibited c-Met phosphorylation and c-Met-dependent proliferation, migration, or invasion of human tumor cells in vitro (IC50 values, 5-20 nmol/L).  In addn., PF-2341066 potently inhibited HGF-stimulated endothelial cell survival or invasion and serum-stimulated tubulogenesis in vitro, suggesting that this agent also exhibits antiangiogenic properties.  PF-2341066 showed efficacy at well-tolerated doses, including marked cytoreductive antitumor activity, in several tumor models that expressed activated c-Met.  The antitumor efficacy of PF-2341066 was dose dependent and showed a strong correlation to inhibition of c-Met phosphorylation in vivo.  Near-maximal inhibition of c-Met activity for the full dosing interval was necessary to maximize the efficacy of PF-2341066.  Addnl. mechanism-of-action studies showed dose-dependent inhibition of c-Met-dependent signal transduction, tumor cell proliferation (Ki67), induction of apoptosis (caspase-3), and redn. of microvessel d. (CD31).  These results indicated that the antitumor activity of PF-2341066 may be mediated by direct effects on tumor cell growth or survival as well as antiangiogenic mechanisms.  Collectively, these results show the therapeutic potential of targeting c-Met with selective small-mol. inhibitors for the treatment of human cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEAWtGPOBHC7Vg90H21EOLACvtfcHk0lgHethOMcGrmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltVyrsbg%253D&md5=798bf93e6cf8d5e9897e27485cba9002</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-4443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-4443%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DArango%26aufirst%3DM.%2BE.%26aulast%3DMcDonnell%26aufirst%3DS.%2BR.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DKoudriakova%26aufirst%3DT.%2BB.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DKung%26aufirst%3DP.%2BP.%26aulast%3DNambu%26aufirst%3DM.%2BD.%26aulast%3DLos%26aufirst%3DG.%26aulast%3DBender%26aufirst%3DS.%2BL.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26atitle%3DAn%2520orally%2520available%2520small-molecule%2520inhibitor%2520of%2520c-Met%252C%2520PF-2341066%252C%2520exhibits%2520cytoreductive%2520antitumor%2520efficacy%2520through%2520antiproliferative%2520and%2520antiangiogenic%2520mechanisms%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D4408%26epage%3D4417%26doi%3D10.1158%2F0008-5472.CAN-06-4443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crino, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Pas, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besse, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackhall, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Byrne, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moro-Sibilot, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mok, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsh, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iyer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tassell, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span> </span><span class="NLM_article-title">Crizotinib versus chemotherapy in advanced ALK-positive lung cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">368</span><span class="NLM_x">, </span> <span class="NLM_fpage">2385</span><span class="NLM_x">–</span> <span class="NLM_lpage">2394</span><span class="refDoi"> DOI: 10.1056/NEJMoa1214886</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1056%2FNEJMoa1214886" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=23724913" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVSnu7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2013&pages=2385-2394&author=A.+T.+Shawauthor=D.+W.+Kimauthor=K.+Nakagawaauthor=T.+Setoauthor=L.+Crinoauthor=M.+J.+Ahnauthor=T.+De+Pasauthor=B.+Besseauthor=B.+J.+Solomonauthor=F.+Blackhallauthor=Y.+L.+Wuauthor=M.+Thomasauthor=K.+J.+O%E2%80%99Byrneauthor=D.+Moro-Sibilotauthor=D.+R.+Camidgeauthor=T.+Mokauthor=V.+Hirshauthor=G.+J.+Rielyauthor=S.+Iyerauthor=V.+Tassellauthor=A.+Polliauthor=K.+D.+Wilnerauthor=P.+A.+Janne&title=Crizotinib+versus+chemotherapy+in+advanced+ALK-positive+lung+cancer&doi=10.1056%2FNEJMoa1214886"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Crizotinib versus chemotherapy in advanced ALK-positive lung cancer</span></div><div class="casAuthors">Shaw, Alice T.; Kim, Dong-Wan; Nakagawa, Kazuhiko; Seto, Takashi; Crino, Lucio; Ahn, Myung-Ju; De Pas, Tommaso; Besse, Benjamin; Solomon, Benjamin J.; Blackhall, Fiona; Wu, Yi-Long; Thomas, Michael; O'Byrne, Kenneth J.; Moro-Sibilot, Denis; Camidge, D. Ross; Mok, Tony; Hirsh, Vera; Riely, Gregory J.; Iyer, Shrividya; Tassell, Vanessa; Polli, Anna; Wilner, Keith D.; Janne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">368</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2385-2394</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">In single-group studies, chromosomal rearrangements of the anaplastic lymphoma kinase gene (ALK) have been assocd. with marked clin. responses to crizotinib, an oral tyrosine kinase inhibitor targeting ALK.  Whether crizotinib is superior to std. chemotherapy with respect to efficacy is unknown.  We conducted a phase 3, open-label trial comparing crizotinib with chemotherapy in 347 patients with locally advanced or metastatic ALK-pos. lung cancer who had received one prior platinum-based regimen.  Patients were randomly assigned to receive oral treatment with crizotinib (250 mg) twice daily or i.v. chemotherapy with either pemetrexed (500 mg per square meter of body-surface area) or docetaxel (75 mg per square meter) every 3 wk.  Patients in the chemotherapy group who had disease progression were permitted to cross over to crizotinib as part of a sep. study.  The primary end point was progression-free survival.  The median progression-free survival was 7.7 mo in the crizotinib group and 3.0 mo in the chemotherapy group (hazard ratio for progression or death with crizotinib, 0.49; 95% confidence interval [CI], 0.37 to 0.64; P<0.001).  The response rates were 65% (95% CI, 58 to 72) with crizotinib, as compared with 20% (95% CI, 14 to 26) with chemotherapy (P<0.001).  An interim anal. of overall survival showed no significant improvement with crizotinib as compared with chemotherapy (hazard ratio for death in the crizotinib group, 1.02; 95% CI, 0.68 to 1.54; P = 0.54).  Common adverse events assocd. with crizotinib were visual disorder, gastrointestinal side effects, and elevated liver aminotransferase levels, whereas common adverse events with chemotherapy were fatigue, alopecia, and dyspnea.  Patients reported greater redns. in symptoms of lung cancer and greater improvement in global quality of life with crizotinib than with chemotherapy.  Crizotinib is superior to std. chemotherapy in patients with previously treated, advanced non-small-cell lung cancer with ALK rearrangement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrk62MsVCiljLVg90H21EOLACvtfcHk0ljl7vprz1fBUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVSnu7%252FM&md5=8c6f1a73472f87fa9a19ceac6fdbb132</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1214886&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1214886%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DNakagawa%26aufirst%3DK.%26aulast%3DSeto%26aufirst%3DT.%26aulast%3DCrino%26aufirst%3DL.%26aulast%3DAhn%26aufirst%3DM.%2BJ.%26aulast%3DDe%2BPas%26aufirst%3DT.%26aulast%3DBesse%26aufirst%3DB.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DBlackhall%26aufirst%3DF.%26aulast%3DWu%26aufirst%3DY.%2BL.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Byrne%26aufirst%3DK.%2BJ.%26aulast%3DMoro-Sibilot%26aufirst%3DD.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DMok%26aufirst%3DT.%26aulast%3DHirsh%26aufirst%3DV.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DIyer%26aufirst%3DS.%26aulast%3DTassell%26aufirst%3DV.%26aulast%3DPolli%26aufirst%3DA.%26aulast%3DWilner%26aufirst%3DK.%2BD.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DCrizotinib%2520versus%2520chemotherapy%2520in%2520advanced%2520ALK-positive%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D368%26spage%3D2385%26epage%3D2394%26doi%3D10.1056%2FNEJMoa1214886" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Solomon, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mok, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mekhail, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felip, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cappuzzo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paolini, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Usari, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iyer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reisman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tursi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackhall, F.</span><span> </span><span class="NLM_article-title">First-line crizotinib versus chemotherapy in ALK-positive lung cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">371</span><span class="NLM_x">, </span> <span class="NLM_fpage">2167</span><span class="NLM_x">–</span> <span class="NLM_lpage">2177</span><span class="refDoi"> DOI: 10.1056/NEJMoa1408440</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1056%2FNEJMoa1408440" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=25470694" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1ekt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2014&pages=2167-2177&author=B.+J.+Solomonauthor=T.+Mokauthor=D.+W.+Kimauthor=Y.+L.+Wuauthor=K.+Nakagawaauthor=T.+Mekhailauthor=E.+Felipauthor=F.+Cappuzzoauthor=J.+Paoliniauthor=T.+Usariauthor=S.+Iyerauthor=A.+Reismanauthor=K.+D.+Wilnerauthor=J.+Tursiauthor=F.+Blackhall&title=First-line+crizotinib+versus+chemotherapy+in+ALK-positive+lung+cancer&doi=10.1056%2FNEJMoa1408440"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">First-line crizotinib versus chemotherapy in ALK-positive lung cancer</span></div><div class="casAuthors">Solomon, Benjamin J.; Mok, Tony; Kim, Dong-Wan; Wu, Yi-Long; Nakagawa, Kazuhiko; Mekhail, Tarek; Felip, Enriqueta; Cappuzzo, Federico; Paolini, Jolanda; Usari, Tiziana; Iyer, Shrividya; Reisman, Arlene; Wilner, Keith D.; Tursi, Jennifer; Blackhall, Fiona</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2167-2177/1-2167-2177/11, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND The efficacy of the ALK inhibitor crizotinib as compared with std. chemotherapy as first-line treatment for advanced ALK-pos. non-small-cell lung cancer (NSCLC) is unknown.  METHODS We conducted an open-label, phase 3 trial comparing crizotinib with chemotherapy in 343 patients with advanced ALK-pos. nonsquamous NSCLC who had received no previous systemic treatment for advanced disease.  Patients were randomly assigned to receive oral crizotinib at a dose of 250 mg twice daily or to receive i.v. chemotherapy (pemetrexed, 500 mg per square meter of bodysurface area, plus either cisplatin, 75 mg per square meter, or carboplatin, target area under the curve of 5 to 6 mg per mL per min) every 3 wk for up to six cycles.  Crossover to crizotinib treatment after disease progression was permitted for patients receiving chemotherapy.  The primary end point was progression-free survival as assessed by independent radiol. review.  RESULTS Progression-free survival was significantly longer with crizotinib than with chemotherapy (median, 10.9 mo vs. 7.0 mo; hazard ratio for progression or death with crizotinib, 0.45; 95% confidence interval [CI], 0.35 to 0.60; P<0.001).  Objective response rates were 74% and 45 %, resp. (P<0.001).  Median overall survival was not reached in either group (hazard ratio for death with crizotinib, 0.82; 95% CI, 0.54 to 1.26; P = 0.36); the probability of 1-yr survival was 84% with crizotinib and 79% with chemotherapy.  The most common adverse events with crizotinib were vision disorders, diarrhea, nausea, and edema, and the most common events with chemotherapy were nausea, fatigue, vomiting, and decreased appetite.  As compared with chemotherapy, crizotinib was assocd. with greater redn. in lung cancer symptoms and greater improvement in quality of life.  CONCLUSIONS Crizotinib was superior to std. first-line pemetrexed-plus-platinum chemotherapy in patients with previously untreated advanced ALK-pos. NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoV7N7XM7ywBLVg90H21EOLACvtfcHk0ljl7vprz1fBUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1ekt74%253D&md5=afd3c75ef95aff5c0fa12b6b7e22b46a</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1408440&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1408440%26sid%3Dliteratum%253Aachs%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DMok%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DWu%26aufirst%3DY.%2BL.%26aulast%3DNakagawa%26aufirst%3DK.%26aulast%3DMekhail%26aufirst%3DT.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DCappuzzo%26aufirst%3DF.%26aulast%3DPaolini%26aufirst%3DJ.%26aulast%3DUsari%26aufirst%3DT.%26aulast%3DIyer%26aufirst%3DS.%26aulast%3DReisman%26aufirst%3DA.%26aulast%3DWilner%26aufirst%3DK.%2BD.%26aulast%3DTursi%26aufirst%3DJ.%26aulast%3DBlackhall%26aufirst%3DF.%26atitle%3DFirst-line%2520crizotinib%2520versus%2520chemotherapy%2520in%2520ALK-positive%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D371%26spage%3D2167%26epage%3D2177%26doi%3D10.1056%2FNEJMoa1408440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Steuer, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramalingam, S. S.</span><span> </span><span class="NLM_article-title">ALK-positive non-small cell lung cancer: mechanisms of resistance and emerging treatment options</span> <span class="citation_source-journal">Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">120</span><span class="NLM_x">, </span> <span class="NLM_fpage">2392</span><span class="NLM_x">–</span> <span class="NLM_lpage">2402</span><span class="refDoi"> DOI: 10.1002/cncr.28597</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1002%2Fcncr.28597" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2014&pages=2392-2402&author=C.+E.+Steuerauthor=S.+S.+Ramalingam&title=ALK-positive+non-small+cell+lung+cancer%3A+mechanisms+of+resistance+and+emerging+treatment+options&doi=10.1002%2Fcncr.28597"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1002%2Fcncr.28597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.28597%26sid%3Dliteratum%253Aachs%26aulast%3DSteuer%26aufirst%3DC.%2BE.%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26atitle%3DALK-positive%2520non-small%2520cell%2520lung%2520cancer%253A%2520mechanisms%2520of%2520resistance%2520and%2520emerging%2520treatment%2520options%26jtitle%3DCancer%26date%3D2014%26volume%3D120%26spage%3D2392%26epage%3D2402%26doi%3D10.1002%2Fcncr.28597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Toyokawa, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seto, T.</span><span> </span><span class="NLM_article-title">Updated evidence on the mechanisms of resistance to ALK inhibitors and strategies to overcome such resistance: clinical and preclinical data</span> <span class="citation_source-journal">Oncol. Res. Treat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">291</span><span class="NLM_x">–</span> <span class="NLM_lpage">298</span><span class="refDoi"> DOI: 10.1159/000430852</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1159%2F000430852" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=26045026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpvVKit7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2015&pages=291-298&author=G.+Toyokawaauthor=T.+Seto&title=Updated+evidence+on+the+mechanisms+of+resistance+to+ALK+inhibitors+and+strategies+to+overcome+such+resistance%3A+clinical+and+preclinical+data&doi=10.1159%2F000430852"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Updated Evidence on the Mechanisms of Resistance to ALK Inhibitors and Strategies to Overcome Such Resistance: Clinical and Preclinical Data</span></div><div class="casAuthors">Toyokawa, Gouji; Seto, Takashi</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Research and Treatment</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">291-298</span>CODEN:
                <span class="NLM_cas:coden">ORTNB2</span>;
        ISSN:<span class="NLM_cas:issn">2296-5270</span>.
    
            (<span class="NLM_cas:orgname">S. Karger GmbH</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase(ALK) rearrangement is one of the oncogenes in non-small cell lung cancer (NSCLC) identified in 2007.  The PROFILE trials demonstrated that patients with ALK-rearranged NSCLC can be successfully treated with crizotinib, and that crizotinib is superior to chemotherapy in both first- and second-line settings.  Furthermore, next-generation ALK inhibitors, such as alectinib and ceritinib, have been shown to harbor excellent efficacy for NSCLC patients with ALK rearrangement.  However, it is known that many cases ultimately acquire resistance to ALK inhibitors.  Some potential mechanisms of resistance to ALK inhibitors are as follows: ALK dominant resistance, such as secondary mutations and copy no. gain in the ALK gene; activation of the bypass tracks, including EGFR, KRAS, KIT, MET, and IGF-1R.  Furthermore, treatment strategies to overcome these resistance mechanisms have been proposed, and next-generation ALK inhibitors, agents which inhibit the bypass tracks, and heat shock protein 90 inhibitors are thought to be promising.  Thus, clin. and pre-clin. evidence on the resistance mechanisms to ALK inhibitors and treatment strategies to overcome the resistance have been gradually obtained.  Herein, we concisely review the current clin. and pre-clin. data regarding the mechanisms of resistance to ALK inhibitors and treatments to overcome such resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodLzrCSGMfxbVg90H21EOLACvtfcHk0ljl7vprz1fBUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpvVKit7g%253D&md5=2cc77bae5e32bd39cee710ecfbbc205d</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1159%2F000430852&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000430852%26sid%3Dliteratum%253Aachs%26aulast%3DToyokawa%26aufirst%3DG.%26aulast%3DSeto%26aufirst%3DT.%26atitle%3DUpdated%2520evidence%2520on%2520the%2520mechanisms%2520of%2520resistance%2520to%2520ALK%2520inhibitors%2520and%2520strategies%2520to%2520overcome%2520such%2520resistance%253A%2520clinical%2520and%2520preclinical%2520data%26jtitle%3DOncol.%2520Res.%2520Treat.%26date%3D2015%26volume%3D38%26spage%3D291%26epage%3D298%26doi%3D10.1159%2F000430852" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Awad, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span> </span><span class="NLM_article-title">ALK inhibitors in non-small cell lung cancer: crizotinib and beyond</span> <span class="citation_source-journal">Clin. Adv. Hematol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">429</span><span class="NLM_x">–</span> <span class="NLM_lpage">439</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=25322323" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A280%3ADC%252BC2M3htl2qug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2014&pages=429-439&author=M.+M.+Awadauthor=A.+T.+Shaw&title=ALK+inhibitors+in+non-small+cell+lung+cancer%3A+crizotinib+and+beyond"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">ALK inhibitors in non-small cell lung cancer: crizotinib and beyond</span></div><div class="casAuthors">Awad Mark M; Shaw Alice T</div><div class="citationInfo"><span class="NLM_cas:title">Clinical advances in hematology & oncology : H&O</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">429-39</span>
        ISSN:<span class="NLM_cas:issn">1543-0790</span>.
    </div><div class="casAbstract">The treatment of patients with advanced non-small cell lung cancer (NSCLC) harboring chromosomal rearrangements of anaplastic lymphoma kinase (ALK) has been revolutionized by the development of crizotinib, a small molecule inhibitor of the tyrosine kinases ALK, ROS1, and MET.  Resistance to crizotinib invariably develops, however, through a variety of mechanisms.  In the last few years, a flurry of new and more potent ALK inhibitors has emerged for the treatment of ALK-positive NSCLC, including ceritinib (LDK378), alectinib (RO5424802/CH5424802), AP26113, ASP3026, TSR-011, PF-06463922, RXDX-101, X-396, and CEP-37440.  Cancers harboring ALK rearrangements may also be susceptible to treatment with heat shock protein 90 inhibitors.  This review focuses on the pharmacologic and clinical properties of these compounds, either as monotherapies or in combination with other drugs.  With so many ALK inhibitors in development, the challenges of how these agents should be studied and ultimately prescribed are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSTc4MrEK-FRv9pSBfyDvp7fW6udTcc2eYU4cBmWp5goLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M3htl2qug%253D%253D&md5=ae4655774258c9265a283749559ac393</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAwad%26aufirst%3DM.%2BM.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DALK%2520inhibitors%2520in%2520non-small%2520cell%2520lung%2520cancer%253A%2520crizotinib%2520and%2520beyond%26jtitle%3DClin.%2520Adv.%2520Hematol.%2520Oncol.%26date%3D2014%26volume%3D12%26spage%3D429%26epage%3D439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Marsilje, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pei, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uno, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warmuth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarkisova, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steffy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pferdekamper, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joseph, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuntland, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steensma, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chopiuk, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richmond, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groessl, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phimister, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aycinena, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bursulaya, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karanewsky, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seidel, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michellys, P. Y.</span><span> </span><span class="NLM_article-title">Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N<sup>2</sup>-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N<sup>4</sup>-(2-(isopropylsulf onyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">5675</span><span class="NLM_x">–</span> <span class="NLM_lpage">5690</span><span class="refDoi"> DOI: 10.1021/jm400402q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400402q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptVWjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=5675-5690&author=T.+H.+Marsiljeauthor=W.+Peiauthor=B.+Chenauthor=W.+Luauthor=T.+Unoauthor=Y.+Jinauthor=T.+Jiangauthor=S.+Kimauthor=N.+Liauthor=M.+Warmuthauthor=Y.+Sarkisovaauthor=F.+Sunauthor=A.+Steffyauthor=A.+C.+Pferdekamperauthor=A.+G.+Liauthor=S.+B.+Josephauthor=Y.+Kimauthor=B.+Liuauthor=T.+Tuntlandauthor=X.+Cuiauthor=N.+S.+Grayauthor=R.+Steensmaauthor=Y.+Wanauthor=J.+Jiangauthor=G.+Chopiukauthor=J.+Liauthor=W.+P.+Gordonauthor=W.+Richmondauthor=K.+Johnsonauthor=J.+Changauthor=T.+Groesslauthor=Y.+Q.+Heauthor=A.+Phimisterauthor=A.+Aycinenaauthor=C.+C.+Leeauthor=B.+Bursulayaauthor=D.+S.+Karanewskyauthor=H.+M.+Seidelauthor=J.+L.+Harrisauthor=P.+Y.+Michellys&title=Synthesis%2C+structure-activity+relationships%2C+and+in+vivo+efficacy+of+the+novel+potent+and+selective+anaplastic+lymphoma+kinase+%28ALK%29+inhibitor+5-chloro-N2-%282-isopropoxy-5-methyl-4-%28piperidin-4-yl%29phenyl%29-N4-%282-%28isopropylsulf+onyl%29phenyl%29pyrimidine-2%2C4-diamine+%28LDK378%29+currently+in+phase+1+and+phase+2+clinical+trials&doi=10.1021%2Fjm400402q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Structure-Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials</span></div><div class="casAuthors">Marsilje, Thomas H.; Pei, Wei; Chen, Bei; Lu, Wenshuo; Uno, Tetsuo; Jin, Yunho; Jiang, Tao; Kim, Sungjoon; Li, Nanxin; Warmuth, Markus; Sarkisova, Yelena; Sun, Frank; Steffy, Auzon; Pferdekamper, AnneMarie C.; Li, Allen G.; Joseph, Sean B.; Kim, Young; Liu, Bo; Tuntland, Tove; Cui, Xiaoming; Gray, Nathanael S.; Steensma, Ruo; Wan, Yongqin; Jiang, Jiqing; Chopiuk, Greg; Li, Jie; Gordon, W. Perry; Richmond, Wendy; Johnson, Kevin; Chang, Jonathan; Groessl, Todd; He, You-Qun; Phimister, Andrew; Aycinena, Alex; Lee, Christian C.; Bursulaya, Badry; Karanewsky, Donald S.; Seidel, H. Martin; Harris, Jennifer L.; Michellys, Pierre-Yves</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5675-5690</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis, preclin. profile, and in vivo efficacy in rat xenograft models of the novel and selective anaplastic lymphoma kinase inhibitor (I; LDK378) are described.  In this initial report, preliminary structure-activity relationships (SARs) are described as well as the rational design strategy employed to overcome the development deficiencies of the first generation ALK inhibitor (II; TAE684).  Compd. I is currently in phase 1 and phase 2 clin. trials with substantial antitumor activity being obsd. in ALK-pos. cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZ-y7ZuX2XLLVg90H21EOLACvtfcHk0ljrSLAnujbnfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptVWjs7g%253D&md5=4b8f66e4acb27efe814956d7d0016068</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm400402q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400402q%26sid%3Dliteratum%253Aachs%26aulast%3DMarsilje%26aufirst%3DT.%2BH.%26aulast%3DPei%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DUno%26aufirst%3DT.%26aulast%3DJin%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DSarkisova%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DSteffy%26aufirst%3DA.%26aulast%3DPferdekamper%26aufirst%3DA.%2BC.%26aulast%3DLi%26aufirst%3DA.%2BG.%26aulast%3DJoseph%26aufirst%3DS.%2BB.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DSteensma%26aufirst%3DR.%26aulast%3DWan%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DChopiuk%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DGordon%26aufirst%3DW.%2BP.%26aulast%3DRichmond%26aufirst%3DW.%26aulast%3DJohnson%26aufirst%3DK.%26aulast%3DChang%26aufirst%3DJ.%26aulast%3DGroessl%26aufirst%3DT.%26aulast%3DHe%26aufirst%3DY.%2BQ.%26aulast%3DPhimister%26aufirst%3DA.%26aulast%3DAycinena%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DC.%2BC.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DKaranewsky%26aufirst%3DD.%2BS.%26aulast%3DSeidel%26aufirst%3DH.%2BM.%26aulast%3DHarris%26aufirst%3DJ.%2BL.%26aulast%3DMichellys%26aufirst%3DP.%2BY.%26atitle%3DSynthesis%252C%2520structure-activity%2520relationships%252C%2520and%2520in%2520vivo%2520efficacy%2520of%2520the%2520novel%2520potent%2520and%2520selective%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520inhibitor%25205-chloro-N2-%25282-isopropoxy-5-methyl-4-%2528piperidin-4-yl%2529phenyl%2529-N4-%25282-%2528isopropylsulf%2520onyl%2529phenyl%2529pyrimidine-2%252C4-diamine%2520%2528LDK378%2529%2520currently%2520in%2520phase%25201%2520and%2520phase%25202%2520clinical%2520trials%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D5675%26epage%3D5690%26doi%3D10.1021%2Fjm400402q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Friboulet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katayama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gainor, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crystal, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michellys, P. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Awad, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yanagitani, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pferdekamper, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasibhatla, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hua, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahmood, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockerman, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujita, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span> </span><span class="NLM_article-title">The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">662</span><span class="NLM_x">–</span> <span class="NLM_lpage">673</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-13-0846</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1158%2F2159-8290.CD-13-0846" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=24675041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpsVGgs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=662-673&author=L.+Fribouletauthor=N.+Liauthor=R.+Katayamaauthor=C.+C.+Leeauthor=J.+F.+Gainorauthor=A.+S.+Crystalauthor=P.+Y.+Michellysauthor=M.+M.+Awadauthor=N.+Yanagitaniauthor=S.+Kimauthor=A.+C.+Pferdekamperauthor=J.+Liauthor=S.+Kasibhatlaauthor=F.+Sunauthor=X.+Sunauthor=S.+Huaauthor=P.+McNamaraauthor=S.+Mahmoodauthor=E.+L.+Lockermanauthor=N.+Fujitaauthor=M.+Nishioauthor=J.+L.+Harrisauthor=A.+T.+Shawauthor=J.+A.+Engelman&title=The+ALK+inhibitor+ceritinib+overcomes+crizotinib+resistance+in+non-small+cell+lung+cancer&doi=10.1158%2F2159-8290.CD-13-0846"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Friboulet, Luc; Li, Nanxin; Katayama, Ryohei; Lee, Christian C.; Gainor, Justin F.; Crystal, Adam S.; Michellys, Pierre-Yves; Awad, Mark M.; Yanagitani, Noriko; Kim, Sungjoon; Pferdekamper, AnneMarie C.; Li, Jie; Kasibhatla, Shailaja; Sun, Frank; Sun, Xiuying; Hua, Su; McNamara, Peter; Mahmood, Sidra; Lockerman, Elizabeth L.; Fujita, Naoya; Nishio, Makoto; Harris, Jennifer L.; Shaw, Alice T.; Engelman, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">662-673</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Non-small cell lung cancers (NSCLC) harboring anaplastic lymphoma kinase (ALK) gene rearrangements invariably develop resistance to the ALK tyrosine kinase inhibitor (TKI) crizotinib.  Herein, we report the first preclin. evaluation of the next-generation ALK TKI, ceritinib (LDKB78), in the setting of crizotinib resistance.  An interrogation of in vitro and in vivo models of acquired resistance to crizotinib, including cell lines established from biopsies of patients with crizotinib-resistant NSCLC, revealed that ceritinib potently overcomes crizotinib-resistant mutations.  In particular, ceritinib effectively inhibits ALK harboring L1196M, G1269A, 11171T1 and S1206Y mutations, and a cocrystal structure of ceritinib bound to ALK provides structural bases for this increased potency.  However, we obsd. that ceritinib did not overcome two crizotinib-resistant ALK mutations, G1202R and F1174C, and one of these mutations was identified in 5 of 11 biopsies from patients with acquired resistance to ceritinib.  Altogether, our results demonstrate that ceritinib can overcome crizotinib resistance, consistent with clin. data showing marked efficacy of ceritinib in patients with crizotinib-resistant disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRf8PgZpJ60bVg90H21EOLACvtfcHk0lhWzK-YsJiy9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpsVGgs78%253D&md5=f60c45d0debfa6e86ff10c758c95da8d</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0846&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0846%26sid%3Dliteratum%253Aachs%26aulast%3DFriboulet%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DC.%2BC.%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DCrystal%26aufirst%3DA.%2BS.%26aulast%3DMichellys%26aufirst%3DP.%2BY.%26aulast%3DAwad%26aufirst%3DM.%2BM.%26aulast%3DYanagitani%26aufirst%3DN.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DPferdekamper%26aufirst%3DA.%2BC.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DKasibhatla%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DSun%26aufirst%3DX.%26aulast%3DHua%26aufirst%3DS.%26aulast%3DMcNamara%26aufirst%3DP.%26aulast%3DMahmood%26aufirst%3DS.%26aulast%3DLockerman%26aufirst%3DE.%2BL.%26aulast%3DFujita%26aufirst%3DN.%26aulast%3DNishio%26aufirst%3DM.%26aulast%3DHarris%26aufirst%3DJ.%2BL.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520ALK%2520inhibitor%2520ceritinib%2520overcomes%2520crizotinib%2520resistance%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26spage%3D662%26epage%3D673%26doi%3D10.1158%2F2159-8290.CD-13-0846" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Kinoshita, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asoh, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furuichi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawada, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohwada, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyagi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takanashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukaguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukuda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oikawa, N.</span><span> </span><span class="NLM_article-title">Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802)</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1271</span><span class="NLM_x">–</span> <span class="NLM_lpage">1280</span><span class="refDoi"> DOI: 10.1016/j.bmc.2011.12.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1016%2Fj.bmc.2011.12.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=22225917" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFSmu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=1271-1280&author=K.+Kinoshitaauthor=K.+Asohauthor=N.+Furuichiauthor=T.+Itoauthor=H.+Kawadaauthor=S.+Haraauthor=J.+Ohwadaauthor=T.+Miyagiauthor=T.+Kobayashiauthor=K.+Takanashiauthor=T.+Tsukaguchiauthor=H.+Sakamotoauthor=T.+Tsukudaauthor=N.+Oikawa&title=Design+and+synthesis+of+a+highly+selective%2C+orally+active+and+potent+anaplastic+lymphoma+kinase+inhibitor+%28CH5424802%29&doi=10.1016%2Fj.bmc.2011.12.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802)</span></div><div class="casAuthors">Kinoshita, Kazutomo; Asoh, Kohsuke; Furuichi, Noriyuki; Ito, Toshiya; Kawada, Hatsuo; Hara, Sousuke; Ohwada, Jun; Miyagi, Takuho; Kobayashi, Takamitsu; Takanashi, Kenji; Tsukaguchi, Toshiyuki; Sakamoto, Hiroshi; Tsukuda, Takuo; Oikawa, Nobuhiro</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1271-1280</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) receptor tyrosine kinase is considered an attractive therapeutic target for human cancers, esp. non-small cell lung cancer (NSCLC).  Our previous study revealed that 8,9-side-chains of 6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole scaffold crucially affected kinase selectivity, cellular activity, and metabolic stability.  In this work, we optimized the side-chains and identified highly selective, orally active and potent ALK inhibitor CH5424802 (18a) as the clin. candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpG6Im56-4v17Vg90H21EOLACvtfcHk0lhWzK-YsJiy9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFSmu70%253D&md5=cff263d2dd8c66de9fd687530fdadb06</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2011.12.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2011.12.021%26sid%3Dliteratum%253Aachs%26aulast%3DKinoshita%26aufirst%3DK.%26aulast%3DAsoh%26aufirst%3DK.%26aulast%3DFuruichi%26aufirst%3DN.%26aulast%3DIto%26aufirst%3DT.%26aulast%3DKawada%26aufirst%3DH.%26aulast%3DHara%26aufirst%3DS.%26aulast%3DOhwada%26aufirst%3DJ.%26aulast%3DMiyagi%26aufirst%3DT.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DTakanashi%26aufirst%3DK.%26aulast%3DTsukaguchi%26aufirst%3DT.%26aulast%3DSakamoto%26aufirst%3DH.%26aulast%3DTsukuda%26aufirst%3DT.%26aulast%3DOikawa%26aufirst%3DN.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520a%2520highly%2520selective%252C%2520orally%2520active%2520and%2520potent%2520anaplastic%2520lymphoma%2520kinase%2520inhibitor%2520%2528CH5424802%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26spage%3D1271%26epage%3D1280%26doi%3D10.1016%2Fj.bmc.2011.12.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Sakamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukaguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiroshima, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kodama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukami, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oikawa, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukuda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishii, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoki, Y.</span><span> </span><span class="NLM_article-title">CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">679</span><span class="NLM_x">–</span> <span class="NLM_lpage">690</span><span class="refDoi"> DOI: 10.1016/j.ccr.2011.04.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1016%2Fj.ccr.2011.04.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=21575866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtFGlsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=679-690&author=H.+Sakamotoauthor=T.+Tsukaguchiauthor=S.+Hiroshimaauthor=T.+Kodamaauthor=T.+Kobayashiauthor=T.+A.+Fukamiauthor=N.+Oikawaauthor=T.+Tsukudaauthor=N.+Ishiiauthor=Y.+Aoki&title=CH5424802%2C+a+selective+ALK+inhibitor+capable+of+blocking+the+resistant+gatekeeper+mutant&doi=10.1016%2Fj.ccr.2011.04.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant</span></div><div class="casAuthors">Sakamoto, Hiroshi; Tsukaguchi, Toshiyuki; Hiroshima, Sayuri; Kodama, Tatsushi; Kobayashi, Takamitsu; Fukami, Takaaki A.; Oikawa, Nobuhiro; Tsukuda, Takuo; Ishii, Nobuya; Aoki, Yuko</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">679-690</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is a tyrosine kinase that is constitutively activated in certain cancers, following gene alterations such as chromosomal translocation, amplification, or point mutation.  Here, the authors identified CH5424802, a potent, selective, and orally available ALK inhibitor with a unique chem. scaffold, showing preferential antitumor activity against cancers with gene alterations of ALK, such as non-small cell lung cancer (NSCLC) cells expressing EML4-ALK fusion and anaplastic large-cell lymphoma (ALCL) cells expressing NPM-ALK fusion in vitro and in vivo.  CH5424802 inhibited ALK L1196M, which corresponds to the gatekeeper mutation conferring common resistance to kinase inhibitors, and blocked EML4-ALK L1196M-driven cell growth.  The authors' results support the potential for clin. evaluation of CH5424802 for the treatment of patients with ALK-driven tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrk3zvzF9p67Vg90H21EOLACvtfcHk0ljjSywc4cCH0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtFGlsL8%253D&md5=cae32f3a3647926ba835293b68e776f8</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2011.04.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2011.04.004%26sid%3Dliteratum%253Aachs%26aulast%3DSakamoto%26aufirst%3DH.%26aulast%3DTsukaguchi%26aufirst%3DT.%26aulast%3DHiroshima%26aufirst%3DS.%26aulast%3DKodama%26aufirst%3DT.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DFukami%26aufirst%3DT.%2BA.%26aulast%3DOikawa%26aufirst%3DN.%26aulast%3DTsukuda%26aufirst%3DT.%26aulast%3DIshii%26aufirst%3DN.%26aulast%3DAoki%26aufirst%3DY.%26atitle%3DCH5424802%252C%2520a%2520selective%2520ALK%2520inhibitor%2520capable%2520of%2520blocking%2520the%2520resistant%2520gatekeeper%2520mutant%26jtitle%3DCancer%2520Cell%26date%3D2011%26volume%3D19%26spage%3D679%26epage%3D690%26doi%3D10.1016%2Fj.ccr.2011.04.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Ou, S.-H. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsiang, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herman, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kain, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siwak-Tapp, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casey, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klempner, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span> </span><span class="NLM_article-title">Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib</span> <span class="citation_source-journal">J. Thorac. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">549</span><span class="NLM_x">–</span> <span class="NLM_lpage">553</span><span class="refDoi"> DOI: 10.1097/JTO.0000000000000094</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1097%2FJTO.0000000000000094" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=24736079" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=549-553&author=S.-H.+I.+Ouauthor=M.+Azadaauthor=D.+J.+Hsiangauthor=J.+M.+Hermanauthor=T.+S.+Kainauthor=C.+Siwak-Tappauthor=C.+Caseyauthor=J.+Heauthor=S.+M.+Aliauthor=S.+J.+Klempnerauthor=V.+A.+Miller&title=Next-generation+sequencing+reveals+a+Novel+NSCLC+ALK+F1174V+mutation+and+confirms+ALK+G1202R+mutation+confers+high-level+resistance+to+alectinib+%28CH5424802%2FRO5424802%29+in+ALK-rearranged+NSCLC+patients+who+progressed+on+crizotinib&doi=10.1097%2FJTO.0000000000000094"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1097%2FJTO.0000000000000094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJTO.0000000000000094%26sid%3Dliteratum%253Aachs%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26aulast%3DAzada%26aufirst%3DM.%26aulast%3DHsiang%26aufirst%3DD.%2BJ.%26aulast%3DHerman%26aufirst%3DJ.%2BM.%26aulast%3DKain%26aufirst%3DT.%2BS.%26aulast%3DSiwak-Tapp%26aufirst%3DC.%26aulast%3DCasey%26aufirst%3DC.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DAli%26aufirst%3DS.%2BM.%26aulast%3DKlempner%26aufirst%3DS.%2BJ.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26atitle%3DNext-generation%2520sequencing%2520reveals%2520a%2520Novel%2520NSCLC%2520ALK%2520F1174V%2520mutation%2520and%2520confirms%2520ALK%2520G1202R%2520mutation%2520confers%2520high-level%2520resistance%2520to%2520alectinib%2520%2528CH5424802%252FRO5424802%2529%2520in%2520ALK-rearranged%2520NSCLC%2520patients%2520who%2520progressed%2520on%2520crizotinib%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2014%26volume%3D9%26spage%3D549%26epage%3D553%26doi%3D10.1097%2FJTO.0000000000000094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Katayama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friboulet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koike, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockerman, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gainor, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeuchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taiji, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okuno, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujita, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span> </span><span class="NLM_article-title">Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">5686</span><span class="NLM_x">–</span> <span class="NLM_lpage">5696</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-1511</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1158%2F1078-0432.CCR-14-1511" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=25228534" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFGgs7fJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=5686-5696&author=R.+Katayamaauthor=L.+Fribouletauthor=S.+Koikeauthor=E.+L.+Lockermanauthor=T.+M.+Khanauthor=J.+F.+Gainorauthor=A.+J.+Iafrateauthor=K.+Takeuchiauthor=M.+Taijiauthor=Y.+Okunoauthor=N.+Fujitaauthor=J.+A.+Engelmanauthor=A.+T.+Shaw&title=Two+novel+ALK+mutations+mediate+acquired+resistance+to+the+next-generation+ALK+inhibitor+alectinib&doi=10.1158%2F1078-0432.CCR-14-1511"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib</span></div><div class="casAuthors">Katayama, Ryohei; Friboulet, Luc; Koike, Sumie; Lockerman, Elizabeth L.; Khan, Tahsin M.; Gainor, Justin F.; Iafrate, A. John; Takeuchi, Kengo; Taiji, Makoto; Okuno, Yasushi; Fujita, Naoya; Engelman, Jeffrey A.; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5686-5696</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The first-generation ALK tyrosine kinase inhibitor (TKI) crizotinib is a std. therapy for patients with ALK-rearranged non-small cell lung cancer (NSCLC).  Several next-generation ALK-TKIs have entered the clinic and have shown promising activity in crizotinib-resistant patients.  As patients still relapse even on these next-generation ALK-TKIs, we examd. mechanisms of resistance to the next-generation ALK-TKI alectinib and potential strategies to overcome this resistance.  Exptl. Design: We established a cell line model of alectinib resistance, and analyzed a resistant tumor specimen from a patient who had relapsed on alectinib.  We developed Ba/F3 models harboring alectinib-resistant ALK mutations and evaluated the potency of other next-generation ALK-TKIs in these models.  We tested the antitumor activity of the next-generation ALK-TKI ceritinib in the patient with acquired resistance to alectinib.  To elucidate structure-activity relationships of ALK mutations, we performed computational thermodn. simulation with MP-CAFEE.  Results: We identified a novel V1180L gatekeeper mutation from the cell line model and a second novel I1171T mutation from the patient who developed resistance to alectinib.  Both ALK mutations conferred resistance to alectinib as well as to crizotinib, but were sensitive to ceritinib and other next-generation ALK-TKIs.  Treatment of the patient with ceritinib led to a marked response.  Thermodn. simulation suggests that both mutations lead to distinct structural alterations that decrease the binding affinity with alectinib.  Conclusions: We have identified two novel ALK mutations arising after alectinib exposure that are sensitive to other next-generation ALK-TKIs.  The ability of ceritinib to overcome alectinib-resistance mutations suggests a potential role for sequential therapy with multiple next-generation ALK-TKIs.  Clin Cancer Res; 20(22); 5686-96. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnIA7-P96QUrVg90H21EOLACvtfcHk0ljjSywc4cCH0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFGgs7fJ&md5=b95f2f96f90fa09b48c82e0baf1b6525</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-1511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-1511%26sid%3Dliteratum%253Aachs%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DFriboulet%26aufirst%3DL.%26aulast%3DKoike%26aufirst%3DS.%26aulast%3DLockerman%26aufirst%3DE.%2BL.%26aulast%3DKhan%26aufirst%3DT.%2BM.%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DTakeuchi%26aufirst%3DK.%26aulast%3DTaiji%26aufirst%3DM.%26aulast%3DOkuno%26aufirst%3DY.%26aulast%3DFujita%26aufirst%3DN.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DTwo%2520novel%2520ALK%2520mutations%2520mediate%2520acquired%2520resistance%2520to%2520the%2520next-generation%2520ALK%2520inhibitor%2520alectinib%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D5686%26epage%3D5696%26doi%3D10.1158%2F1078-0432.CCR-14-1511" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Mori, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueno, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konagai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fushiki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimada, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondoh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saito, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shindou, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soga, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakagami, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furutani, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doihara, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kudoh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuromitsu, S.</span><span> </span><span class="NLM_article-title">The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">329</span><span class="NLM_x">–</span> <span class="NLM_lpage">340</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0395</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1158%2F1535-7163.MCT-13-0395" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=24419060" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFWmsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=329-340&author=M.+Moriauthor=Y.+Uenoauthor=S.+Konagaiauthor=H.+Fushikiauthor=I.+Shimadaauthor=Y.+Kondohauthor=R.+Saitoauthor=K.+Moriauthor=N.+Shindouauthor=T.+Sogaauthor=H.+Sakagamiauthor=T.+Furutaniauthor=H.+Doiharaauthor=M.+Kudohauthor=S.+Kuromitsu&title=The+selective+anaplastic+lymphoma+receptor+tyrosine+kinase+inhibitor+ASP3026+induces+tumor+regression+and+prolongs+survival+in+non-small+cell+lung+cancer+model+mice&doi=10.1158%2F1535-7163.MCT-13-0395"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">The Selective Anaplastic Lymphoma Receptor Tyrosine Kinase Inhibitor ASP3026 Induces Tumor Regression and Prolongs Survival in Non-Small Cell Lung Cancer Model Mice</span></div><div class="casAuthors">Mori, Masamichi; Ueno, Yoko; Konagai, Satoshi; Fushiki, Hiroshi; Shimada, Itsuro; Kondoh, Yutaka; Saito, Rika; Mori, Kenichi; Shindou, Nobuaki; Soga, Takatoshi; Sakagami, Hideki; Furutani, Takashi; Doihara, Hitoshi; Kudoh, Masafumi; Kuromitsu, Sadao</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">329-340</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Activation of anaplastic lymphoma receptor tyrosine kinase (ALK) is involved in the pathogenesis of several carcinomas, including non-small cell lung cancer (NSCLC).  Echinoderm microtubule-assocd. protein like 4 (EML4)-ALK, which is derived from the rearrangement of ALK and EML4 genes, has been validated as a therapeutic target in a subset of patients with NSCLC.  Here, we investigated the effects of ASP3026, a novel small-mol. ALK inhibitor, against ALK-driven NSCLC.  ASP3026 inhibited ALK activity in an ATP-competitive manner and had an inhibitory spectrum that differed from that of crizotinib, a dual ALK/MET inhibitor.  In mice xenografted with NCI-H2228 cells expressing EML4-ALK, orally administered ASP3026 was well absorbed in tumor tissues, reaching concns. >10-fold higher than those in plasma, and induced tumor regression with a wide therapeutic margin between efficacious and toxic doses.  In the same mouse model, ASP3026 enhanced the antitumor activities of paclitaxel and pemetrexed without affecting body wt.  ASP3026 also showed potent antitumor activities, including tumor shrinkage to a nondetectable level, in hEML4-ALK transgenic mice and prolonged survival in mice with intrapleural NCI-H2228 xenografts.  In an intrahepatic xenograft model using NCI-H2228 cells, ASP3026 induced continuous tumor regression, whereas mice treated with crizotinib showed tumor relapse after an initial response.  Finally, ASP3026 exhibited potent antitumor activity against cells expressing EML4-ALK with a mutation in the gatekeeper position (L1196M) that confers crizotinib resistance.  Taken together, these findings indicate that ASP3026 has potential efficacy for NSCLC and is expected to improve the therapeutic outcomes of patients with cancer with ALK abnormality.  Mol Cancer Ther; 13(2); 329-40. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpU-kqfwbUJrLVg90H21EOLACvtfcHk0liVfgu5ajzt4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFWmsb8%253D&md5=4d8de3814f3f8fa198f2d3acb5d3860a</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0395%26sid%3Dliteratum%253Aachs%26aulast%3DMori%26aufirst%3DM.%26aulast%3DUeno%26aufirst%3DY.%26aulast%3DKonagai%26aufirst%3DS.%26aulast%3DFushiki%26aufirst%3DH.%26aulast%3DShimada%26aufirst%3DI.%26aulast%3DKondoh%26aufirst%3DY.%26aulast%3DSaito%26aufirst%3DR.%26aulast%3DMori%26aufirst%3DK.%26aulast%3DShindou%26aufirst%3DN.%26aulast%3DSoga%26aufirst%3DT.%26aulast%3DSakagami%26aufirst%3DH.%26aulast%3DFurutani%26aufirst%3DT.%26aulast%3DDoihara%26aufirst%3DH.%26aulast%3DKudoh%26aufirst%3DM.%26aulast%3DKuromitsu%26aufirst%3DS.%26atitle%3DThe%2520selective%2520anaplastic%2520lymphoma%2520receptor%2520tyrosine%2520kinase%2520inhibitor%2520ASP3026%2520induces%2520tumor%2520regression%2520and%2520prolongs%2520survival%2520in%2520non-small%2520cell%2520lung%2520cancer%2520model%2520mice%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D329%26epage%3D340%26doi%3D10.1158%2F1535-7163.MCT-13-0395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Lovly, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Infante, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumenschein, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reckamp, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakelee, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waqar, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gockerman, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dukart, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrow, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horn, L.</span><span> </span><span class="NLM_article-title">Phase I/II trial of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor, in patients with ALK+ non-small cell lung cancer (NSCLC)</span> <span class="citation_source-journal">AACR Annu. Meet. Proc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span><span class="NLM_elocation-id">CT088</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=C.+M.+Lovlyauthor=J.+R.+Infanteauthor=G.+R.+Blumenscheinauthor=K.+Reckampauthor=H.+Wakeleeauthor=C.+A.+Carterauthor=S.+N.+Waqarauthor=J.+Nealauthor=J.+P.+Gockermanauthor=G.+Dukartauthor=K.+Harrowauthor=C.+Liangauthor=J.+J.+Gibbonsauthor=L.+Horn&title=Phase+I%2FII+trial+of+X-396%2C+a+novel+anaplastic+lymphoma+kinase+%28ALK%29+inhibitor%2C+in+patients+with+ALK%2B+non-small+cell+lung+cancer+%28NSCLC%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLovly%26aufirst%3DC.%2BM.%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26aulast%3DBlumenschein%26aufirst%3DG.%2BR.%26aulast%3DReckamp%26aufirst%3DK.%26aulast%3DWakelee%26aufirst%3DH.%26aulast%3DCarter%26aufirst%3DC.%2BA.%26aulast%3DWaqar%26aufirst%3DS.%2BN.%26aulast%3DNeal%26aufirst%3DJ.%26aulast%3DGockerman%26aufirst%3DJ.%2BP.%26aulast%3DDukart%26aufirst%3DG.%26aulast%3DHarrow%26aufirst%3DK.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DGibbons%26aufirst%3DJ.%2BJ.%26aulast%3DHorn%26aufirst%3DL.%26atitle%3DPhase%2520I%252FII%2520trial%2520of%2520X-396%252C%2520a%2520novel%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520inhibitor%252C%2520in%2520patients%2520with%2520ALK%252B%2520non-small%2520cell%2520lung%2520cancer%2520%2528NSCLC%2529%26jtitle%3DAACR%2520Annu.%2520Meet.%2520Proc.%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Jacobs, M. J.; Ott, G. R.</span><span> </span><span class="NLM_article-title">Preparation of fused bicyclic 2, 4- diaminopyrimidine derivatives as a dual ALK and FAK inhibitor</span>. PCT Int. Appl. WO 2013134353,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=M.+J.+Jacobs&author=G.+R.+Ott&title=Preparation+of+fused+bicyclic+2%2C+4-+diaminopyrimidine+derivatives+as+a+dual+ALK+and+FAK+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJacobs%26aufirst%3DM.%2BJ.%26atitle%3DPreparation%2520of%2520fused%2520bicyclic%25202%252C%25204-%2520diaminopyrimidine%2520derivatives%2520as%2520a%2520dual%2520ALK%2520and%2520FAK%2520inhibitor%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Wiess, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sachdev, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Infante, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mita, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Natale, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arkenau, H.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilcoxen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kansra, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laken, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooks, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martell, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anthony, S. P.</span><span> </span><span class="NLM_article-title">Phase (Ph) 1/2 study of TSR-011, a potent inhibitor of ALK and TRK, including crizotinib-resistant ALK mutations</span> <span class="citation_source-journal">ASCO Annu. Meet. Proc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_elocation-id">e19005</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&author=G.+J.+Wiessauthor=J.+C.+Sachdevauthor=J.+R.+Infanteauthor=M.+M.+Mitaauthor=R.+B.+Nataleauthor=H.-T.+Arkenauauthor=K.+Wilcoxenauthor=V.+Kansraauthor=H.+Lakenauthor=L.+Hughesauthor=D.+G.+Brooksauthor=R.+E.+Martellauthor=S.+P.+Anthony&title=Phase+%28Ph%29+1%2F2+study+of+TSR-011%2C+a+potent+inhibitor+of+ALK+and+TRK%2C+including+crizotinib-resistant+ALK+mutations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWiess%26aufirst%3DG.%2BJ.%26aulast%3DSachdev%26aufirst%3DJ.%2BC.%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26aulast%3DMita%26aufirst%3DM.%2BM.%26aulast%3DNatale%26aufirst%3DR.%2BB.%26aulast%3DArkenau%26aufirst%3DH.-T.%26aulast%3DWilcoxen%26aufirst%3DK.%26aulast%3DKansra%26aufirst%3DV.%26aulast%3DLaken%26aufirst%3DH.%26aulast%3DHughes%26aufirst%3DL.%26aulast%3DBrooks%26aufirst%3DD.%2BG.%26aulast%3DMartell%26aufirst%3DR.%2BE.%26aulast%3DAnthony%26aufirst%3DS.%2BP.%26atitle%3DPhase%2520%2528Ph%2529%25201%252F2%2520study%2520of%2520TSR-011%252C%2520a%2520potent%2520inhibitor%2520of%2520ALK%2520and%2520TRK%252C%2520including%2520crizotinib-resistant%2520ALK%2520mutations%26jtitle%3DASCO%2520Annu.%2520Meet.%2520Proc.%26date%3D2014%26volume%3D32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friboulet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kodack, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engstrom, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsaparikos, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timofeevski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katayama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinh, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bezwada, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frias, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lifshits, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahmood, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gainor, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Affolter, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lappin, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gukasyan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jain, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fantin, V. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smeal, T.</span><span> </span><span class="NLM_article-title">PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">70</span><span class="NLM_x">–</span> <span class="NLM_lpage">81</span><span class="refDoi"> DOI: 10.1016/j.ccell.2015.05.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1016%2Fj.ccell.2015.05.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=26144315" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFahsr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2015&pages=70-81&author=H.+Y.+Zouauthor=L.+Fribouletauthor=D.+P.+Kodackauthor=L.+D.+Engstromauthor=Q.+Liauthor=M.+Westauthor=R.+W.+Tangauthor=H.+Wangauthor=K.+Tsaparikosauthor=J.+Wangauthor=S.+Timofeevskiauthor=R.+Katayamaauthor=D.+M.+Dinhauthor=H.+Lamauthor=J.+L.+Lamauthor=S.+Yamazakiauthor=W.+Huauthor=B.+Patelauthor=D.+Bezwadaauthor=R.+L.+Friasauthor=E.+Lifshitsauthor=S.+Mahmoodauthor=J.+F.+Gainorauthor=T.+Affolterauthor=P.+B.+Lappinauthor=H.+Gukasyanauthor=N.+Leeauthor=S.+Dengauthor=R.+K.+Jainauthor=T.+W.+Johnsonauthor=A.+T.+Shawauthor=V.+R.+Fantinauthor=T.+Smeal&title=PF-06463922%2C+an+ALK%2FROS1+inhibitor%2C+overcomes+resistance+to+first+and+second+generation+ALK+inhibitors+in+preclinical+models&doi=10.1016%2Fj.ccell.2015.05.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models</span></div><div class="casAuthors">Zou, Helen Y.; Friboulet, Luc; Kodack, David P.; Engstrom, Lars D.; Li, Qiuhua; West, Melissa; Tang, Ruth W.; Wang, Hui; Tsaparikos, Konstantinos; Wang, Jinwei; Timofeevski, Sergei; Katayama, Ryohei; Dinh, Dac M.; Lam, Hieu; Lam, Justine L.; Yamazaki, Shinji; Hu, Wenyue; Patel, Bhushankumar; Bezwada, Divya; Frias, Rosa L.; Lifshits, Eugene; Mahmood, Sidra; Gainor, Justin F.; Affolter, Timothy; Lappin, Patrick B.; Gukasyan, Hovhannes; Lee, Nathan; Deng, Shibing; Jain, Rakesh K.; Johnson, Ted W.; Shaw, Alice T.; Fantin, Valeria R.; Smeal, Tod</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">70-81</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">We report the preclin. evaluation of PF-06463922, a potent and brain-penetrant ALK/ROS1 inhibitor.  Compared with other clin. available ALK inhibitors, PF-06463922 displayed superior potency against all known clin. acquired ALK mutations, including the highly resistant G1202R mutant.  Furthermore, PF-06463922 treatment led to regression of EML4-ALK-driven brain metastases, leading to prolonged mouse survival, in a superior manner.  Finally, PF-06463922 demonstrated high selectivity and safety margins in a variety of preclin. studies.  These results suggest that PF-06463922 will be highly effective for the treatment of patients with ALK-driven lung cancers, including those who relapsed on clin. available ALK inhibitors because of secondary ALK kinase domain mutations and/or brain metastases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3jseXrLwlSLVg90H21EOLACvtfcHk0liVfgu5ajzt4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFahsr7E&md5=5bd2b7be6086f607b33b2255ad350486</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2015.05.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2015.05.010%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DFriboulet%26aufirst%3DL.%26aulast%3DKodack%26aufirst%3DD.%2BP.%26aulast%3DEngstrom%26aufirst%3DL.%2BD.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DWest%26aufirst%3DM.%26aulast%3DTang%26aufirst%3DR.%2BW.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DTsaparikos%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DDinh%26aufirst%3DD.%2BM.%26aulast%3DLam%26aufirst%3DH.%26aulast%3DLam%26aufirst%3DJ.%2BL.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DPatel%26aufirst%3DB.%26aulast%3DBezwada%26aufirst%3DD.%26aulast%3DFrias%26aufirst%3DR.%2BL.%26aulast%3DLifshits%26aufirst%3DE.%26aulast%3DMahmood%26aufirst%3DS.%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DAffolter%26aufirst%3DT.%26aulast%3DLappin%26aufirst%3DP.%2BB.%26aulast%3DGukasyan%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DN.%26aulast%3DDeng%26aufirst%3DS.%26aulast%3DJain%26aufirst%3DR.%2BK.%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DFantin%26aufirst%3DV.%2BR.%26aulast%3DSmeal%26aufirst%3DT.%26atitle%3DPF-06463922%252C%2520an%2520ALK%252FROS1%2520inhibitor%252C%2520overcomes%2520resistance%2520to%2520first%2520and%2520second%2520generation%2520ALK%2520inhibitors%2520in%2520preclinical%2520models%26jtitle%3DCancer%2520Cell%26date%3D2015%26volume%3D28%26spage%3D70%26epage%3D81%26doi%3D10.1016%2Fj.ccell.2015.05.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Johnson, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooun, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deal, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engstrom, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kania, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kath, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lingardo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sach, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smeal, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timofeevski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. P.</span><span> </span><span class="NLM_article-title">Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(m etheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">4720</span><span class="NLM_x">–</span> <span class="NLM_lpage">4744</span><span class="refDoi"> DOI: 10.1021/jm500261q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500261q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnvVSgtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4720-4744&author=T.+W.+Johnsonauthor=P.+F.+Richardsonauthor=S.+Baileyauthor=A.+Broounauthor=B.+J.+Burkeauthor=M.+R.+Collinsauthor=J.+J.+Cuiauthor=J.+G.+Dealauthor=Y.+L.+Dengauthor=D.+Dinhauthor=L.+D.+Engstromauthor=M.+Heauthor=J.+Hoffmanauthor=R.+L.+Hoffmanauthor=Q.+Huangauthor=R.+S.+Kaniaauthor=J.+C.+Kathauthor=H.+Lamauthor=J.+L.+Lamauthor=P.+T.+Leauthor=L.+Lingardoauthor=W.+Liuauthor=M.+McTigueauthor=C.+L.+Palmerauthor=N.+W.+Sachauthor=T.+Smealauthor=G.+L.+Smithauthor=A.+E.+Stewartauthor=S.+Timofeevskiauthor=H.+Zhuauthor=J.+Zhuauthor=H.+Y.+Zouauthor=M.+P.+Edwards&title=Discovery+of+%2810R%29-7-amino-12-fluoro-2%2C10%2C16-trimethyl-15-oxo-10%2C15%2C16%2C17-tetrahydro-2H-8%2C4-%28m+etheno%29pyrazolo%5B4%2C3-h%5D%5B2%2C5%2C11%5D-benzoxadiazacyclotetradecine-3-carbonitrile+%28PF-06463922%29%2C+a+macrocyclic+inhibitor+of+anaplastic+lymphoma+kinase+%28ALK%29+and+c-ros+oncogene+1+%28ROS1%29+with+preclinical+brain+exposure+and+broad-spectrum+potency+against+ALK-resistant+mutations&doi=10.1021%2Fjm500261q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations</span></div><div class="casAuthors">Johnson, Ted W.; Richardson, Paul F.; Bailey, Simon; Brooun, Alexei; Burke, Benjamin J.; Collins, Michael R.; Cui, J. Jean; Deal, Judith G.; Deng, Ya-Li; Dinh, Dac; Engstrom, Lars D.; He, Mingying; Hoffman, Jacqui; Hoffman, Robert L.; Huang, Qinhua; Kania, Robert S.; Kath, John C.; Lam, Hieu; Lam, Justine L.; Le, Phuong T.; Lingardo, Laura; Liu, Wei; McTigue, Michele; Palmer, Cynthia L.; Sach, Neal W.; Smeal, Tod; Smith, Graham L.; Stewart, Albert E.; Timofeevski, Sergei; Zhu, Huichun; Zhu, Jinjiang; Zou, Helen Y.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4720-4744</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Although crizotinib demonstrates robust efficacy in anaplastic lymphoma kinase (ALK)-pos. non-small-cell lung carcinoma patients, progression during treatment eventually develops.  Resistant patient samples revealed a variety of point mutations in the kinase domain of ALK, including the L1196M gatekeeper mutation.  In addn., some patients progress due to cancer metastasis in the brain.  Using structure-based drug design, lipophilic efficiency, and phys.-property-based optimization, highly potent macrocyclic ALK inhibitors were prepd. with good absorption, distribution, metab., and excretion (ADME), low propensity for p-glycoprotein 1-mediated efflux, and good passive permeability.  These structurally unusual macrocyclic inhibitors were potent against wild-type ALK and clin. reported ALK kinase domain mutations.  Significant synthetic challenges were overcome, utilizing novel transformations to enable the use of these macrocycles in drug discovery paradigms.  This work led to the discovery of 8k (PF-06463922), combining broad-spectrum potency, central nervous system ADME, and a high degree of kinase selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqXkb49ad31bVg90H21EOLACvtfcHk0ljqDfvkI8BoXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnvVSgtL4%253D&md5=db21844f8e9a2f9ca5953bca56ad7b1c</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm500261q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500261q%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DRichardson%26aufirst%3DP.%2BF.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DBrooun%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DB.%2BJ.%26aulast%3DCollins%26aufirst%3DM.%2BR.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DDeal%26aufirst%3DJ.%2BG.%26aulast%3DDeng%26aufirst%3DY.%2BL.%26aulast%3DDinh%26aufirst%3DD.%26aulast%3DEngstrom%26aufirst%3DL.%2BD.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DHoffman%26aufirst%3DJ.%26aulast%3DHoffman%26aufirst%3DR.%2BL.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DLam%26aufirst%3DH.%26aulast%3DLam%26aufirst%3DJ.%2BL.%26aulast%3DLe%26aufirst%3DP.%2BT.%26aulast%3DLingardo%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DPalmer%26aufirst%3DC.%2BL.%26aulast%3DSach%26aufirst%3DN.%2BW.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DG.%2BL.%26aulast%3DStewart%26aufirst%3DA.%2BE.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DDiscovery%2520of%2520%252810R%2529-7-amino-12-fluoro-2%252C10%252C16-trimethyl-15-oxo-10%252C15%252C16%252C17-tetrahydro-2H-8%252C4-%2528m%2520etheno%2529pyrazolo%255B4%252C3-h%255D%255B2%252C5%252C11%255D-benzoxadiazacyclotetradecine-3-carbonitrile%2520%2528PF-06463922%2529%252C%2520a%2520macrocyclic%2520inhibitor%2520of%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520and%2520c-ros%2520oncogene%25201%2520%2528ROS1%2529%2520with%2520preclinical%2520brain%2520exposure%2520and%2520broad-spectrum%2520potency%2520against%2520ALK-resistant%2520mutations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4720%26epage%3D4744%26doi%3D10.1021%2Fjm500261q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Infarinato, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krytska, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryles, H. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sano, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szigety, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, N. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smeal, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemmon, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosse, Y. P.</span><span> </span><span class="NLM_article-title">The ALK/ROS1 inhibitor PF-06463922 overcomes primary resistance to crizotinib in ALK-driven neuroblastoma</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">96</span><span class="NLM_x">–</span> <span class="NLM_lpage">107</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-15-1056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1158%2F2159-8290.CD-15-1056" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=96-107&author=N.+R.+Infarinatoauthor=J.+H.+Parkauthor=K.+Krytskaauthor=H.+T.+Rylesauthor=R.+Sanoauthor=K.+M.+Szigetyauthor=Y.+Liauthor=H.+Y.+Zouauthor=N.+V.+Leeauthor=T.+Smealauthor=M.+A.+Lemmonauthor=Y.+P.+Mosse&title=The+ALK%2FROS1+inhibitor+PF-06463922+overcomes+primary+resistance+to+crizotinib+in+ALK-driven+neuroblastoma&doi=10.1158%2F2159-8290.CD-15-1056"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-15-1056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-15-1056%26sid%3Dliteratum%253Aachs%26aulast%3DInfarinato%26aufirst%3DN.%2BR.%26aulast%3DPark%26aufirst%3DJ.%2BH.%26aulast%3DKrytska%26aufirst%3DK.%26aulast%3DRyles%26aufirst%3DH.%2BT.%26aulast%3DSano%26aufirst%3DR.%26aulast%3DSzigety%26aufirst%3DK.%2BM.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DLee%26aufirst%3DN.%2BV.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DLemmon%26aufirst%3DM.%2BA.%26aulast%3DMosse%26aufirst%3DY.%2BP.%26atitle%3DThe%2520ALK%252FROS1%2520inhibitor%2520PF-06463922%2520overcomes%2520primary%2520resistance%2520to%2520crizotinib%2520in%2520ALK-driven%2520neuroblastoma%26jtitle%3DCancer%2520Discovery%26date%3D2016%26volume%3D6%26spage%3D96%26epage%3D107%26doi%3D10.1158%2F2159-8290.CD-15-1056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Ardini, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menichincheri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banfi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bosotti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Ponti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pulci, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballinari, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciomei, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Texido, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Degrassi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avanzi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amboldi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saccardo, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casero, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orsini, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bandiera, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mologni, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vernier, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felder, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donati, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isacchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesenti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnaghi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galvani, A.</span><span> </span><span class="NLM_article-title">Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">628</span><span class="NLM_x">–</span> <span class="NLM_lpage">639</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-15-0758</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1158%2F1535-7163.MCT-15-0758" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=26939704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsVSqtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=628-639&author=E.+Ardiniauthor=M.+Menichincheriauthor=P.+Banfiauthor=R.+Bosottiauthor=C.+De+Pontiauthor=R.+Pulciauthor=D.+Ballinariauthor=M.+Ciomeiauthor=G.+Texidoauthor=A.+Degrassiauthor=N.+Avanziauthor=N.+Amboldiauthor=M.+B.+Saccardoauthor=D.+Caseroauthor=P.+Orsiniauthor=T.+Bandieraauthor=L.+Mologniauthor=D.+Andersonauthor=G.+Weiauthor=J.+Harrisauthor=J.+M.+Vernierauthor=G.+Liauthor=E.+Felderauthor=D.+Donatiauthor=A.+Isacchiauthor=E.+Pesentiauthor=P.+Magnaghiauthor=A.+Galvani&title=Entrectinib%2C+a+Pan-TRK%2C+ROS1%2C+and+ALK+Inhibitor+with+Activity+in+Multiple+Molecularly+Defined+Cancer+Indications&doi=10.1158%2F1535-7163.MCT-15-0758"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications</span></div><div class="casAuthors">Ardini, Elena; Menichincheri, Maria; Banfi, Patrizia; Bosotti, Roberta; De Ponti, Cristina; Pulci, Romana; Ballinari, Dario; Ciomei, Marina; Texido, Gemma; Degrassi, Anna; Avanzi, Nilla; Amboldi, Nadia; Saccardo, Maria Beatrice; Casero, Daniele; Orsini, Paolo; Bandiera, Tiziano; Mologni, Luca; Anderson, David; Wei, Ge; Harris, Jason; Vernier, Jean-Michel; Li, Gang; Felder, Eduard; Donati, Daniele; Isacchi, Antonella; Pesenti, Enrico; Magnaghi, Paola; Galvani, Arturo</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">628-639</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Activated ALK and ROS1 tyrosine kinases, resulting from chromosomal rearrangements, occur in a subset of non-small cell lung cancers (NSCLC) as well as other tumor types and their oncogenic relevance as actionable targets has been demonstrated by the efficacy of selective kinase inhibitors such as crizotinib, ceritinib, and alectinib.  More recently, low-frequency rearrangements of TRK kinases have been described in NSCLC, colorectal carcinoma, glioblastoma, and Spitzoid melanoma.  Entrectinib, whose discovery and preclin. characterization are reported herein, is a novel, potent inhibitor of ALK, ROS1, and, importantly, of TRK family kinases, which shows promise for therapy of tumors bearing oncogenic forms of these proteins.  Proliferation profiling against over 200 human tumor cell lines revealed that entrectinib is exquisitely potent in vitro against lines that are dependent on the drug's pharmacol. targets.  Oral administration of entrectinib to tumor-bearing mice induced regression in relevant human xenograft tumors, including the TRKA-dependent colorectal carcinoma KM12, ROS1-driven tumors, and several ALK-dependent models of different tissue origins, including a model of brain-localized lung cancer metastasis.  Entrectinib is currently showing great promise in phase I/II clin. trials, including the first documented objective responses to a TRK inhibitor in colorectal carcinoma and in NSCLC.  The drug is, thus, potentially suited to the therapy of several molecularly defined cancer settings, esp. that of TRK-dependent tumors, for which no approved drugs are currently available.  Mol Cancer Ther; 15(4); 628-39. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOaNX-kFz2qbVg90H21EOLACvtfcHk0lhZAxFSM8QpzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsVSqtL4%253D&md5=dd75115cb344f0e3a6d299781043d7d6</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-15-0758&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-15-0758%26sid%3Dliteratum%253Aachs%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DMenichincheri%26aufirst%3DM.%26aulast%3DBanfi%26aufirst%3DP.%26aulast%3DBosotti%26aufirst%3DR.%26aulast%3DDe%2BPonti%26aufirst%3DC.%26aulast%3DPulci%26aufirst%3DR.%26aulast%3DBallinari%26aufirst%3DD.%26aulast%3DCiomei%26aufirst%3DM.%26aulast%3DTexido%26aufirst%3DG.%26aulast%3DDegrassi%26aufirst%3DA.%26aulast%3DAvanzi%26aufirst%3DN.%26aulast%3DAmboldi%26aufirst%3DN.%26aulast%3DSaccardo%26aufirst%3DM.%2BB.%26aulast%3DCasero%26aufirst%3DD.%26aulast%3DOrsini%26aufirst%3DP.%26aulast%3DBandiera%26aufirst%3DT.%26aulast%3DMologni%26aufirst%3DL.%26aulast%3DAnderson%26aufirst%3DD.%26aulast%3DWei%26aufirst%3DG.%26aulast%3DHarris%26aufirst%3DJ.%26aulast%3DVernier%26aufirst%3DJ.%2BM.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DFelder%26aufirst%3DE.%26aulast%3DDonati%26aufirst%3DD.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DMagnaghi%26aufirst%3DP.%26aulast%3DGalvani%26aufirst%3DA.%26atitle%3DEntrectinib%252C%2520a%2520Pan-TRK%252C%2520ROS1%252C%2520and%2520ALK%2520Inhibitor%2520with%2520Activity%2520in%2520Multiple%2520Molecularly%2520Defined%2520Cancer%2520Indications%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26spage%3D628%26epage%3D639%26doi%3D10.1158%2F1535-7163.MCT-15-0758" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Menichincheri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ardini, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnaghi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avanzi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banfi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bossi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buffa, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canevari, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ceriani, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colombo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corti, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donati, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fasolini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felder, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiorelli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiorentini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galvani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isacchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borgia, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marchionni, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nesi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orrenius, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panzeri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesenti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusconi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saccardo, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanotti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perrone, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orsini, P.</span><span> </span><span class="NLM_article-title">Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">3392</span><span class="NLM_x">–</span> <span class="NLM_lpage">3408</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00064</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00064" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BC28Xks1eitL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=3392-3408&author=M.+Menichincheriauthor=E.+Ardiniauthor=P.+Magnaghiauthor=N.+Avanziauthor=P.+Banfiauthor=R.+Bossiauthor=L.+Buffaauthor=G.+Canevariauthor=L.+Cerianiauthor=M.+Colomboauthor=L.+Cortiauthor=D.+Donatiauthor=M.+Fasoliniauthor=E.+Felderauthor=C.+Fiorelliauthor=F.+Fiorentiniauthor=A.+Galvaniauthor=A.+Isacchiauthor=A.+L.+Borgiaauthor=C.+Marchionniauthor=M.+Nesiauthor=C.+Orreniusauthor=A.+Panzeriauthor=E.+Pesentiauthor=L.+Rusconiauthor=M.+B.+Saccardoauthor=E.+Vanottiauthor=E.+Perroneauthor=P.+Orsini&title=Discovery+of+Entrectinib%3A+A+New+3-Aminoindazole+As+a+Potent+Anaplastic+Lymphoma+Kinase+%28ALK%29%2C+c-ros+Oncogene+1+Kinase+%28ROS1%29%2C+and+Pan-Tropomyosin+Receptor+Kinases+%28Pan-TRKs%29+inhibitor&doi=10.1021%2Facs.jmedchem.6b00064"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor</span></div><div class="casAuthors">Menichincheri, Maria; Ardini, Elena; Magnaghi, Paola; Avanzi, Nilla; Banfi, Patrizia; Bossi, Roberto; Buffa, Laura; Canevari, Giulia; Ceriani, Lucio; Colombo, Maristella; Corti, Luca; Donati, Daniele; Fasolini, Marina; Felder, Eduard; Fiorelli, Claudio; Fiorentini, Francesco; Galvani, Arturo; Isacchi, Antonella; Borgia, Andrea Lombardi; Marchionni, Chiara; Nesi, Marcella; Orrenius, Christian; Panzeri, Achille; Pesenti, Enrico; Rusconi, Luisa; Saccardo, Maria Beatrice; Vanotti, Ermes; Perrone, Ettore; Orsini, Paolo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3392-3408</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase responsible for the development of different tumor types.  Despite the remarkable clin. activity of crizotinib (Xalkori), the first ALK inhibitor approved in 2011, the emergence of resistance mutations and of brain metastases frequently causes relapse in patients.  Within the ALK drug discovery program, the authors identified compd. I, a novel 3-aminoindazole active on ALK in biochem. and in cellular assays.  Its optimization led to compd. II (entrectinib), a potent orally available ALK inhibitor active on ALK-dependent cell lines, efficiently penetrant the blood-brain barrier (BBB) in different animal species and highly efficacious in in vivo xenograft models.  Moreover, entrectinib resulted to be strictly potent on the closely related tyrosine kinases ROS1 and TRKs recently found constitutively activated in several tumor types.  Entrectinib is currently undergoing phase I/II clin. trial for the treatment of patients affected by ALK-, ROS1-, and TRK-pos. tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpU_xyLC5-GabVg90H21EOLACvtfcHk0lhZAxFSM8QpzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xks1eitL8%253D&md5=140217fba2ac81d71600f7344f2d8a3e</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00064%26sid%3Dliteratum%253Aachs%26aulast%3DMenichincheri%26aufirst%3DM.%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DMagnaghi%26aufirst%3DP.%26aulast%3DAvanzi%26aufirst%3DN.%26aulast%3DBanfi%26aufirst%3DP.%26aulast%3DBossi%26aufirst%3DR.%26aulast%3DBuffa%26aufirst%3DL.%26aulast%3DCanevari%26aufirst%3DG.%26aulast%3DCeriani%26aufirst%3DL.%26aulast%3DColombo%26aufirst%3DM.%26aulast%3DCorti%26aufirst%3DL.%26aulast%3DDonati%26aufirst%3DD.%26aulast%3DFasolini%26aufirst%3DM.%26aulast%3DFelder%26aufirst%3DE.%26aulast%3DFiorelli%26aufirst%3DC.%26aulast%3DFiorentini%26aufirst%3DF.%26aulast%3DGalvani%26aufirst%3DA.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DBorgia%26aufirst%3DA.%2BL.%26aulast%3DMarchionni%26aufirst%3DC.%26aulast%3DNesi%26aufirst%3DM.%26aulast%3DOrrenius%26aufirst%3DC.%26aulast%3DPanzeri%26aufirst%3DA.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DRusconi%26aufirst%3DL.%26aulast%3DSaccardo%26aufirst%3DM.%2BB.%26aulast%3DVanotti%26aufirst%3DE.%26aulast%3DPerrone%26aufirst%3DE.%26aulast%3DOrsini%26aufirst%3DP.%26atitle%3DDiscovery%2520of%2520Entrectinib%253A%2520A%2520New%25203-Aminoindazole%2520As%2520a%2520Potent%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%252C%2520c-ros%2520Oncogene%25201%2520Kinase%2520%2528ROS1%2529%252C%2520and%2520Pan-Tropomyosin%2520Receptor%2520Kinases%2520%2528Pan-TRKs%2529%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D3392%26epage%3D3408%26doi%3D10.1021%2Facs.jmedchem.6b00064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Song, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, A.</span><span> </span><span class="NLM_article-title">Discovery of novel 2,4-diarylaminopyrimidine analogues (DAAPalogues) showing potent inhibitory activities against both wild-type and mutant ALK kinases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">197</span><span class="NLM_x">–</span> <span class="NLM_lpage">211</span><span class="refDoi"> DOI: 10.1021/jm5005144</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5005144" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=197-211&author=Z.+Songauthor=Y.+Yangauthor=Z.+Liuauthor=X.+Pengauthor=J.+Guoauthor=X.+Yangauthor=K.+Wuauthor=J.+Aiauthor=J.+Dingauthor=M.+Gengauthor=A.+Zhang&title=Discovery+of+novel+2%2C4-diarylaminopyrimidine+analogues+%28DAAPalogues%29+showing+potent+inhibitory+activities+against+both+wild-type+and+mutant+ALK+kinases&doi=10.1021%2Fjm5005144"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm5005144&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5005144%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DPeng%26aufirst%3DX.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DK.%26aulast%3DAi%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520novel%25202%252C4-diarylaminopyrimidine%2520analogues%2520%2528DAAPalogues%2529%2520showing%2520potent%2520inhibitory%2520activities%2520against%2520both%2520wild-type%2520and%2520mutant%2520ALK%2520kinases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D197%26epage%3D211%26doi%3D10.1021%2Fjm5005144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Liu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, A.</span><span> </span><span class="NLM_article-title">Novel 2,4-diarylaminopyrimidine analogues (DAAPalogues) showing potent c-Met/ALK multikinase inhibitory activities</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">304</span><span class="NLM_x">–</span> <span class="NLM_lpage">308</span><span class="refDoi"> DOI: 10.1021/ml400373j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml400373j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=304-308&author=Z.+Liuauthor=J.+Aiauthor=X.+Pengauthor=Z.+Songauthor=K.+Wuauthor=J.+Zhangauthor=Q.+Yaoauthor=Y.+Chenauthor=Y.+Jiauthor=Y.+Yangauthor=M.+Gengauthor=A.+Zhang&title=Novel+2%2C4-diarylaminopyrimidine+analogues+%28DAAPalogues%29+showing+potent+c-Met%2FALK+multikinase+inhibitory+activities&doi=10.1021%2Fml400373j"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fml400373j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml400373j%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DAi%26aufirst%3DJ.%26aulast%3DPeng%26aufirst%3DX.%26aulast%3DSong%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYao%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DJi%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DA.%26atitle%3DNovel%25202%252C4-diarylaminopyrimidine%2520analogues%2520%2528DAAPalogues%2529%2520showing%2520potent%2520c-Met%252FALK%2520multikinase%2520inhibitory%2520activities%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26spage%3D304%26epage%3D308%26doi%3D10.1021%2Fml400373j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Lewis, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bode, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choquette, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potashman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stellwagen, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teffera, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittington, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Epstein, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emkey, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrews, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saffran, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drew, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merkel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szilvassy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brake, R. L.</span><span> </span><span class="NLM_article-title">The discovery and optimization of a novel class of potent, selective, and orally bioavailable anaplastic lymphoma kinase (ALK) inhibitors with potential utility for the treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">6523</span><span class="NLM_x">–</span> <span class="NLM_lpage">6540</span><span class="refDoi"> DOI: 10.1021/jm3005866</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3005866" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BC38XptF2hsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6523-6540&author=R.+T.+Lewisauthor=C.+M.+Bodeauthor=D.+M.+Choquetteauthor=M.+Potashmanauthor=K.+Romeroauthor=J.+C.+Stellwagenauthor=Y.+Tefferaauthor=E.+Mooreauthor=D.+A.+Whittingtonauthor=H.+Chenauthor=L.+F.+Epsteinauthor=R.+Emkeyauthor=P.+S.+Andrewsauthor=V.+L.+Yuauthor=D.+C.+Saffranauthor=M.+Xuauthor=A.+Drewauthor=P.+Merkelauthor=S.+Szilvassyauthor=R.+L.+Brake&title=The+discovery+and+optimization+of+a+novel+class+of+potent%2C+selective%2C+and+orally+bioavailable+anaplastic+lymphoma+kinase+%28ALK%29+inhibitors+with+potential+utility+for+the+treatment+of+cancer&doi=10.1021%2Fjm3005866"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">The Discovery and Optimization of a Novel Class of Potent, Selective, and Orally Bioavailable Anaplastic Lymphoma Kinase (ALK) Inhibitors with Potential Utility for the Treatment of Cancer</span></div><div class="casAuthors">Lewis, Richard T.; Bode, Christiane M.; Choquette, Deborah M.; Potashman, Michele; Romero, Karina; Stellwagen, John C.; Teffera, Yohannes; Moore, Earl; Whittington, Douglas A.; Chen, Hao; Epstein, Linda F.; Emkey, Renee; Andrews, Paul S.; Yu, Violeta L.; Saffran, Douglas C.; Xu, Man; Drew, Allison; Merkel, Patricia; Szilvassy, Steven; Brake, Rachael L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6523-6540</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A class of 2-acyliminobenzimidazoles has been developed as potent and selective inhibitors of anaplastic lymphoma kinase (ALK).  Structure based design facilitated the rapid development of structure-activity relationships (SAR) and the optimization of kinase selectivity.  Introduction of an optimally placed polar substituent was key to solving issues of metabolic stability and led to the development of potent, selective, orally bioavailable ALK inhibitors.  Compd. I [Ar = 3,5-F2Ph] achieved substantial tumor regression in an NPM-ALK driven murine tumor xenograft model when dosed qd.  Compd. I [Ar = 3,5-F2Ph, 4-FPh] show favorable potency and PK characteristics in preclin. species indicative of suitability for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDAwmBMVhyL7Vg90H21EOLACvtfcHk0ljBw_JjQiqVkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XptF2hsbo%253D&md5=a3c2f9e8dbf7d73319657e456bd45076</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjm3005866&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3005866%26sid%3Dliteratum%253Aachs%26aulast%3DLewis%26aufirst%3DR.%2BT.%26aulast%3DBode%26aufirst%3DC.%2BM.%26aulast%3DChoquette%26aufirst%3DD.%2BM.%26aulast%3DPotashman%26aufirst%3DM.%26aulast%3DRomero%26aufirst%3DK.%26aulast%3DStellwagen%26aufirst%3DJ.%2BC.%26aulast%3DTeffera%26aufirst%3DY.%26aulast%3DMoore%26aufirst%3DE.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DEpstein%26aufirst%3DL.%2BF.%26aulast%3DEmkey%26aufirst%3DR.%26aulast%3DAndrews%26aufirst%3DP.%2BS.%26aulast%3DYu%26aufirst%3DV.%2BL.%26aulast%3DSaffran%26aufirst%3DD.%2BC.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DDrew%26aufirst%3DA.%26aulast%3DMerkel%26aufirst%3DP.%26aulast%3DSzilvassy%26aufirst%3DS.%26aulast%3DBrake%26aufirst%3DR.%2BL.%26atitle%3DThe%2520discovery%2520and%2520optimization%2520of%2520a%2520novel%2520class%2520of%2520potent%252C%2520selective%252C%2520and%2520orally%2520bioavailable%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520inhibitors%2520with%2520potential%2520utility%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6523%26epage%3D6540%26doi%3D10.1021%2Fjm3005866" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Ott, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thieu, T. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quail, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lisko, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mesaros, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gingrich, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghose, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albom, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsey, B. D.</span><span> </span><span class="NLM_article-title">2,7-disubstituted-pyrrolo[2,1-f][1,2,4]triazines: new variant of an old template and application to the discovery of anaplastic lymphoma kinase (ALK) inhibitors with in vivo antitumor activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">6328</span><span class="NLM_x">–</span> <span class="NLM_lpage">6341</span><span class="refDoi"> DOI: 10.1021/jm200758k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200758k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVGmsr%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6328-6341&author=G.+R.+Ottauthor=G.+J.+Wellsauthor=T.+V.+Thieuauthor=M.+R.+Quailauthor=J.+G.+Liskoauthor=E.+F.+Mesarosauthor=D.+E.+Gingrichauthor=A.+K.+Ghoseauthor=W.+Wanauthor=L.+Luauthor=M.+Chengauthor=M.+S.+Albomauthor=T.+S.+Angelesauthor=Z.+Huangauthor=L.+D.+Aimoneauthor=M.+A.+Atorauthor=B.+A.+Ruggeriauthor=B.+D.+Dorsey&title=2%2C7-disubstituted-pyrrolo%5B2%2C1-f%5D%5B1%2C2%2C4%5Dtriazines%3A+new+variant+of+an+old+template+and+application+to+the+discovery+of+anaplastic+lymphoma+kinase+%28ALK%29+inhibitors+with+in+vivo+antitumor+activity&doi=10.1021%2Fjm200758k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">2,7-Disubstituted-pyrrolo[2,1-f][1,2,4]triazines: New Variant of an Old Template and Application to the Discovery of Anaplastic Lymphoma Kinase (ALK) Inhibitors with in Vivo Antitumor Activity</span></div><div class="casAuthors">Ott, Gregory R.; Wells, Gregory J.; Thieu, Tho-V.; Quail, Matthew R.; Lisko, Joseph G.; Mesaros, Eugen F.; Gingrich, Diane E.; Ghose, Arup K.; Wan, Wei-Hua; Lu, Li-Hui; Cheng, Man-Geng; Albom, Mark S.; Angeles, Thelma S.; Huang, Ze-Qi; Aimone, Lisa D.; Ator, Mark A.; Ruggeri, Bruce A.; Dorsey, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6328-6341</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel 2,7-disubstituted-pyrrolo[2,1-f][1,2,4]triazine scaffold has been designed as a new kinase inhibitor platform mimicking the bioactive conformation of the well-known diaminopyrimidine motif.  Herein the design, synthesis, and validation of this new pyrrolo[2,1-f][1,2,4]triazine scaffold is described for inhibitors of anaplastic lymphoma kinase (ALK).  Importantly, incorporation of appropriate potency and selectivity determinants has led to the discovery of several advanced leads that were orally efficacious in animal models of anaplastic large cell lymphoma (ALCL).  A lead inhibitor I displaying superior efficacy was identified.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQP33sAtk5w7Vg90H21EOLACvtfcHk0ljBw_JjQiqVkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVGmsr%252FK&md5=a591238a89465683c709e6a965108212</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm200758k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200758k%26sid%3Dliteratum%253Aachs%26aulast%3DOtt%26aufirst%3DG.%2BR.%26aulast%3DWells%26aufirst%3DG.%2BJ.%26aulast%3DThieu%26aufirst%3DT.%2BV.%26aulast%3DQuail%26aufirst%3DM.%2BR.%26aulast%3DLisko%26aufirst%3DJ.%2BG.%26aulast%3DMesaros%26aufirst%3DE.%2BF.%26aulast%3DGingrich%26aufirst%3DD.%2BE.%26aulast%3DGhose%26aufirst%3DA.%2BK.%26aulast%3DWan%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26atitle%3D2%252C7-disubstituted-pyrrolo%255B2%252C1-f%255D%255B1%252C2%252C4%255Dtriazines%253A%2520new%2520variant%2520of%2520an%2520old%2520template%2520and%2520application%2520to%2520the%2520discovery%2520of%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520inhibitors%2520with%2520in%2520vivo%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6328%26epage%3D6341%26doi%3D10.1021%2Fjm200758k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Deng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sim, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luther, W.,  2nd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Discovery of 3,5-diamino-1,2,4-triazole ureas as potent anaplastic lymphoma kinase inhibitors</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">379</span><span class="NLM_x">–</span> <span class="NLM_lpage">384</span><span class="refDoi"> DOI: 10.1021/ml200002a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200002a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjtFersrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=379-384&author=X.+Dengauthor=J.+Wangauthor=J.+Zhangauthor=T.+Simauthor=N.+D.+Kimauthor=T.+Sasakiauthor=W.+Lutherauthor=R.+E.+Georgeauthor=P.+A.+Janneauthor=N.+S.+Gray&title=Discovery+of+3%2C5-diamino-1%2C2%2C4-triazole+ureas+as+potent+anaplastic+lymphoma+kinase+inhibitors&doi=10.1021%2Fml200002a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 3,5-Diamino-1,2,4-triazole Ureas as Potent Anaplastic Lymphoma Kinase Inhibitors</span></div><div class="casAuthors">Deng, Xianming; Wang, Jinhua; Zhang, Jianming; Sim, Taebo; Kim, Nam Doo; Sasaki, Takaaki; Luther, William, II; George, Rani E.; Janne, Pasi A.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">379-384</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of novel 3,5-diamino-1,2,4-triazole benzyl ureas was identified as having potent anaplastic lymphoma kinase (ALK) inhibition exemplified by I (X = O), II, and I (X = S), which exhibited antiproliferative IC50 values of 70, 40, and 20 nM in Tel-ALK transformed Ba/F3 cells, resp.  Moreover, I (X = O, S) potently inhibited the growth and survival of NPM-ALK pos. anaplastic large cell lymphoma cell (SU-DHL-1) and neuroblastoma cell lines (KELLY, SH-SY5Y) contg. the F1174L ALK mutation.  These compds. provide novel leads for the development of small-mol. ALK inhibitors for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_KXj1NxtfHLVg90H21EOLACvtfcHk0liHmPtK7_GiBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjtFersrc%253D&md5=cd4a0e5eefcf0b1b6e3c5dab5dc87d81</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fml200002a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200002a%26sid%3Dliteratum%253Aachs%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DN.%2BD.%26aulast%3DSasaki%26aufirst%3DT.%26aulast%3DLuther%26aufirst%3DW.%26aulast%3DGeorge%26aufirst%3DR.%2BE.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520of%25203%252C5-diamino-1%252C2%252C4-triazole%2520ureas%2520as%2520potent%2520anaplastic%2520lymphoma%2520kinase%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D379%26epage%3D384%26doi%3D10.1021%2Fml200002a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Ott, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tripathy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHugh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anzalone, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Underiner, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curry, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quail, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albom, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsey, B. D.</span><span> </span><span class="NLM_article-title">Discovery of a potent inhibitor of anaplastic lymphoma kinase with in vivo antitumor activity</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">493</span><span class="NLM_x">–</span> <span class="NLM_lpage">498</span><span class="refDoi"> DOI: 10.1021/ml100158s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml100158s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtV2jtrrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=493-498&author=G.+R.+Ottauthor=R.+Tripathyauthor=M.+Chengauthor=R.+McHughauthor=A.+V.+Anzaloneauthor=T.+L.+Underinerauthor=M.+A.+Curryauthor=M.+R.+Quailauthor=L.+Luauthor=W.+Wanauthor=T.+S.+Angelesauthor=M.+S.+Albomauthor=L.+D.+Aimoneauthor=M.+A.+Atorauthor=B.+A.+Ruggeriauthor=B.+D.+Dorsey&title=Discovery+of+a+potent+inhibitor+of+anaplastic+lymphoma+kinase+with+in+vivo+antitumor+activity&doi=10.1021%2Fml100158s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent Inhibitor of Anaplastic Lymphoma Kinase with in Vivo Antitumor Activity</span></div><div class="casAuthors">Ott, Gregory R.; Tripathy, Rabindranath; Cheng, Mangeng; McHugh, Robert; Anzalone, Andrew V.; Underiner, Ted L.; Curry, Matthew A.; Quail, Matthew R.; Lu, Lihui; Wan, Weihua; Angeles, Thelma S.; Albom, Mark S.; Aimone, Lisa D.; Ator, Mark A.; Ruggeri, Bruce A.; Dorsey, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">493-498</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of novel 7-amino-1,3,4,5-tetrahydrobenzo[b]azepin-2-one derivs. within the diaminopyrimidine class of kinase inhibitors were identified that target anaplastic lymphoma kinase (ALK).  These inhibitors are potent against ALK in an isolated enzyme assay and inhibit autophosphorylation of the oncogenic fusion protein NPM-ALK in anaplastic large cell lymphoma (ALCL) cell lines.  The lead inhibitor 15 (I), which incorporates a bicyclo[2.2.1]hept-5-ene ring system in place of an aryl moiety, activates the pro-apoptotic caspases (3 and 7) and displays selective cytotoxicity against ALK-pos. ALCL cells.  Furthermore, 15 provides more than 40-fold selectivity against the structurally related insulin receptor, is orally bioavailable in multiple species, and displays in vivo antitumor efficacy when dosed orally in ALK-pos. ALCL tumor xenografts in Scid mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGof0qilbcAbZ7Vg90H21EOLACvtfcHk0liHmPtK7_GiBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtV2jtrrJ&md5=15d4f7aea64f212338d8c9cd88a36c64</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fml100158s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml100158s%26sid%3Dliteratum%253Aachs%26aulast%3DOtt%26aufirst%3DG.%2BR.%26aulast%3DTripathy%26aufirst%3DR.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DMcHugh%26aufirst%3DR.%26aulast%3DAnzalone%26aufirst%3DA.%2BV.%26aulast%3DUnderiner%26aufirst%3DT.%2BL.%26aulast%3DCurry%26aufirst%3DM.%2BA.%26aulast%3DQuail%26aufirst%3DM.%2BR.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DWan%26aufirst%3DW.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26atitle%3DDiscovery%2520of%2520a%2520potent%2520inhibitor%2520of%2520anaplastic%2520lymphoma%2520kinase%2520with%2520in%2520vivo%2520antitumor%2520activity%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D1%26spage%3D493%26epage%3D498%26doi%3D10.1021%2Fml100158s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Cheng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ott, G. R.</span><span> </span><span class="NLM_article-title">Anaplastic lymphoma kinase as a therapeutic target in anaplastic large cell lymphoma, non-small cell lung cancer and neuroblastoma</span> <span class="citation_source-journal">Anti-Cancer Agents Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">236</span><span class="NLM_x">–</span> <span class="NLM_lpage">249</span><span class="refDoi"> DOI: 10.2174/1871520611009030236</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.2174%2F1871520611009030236" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=236-249&author=M.+Chengauthor=G.+R.+Ott&title=Anaplastic+lymphoma+kinase+as+a+therapeutic+target+in+anaplastic+large+cell+lymphoma%2C+non-small+cell+lung+cancer+and+neuroblastoma&doi=10.2174%2F1871520611009030236"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.2174%2F1871520611009030236&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1871520611009030236%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DOtt%26aufirst%3DG.%2BR.%26atitle%3DAnaplastic%2520lymphoma%2520kinase%2520as%2520a%2520therapeutic%2520target%2520in%2520anaplastic%2520large%2520cell%2520lymphoma%252C%2520non-small%2520cell%2520lung%2520cancer%2520and%2520neuroblastoma%26jtitle%3DAnti-Cancer%2520Agents%2520Med.%2520Chem.%26date%3D2010%26volume%3D10%26spage%3D236%26epage%3D249%26doi%3D10.2174%2F1871520611009030236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Webb, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slavish, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Look, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rentrop, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, S. W.</span><span> </span><span class="NLM_article-title">Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy</span> <span class="citation_source-journal">Expert Rev. Anticancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">331</span><span class="NLM_x">–</span> <span class="NLM_lpage">356</span><span class="refDoi"> DOI: 10.1586/14737140.9.3.331</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1586%2F14737140.9.3.331" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=19275511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtFaltrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=331-356&author=T.+R.+Webbauthor=J.+Slavishauthor=R.+E.+Georgeauthor=A.+T.+Lookauthor=L.+Xueauthor=Q.+Jiangauthor=X.+Cuiauthor=W.+B.+Rentropauthor=S.+W.+Morris&title=Anaplastic+lymphoma+kinase%3A+role+in+cancer+pathogenesis+and+small-molecule+inhibitor+development+for+therapy&doi=10.1586%2F14737140.9.3.331"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy</span></div><div class="casAuthors">Webb, Thomas R.; Slavish, Jake; George, Rani E.; Look, A. Thomas; Xue, Liquan; Jiang, Qin; Cui, Xiaoli; Rentrop, Walter B.; Morris, Stephan W.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anticancer Therapy</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">331-356</span>CODEN:
                <span class="NLM_cas:coden">ERATBJ</span>;
        ISSN:<span class="NLM_cas:issn">1473-7140</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  Anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase in the insulin receptor superfamily, was initially identified in constitutively activated oncogenic fusion forms - the most common being nucleophosmin-ALK - in anaplastic large-cell lymphomas, and subsequent studies have identified ALK fusions in diffuse large B-cell lymphomas, systemic histiocytosis, inflammatory myofibroblastic tumors, esophageal squamous cell carcinomas and non-small-cell lung carcinomas.  More recently, genomic DNA amplification and protein overexpression, as well as activating point mutations, of ALK have been described in neuroblastomas.  In addn. to those cancers for which a causative role for aberrant ALK activity is well validated, more circumstantial links implicate the full-length, normal ALK receptor in the genesis of other malignancies - including glioblastoma and breast cancer - via a mechanism of receptor activation involving autocrine and/or paracrine growth loops with the reported ALK ligands, pleiotrophin and midkine.  This review summarizes normal ALK biol., the confirmed and putative roles of ALK in the development of human cancers and efforts to target ALK using small-mol. kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoERzbvlik_c7Vg90H21EOLACvtfcHk0lg1cL0pOd6tkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtFaltrc%253D&md5=a980ef18ac316bd3894b72ddd2748c17</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1586%2F14737140.9.3.331&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14737140.9.3.331%26sid%3Dliteratum%253Aachs%26aulast%3DWebb%26aufirst%3DT.%2BR.%26aulast%3DSlavish%26aufirst%3DJ.%26aulast%3DGeorge%26aufirst%3DR.%2BE.%26aulast%3DLook%26aufirst%3DA.%2BT.%26aulast%3DXue%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DQ.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DRentrop%26aufirst%3DW.%2BB.%26aulast%3DMorris%26aufirst%3DS.%2BW.%26atitle%3DAnaplastic%2520lymphoma%2520kinase%253A%2520role%2520in%2520cancer%2520pathogenesis%2520and%2520small-molecule%2520inhibitor%2520development%2520for%2520therapy%26jtitle%3DExpert%2520Rev.%2520Anticancer%2520Ther.%26date%3D2009%26volume%3D9%26spage%3D331%26epage%3D356%26doi%3D10.1586%2F14737140.9.3.331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Smith, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eastman, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Njardarson, J. T.</span><span> </span><span class="NLM_article-title">Beyond C, H, O, and N. Analysis of the elemental composition of U.S. FDA approved drug architectures</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">9764</span><span class="NLM_x">–</span> <span class="NLM_lpage">9773</span><span class="refDoi"> DOI: 10.1021/jm501105n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501105n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=9764-9773&author=B.+R.+Smithauthor=C.+M.+Eastmanauthor=J.+T.+Njardarson&title=Beyond+C%2C+H%2C+O%2C+and+N.+Analysis+of+the+elemental+composition+of+U.S.+FDA+approved+drug+architectures&doi=10.1021%2Fjm501105n"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm501105n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501105n%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DB.%2BR.%26aulast%3DEastman%26aufirst%3DC.%2BM.%26aulast%3DNjardarson%26aufirst%3DJ.%2BT.%26atitle%3DBeyond%2520C%252C%2520H%252C%2520O%252C%2520and%2520N.%2520Analysis%2520of%2520the%2520elemental%2520composition%2520of%2520U.S.%2520FDA%2520approved%2520drug%2520architectures%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D9764%26epage%3D9773%26doi%3D10.1021%2Fjm501105n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Rivera, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Squillace, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berk, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardwell, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ning, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollock, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narasimhan, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iuliucci, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span> </span><span class="NLM_article-title">Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1059</span><span class="NLM_x">–</span> <span class="NLM_lpage">1071</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-10-0792</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1158%2F1535-7163.MCT-10-0792" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=21482695" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnt1anurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=1059-1071&author=V.+M.+Riveraauthor=R.+M.+Squillaceauthor=D.+Millerauthor=L.+Berkauthor=S.+D.+Wardwellauthor=Y.+Ningauthor=R.+Pollockauthor=N.+I.+Narasimhanauthor=J.+D.+Iuliucciauthor=F.+Wangauthor=T.+Clackson&title=Ridaforolimus+%28AP23573%3B+MK-8669%29%2C+a+potent+mTOR+inhibitor%2C+has+broad+antitumor+activity+and+can+be+optimally+administered+using+intermittent+dosing+regimens&doi=10.1158%2F1535-7163.MCT-10-0792"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens</span></div><div class="casAuthors">Rivera, Victor M.; Squillace, Rachel M.; Miller, David; Berk, Lori; Wardwell, Scott D.; Ning, Yaoyu; Pollock, Roy; Narasimhan, Narayana I.; Iuliucci, John D.; Wang, Frank; Clackson, Tim</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1059-1071</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The mTOR pathway is hyperactivated through oncogenic transformation in many human malignancies.  Ridaforolimus (AP23573; MK-8669) is a novel rapamycin analog that selectively targets mTOR and is currently under clin. evaluation.  In this study, we investigated the mechanistic basis for the antitumor activity of ridaforolimus in a range of human tumor types, exploring potential markers of response, and detg. optimal dosing regimens to guide clin. studies.  Administration of ridaforolimus to tumor cells in vitro elicited dose-dependent inhibition of mTOR activity with concomitant effects on cell growth and division.  We showed that ridaforolimus exhibits a predominantly cytostatic mode of action, consistent with the findings for other mTOR inhibitors.  Potent inhibitory effects on vascular endothelial growth factor secretion, endothelial cell growth, and glucose metab. were also obsd.  Although PTEN and/or phosphorylated AKT status have been proposed as potential mTOR pathway biomarkers, neither was predictive for ridaforolimus responsiveness in the heterogeneous panel of cancer cell lines examd.  In mouse models, robust antitumor activity was obsd. in human tumor xenografts using a series of intermittent dosing schedules, consistent with pharmacodynamic observations of mTOR pathway inhibition for at least 72 h following dosing.  Parallel skin-graft rejection studies established that intermittent dosing schedules lack the immunosuppressive effects seen with daily dosing.  Overall these findings show the broad inhibitory effects of ridaforolimus on cell growth, division, metab., and angiogenesis, and support the use of intermittent dosing as a means to optimize antitumor activity while minimizing systemic effects.  Mol Cancer Ther; 10(6); 1059-71.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHghCGdAPjCrVg90H21EOLACvtfcHk0lg1cL0pOd6tkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnt1anurs%253D&md5=a23835227e1a0b27332ca973c87f202a</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-10-0792&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-10-0792%26sid%3Dliteratum%253Aachs%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DSquillace%26aufirst%3DR.%2BM.%26aulast%3DMiller%26aufirst%3DD.%26aulast%3DBerk%26aufirst%3DL.%26aulast%3DWardwell%26aufirst%3DS.%2BD.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DPollock%26aufirst%3DR.%26aulast%3DNarasimhan%26aufirst%3DN.%2BI.%26aulast%3DIuliucci%26aufirst%3DJ.%2BD.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DClackson%26aufirst%3DT.%26atitle%3DRidaforolimus%2520%2528AP23573%253B%2520MK-8669%2529%252C%2520a%2520potent%2520mTOR%2520inhibitor%252C%2520has%2520broad%2520antitumor%2520activity%2520and%2520can%2520be%2520optimally%2520administered%2520using%2520intermittent%2520dosing%2520regimens%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26spage%3D1059%26epage%3D1071%26doi%3D10.1158%2F1535-7163.MCT-10-0792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bohacek, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keenan, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundaramoorthi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, C.,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dilauro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roeloffzen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saltmarsh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paramanathan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narula, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pradeepan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Schravendijk, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ram, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liou, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardwell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bogus, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iuliucci, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weigele, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xing, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyce, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, T. K.</span><span> </span><span class="NLM_article-title">SAR of carbon-linked, 2-substituted purines: synthesis and characterization of AP23451 as a novel bone-targeted inhibitor of Src tyrosine kinase with in vivo anti-resorptive activity</span> <span class="citation_source-journal">Chem. Biol. Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">97</span><span class="NLM_x">–</span> <span class="NLM_lpage">105</span><span class="refDoi"> DOI: 10.1111/j.1747-0285.2007.00615.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1111%2Fj.1747-0285.2007.00615.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=18179464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFSntbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2008&pages=97-105&author=W.+C.+Shakespeareauthor=Y.+Wangauthor=R.+Bohacekauthor=T.+Keenanauthor=R.+Sundaramoorthiauthor=C.+Metcalfauthor=A.+Dilauroauthor=S.+Roeloffzenauthor=S.+Liuauthor=J.+Saltmarshauthor=G.+Paramanathanauthor=D.+Dalgarnoauthor=S.+Narulaauthor=S.+Pradeepanauthor=M.+R.+van+Schravendijkauthor=J.+Keatsauthor=M.+Ramauthor=S.+Liouauthor=S.+Adamsauthor=S.+Wardwellauthor=J.+Bogusauthor=J.+Iuliucciauthor=M.+Weigeleauthor=L.+Xingauthor=B.+Boyceauthor=T.+K.+Sawyer&title=SAR+of+carbon-linked%2C+2-substituted+purines%3A+synthesis+and+characterization+of+AP23451+as+a+novel+bone-targeted+inhibitor+of+Src+tyrosine+kinase+with+in+vivo+anti-resorptive+activity&doi=10.1111%2Fj.1747-0285.2007.00615.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">SAR of carbon-linked, 2-substituted purines: synthesis and characterization of AP23451 as a novel bone-targeted inhibitor of Src tyrosine kinase with in vivo anti-resorptive activity</span></div><div class="casAuthors">Shakespeare, William C.; Wang, Yihan; Bohacek, Regine; Keenan, Terry; Sundaramoorthi, Raji; Metcalf, Chet, III; Dilauro, Anne; Roeloffzen, Sonya; Liu, Shuangying; Saltmarsh, Jennifer; Paramanathan, Guru; Dalgarno, David; Narula, Surinder; Pradeepan, Selvi; van Schravendijk, Marie Rose; Keats, Jeff; Ram, Mary; Liou, Shuenn; Adams, Susan; Wardwell, Scott; Bogus, Julie; Iuliucci, John; Weigele, Manfred; Xing, Lianping; Boyce, Brendan; Sawyer, Tomi K.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">97-105</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Targeted disruption of the pp60src (Src) gene has implicated this tyrosine kinase in osteoclast-mediated bone resorption and as a therapeutic target for the treatment of osteoporosis and other bone-related diseases.  Here, we describe structure activity relationships of a novel series of carbon-linked, 2-substituted purines that led to the identification of AP23451 as a potent inhibitor of Src tyrosine kinase with antiresorptive activity in vivo.  AP23451 features the use of an arylphosphinylmethylphosphinic acid moiety which confers bone-targeting properties to the mol., thereby increasing local concns. of the inhibitor to actively resorbing osteoclasts at the bone interface.  AP23451 exhibited an IC50 = 68 nM against Src kinase; an x-ray crystal structure of the mol. complexed with Src detailed the mol. interactions responsible for its Src inhibition.  In vivo, AP23451 demonstrated a dose-dependent decrease in PTH-induced hypercalcemia.  Moreover, AP23517, a structurally and biochem. similar mol. with comparable activity (IC50 = 73 nM) except devoid of the bone-targeting element, demonstrated significantly reduced in vivo efficacy, suggesting that Src activity was necessary but not sufficient for in vivo activity in this series of compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMOkUhcT4xFrVg90H21EOLACvtfcHk0lg1cL0pOd6tkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFSntbs%253D&md5=256b265a9c89d3702881efdd357c31f9</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2007.00615.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2007.00615.x%26sid%3Dliteratum%253Aachs%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DBohacek%26aufirst%3DR.%26aulast%3DKeenan%26aufirst%3DT.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DMetcalf%26aufirst%3DC.%26aulast%3DDilauro%26aufirst%3DA.%26aulast%3DRoeloffzen%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DSaltmarsh%26aufirst%3DJ.%26aulast%3DParamanathan%26aufirst%3DG.%26aulast%3DDalgarno%26aufirst%3DD.%26aulast%3DNarula%26aufirst%3DS.%26aulast%3DPradeepan%26aufirst%3DS.%26aulast%3Dvan%2BSchravendijk%26aufirst%3DM.%2BR.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DRam%26aufirst%3DM.%26aulast%3DLiou%26aufirst%3DS.%26aulast%3DAdams%26aufirst%3DS.%26aulast%3DWardwell%26aufirst%3DS.%26aulast%3DBogus%26aufirst%3DJ.%26aulast%3DIuliucci%26aufirst%3DJ.%26aulast%3DWeigele%26aufirst%3DM.%26aulast%3DXing%26aufirst%3DL.%26aulast%3DBoyce%26aufirst%3DB.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26atitle%3DSAR%2520of%2520carbon-linked%252C%25202-substituted%2520purines%253A%2520synthesis%2520and%2520characterization%2520of%2520AP23451%2520as%2520a%2520novel%2520bone-targeted%2520inhibitor%2520of%2520Src%2520tyrosine%2520kinase%2520with%2520in%2520vivo%2520anti-resorptive%2520activity%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2008%26volume%3D71%26spage%3D97%26epage%3D105%26doi%3D10.1111%2Fj.1747-0285.2007.00615.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">O’Hare, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollock, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoffregen, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abdullah, O. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moseson, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, C. A.,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bohacek, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundaramoorthi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span> </span><span class="NLM_article-title">Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">2532</span><span class="NLM_x">–</span> <span class="NLM_lpage">2539</span><span class="refDoi"> DOI: 10.1182/blood-2004-05-1851</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1182%2Fblood-2004-05-1851" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2004&pages=2532-2539&author=T.+O%E2%80%99Hareauthor=R.+Pollockauthor=E.+P.+Stoffregenauthor=J.+A.+Keatsauthor=O.+M.+Abdullahauthor=E.+M.+Mosesonauthor=V.+M.+Riveraauthor=H.+Tangauthor=C.+A.+Metcalfauthor=R.+S.+Bohacekauthor=Y.+Wangauthor=R.+Sundaramoorthiauthor=W.+C.+Shakespeareauthor=D.+Dalgarnoauthor=T.+Clacksonauthor=T.+K.+Sawyerauthor=M.+W.+Deiningerauthor=B.+J.+Druker&title=Inhibition+of+wild-type+and+mutant+Bcr-Abl+by+AP23464%2C+a+potent+ATP-based+oncogenic+protein+kinase+inhibitor%3A+implications+for+CML&doi=10.1182%2Fblood-2004-05-1851"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1182%2Fblood-2004-05-1851&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2004-05-1851%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DPollock%26aufirst%3DR.%26aulast%3DStoffregen%26aufirst%3DE.%2BP.%26aulast%3DKeats%26aufirst%3DJ.%2BA.%26aulast%3DAbdullah%26aufirst%3DO.%2BM.%26aulast%3DMoseson%26aufirst%3DE.%2BM.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DTang%26aufirst%3DH.%26aulast%3DMetcalf%26aufirst%3DC.%2BA.%26aulast%3DBohacek%26aufirst%3DR.%2BS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DDalgarno%26aufirst%3DD.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26atitle%3DInhibition%2520of%2520wild-type%2520and%2520mutant%2520Bcr-Abl%2520by%2520AP23464%252C%2520a%2520potent%2520ATP-based%2520oncogenic%2520protein%2520kinase%2520inhibitor%253A%2520implications%2520for%2520CML%26jtitle%3DBlood%26date%3D2004%26volume%3D104%26spage%3D2532%26epage%3D2539%26doi%3D10.1182%2Fblood-2004-05-1851" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Dalgarno, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stehle, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narula, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schelling, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Schravendijk, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrade, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ram, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grossman, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacNeil, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, C.,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keenan, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundaramoorthi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bohacek, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weigele, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, T.</span><span> </span><span class="NLM_article-title">Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds</span> <span class="citation_source-journal">Chem. Biol. Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">46</span><span class="NLM_x">–</span> <span class="NLM_lpage">57</span><span class="refDoi"> DOI: 10.1111/j.1747-0285.2005.00316.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1111%2Fj.1747-0285.2005.00316.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=16492148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BD28XhsVSjt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2006&pages=46-57&author=D.+Dalgarnoauthor=T.+Stehleauthor=S.+Narulaauthor=P.+Schellingauthor=M.+R.+van+Schravendijkauthor=S.+Adamsauthor=L.+Andradeauthor=J.+Keatsauthor=M.+Ramauthor=L.+Jinauthor=T.+Grossmanauthor=I.+MacNeilauthor=C.+Metcalfauthor=W.+Shakespeareauthor=Y.+Wangauthor=T.+Keenanauthor=R.+Sundaramoorthiauthor=R.+Bohacekauthor=M.+Weigeleauthor=T.+Sawyer&title=Structural+basis+of+Src+tyrosine+kinase+inhibition+with+a+new+class+of+potent+and+selective+trisubstituted+purine-based+compounds&doi=10.1111%2Fj.1747-0285.2005.00316.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds</span></div><div class="casAuthors">Dalgarno, David; Stehle, Thilo; Narula, Surinder; Schelling, Pierre; van Schravendijk, Marie Rose; Adams, Susan; Andrade, Lawrence; Keats, Jeff; Ram, Mary; Jin, Lei; Grossman, Trudy; MacNeil, Ian; Metcalf, Chester, III; Shakespeare, William; Wang, Yihan; Keenan, Terry; Sundaramoorthi, Raji; Bohacek, Regine; Weigele, Manfred; Sawyer, Tomi</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">46-57</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">The tyrosine kinase pp60src (Src) is the prototypical member of a family of proteins that participate in a broad array of cellular signal transduction processes, including cell growth, differentiation, survival, adhesion, and migration.  Abnormal Src family kinase (SFK) signaling has been linked to several disease states, including osteoporosis and cancer metastases.  Src has thus emerged as a mol. target for the discovery of small-mol. inhibitors that regulate Src kinase activity by binding to the ATP pocket within the catalytic domain.  Here, we present crystal structures of the kinase domain of Src in complex with two purine-based inhibitors: AP23451, a small-mol. inhibitor designed to inhibit Src-dependent bone resorption, and AP23464, a small-mol. inhibitor designed to inhibit the Src-dependent metastatic spread of cancer.  In each case, a trisubstituted purine template core was elaborated using structure-based drug design to yield a potent Src kinase inhibitor.  These structures represent early examples of high affinity purine-based Src family kinase-inhibitor complexes, and they provide a detailed view of the specific protein-ligand interactions that lead to potent inhibition of Src.  In particular, the 3-hydroxyphenethyl N9 substituent of AP23464 forms unique interactions with the protein that are crit. to the picomolar affinity of this compd. for Src.  The comparison of these new structures with two relevant kinase-inhibitor complexes provides a structural basis for the obsd. kinase inhibitory selectivity.  Further comparisons reveal a concerted induced-fit movement between the N- and C-terminal lobes of the kinase that correlates with the affinity of the ligand.  Binding of the most potent inhibitor, AP23464, results in the largest induced-fit movement, which can be directly linked to interactions of the hydrophenethyl N9 substituent with a region at the interface between the two lobes.  A less pronounced induced-fit movement is also obsd. in the Src-AP23451 complex.  These new structures illustrate how the combination of structural, computational, and medicinal chem. can be used to rationalize the process of developing high affinity, selective tyrosine kinase inhibitors as potential therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqAcWZyLy8JrVg90H21EOLACvtfcHk0ljWE_pARHwHBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhsVSjt7Y%253D&md5=5a89de976e29e65aec0553c84e2e0b92</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2005.00316.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2005.00316.x%26sid%3Dliteratum%253Aachs%26aulast%3DDalgarno%26aufirst%3DD.%26aulast%3DStehle%26aufirst%3DT.%26aulast%3DNarula%26aufirst%3DS.%26aulast%3DSchelling%26aufirst%3DP.%26aulast%3Dvan%2BSchravendijk%26aufirst%3DM.%2BR.%26aulast%3DAdams%26aufirst%3DS.%26aulast%3DAndrade%26aufirst%3DL.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DRam%26aufirst%3DM.%26aulast%3DJin%26aufirst%3DL.%26aulast%3DGrossman%26aufirst%3DT.%26aulast%3DMacNeil%26aufirst%3DI.%26aulast%3DMetcalf%26aufirst%3DC.%26aulast%3DShakespeare%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DKeenan%26aufirst%3DT.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DBohacek%26aufirst%3DR.%26aulast%3DWeigele%26aufirst%3DM.%26aulast%3DSawyer%26aufirst%3DT.%26atitle%3DStructural%2520basis%2520of%2520Src%2520tyrosine%2520kinase%2520inhibition%2520with%2520a%2520new%2520class%2520of%2520potent%2520and%2520selective%2520trisubstituted%2520purine-based%2520compounds%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2006%26volume%3D67%26spage%3D46%26epage%3D57%26doi%3D10.1111%2Fj.1747-0285.2005.00316.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Zhang, S.; Anjum, R.; Squillace, R.; Nadworny, S.; Zhou, T.; Keats, J.; Ning, Y.; Wardwell, S. D.; Miller, D.; Song, Y.; Eichinger, L.; Moran, L.; Huang, W.-S.; Liu, S.; Zou, D.; Wang, Y.; Mohemmad, Q.; Jang, H. G.; Ye, E.; Narasimhan, N.; Wang, F.; Miret, J.; Zhu, X.; Clackson, T.; Dalgarno, D.; Shakespeare, W.; Rivera, V. M.</span><span> </span><span class="NLM_article-title">The potent ALK inhibitor brigatinib (AP26113) overcomes mechanisms of resistance to first- and second-generation ALK inhibitors in preclinical models</span>. Clin. Cancer Res.<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">, </span>submitted for publication</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=S.+Zhang&author=R.+Anjum&author=R.+Squillace&author=S.+Nadworny&author=T.+Zhou&author=J.+Keats&author=Y.+Ning&author=S.+D.+Wardwell&author=D.+Miller&author=Y.+Song&author=L.+Eichinger&author=L.+Moran&author=W.-S.+Huang&author=S.+Liu&author=D.+Zou&author=Y.+Wang&author=Q.+Mohemmad&author=H.+G.+Jang&author=E.+Ye&author=N.+Narasimhan&author=F.+Wang&author=J.+Miret&author=X.+Zhu&author=T.+Clackson&author=D.+Dalgarno&author=W.+Shakespeare&author=V.+M.+Rivera&title=The+potent+ALK+inhibitor+brigatinib+%28AP26113%29+overcomes+mechanisms+of+resistance+to+first-+and+second-generation+ALK+inhibitors+in+preclinical+models"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DS.%26atitle%3DThe%2520potent%2520ALK%2520inhibitor%2520brigatinib%2520%2528AP26113%2529%2520overcomes%2520mechanisms%2520of%2520resistance%2520to%2520first-%2520and%2520second-generation%2520ALK%2520inhibitors%2520in%2520preclinical%2520models%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Huang, W.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardwell, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ning, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohlmann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, E. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narasimhan, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C. .</span><span> </span><span class="NLM_article-title">Discovery of AP26113, a potent, orally active inhibitor of anaplastic lymphoma kinase and clinically relevant mutants</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x"> (</span><span class="NLM_issue">15 suppl</span><span class="NLM_x">) </span> <span class="NLM_fpage">No. 2827</span><span class="refDoi"> DOI: 10.1158/1538-7445.AM2015-2827</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1158%2F1538-7445.AM2015-2827" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=No.+2827&issue=15+suppl&author=W.-S.+Huangauthor=F.+Liauthor=L.+Caiauthor=Y.+Xuauthor=S.+Zhangauthor=S.+D.+Wardwellauthor=Y.+Ningauthor=A.+Kohlmannauthor=T.+Zhouauthor=E.+Y.+Yeauthor=X.+Zhuauthor=N.+I.+Narasimhanauthor=T.+Clacksonauthor=V.+M.+Riveraauthor=D.+Dalgarnoauthor=W.+C.+.+Shakespeare&title=Discovery+of+AP26113%2C+a+potent%2C+orally+active+inhibitor+of+anaplastic+lymphoma+kinase+and+clinically+relevant+mutants&doi=10.1158%2F1538-7445.AM2015-2827"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2015-2827&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2015-2827%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.-S.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DCai%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DWardwell%26aufirst%3DS.%2BD.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DKohlmann%26aufirst%3DA.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DYe%26aufirst%3DE.%2BY.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DNarasimhan%26aufirst%3DN.%2BI.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DDalgarno%26aufirst%3DD.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%2B.%26atitle%3DDiscovery%2520of%2520AP26113%252C%2520a%2520potent%252C%2520orally%2520active%2520inhibitor%2520of%2520anaplastic%2520lymphoma%2520kinase%2520and%2520clinically%2520relevant%2520mutants%26jtitle%3DCancer%2520Res.%26date%3D2015%26volume%3D75%26issue%3D15%2520suppl%26spage%3DNo.%25202827%26doi%3D10.1158%2F1538-7445.AM2015-2827" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Li, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, S. W.</span><span> </span><span class="NLM_article-title">Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy</span> <span class="citation_source-journal">Med. Res. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">372</span><span class="NLM_x">–</span> <span class="NLM_lpage">412</span><span class="refDoi"> DOI: 10.1002/med.20109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1002%2Fmed.20109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=17694547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsVyltLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2008&pages=372-412&author=R.+Liauthor=S.+W.+Morris&title=Development+of+anaplastic+lymphoma+kinase+%28ALK%29+small-molecule+inhibitors+for+cancer+therapy&doi=10.1002%2Fmed.20109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy</span></div><div class="casAuthors">Li, Rongshi; Morris, Stephan W.</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">372-412</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase (RTK) involved in the genesis of several human cancers; indeed, ALK was initially identified in constitutively activated and oncogenic fusion forms-the most common being nucleophosmin (NPM)-ALK-in a nonHodgkin's lymphoma (NHL) known as anaplastic large-cell lymphoma (ALCL) and subsequent studies identified ALK fusions in the human sarcomas called inflammatory myofibroblastic tumors (IMTs).  In addn., two recent reports have suggested that the ALK fusion, TPM4-ALK, may be involved in the genesis of a subset of esophageal squamous cell carcinomas.  While the cause-effect relationship between ALK fusions and malignancies such as ALCL and IMT is very well established, more circumstantial links implicate the involvement of the full-length, normal ALK receptor in the genesis of addnl. malignancies including glioblastoma, neuroblastoma, breast cancer, and others; in these instances, ALK is believed to foster tumorigenesis following activation by autocrine and/or paracrine growth loops involving the reported ALK ligands, pleiotrophin (PTN) and midkine (MK).  There are no currently available ALK small-mol. inhibitors approved for clin. cancer therapy; however, recognition of the variety of malignancies in which ALK may play a causative role has recently begun to prompt developmental efforts in this area.  This review provides a succinct summary of normal ALK biol., the confirmed and putative roles of ALK fusions and the full-length ALK receptor in the development of human cancers, and efforts to target ALK using small-mol. kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoB3B7c_OpT2LVg90H21EOLACvtfcHk0lj4xLoY9QQjjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsVyltLs%253D&md5=d8521d00232b6b3d1c807fb65645ac67</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1002%2Fmed.20109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.20109%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DR.%26aulast%3DMorris%26aufirst%3DS.%2BW.%26atitle%3DDevelopment%2520of%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520small-molecule%2520inhibitors%2520for%2520cancer%2520therapy%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2008%26volume%3D28%26spage%3D372%26epage%3D412%26doi%3D10.1002%2Fmed.20109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Galkin, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melnick, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hood, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steensma, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chopiuk, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warmuth, M.</span><span> </span><span class="NLM_article-title">Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">270</span><span class="NLM_x">–</span> <span class="NLM_lpage">275</span><span class="refDoi"> DOI: 10.1073/pnas.0609412103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1073%2Fpnas.0609412103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=17185414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjt12jsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=270-275&author=A.+V.+Galkinauthor=J.+S.+Melnickauthor=S.+Kimauthor=T.+L.+Hoodauthor=N.+Liauthor=L.+Liauthor=G.+Xiaauthor=R.+Steensmaauthor=G.+Chopiukauthor=J.+Jiangauthor=Y.+Wanauthor=P.+Dingauthor=Y.+Liuauthor=F.+Sunauthor=P.+G.+Schultzauthor=N.+S.+Grayauthor=M.+Warmuth&title=Identification+of+NVP-TAE684%2C+a+potent%2C+selective%2C+and+efficacious+inhibitor+of+NPM-ALK&doi=10.1073%2Fpnas.0609412103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK</span></div><div class="casAuthors">Galkin, Anna V.; Melnick, Jonathon S.; Kim, Sunjoon; Hood, Tami L.; Li, Nanxin; Li, Lintong; Xia, Gang; Steensma, Ruo; Chopiuk, Greg; Wan, Yongqin; Ding, Peter; Liu, Yi; Sun, Fangxian; Schultz, Peter G.; Gray, Nathanael S.; Warmuth, Markus</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">270-275</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Constitutive overexpression and activation of NPM-ALK fusion protein [t(2:5)(p23;q35)] is a key oncogenic event that drives the survival and proliferation of anaplastic large cell lymphomas (ALCLs).  We have identified a highly potent and selective small-mol. ALK inhibitor, NVP-TAE684, which blocked the growth of ALCL-derived and ALK-dependent cell lines with IC50 values between 2 and 10 nM.  NVP-TAE684 treatment resulted in a rapid and sustained inhibition of phosphorylation of NPM-ALK and its downstream effectors and subsequent induction of apoptosis and cell cycle arrest.  In vivo, NVP-TAE684 suppressed lymphomagenesis in two independent models of ALK-pos. ALCL and induced regression of established Karpas-299 lymphomas.  NVP-TAE684 also induced down-regulation of CD30 expression, suggesting that CD30 may be used as a biomarker of therapeutic NPM-ALK kinase activity inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLbZwqZzPX-bVg90H21EOLACvtfcHk0lj4xLoY9QQjjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjt12jsQ%253D%253D&md5=4a3441ee637a67dc496c80730bd0e184</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0609412103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0609412103%26sid%3Dliteratum%253Aachs%26aulast%3DGalkin%26aufirst%3DA.%2BV.%26aulast%3DMelnick%26aufirst%3DJ.%2BS.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DHood%26aufirst%3DT.%2BL.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DXia%26aufirst%3DG.%26aulast%3DSteensma%26aufirst%3DR.%26aulast%3DChopiuk%26aufirst%3DG.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DWan%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DWarmuth%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520NVP-TAE684%252C%2520a%2520potent%252C%2520selective%252C%2520and%2520efficacious%2520inhibitor%2520of%2520NPM-ALK%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2007%26volume%3D104%26spage%3D270%26epage%3D275%26doi%3D10.1073%2Fpnas.0609412103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Huang, W.-S.; Thomas, R. M.</span><span> </span><span class="NLM_article-title">Pyrazinopyrazine derivatives as kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of cancer</span>. PCT Int. Appl. WO 2010056311,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=W.-S.+Huang&author=R.+M.+Thomas&title=Pyrazinopyrazine+derivatives+as+kinase+inhibitors+and+their+preparation%2C+pharmaceutical+compositions+and+use+in+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.-S.%26atitle%3DPyrazinopyrazine%2520derivatives%2520as%2520kinase%2520inhibitors%2520and%2520their%2520preparation%252C%2520pharmaceutical%2520compositions%2520and%2520use%2520in%2520the%2520treatment%2520of%2520cancer%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Kothe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohls, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Low, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rennie, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feru, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhn, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, Y. H.</span><span> </span><span class="NLM_article-title">Selectivity-determining residues in Plk1</span> <span class="citation_source-journal">Chem. Biol. Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">540</span><span class="NLM_x">–</span> <span class="NLM_lpage">546</span><span class="refDoi"> DOI: 10.1111/j.1747-0285.2007.00594.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1111%2Fj.1747-0285.2007.00594.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=18005335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVGhsbrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2007&pages=540-546&author=M.+Kotheauthor=D.+Kohlsauthor=S.+Lowauthor=R.+Coliauthor=G.+R.+Rennieauthor=F.+Feruauthor=C.+Kuhnauthor=Y.+H.+Ding&title=Selectivity-determining+residues+in+Plk1&doi=10.1111%2Fj.1747-0285.2007.00594.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Selectivity-determining residues in Plk1</span></div><div class="casAuthors">Kothe, Michael; Kohls, Darcy; Low, Simon; Coli, Rocco; Rennie, Glen R.; Feru, Frederic; Kuhn, Cyrille; Ding, Yuan-Hua</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">540-546</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Polo-like kinase 1 is an important regulator of cell cycle progression whose over-expression is often assocd. with oncogenesis.  Polo-like kinase 1 hence represents an attractive target for cancer intervention.  BI 2536 (Boehringer Ingelheim, Ingelheim, Germany), a Polo-like kinase 1 inhibitor currently in clin. trials, exhibits nanomolar potency against Polo-like kinase isoforms and high selectivity against other kinases.  The authors have previously published the crystal structures of the Polo-like kinase 1 domain in complex with AMPPNP and an Aurora A inhibitor.  In this work, the authors present the cocrystal structure of Polo-like kinase 1 with BI 2536.  The structure, in combination with selectivity data for BI 2536 and related compds., illustrates important features for potency and selectivity.  In particular, the authors show that the methoxy group of BI 2536 is an important specificity determinant against non-Polo-like kinases by taking advantage of a small pocket generated by Leu 132 in the hinge region of Polo-like kinase 1.  The work presented here provides a framework for structure-based drug design of Polo-like kinase 1-specific inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjA3mwWD7K0bVg90H21EOLACvtfcHk0ljksZWel2Zusw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVGhsbrJ&md5=0f976bb98fe7d0413e8d2314abc68e2b</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2007.00594.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2007.00594.x%26sid%3Dliteratum%253Aachs%26aulast%3DKothe%26aufirst%3DM.%26aulast%3DKohls%26aufirst%3DD.%26aulast%3DLow%26aufirst%3DS.%26aulast%3DColi%26aufirst%3DR.%26aulast%3DRennie%26aufirst%3DG.%2BR.%26aulast%3DFeru%26aufirst%3DF.%26aulast%3DKuhn%26aufirst%3DC.%26aulast%3DDing%26aufirst%3DY.%2BH.%26atitle%3DSelectivity-determining%2520residues%2520in%2520Plk1%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2007%26volume%3D70%26spage%3D540%26epage%3D546%26doi%3D10.1111%2Fj.1747-0285.2007.00594.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Laurence, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brameld, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graton, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Questel, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renault, E.</span><span> </span><span class="NLM_article-title">The pK(BHX) Database: toward a better understanding of hydrogen-bond basicity for medicinal chemists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">4073</span><span class="NLM_x">–</span> <span class="NLM_lpage">4086</span><span class="refDoi"> DOI: 10.1021/jm801331y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801331y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnsFKns7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=4073-4086&author=C.+Laurenceauthor=K.+A.+Brameldauthor=J.+Gratonauthor=J.+Y.+Le+Questelauthor=E.+Renault&title=The+pK%28BHX%29+Database%3A+toward+a+better+understanding+of+hydrogen-bond+basicity+for+medicinal+chemists&doi=10.1021%2Fjm801331y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">The pKBHX Database: Toward a Better Understanding of Hydrogen-Bond Basicity for Medicinal Chemists</span></div><div class="casAuthors">Laurence, Christian; Brameld, Ken A.; Graton, Jerome; Le Questel, Jean-Yves; Renault, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4073-4086</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The pKBHX database is presented, which corresponds to three main fields of data: hydrogen bond donor identification, thermodn. data and spectroscopic data.  The pKBHX scale of hydrogen donor basicity differs considerable from the pKBH+ scale of proton transfer basicity.  The hydrogen bond basicities of functional groups relevant to medicinal chem. and drug design is reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGql9OhmMu2VILVg90H21EOLACvtfcHk0ljksZWel2Zusw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnsFKns7w%253D&md5=9ce4bea3e810752baba6ea5784b55ea0</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fjm801331y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801331y%26sid%3Dliteratum%253Aachs%26aulast%3DLaurence%26aufirst%3DC.%26aulast%3DBrameld%26aufirst%3DK.%2BA.%26aulast%3DGraton%26aufirst%3DJ.%26aulast%3DLe%2BQuestel%26aufirst%3DJ.%2BY.%26aulast%3DRenault%26aufirst%3DE.%26atitle%3DThe%2520pK%2528BHX%2529%2520Database%253A%2520toward%2520a%2520better%2520understanding%2520of%2520hydrogen-bond%2520basicity%2520for%2520medicinal%2520chemists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D4073%26epage%3D4086%26doi%3D10.1021%2Fjm801331y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Rai, U. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Symons, M. C. R.</span><span> </span><span class="NLM_article-title">EPR data do not support the P═O representation for trialkyl phosphates and phosphine oxides or sulfides</span> <span class="citation_source-journal">J. Chem. Soc., Faraday Trans.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">90</span><span class="NLM_x">, </span> <span class="NLM_fpage">2649</span><span class="NLM_x">–</span> <span class="NLM_lpage">2652</span><span class="refDoi"> DOI: 10.1039/FT9949002649</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1039%2FFT9949002649" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=1994&pages=2649-2652&author=U.+S.+Raiauthor=M.+C.+R.+Symons&title=EPR+data+do+not+support+the+P%E2%95%90O+representation+for+trialkyl+phosphates+and+phosphine+oxides+or+sulfides&doi=10.1039%2FFT9949002649"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1039%2FFT9949002649&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FFT9949002649%26sid%3Dliteratum%253Aachs%26aulast%3DRai%26aufirst%3DU.%2BS.%26aulast%3DSymons%26aufirst%3DM.%2BC.%2BR.%26atitle%3DEPR%2520data%2520do%2520not%2520support%2520the%2520P%25E2%2595%2590O%2520representation%2520for%2520trialkyl%2520phosphates%2520and%2520phosphine%2520oxides%2520or%2520sulfides%26jtitle%3DJ.%2520Chem.%2520Soc.%252C%2520Faraday%2520Trans.%26date%3D1994%26volume%3D90%26spage%3D2649%26epage%3D2652%26doi%3D10.1039%2FFT9949002649" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Power, W. P.</span><span> </span><span class="NLM_article-title">P-31 solid-state NMR of a phosphine borane adduct - phosphorus chemical shielding trends in the isoelectronic series R(3)PX, where X = BH3, CH2, NH, O</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">117</span><span class="NLM_x">, </span> <span class="NLM_fpage">1800</span><span class="NLM_x">–</span> <span class="NLM_lpage">1806</span><span class="refDoi"> DOI: 10.1021/ja00111a019</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja00111a019" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=1995&pages=1800-1806&author=W.+P.+Power&title=P-31+solid-state+NMR+of+a+phosphine+borane+adduct+-+phosphorus+chemical+shielding+trends+in+the+isoelectronic+series+R%283%29PX%2C+where+X+%3D+BH3%2C+CH2%2C+NH%2C+O&doi=10.1021%2Fja00111a019"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Fja00111a019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00111a019%26sid%3Dliteratum%253Aachs%26aulast%3DPower%26aufirst%3DW.%2BP.%26atitle%3DP-31%2520solid-state%2520NMR%2520of%2520a%2520phosphine%2520borane%2520adduct%2520-%2520phosphorus%2520chemical%2520shielding%2520trends%2520in%2520the%2520isoelectronic%2520series%2520R%25283%2529PX%252C%2520where%2520X%2520%253D%2520BH3%252C%2520CH2%252C%2520NH%252C%2520O%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1995%26volume%3D117%26spage%3D1800%26epage%3D1806%26doi%3D10.1021%2Fja00111a019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Chesnut, D. B.</span><span> </span><span class="NLM_article-title">An ab initio nuclear magnetic resonance and atoms-in-molecules study of the PO bond in phosphine oxides</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">120</span><span class="NLM_x">, </span> <span class="NLM_fpage">10504</span><span class="NLM_x">–</span> <span class="NLM_lpage">10510</span><span class="refDoi"> DOI: 10.1021/ja9822198</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja9822198" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=1998&pages=10504-10510&author=D.+B.+Chesnut&title=An+ab+initio+nuclear+magnetic+resonance+and+atoms-in-molecules+study+of+the+PO+bond+in+phosphine+oxides&doi=10.1021%2Fja9822198"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Fja9822198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja9822198%26sid%3Dliteratum%253Aachs%26aulast%3DChesnut%26aufirst%3DD.%2BB.%26atitle%3DAn%2520ab%2520initio%2520nuclear%2520magnetic%2520resonance%2520and%2520atoms-in-molecules%2520study%2520of%2520the%2520PO%2520bond%2520in%2520phosphine%2520oxides%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1998%26volume%3D120%26spage%3D10504%26epage%3D10510%26doi%3D10.1021%2Fja9822198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Dobado, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez-Garcia, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molina, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundberg, M. R.</span><span> </span><span class="NLM_article-title">Chemical bonding in hypervalent molecules revised. Application of the atoms in molecules theory to Y-3 X and Y-3 XZ (Y = H or CH3; X = N, P or As; Z = O or S) compounds</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">120</span><span class="NLM_x">, </span> <span class="NLM_fpage">8461</span><span class="NLM_x">–</span> <span class="NLM_lpage">8471</span><span class="refDoi"> DOI: 10.1021/ja980141p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja980141p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=1998&pages=8461-8471&author=J.+A.+Dobadoauthor=H.+Martinez-Garciaauthor=J.+M.+Molinaauthor=M.+R.+Sundberg&title=Chemical+bonding+in+hypervalent+molecules+revised.+Application+of+the+atoms+in+molecules+theory+to+Y-3+X+and+Y-3+XZ+%28Y+%3D+H+or+CH3%3B+X+%3D+N%2C+P+or+As%3B+Z+%3D+O+or+S%29+compounds&doi=10.1021%2Fja980141p"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fja980141p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja980141p%26sid%3Dliteratum%253Aachs%26aulast%3DDobado%26aufirst%3DJ.%2BA.%26aulast%3DMartinez-Garcia%26aufirst%3DH.%26aulast%3DMolina%26aufirst%3DJ.%2BM.%26aulast%3DSundberg%26aufirst%3DM.%2BR.%26atitle%3DChemical%2520bonding%2520in%2520hypervalent%2520molecules%2520revised.%2520Application%2520of%2520the%2520atoms%2520in%2520molecules%2520theory%2520to%2520Y-3%2520X%2520and%2520Y-3%2520XZ%2520%2528Y%2520%253D%2520H%2520or%2520CH3%253B%2520X%2520%253D%2520N%252C%2520P%2520or%2520As%253B%2520Z%2520%253D%2520O%2520or%2520S%2529%2520compounds%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1998%26volume%3D120%26spage%3D8461%26epage%3D8471%26doi%3D10.1021%2Fja980141p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Alkorta, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elguero, J.</span><span> </span><span class="NLM_article-title">Theoretical study of strong hydrogen bonds between neutral molecules: the case of amine oxides and phosphine oxides as hydrogen bond acceptors</span> <span class="citation_source-journal">J. Phys. Chem. A</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">272</span><span class="NLM_x">–</span> <span class="NLM_lpage">279</span><span class="refDoi"> DOI: 10.1021/jp982644n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jp982644n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADyaK1cXotVOmtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=1999&pages=272-279&author=I.+Alkortaauthor=J.+Elguero&title=Theoretical+study+of+strong+hydrogen+bonds+between+neutral+molecules%3A+the+case+of+amine+oxides+and+phosphine+oxides+as+hydrogen+bond+acceptors&doi=10.1021%2Fjp982644n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Theoretical Study of Strong Hydrogen Bonds between Neutral Molecules: The Case of Amine Oxides and Phosphine Oxides as Hydrogen Bond Acceptors</span></div><div class="casAuthors">Alkorta, Ibon; Elguero, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physical Chemistry A</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">272-279</span>CODEN:
                <span class="NLM_cas:coden">JPCAFH</span>;
        ISSN:<span class="NLM_cas:issn">1089-5639</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A theor. study of the ability of amine oxides and phosphine oxides as hydrogen bond (HB) acceptors has been carried out using ammonium oxide, trimethylamine oxide, and phosphine oxide as model systems.  The anal. of the energetic results indicate that only small spatial preferences are obsd. in the HB interaction.  The value of the interaction energies are in several cases within the range of strong HB (>12 kcal/mol), and in complexes between amine oxides and strong acids in the gas phase, a spontaneous proton transfer is obtained.  A logarithmic correlation between the electron d. at the HB crit. points and the HB distance that is able to fit not only calcd. data but also exptl. ones has been obtained. Finally, a linear relationship has been found between the no. of HBs and the 31P NMR shielding in the H3PO···(HF)n series, in good agreement with exptl. reports.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC_Hcc8nS0z7Vg90H21EOLACvtfcHk0lhsJuXS5fN8-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXotVOmtL0%253D&md5=75c0da9fa02cf656f817f5b3f04ea94d</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Fjp982644n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjp982644n%26sid%3Dliteratum%253Aachs%26aulast%3DAlkorta%26aufirst%3DI.%26aulast%3DElguero%26aufirst%3DJ.%26atitle%3DTheoretical%2520study%2520of%2520strong%2520hydrogen%2520bonds%2520between%2520neutral%2520molecules%253A%2520the%2520case%2520of%2520amine%2520oxides%2520and%2520phosphine%2520oxides%2520as%2520hydrogen%2520bond%2520acceptors%26jtitle%3DJ.%2520Phys.%2520Chem.%2520A%26date%3D1999%26volume%3D103%26spage%3D272%26epage%3D279%26doi%3D10.1021%2Fjp982644n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Xu, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, J. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Y. Z.</span><span> </span><span class="NLM_article-title">Palladium-catalyzed synthesis of alkylarylphenylphosphine oxides</span> <span class="citation_source-journal">Synthesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1984</span><span class="NLM_x">, </span> <span class="NLM_volume">1984</span><span class="NLM_x">, </span> <span class="NLM_fpage">781</span><span class="NLM_x">–</span> <span class="NLM_lpage">782</span><span class="refDoi"> DOI: 10.1055/s-1984-30972</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1055%2Fs-1984-30972" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1984&publication_year=1984&pages=781-782&author=Y.+Y.+Xuauthor=Z.+Liauthor=J.+Z.+Xiaauthor=H.+J.+Guoauthor=Y.+Z.+Huang&title=Palladium-catalyzed+synthesis+of+alkylarylphenylphosphine+oxides&doi=10.1055%2Fs-1984-30972"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1055%2Fs-1984-30972&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-1984-30972%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DY.%2BY.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DXia%26aufirst%3DJ.%2BZ.%26aulast%3DGuo%26aufirst%3DH.%2BJ.%26aulast%3DHuang%26aufirst%3DY.%2BZ.%26atitle%3DPalladium-catalyzed%2520synthesis%2520of%2520alkylarylphenylphosphine%2520oxides%26jtitle%3DSynthesis%26date%3D1984%26volume%3D1984%26spage%3D781%26epage%3D782%26doi%3D10.1055%2Fs-1984-30972" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Kim, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harden, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyer, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubyak, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burnstock, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, K. A.</span><span> </span><span class="NLM_article-title">Structure-activity relationships of pyridoxal phosphate derivatives as potent and selective antagonists of P2 × 1 receptors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">340</span><span class="NLM_x">–</span> <span class="NLM_lpage">349</span><span class="refDoi"> DOI: 10.1021/jm9904203</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9904203" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=340-349&author=Y.+C.+Kimauthor=S.+G.+Brownauthor=T.+K.+Hardenauthor=J.+L.+Boyerauthor=G.+Dubyakauthor=B.+F.+Kingauthor=G.+Burnstockauthor=K.+A.+Jacobson&title=Structure-activity+relationships+of+pyridoxal+phosphate+derivatives+as+potent+and+selective+antagonists+of+P2+%C3%97+1+receptors&doi=10.1021%2Fjm9904203"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Fjm9904203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9904203%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DY.%2BC.%26aulast%3DBrown%26aufirst%3DS.%2BG.%26aulast%3DHarden%26aufirst%3DT.%2BK.%26aulast%3DBoyer%26aufirst%3DJ.%2BL.%26aulast%3DDubyak%26aufirst%3DG.%26aulast%3DKing%26aufirst%3DB.%2BF.%26aulast%3DBurnstock%26aufirst%3DG.%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26atitle%3DStructure-activity%2520relationships%2520of%2520pyridoxal%2520phosphate%2520derivatives%2520as%2520potent%2520and%2520selective%2520antagonists%2520of%2520P2%2520%25C3%2597%25201%2520receptors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D340%26epage%3D349%26doi%3D10.1021%2Fjm9904203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group">Xuan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, L. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, W. J.</span><span> </span><span class="NLM_article-title">Room temperature C-P bond formation enabled by merging nickel catalysis and visible-light-induced photoredox catalysis</span> <span class="citation_source-journal">Chem. - Eur. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">4962</span><span class="NLM_x">–</span> <span class="NLM_lpage">4965</span><span class="refDoi"> DOI: 10.1002/chem.201500227</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1002%2Fchem.201500227" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=25688851" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsl2qs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=4962-4965&author=J.+Xuanauthor=T.+T.+Zengauthor=J.+R.+Chenauthor=L.+Q.+Luauthor=W.+J.+Xiao&title=Room+temperature+C-P+bond+formation+enabled+by+merging+nickel+catalysis+and+visible-light-induced+photoredox+catalysis&doi=10.1002%2Fchem.201500227"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Room temperature C-P bond formation enabled by merging nickel catalysis and visible-light-induced photoredox catalysis</span></div><div class="casAuthors">Xuan, Jun; Zeng, Ting-Ting; Chen, Jia-Rong; Lu, Liang-Qiu; Xiao, Wen-Jing</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4962-4965</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A novel and efficient C-P bond formation reaction of diarylphosphine oxides with aryl iodides was achieved by combining nickel catalysis and visible-light-induced photoredox catalysis.  Reaction of secondary phosphine oxide, Ph2P(O)H with aryl iodides ArI, catalyzed by a combination of 2 mol% of a Ni(0) source, Ni(cod)2, 2 mol% of the nitrogen ligand, 4,4'-di-tert-butyl-2,2'-bipyridine (dtbbpy) and 5 mol% of [Ru(bpy)3]Cl2·6H2O as a photoredox catalyst, gave the triarylphosphine oxides Ph2ArPO (3a-n, Ar = Ph, MeOC6H4, FC6H4, ClC6H4, BrC6H4, HOC6H4, H2NC6H4, 1-naphthyl, 2-pyridyl) with 71-91% yields.  This dual-catalytic reaction showed a broad substrate scope, excellent functional group tolerance, and afforded the corresponding products in good to excellent yields.  Compared with the previously reported use of photoredox/nickel dual catalysis in the construction of C-C bonds, the methodol. described herein was obsd. to be the first to allow for C-heteroatom bond formation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHg41nsc7WZrVg90H21EOLACvtfcHk0lhsJuXS5fN8-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsl2qs7o%253D&md5=ae1d0b928d31e7cffad1cbc3d9dc8030</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1002%2Fchem.201500227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.201500227%26sid%3Dliteratum%253Aachs%26aulast%3DXuan%26aufirst%3DJ.%26aulast%3DZeng%26aufirst%3DT.%2BT.%26aulast%3DChen%26aufirst%3DJ.%2BR.%26aulast%3DLu%26aufirst%3DL.%2BQ.%26aulast%3DXiao%26aufirst%3DW.%2BJ.%26atitle%3DRoom%2520temperature%2520C-P%2520bond%2520formation%2520enabled%2520by%2520merging%2520nickel%2520catalysis%2520and%2520visible-light-induced%2520photoredox%2520catalysis%26jtitle%3DChem.%2520-%2520Eur.%2520J.%26date%3D2015%26volume%3D21%26spage%3D4962%26epage%3D4965%26doi%3D10.1002%2Fchem.201500227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 155 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Shaowen Xie, Yuan Sun, Yulin Liu, Xinnan Li, Xinuo Li, Wenyi Zhong, Feiyan Zhan, Jingjie Zhu, Hong Yao, Dong-Hua Yang, Zhe-Sheng Chen, Jinyi Xu, <span class="NLM_string-name hlFld-ContribAuthor">Shengtao Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Development of Alectinib-Based PROTACs as Novel Potent Degraders of Anaplastic Lymphoma Kinase (ALK). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (13)
                                     , 9120-9140. <a href="https://doi.org/10.1021/acs.jmedchem.1c00270" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00270</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00270%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDevelopment%252Bof%252BAlectinib-Based%252BPROTACs%252Bas%252BNovel%252BPotent%252BDegraders%252Bof%252BAnaplastic%252BLymphoma%252BKinase%252B%252528ALK%252529%26aulast%3DXie%26aufirst%3DShaowen%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D11022021%26date%3D28062021%26volume%3D64%26issue%3D13%26spage%3D9120%26epage%3D9140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Chaowei Ren, Ning Sun, Haixia Liu, Ying Kong, Renhong Sun, Xing Qiu, Jinju Chen, Yan Li, Jianshui Zhang, Yuedong Zhou, Hui Zhong, Qianqian Yin, Xiaoling Song, Xiaobao Yang, <span class="NLM_string-name hlFld-ContribAuthor">Biao Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a Brigatinib Degrader SIAIS164018 with Destroying Metastasis-Related Oncoproteins and a Reshuffling Kinome Profile. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (13)
                                     , 9152-9165. <a href="https://doi.org/10.1021/acs.jmedchem.1c00373" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00373</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00373%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ba%252BBrigatinib%252BDegrader%252BSIAIS164018%252Bwith%252BDestroying%252BMetastasis-Related%252BOncoproteins%252Band%252Ba%252BReshuffling%252BKinome%252BProfile%26aulast%3DRen%26aufirst%3DChaowei%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D01032021%26date%3D17062021%26volume%3D64%26issue%3D13%26spage%3D9152%26epage%3D9165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ikuo Fujimori, Takeshi Wakabayashi, Morio Murakami, Atsutoshi Okabe, Tsuyoshi Ishii, Aaron McGrath, Hua Zou, Kumar Singh Saikatendu, <span class="NLM_string-name hlFld-ContribAuthor">Hiroshi Imoto</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel and Highly Selective Cyclopropane ALK Inhibitors through a Fragment-Assisted, Structure-Based Drug Design. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2020,</strong> <em>5 </em>
                                    (49)
                                     , 31984-32001. <a href="https://doi.org/10.1021/acsomega.0c04900" title="DOI URL">https://doi.org/10.1021/acsomega.0c04900</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.0c04900&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.0c04900%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DDiscovery%252Bof%252BNovel%252Band%252BHighly%252BSelective%252BCyclopropane%252BALK%252BInhibitors%252Bthrough%252Ba%252BFragment-Assisted%25252C%252BStructure-Based%252BDrug%252BDesign%26aulast%3DFujimori%26aufirst%3DIkuo%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D07102020%26date%3D13112020%26date%3D30112020%26volume%3D5%26issue%3D49%26spage%3D31984%26epage%3D32001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Aofeng Guo, Qiankun Zhang, Junming Zhang, Jiale Chen, Jiaqi Chen, <span class="NLM_string-name hlFld-ContribAuthor">Yu Sha</span>. </span><span class="cited-content_cbyCitation_article-title">Investigation into the Formation of Impurities during the Optimization of Brigatinib. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2020,</strong> <em>5 </em>
                                    (45)
                                     , 29265-29271. <a href="https://doi.org/10.1021/acsomega.0c03816" title="DOI URL">https://doi.org/10.1021/acsomega.0c03816</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.0c03816&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.0c03816%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DInvestigation%252Binto%252Bthe%252BFormation%252Bof%252BImpurities%252Bduring%252Bthe%252BOptimization%252Bof%252BBrigatinib%26aulast%3DGuo%26aufirst%3DAofeng%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D20082020%26date%3D12102020%26date%3D03112020%26volume%3D5%26issue%3D45%26spage%3D29265%26epage%3D29271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Andrew C. Flick, Carolyn A. Leverett, Hong X. Ding, Emma McInturff, Sarah J. Fink, Christopher J. Helal, Jacob C. DeForest, Peter D. Morse, Subham Mahapatra, <span class="NLM_string-name hlFld-ContribAuthor">Christopher J. O’Donnell</span>. </span><span class="cited-content_cbyCitation_article-title">Synthetic Approaches to New Drugs Approved during 2018. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (19)
                                     , 10652-10704. <a href="https://doi.org/10.1021/acs.jmedchem.0c00345" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00345</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00345%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthetic%252BApproaches%252Bto%252BNew%252BDrugs%252BApproved%252Bduring%252B2018%26aulast%3DFlick%26aufirst%3DAndrew%2BC.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D26022020%26date%3D22052020%26date%3D27042020%26volume%3D63%26issue%3D19%26spage%3D10652%26epage%3D10704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Feiyang Xu, Olivia M. Duke, Daniel Rojas, Hanka M. Eichelberger, Raphael S. Kim, Timothy B. Clark, <span class="NLM_string-name hlFld-ContribAuthor">Donald A. Watson</span>. </span><span class="cited-content_cbyCitation_article-title">Arylphosphonate-Directed Ortho C–H Borylation: Rapid Entry into Highly-Substituted Phosphoarenes. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2020,</strong> <em>142 </em>
                                    (28)
                                     , 11988-11992. <a href="https://doi.org/10.1021/jacs.0c04159" title="DOI URL">https://doi.org/10.1021/jacs.0c04159</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.0c04159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.0c04159%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DArylphosphonate-Directed%252BOrtho%252BC%2525E2%252580%252593H%252BBorylation%25253A%252BRapid%252BEntry%252Binto%252BHighly-Substituted%252BPhosphoarenes%26aulast%3DXu%26aufirst%3DFeiyang%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D16042020%26date%3D02072020%26date%3D27062020%26volume%3D142%26issue%3D28%26spage%3D11988%26epage%3D11992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Peter Finkbeiner, Jörg P. Hehn, <span class="NLM_string-name hlFld-ContribAuthor">Christian Gnamm</span>. </span><span class="cited-content_cbyCitation_article-title">Phosphine Oxides from a Medicinal Chemist’s Perspective: Physicochemical and in Vitro Parameters Relevant for Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (13)
                                     , 7081-7107. <a href="https://doi.org/10.1021/acs.jmedchem.0c00407" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00407</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00407&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00407%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPhosphine%252BOxides%252Bfrom%252Ba%252BMedicinal%252BChemist%2525E2%252580%252599s%252BPerspective%25253A%252BPhysicochemical%252Band%252Bin%252BVitro%252BParameters%252BRelevant%252Bfor%252BDrug%252BDiscovery%26aulast%3DFinkbeiner%26aufirst%3DPeter%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D10032020%26date%3D17062020%26date%3D01062020%26volume%3D63%26issue%3D13%26spage%3D7081%26epage%3D7107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Rohan Kalyan Rej, Changwei Wang, Jianfeng Lu, Mi Wang, Elyse Petrunak, Kaitlin P. Zawacki, Donna McEachern, Ester Fernandez-Salas, Chao-Yie Yang, Lu Wang, Ruiting Li, Krishnapriya Chinnaswamy, Bo Wen, Duxin Sun, Jeanne Stuckey, Yunlong Zhou, Jianyong Chen, Guozhi Tang, <span class="NLM_string-name hlFld-ContribAuthor">Shaomeng Wang</span>. </span><span class="cited-content_cbyCitation_article-title">EEDi-5285: An Exceptionally Potent, Efficacious, and Orally Active Small-Molecule Inhibitor of Embryonic Ectoderm Development. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (13)
                                     , 7252-7267. <a href="https://doi.org/10.1021/acs.jmedchem.0c00479" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00479</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00479&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00479%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DEEDi-5285%25253A%252BAn%252BExceptionally%252BPotent%25252C%252BEfficacious%25252C%252Band%252BOrally%252BActive%252BSmall-Molecule%252BInhibitor%252Bof%252BEmbryonic%252BEctoderm%252BDevelopment%26aulast%3DRej%26aufirst%3DRohan%2BKalyan%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D21032020%26date%3D24062020%26volume%3D63%26issue%3D13%26spage%3D7252%26epage%3D7267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Nimrod M. Eren, Samantha A. Orr, Christopher D. Thompson, Emily C. Border, Michael A. Stevens, <span class="NLM_string-name hlFld-ContribAuthor">Victoria L. Blair</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, Structure, and Solution Studies of Lithiated Allylic Phosphines and Phosphine Oxides. </span><span class="cited-content_cbyCitation_journal-name">Organometallics</span><span> <strong>2020,</strong> <em>39 </em>
                                    (11)
                                     , 2080-2090. <a href="https://doi.org/10.1021/acs.organomet.0c00144" title="DOI URL">https://doi.org/10.1021/acs.organomet.0c00144</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.organomet.0c00144&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.organomet.0c00144%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganometallics%26atitle%3DSynthesis%25252C%252BStructure%25252C%252Band%252BSolution%252BStudies%252Bof%252BLithiated%252BAllylic%252BPhosphines%252Band%252BPhosphine%252BOxides%26aulast%3DEren%26aufirst%3DNimrod%2BM.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D28022020%26date%3D26052020%26volume%3D39%26issue%3D11%26spage%3D2080%26epage%3D2090" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">David E. Heppner, Marcel Günther, Florian Wittlinger, Stefan A. Laufer, <span class="NLM_string-name hlFld-ContribAuthor">Michael J. Eck</span>. </span><span class="cited-content_cbyCitation_article-title">Structural Basis for EGFR Mutant Inhibition by Trisubstituted Imidazole Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (8)
                                     , 4293-4305. <a href="https://doi.org/10.1021/acs.jmedchem.0c00200" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00200</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00200%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructural%252BBasis%252Bfor%252BEGFR%252BMutant%252BInhibition%252Bby%252BTrisubstituted%252BImidazole%252BInhibitors%26aulast%3DHeppner%26aufirst%3DDavid%2BE.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D04022020%26date%3D14042020%26date%3D03042020%26volume%3D63%26issue%3D8%26spage%3D4293%26epage%3D4305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jian Wang, Yan-Hui Li, Song-Cheng Pan, Ming-Fang Li, Wenting Du, Hong Yin, <span class="NLM_string-name hlFld-ContribAuthor">Jing-Hua Li</span>. </span><span class="cited-content_cbyCitation_article-title">Efficient Phosphorus-Free Chlorination of Hydroxy Aza-Arenes and Their Application in One-Pot Pharmaceutical Synthesis. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2020,</strong> <em>24 </em>
                                    (2)
                                     , 146-153. <a href="https://doi.org/10.1021/acs.oprd.9b00407" title="DOI URL">https://doi.org/10.1021/acs.oprd.9b00407</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.9b00407&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.9b00407%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DEfficient%252BPhosphorus-Free%252BChlorination%252Bof%252BHydroxy%252BAza-Arenes%252Band%252BTheir%252BApplication%252Bin%252BOne-Pot%252BPharmaceutical%252BSynthesis%26aulast%3DWang%26aufirst%3DJian%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D21092019%26date%3D27012020%26date%3D17012020%26volume%3D24%26issue%3D2%26spage%3D146%26epage%3D153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xiaotian Kong, Peichen Pan, Huiyong Sun, Hongguang Xia, Xuwen Wang, Youyong Li, <span class="NLM_string-name hlFld-ContribAuthor">Tingjun Hou</span>. </span><span class="cited-content_cbyCitation_article-title">Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (24)
                                     , 10927-10954. <a href="https://doi.org/10.1021/acs.jmedchem.9b00446" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00446</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00446&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00446%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDrug%252BDiscovery%252BTargeting%252BAnaplastic%252BLymphoma%252BKinase%252B%252528ALK%252529%26aulast%3DKong%26aufirst%3DXiaotian%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D14032019%26date%3D26082019%26date%3D16082019%26volume%3D62%26issue%3D24%26spage%3D10927%26epage%3D10954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Andrew
C. Flick, Carolyn A. Leverett, Hong X. Ding, Emma McInturff, Sarah J. Fink, Christopher J. Helal, <span class="NLM_string-name hlFld-ContribAuthor">Christopher J. O’Donnell</span>. </span><span class="cited-content_cbyCitation_article-title">Synthetic Approaches to the New Drugs Approved During 2017. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (16)
                                     , 7340-7382. <a href="https://doi.org/10.1021/acs.jmedchem.9b00196" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00196</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00196%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthetic%252BApproaches%252Bto%252Bthe%252BNew%252BDrugs%252BApproved%252BDuring%252B2017%26aulast%3DFlick%26aufirst%3DAndrew%2BC.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D30012019%26date%3D15042019%26date%3D02042019%26volume%3D62%26issue%3D16%26spage%3D7340%26epage%3D7382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Shi-Guang Li, Minglei Yuan, Filip Topic, Zhengxu S. Han, Chris H. Senanayake, <span class="NLM_string-name hlFld-ContribAuthor">Youla S. Tsantrizos</span>. </span><span class="cited-content_cbyCitation_article-title">Asymmetric Library Synthesis of P-Chiral t-Butyl-Substituted Secondary and Tertiary Phosphine Oxides. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2019,</strong> <em>84 </em>
                                    (11)
                                     , 7291-7302. <a href="https://doi.org/10.1021/acs.joc.9b00945" title="DOI URL">https://doi.org/10.1021/acs.joc.9b00945</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.9b00945&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.9b00945%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DAsymmetric%252BLibrary%252BSynthesis%252Bof%252BP-Chiral%252Bt-Butyl-Substituted%252BSecondary%252Band%252BTertiary%252BPhosphine%252BOxides%26aulast%3DLi%26aufirst%3DShi-Guang%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D05042019%26date%3D29052019%26date%3D17052019%26volume%3D84%26issue%3D11%26spage%3D7291%26epage%3D7302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Makoto Fushimi, Ikuo Fujimori, Takeshi Wakabayashi, Tomoaki Hasui, Youichi Kawakita, Keisuke Imamura, Tomoko Kato, Morio Murakami, Tsuyoshi Ishii, Yorifumi Kikko, Maki Kasahara, Atsushi Nakatani, Yuto Hiura, Maki Miyamoto, Kumar Saikatendu, Hua Zou, Scott Weston Lane, J. David Lawson, <span class="NLM_string-name hlFld-ContribAuthor">Hiroshi Imoto</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Potent, Selective, and Brain-Penetrant 1H-Pyrazol-5-yl-1H-pyrrolo[2,3-b]pyridines as Anaplastic Lymphoma Kinase (ALK) Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (10)
                                     , 4915-4935. <a href="https://doi.org/10.1021/acs.jmedchem.8b01630" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01630</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01630&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01630%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BPotent%25252C%252BSelective%25252C%252Band%252BBrain-Penetrant%252B1H-Pyrazol-5-yl-1H-pyrrolo%25255B2%25252C3-b%25255Dpyridines%252Bas%252BAnaplastic%252BLymphoma%252BKinase%252B%252528ALK%252529%252BInhibitors%26aulast%3DFushimi%26aufirst%3DMakoto%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D21102018%26date%3D03052019%26date%3D22042019%26volume%3D62%26issue%3D10%26spage%3D4915%26epage%3D4935" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ellen Watts, David Heidenreich, Elizabeth Tucker, Monika Raab, Klaus Strebhardt, Louis Chesler, Stefan Knapp, Benjamin Bellenie, <span class="NLM_string-name hlFld-ContribAuthor">Swen Hoelder</span>. </span><span class="cited-content_cbyCitation_article-title">Designing Dual Inhibitors of Anaplastic Lymphoma Kinase (ALK) and Bromodomain-4 (BRD4) by Tuning Kinase Selectivity. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (5)
                                     , 2618-2637. <a href="https://doi.org/10.1021/acs.jmedchem.8b01947" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01947</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01947&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01947%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesigning%252BDual%252BInhibitors%252Bof%252BAnaplastic%252BLymphoma%252BKinase%252B%252528ALK%252529%252Band%252BBromodomain-4%252B%252528BRD4%252529%252Bby%252BTuning%252BKinase%252BSelectivity%26aulast%3DWatts%26aufirst%3DEllen%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D13122018%26date%3D21022019%26volume%3D62%26issue%3D5%26spage%3D2618%26epage%3D2637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Dean G. Brown, <span class="NLM_string-name hlFld-ContribAuthor">Jonas Boström</span>. </span><span class="cited-content_cbyCitation_article-title">Where Do Recent Small Molecule Clinical Development Candidates Come From?. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (21)
                                     , 9442-9468. <a href="https://doi.org/10.1021/acs.jmedchem.8b00675" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00675</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00675%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DWhere%252BDo%252BRecent%252BSmall%252BMolecule%252BClinical%252BDevelopment%252BCandidates%252BCome%252BFrom%25253F%26aulast%3DBrown%26aufirst%3DDean%2BG.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D27042018%26date%3D09072018%26date%3D19062018%26volume%3D61%26issue%3D21%26spage%3D9442%26epage%3D9468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ted W. Johnson, Ben Bolanos, Alexei Brooun, Rebecca A. Gallego, Dan Gehlhaar, Mehran Jalaie, Michele McTigue, <span class="NLM_string-name hlFld-ContribAuthor">Sergei Timofeevski</span>. </span><span class="cited-content_cbyCitation_article-title">Reviving B-Factors: Activating ALK Mutations Increase Protein Dynamics of the Unphosphorylated Kinase. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>9 </em>
                                    (9)
                                     , 872-877. <a href="https://doi.org/10.1021/acsmedchemlett.8b00348" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.8b00348</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.8b00348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.8b00348%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DReviving%252BB-Factors%25253A%252BActivating%252BALK%252BMutations%252BIncrease%252BProtein%252BDynamics%252Bof%252Bthe%252BUnphosphorylated%252BKinase%26aulast%3DJohnson%26aufirst%3DTed%2BW.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D31072018%26date%3D24082018%26date%3D28082018%26date%3D24082018%26volume%3D9%26issue%3D9%26spage%3D872%26epage%3D877" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Alexandre
A. Mikhailine, Gabriela A. Grasa Mannino, <span class="NLM_string-name hlFld-ContribAuthor">Thomas J. Colacot</span>. </span><span class="cited-content_cbyCitation_article-title">Catalyst-Directed Chemoselective Double Amination of Bromo-chloro(hetero)arenes: A Synthetic Route toward Advanced Amino-aniline Intermediates. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2018,</strong> <em>20 </em>
                                    (8)
                                     , 2301-2305. <a href="https://doi.org/10.1021/acs.orglett.8b00646" title="DOI URL">https://doi.org/10.1021/acs.orglett.8b00646</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.8b00646&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.8b00646%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DCatalyst-Directed%252BChemoselective%252BDouble%252BAmination%252Bof%252BBromo-chloro%252528hetero%252529arenes%25253A%252BA%252BSynthetic%252BRoute%252Btoward%252BAdvanced%252BAmino-aniline%252BIntermediates%26aulast%3DMikhailine%26aufirst%3DAlexandre%2BA.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D23022018%26date%3D05042018%26volume%3D20%26issue%3D8%26spage%3D2301%26epage%3D2305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Subhajit  Bhunia</span>, <span class="hlFld-ContribAuthor ">S. Vijay  Kumar</span>, and <span class="hlFld-ContribAuthor ">Dawei  Ma</span>  . </span><span class="cited-content_cbyCitation_article-title">N,N′-Bisoxalamides Enhance the Catalytic Activity in Cu-Catalyzed Coupling of (Hetero)Aryl Bromides with Anilines and Secondary Amines. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2017,</strong> <em>82 </em>
                                    (23)
                                     , 12603-12612. <a href="https://doi.org/10.1021/acs.joc.7b02363" title="DOI URL">https://doi.org/10.1021/acs.joc.7b02363</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.7b02363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.7b02363%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DN%25252CN%2525E2%252580%2525B2-Bisoxalamides%252BEnhance%252Bthe%252BCatalytic%252BActivity%252Bin%252BCu-Catalyzed%252BCoupling%252Bof%252B%252528Hetero%252529Aryl%252BBromides%252Bwith%252BAnilines%252Band%252BSecondary%252BAmines%26aulast%3DBhunia%26aufirst%3DSubhajit%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D18092017%26date%3D16112017%26date%3D01122017%26date%3D08112017%26volume%3D82%26issue%3D23%26spage%3D12603%26epage%3D12612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peichen  Pan</span>, <span class="hlFld-ContribAuthor ">Huidong  Yu</span>, <span class="hlFld-ContribAuthor ">Qinglan  Liu</span>, <span class="hlFld-ContribAuthor ">Xiaotian  Kong</span>, <span class="hlFld-ContribAuthor ">Hu  Chen</span>, <span class="hlFld-ContribAuthor ">Jiean  Chen</span>, <span class="hlFld-ContribAuthor ">Qi  Liu</span>, <span class="hlFld-ContribAuthor ">Dan  Li</span>, <span class="hlFld-ContribAuthor ">Yu  Kang</span>, <span class="hlFld-ContribAuthor ">Huiyong  Sun</span>, <span class="hlFld-ContribAuthor ">Wenfang  Zhou</span>, <span class="hlFld-ContribAuthor ">Sheng  Tian</span>, <span class="hlFld-ContribAuthor ">Sunliang  Cui</span>, <span class="hlFld-ContribAuthor ">Feng  Zhu</span>, <span class="hlFld-ContribAuthor ">Youyong  Li</span>, <span class="hlFld-ContribAuthor ">Yong  Huang</span>, and <span class="hlFld-ContribAuthor ">Tingjun  Hou</span>  . </span><span class="cited-content_cbyCitation_article-title">Combating Drug-Resistant Mutants of Anaplastic Lymphoma Kinase with Potent and Selective Type-I1/2 Inhibitors by Stabilizing Unique DFG-Shifted Loop Conformation. </span><span class="cited-content_cbyCitation_journal-name">ACS Central Science</span><span> <strong>2017,</strong> <em>3 </em>
                                    (11)
                                     , 1208-1220. <a href="https://doi.org/10.1021/acscentsci.7b00419" title="DOI URL">https://doi.org/10.1021/acscentsci.7b00419</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acscentsci.7b00419&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facscentsci.7b00419%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Central%2520Science%26atitle%3DCombating%252BDrug-Resistant%252BMutants%252Bof%252BAnaplastic%252BLymphoma%252BKinase%252Bwith%252BPotent%252Band%252BSelective%252BType-I1%25252F2%252BInhibitors%252Bby%252BStabilizing%252BUnique%252BDFG-Shifted%252BLoop%252BConformation%26aulast%3DPan%26aufirst%3DPeichen%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D09092017%26date%3D03112017%26date%3D22112017%26volume%3D3%26issue%3D11%26spage%3D1208%26epage%3D1220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Timothy P.  Heffron</span>  . </span><span class="cited-content_cbyCitation_article-title">Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (22)
                                     , 10030-10066. <a href="https://doi.org/10.1021/acs.jmedchem.6b00618" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00618</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00618%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSmall%252BMolecule%252BKinase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BBrain%252BCancer%26aulast%3DHeffron%26aufirst%3DTimothy%2BP.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D21042016%26date%3D03082016%26date%3D23112016%26date%3D14072016%26volume%3D59%26issue%3D22%26spage%3D10030%26epage%3D10066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gregory R.  Ott</span>, <span class="hlFld-ContribAuthor ">Mangeng  Cheng</span>, <span class="hlFld-ContribAuthor ">Keith S.  Learn</span>, <span class="hlFld-ContribAuthor ">Jason  Wagner</span>, <span class="hlFld-ContribAuthor ">Diane E.  Gingrich</span>, <span class="hlFld-ContribAuthor ">Joseph G.  Lisko</span>, <span class="hlFld-ContribAuthor ">Matthew  Curry</span>, <span class="hlFld-ContribAuthor ">Eugen F.  Mesaros</span>, <span class="hlFld-ContribAuthor ">Arup K.  Ghose</span>, <span class="hlFld-ContribAuthor ">Matthew R.  Quail</span>, <span class="hlFld-ContribAuthor ">Weihua  Wan</span>, <span class="hlFld-ContribAuthor ">Lihui  Lu</span>, <span class="hlFld-ContribAuthor ">Pawel  Dobrzanski</span>, <span class="hlFld-ContribAuthor ">Mark S.  Albom</span>, <span class="hlFld-ContribAuthor ">Thelma S.  Angeles</span>, <span class="hlFld-ContribAuthor ">Kevin  Wells-Knecht</span>, <span class="hlFld-ContribAuthor ">Zeqi  Huang</span>, <span class="hlFld-ContribAuthor ">Lisa D.  Aimone</span>, <span class="hlFld-ContribAuthor ">Elizabeth  Bruckheimer</span>, <span class="hlFld-ContribAuthor ">Nathan  Anderson</span>, <span class="hlFld-ContribAuthor ">Jay  Friedman</span>, <span class="hlFld-ContribAuthor ">Sandra V.  Fernandez</span>, <span class="hlFld-ContribAuthor ">Mark A.  Ator</span>, <span class="hlFld-ContribAuthor ">Bruce A.  Ruggeri</span>, and <span class="hlFld-ContribAuthor ">Bruce D.  Dorsey</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (16)
                                     , 7478-7496. <a href="https://doi.org/10.1021/acs.jmedchem.6b00487" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00487</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00487%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BClinical%252BCandidate%252BCEP-37440%25252C%252Ba%252BSelective%252BInhibitor%252Bof%252BFocal%252BAdhesion%252BKinase%252B%252528FAK%252529%252Band%252BAnaplastic%252BLymphoma%252BKinase%252B%252528ALK%252529%26aulast%3DOtt%26aufirst%3DGregory%2BR.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D01042016%26date%3D15082016%26date%3D25082016%26volume%3D59%26issue%3D16%26spage%3D7478%26epage%3D7496" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lei  Zhong</span>, <span class="hlFld-ContribAuthor ">Yueshan  Li</span>, <span class="hlFld-ContribAuthor ">Liang  Xiong</span>, <span class="hlFld-ContribAuthor ">Wenjing  Wang</span>, <span class="hlFld-ContribAuthor ">Ming  Wu</span>, <span class="hlFld-ContribAuthor ">Ting  Yuan</span>, <span class="hlFld-ContribAuthor ">Wei  Yang</span>, <span class="hlFld-ContribAuthor ">Chenyu  Tian</span>, <span class="hlFld-ContribAuthor ">Zhuang  Miao</span>, <span class="hlFld-ContribAuthor ">Tianqi  Wang</span>, <span class="hlFld-ContribAuthor ">Shengyong  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. </span><span class="cited-content_cbyCitation_journal-name">Signal Transduction and Targeted Therapy</span><span> <strong>2021,</strong> <em>6 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41392-021-00572-w" title="DOI URL">https://doi.org/10.1038/s41392-021-00572-w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41392-021-00572-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41392-021-00572-w%26sid%3Dliteratum%253Aachs%26jtitle%3DSignal%2520Transduction%2520and%2520Targeted%2520Therapy%26atitle%3DSmall%252Bmolecules%252Bin%252Btargeted%252Bcancer%252Btherapy%25253A%252Badvances%25252C%252Bchallenges%25252C%252Band%252Bfuture%252Bperspectives%26aulast%3DZhong%26aufirst%3DLei%26date%3D2021%26date%3D2021%26volume%3D6%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Feng  Wu</span>, <span class="hlFld-ContribAuthor ">Han  Yao</span>, <span class="hlFld-ContribAuthor ">Wei  Li</span>, <span class="hlFld-ContribAuthor ">Niuniu  Zhang</span>, <span class="hlFld-ContribAuthor ">Yangyang  Fan</span>, <span class="hlFld-ContribAuthor ">Albert S.C.  Chan</span>, <span class="hlFld-ContribAuthor ">Xingshu  Li</span>, <span class="hlFld-ContribAuthor ">Baijiao  An</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and evaluation of novel 2,4-diaminopyrimidines bearing a sulfoxide moiety as anaplastic lymphoma kinase (ALK) inhibition agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>48 </em>, 128253. <a href="https://doi.org/10.1016/j.bmcl.2021.128253" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.128253</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.128253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.128253%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSynthesis%252Band%252Bevaluation%252Bof%252Bnovel%252B2%25252C4-diaminopyrimidines%252Bbearing%252Ba%252Bsulfoxide%252Bmoiety%252Bas%252Banaplastic%252Blymphoma%252Bkinase%252B%252528ALK%252529%252Binhibition%252Bagents%26aulast%3DWu%26aufirst%3DFeng%26date%3D2021%26volume%3D48%26spage%3D128253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Saad M.  Alshahrani</span>, <span class="hlFld-ContribAuthor ">Munerah M.  Alfadhel</span>, <span class="hlFld-ContribAuthor ">Khalil Y.R.  Abujheisha</span>, <span class="hlFld-ContribAuthor ">Bjad K.  Almutairy</span>, <span class="hlFld-ContribAuthor ">Ahmed S.  Alalaiwe</span>, <span class="hlFld-ContribAuthor ">Abdullah S.  Alshetaili</span>, <span class="hlFld-ContribAuthor ">Mohammed F.  Aldawsari</span>, <span class="hlFld-ContribAuthor ">Md. Khalid  Anwer</span>, <span class="hlFld-ContribAuthor ">Faiyaz  Shakeel</span>. </span><span class="cited-content_cbyCitation_article-title">Solubility determination, computational modeling, Hansen solubility parameters and apparent thermodynamic analysis of brigatinib in (ethanol + water) mixtures. </span><span class="cited-content_cbyCitation_journal-name">Zeitschrift für Physikalische Chemie</span><span> <strong>2021,</strong> <em>235 </em>
                                    (8)
                                     , 961-975. <a href="https://doi.org/10.1515/zpch-2020-1715" title="DOI URL">https://doi.org/10.1515/zpch-2020-1715</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1515/zpch-2020-1715&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1515%2Fzpch-2020-1715%26sid%3Dliteratum%253Aachs%26jtitle%3DZeitschrift%2520f%25C3%25BCr%2520Physikalische%2520Chemie%26atitle%3DSolubility%252Bdetermination%25252C%252Bcomputational%252Bmodeling%25252C%252BHansen%252Bsolubility%252Bparameters%252Band%252Bapparent%252Bthermodynamic%252Banalysis%252Bof%252Bbrigatinib%252Bin%252B%252528ethanol%252B%25252B%252Bwater%252529%252Bmixtures%26aulast%3DAlshahrani%26aufirst%3DSaad%2BM.%26date%3D2021%26date%3D2020%26volume%3D235%26issue%3D8%26spage%3D961%26epage%3D975" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoxia  Liang</span>, <span class="hlFld-ContribAuthor ">Qian  Yang</span>, <span class="hlFld-ContribAuthor ">Pan  Wu</span>, <span class="hlFld-ContribAuthor ">Changliang  He</span>, <span class="hlFld-ContribAuthor ">Lizi  Yin</span>, <span class="hlFld-ContribAuthor ">Funeng  Xu</span>, <span class="hlFld-ContribAuthor ">Zhongqiong  Yin</span>, <span class="hlFld-ContribAuthor ">Guizhou  Yue</span>, <span class="hlFld-ContribAuthor ">Yuanfeng  Zou</span>, <span class="hlFld-ContribAuthor ">Lixia  Li</span>, <span class="hlFld-ContribAuthor ">Xu  Song</span>, <span class="hlFld-ContribAuthor ">Cheng  Lv</span>, <span class="hlFld-ContribAuthor ">Wei  Zhang</span>, <span class="hlFld-ContribAuthor ">Bo  Jing</span>. </span><span class="cited-content_cbyCitation_article-title">The synthesis review of the approved tyrosine kinase inhibitors for anticancer therapy in 2015–2020. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>113 </em>, 105011. <a href="https://doi.org/10.1016/j.bioorg.2021.105011" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.105011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.105011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.105011%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DThe%252Bsynthesis%252Breview%252Bof%252Bthe%252Bapproved%252Btyrosine%252Bkinase%252Binhibitors%252Bfor%252Banticancer%252Btherapy%252Bin%252B2015%2525E2%252580%2525932020%26aulast%3DLiang%26aufirst%3DXiaoxia%26date%3D2021%26volume%3D113%26spage%3D105011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoxia  Liang</span>, <span class="hlFld-ContribAuthor ">Pan  Wu</span>, <span class="hlFld-ContribAuthor ">Qian  Yang</span>, <span class="hlFld-ContribAuthor ">Yunyu  Xie</span>, <span class="hlFld-ContribAuthor ">Changliang  He</span>, <span class="hlFld-ContribAuthor ">Lizi  Yin</span>, <span class="hlFld-ContribAuthor ">Zhongqiong  Yin</span>, <span class="hlFld-ContribAuthor ">Guizhou  Yue</span>, <span class="hlFld-ContribAuthor ">Yuanfeng  Zou</span>, <span class="hlFld-ContribAuthor ">Lixia  Li</span>, <span class="hlFld-ContribAuthor ">Xu  Song</span>, <span class="hlFld-ContribAuthor ">Cheng  Lv</span>, <span class="hlFld-ContribAuthor ">Wei  Zhang</span>, <span class="hlFld-ContribAuthor ">Bo  Jing</span>. </span><span class="cited-content_cbyCitation_article-title">An update of new small-molecule anticancer drugs approved from 2015 to 2020. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>220 </em>, 113473. <a href="https://doi.org/10.1016/j.ejmech.2021.113473" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113473</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113473%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DAn%252Bupdate%252Bof%252Bnew%252Bsmall-molecule%252Banticancer%252Bdrugs%252Bapproved%252Bfrom%252B2015%252Bto%252B2020%26aulast%3DLiang%26aufirst%3DXiaoxia%26date%3D2021%26volume%3D220%26spage%3D113473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Long-Sheng  Chang</span>, <span class="hlFld-ContribAuthor ">Janet L.  Oblinger</span>, <span class="hlFld-ContribAuthor ">Abbi E.  Smith</span>, <span class="hlFld-ContribAuthor ">Marc  Ferrer</span>, <span class="hlFld-ContribAuthor ">Steven P.  Angus</span>, <span class="hlFld-ContribAuthor ">Eric  Hawley</span>, <span class="hlFld-ContribAuthor ">Alejandra M.  Petrilli</span>, <span class="hlFld-ContribAuthor ">Roberta L.  Beauchamp</span>, <span class="hlFld-ContribAuthor ">Lars Björn  Riecken</span>, <span class="hlFld-ContribAuthor ">Serkan  Erdin</span>, <span class="hlFld-ContribAuthor ">Ming  Poi</span>, <span class="hlFld-ContribAuthor ">Jie  Huang</span>, <span class="hlFld-ContribAuthor ">Waylan K.  Bessler</span>, <span class="hlFld-ContribAuthor ">Xiaohu  Zhang</span>, <span class="hlFld-ContribAuthor ">Rajarshi  Guha</span>, <span class="hlFld-ContribAuthor ">Craig  Thomas</span>, <span class="hlFld-ContribAuthor ">Sarah S.  Burns</span>, <span class="hlFld-ContribAuthor ">Thomas S. K.  Gilbert</span>, <span class="hlFld-ContribAuthor ">Li  Jiang</span>, <span class="hlFld-ContribAuthor ">Xiaohong  Li</span>, <span class="hlFld-ContribAuthor ">Qingbo  Lu</span>, <span class="hlFld-ContribAuthor ">Jin  Yuan</span>, <span class="hlFld-ContribAuthor ">Yongzheng  He</span>, <span class="hlFld-ContribAuthor ">Shelley A. H.  Dixon</span>, <span class="hlFld-ContribAuthor ">Andrea  Masters</span>, <span class="hlFld-ContribAuthor ">David R.  Jones</span>, <span class="hlFld-ContribAuthor ">Charles W.  Yates</span>, <span class="hlFld-ContribAuthor ">Stephen J.  Haggarty</span>, <span class="hlFld-ContribAuthor ">Salvatore  La Rosa</span>, <span class="hlFld-ContribAuthor ">D. Bradley  Welling</span>, <span class="hlFld-ContribAuthor ">Anat O.  Stemmer-Rachamimov</span>, <span class="hlFld-ContribAuthor ">Scott R.  Plotkin</span>, <span class="hlFld-ContribAuthor ">James F.  Gusella</span>, <span class="hlFld-ContribAuthor ">Justin  Guinney</span>, <span class="hlFld-ContribAuthor ">Helen  Morrison</span>, <span class="hlFld-ContribAuthor ">Vijaya  Ramesh</span>, <span class="hlFld-ContribAuthor ">Cristina  Fernandez-Valle</span>, <span class="hlFld-ContribAuthor ">Gary L.  Johnson</span>, <span class="hlFld-ContribAuthor ">Jaishri O.  Blakeley</span>, <span class="hlFld-ContribAuthor ">D. Wade  Clapp</span>, , . </span><span class="cited-content_cbyCitation_article-title">Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK. </span><span class="cited-content_cbyCitation_journal-name">PLOS ONE</span><span> <strong>2021,</strong> <em>16 </em>
                                    (7)
                                     , e0252048. <a href="https://doi.org/10.1371/journal.pone.0252048" title="DOI URL">https://doi.org/10.1371/journal.pone.0252048</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.pone.0252048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.pone.0252048%26sid%3Dliteratum%253Aachs%26jtitle%3DPLOS%2520ONE%26atitle%3DBrigatinib%252Bcauses%252Btumor%252Bshrinkage%252Bin%252Bboth%252BNF2-deficient%252Bmeningioma%252Band%252Bschwannoma%252Bthrough%252Binhibition%252Bof%252Bmultiple%252Btyrosine%252Bkinases%252Bbut%252Bnot%252BALK%26aulast%3DChang%26aufirst%3DLong-Sheng%26date%3D2021%26date%3D2021%26volume%3D16%26issue%3D7%26spage%3De0252048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiao-Jing  Pang</span>, <span class="hlFld-ContribAuthor ">Xiu-Juan  Liu</span>, <span class="hlFld-ContribAuthor ">Yuan  Liu</span>, <span class="hlFld-ContribAuthor ">Wen-Bo  Liu</span>, <span class="hlFld-ContribAuthor ">Yin-Ru  Li</span>, <span class="hlFld-ContribAuthor ">Guang-Xi  Yu</span>, <span class="hlFld-ContribAuthor ">Xin-Yi  Tian</span>, <span class="hlFld-ContribAuthor ">Yan-Bing  Zhang</span>, <span class="hlFld-ContribAuthor ">Jian  Song</span>, <span class="hlFld-ContribAuthor ">Cheng-Yun  Jin</span>, <span class="hlFld-ContribAuthor ">Sai-Yang  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Drug Discovery Targeting Focal Adhesion Kinase (FAK) as a Promising Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (14)
                                     , 4250. <a href="https://doi.org/10.3390/molecules26144250" title="DOI URL">https://doi.org/10.3390/molecules26144250</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26144250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26144250%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DDrug%252BDiscovery%252BTargeting%252BFocal%252BAdhesion%252BKinase%252B%252528FAK%252529%252Bas%252Ba%252BPromising%252BCancer%252BTherapy%26aulast%3DPang%26aufirst%3DXiao-Jing%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D14%26spage%3D4250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Debasis  Das</span>, <span class="hlFld-ContribAuthor ">Jingbing  Wang</span>, <span class="hlFld-ContribAuthor ">Jian  Hong</span>. </span><span class="cited-content_cbyCitation_article-title">Next‐Generation Kinase Inhibitors Targeting Specific Biomarkers in Non‐Small Cell Lung Cancer (NSCLC): A Recent Overview. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2021,</strong> <em>71 </em><a href="https://doi.org/10.1002/cmdc.202100166" title="DOI URL">https://doi.org/10.1002/cmdc.202100166</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202100166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202100166%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DNext%2525E2%252580%252590Generation%252BKinase%252BInhibitors%252BTargeting%252BSpecific%252BBiomarkers%252Bin%252BNon%2525E2%252580%252590Small%252BCell%252BLung%252BCancer%252B%252528NSCLC%252529%25253A%252BA%252BRecent%252BOverview%26aulast%3DDas%26aufirst%3DDebasis%26date%3D2021%26date%3D2021%26volume%3D71" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrii  Fedyk</span>, <span class="hlFld-ContribAuthor ">Evgeniy Y.  Slobodyanyuk</span>, <span class="hlFld-ContribAuthor ">Olha  Stotska</span>, <span class="hlFld-ContribAuthor ">Bohdan V.  Vashchenko</span>, <span class="hlFld-ContribAuthor ">Dmitriy M.  Volochnyuk</span>, <span class="hlFld-ContribAuthor ">Dmitriy A.  Sibgatulin</span>, <span class="hlFld-ContribAuthor ">Andrey A.  Tolmachev</span>, <span class="hlFld-ContribAuthor ">Oleksandr O.  Grygorenko</span>. </span><span class="cited-content_cbyCitation_article-title">Heteroaliphatic Dimethylphosphine Oxide Building Blocks: Synthesis and Physico‐Chemical Properties. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2021,</strong> <em>13 </em><a href="https://doi.org/10.1002/ejoc.202100581" title="DOI URL">https://doi.org/10.1002/ejoc.202100581</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.202100581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.202100581%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DHeteroaliphatic%252BDimethylphosphine%252BOxide%252BBuilding%252BBlocks%25253A%252BSynthesis%252Band%252BPhysico%2525E2%252580%252590Chemical%252BProperties%26aulast%3DFedyk%26aufirst%3DAndrii%26date%3D2021%26date%3D2021%26volume%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gabriele  La Monica</span>, <span class="hlFld-ContribAuthor ">Antonino  Lauria</span>, <span class="hlFld-ContribAuthor ">Alessia  Bono</span>, <span class="hlFld-ContribAuthor ">Annamaria  Martorana</span>. </span><span class="cited-content_cbyCitation_article-title">Off-Target-Based Design of Selective HIV-1 PROTEASE Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2021,</strong> <em>22 </em>
                                    (11)
                                     , 6070. <a href="https://doi.org/10.3390/ijms22116070" title="DOI URL">https://doi.org/10.3390/ijms22116070</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms22116070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms22116070%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DOff-Target-Based%252BDesign%252Bof%252BSelective%252BHIV-1%252BPROTEASE%252BInhibitors%26aulast%3DLa%2BMonica%26aufirst%3DGabriele%26date%3D2021%26date%3D2021%26volume%3D22%26issue%3D11%26spage%3D6070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kyu Sic  You</span>, <span class="hlFld-ContribAuthor ">Yong Weon  Yi</span>, <span class="hlFld-ContribAuthor ">Jeonghee  Cho</span>, <span class="hlFld-ContribAuthor ">Jeong-Soo  Park</span>, <span class="hlFld-ContribAuthor ">Yeon-Sun  Seong</span>. </span><span class="cited-content_cbyCitation_article-title">Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceuticals</span><span> <strong>2021,</strong> <em>14 </em>
                                    (6)
                                     , 589. <a href="https://doi.org/10.3390/ph14060589" title="DOI URL">https://doi.org/10.3390/ph14060589</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ph14060589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fph14060589%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceuticals%26atitle%3DPotentiating%252BTherapeutic%252BEffects%252Bof%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252BInhibition%252Bin%252BTriple-Negative%252BBreast%252BCancer%26aulast%3DYou%26aufirst%3DKyu%2BSic%26date%3D2021%26date%3D2021%26volume%3D14%26issue%3D6%26spage%3D589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ian D  Linney</span>, <span class="hlFld-ContribAuthor ">Neelu  Kaila</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibitors of immuno-oncology target HPK1 – a patent review (2016 to 2020). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2021,</strong> <em>24 </em>, 1-18. <a href="https://doi.org/10.1080/13543776.2021.1924671" title="DOI URL">https://doi.org/10.1080/13543776.2021.1924671</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2021.1924671&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2021.1924671%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DInhibitors%252Bof%252Bimmuno-oncology%252Btarget%252BHPK1%252B%2525E2%252580%252593%252Ba%252Bpatent%252Breview%252B%2525282016%252Bto%252B2020%252529%26aulast%3DLinney%26aufirst%3DIan%2BD%26date%3D2021%26date%3D2021%26volume%3D24%26spage%3D1%26epage%3D18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Giuseppe  Bronte</span>, <span class="hlFld-ContribAuthor ">Alessandro  Cafaro</span>, <span class="hlFld-ContribAuthor ">Luigi  Pasini</span>, <span class="hlFld-ContribAuthor ">Ilaria  Priano</span>, <span class="hlFld-ContribAuthor ">Kalliopi  Andrikou</span>, <span class="hlFld-ContribAuthor ">Paola  Cravero</span>, <span class="hlFld-ContribAuthor ">Marco Angelo  Burgio</span>, <span class="hlFld-ContribAuthor ">Angelo  Delmonte</span>, <span class="hlFld-ContribAuthor ">Lucio  Crinò</span>. </span><span class="cited-content_cbyCitation_article-title">Brigatinib in the first-line treatment of ALK+ metastatic NSCLC: safety and efficacy. </span><span class="cited-content_cbyCitation_journal-name">Expert Review of Anticancer Therapy</span><span> <strong>2021,</strong> <em>10 </em>, 1-9. <a href="https://doi.org/10.1080/14737140.2021.1923485" title="DOI URL">https://doi.org/10.1080/14737140.2021.1923485</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14737140.2021.1923485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14737140.2021.1923485%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Review%2520of%2520Anticancer%2520Therapy%26atitle%3DBrigatinib%252Bin%252Bthe%252Bfirst-line%252Btreatment%252Bof%252BALK%25252B%252Bmetastatic%252BNSCLC%25253A%252Bsafety%252Band%252Befficacy%26aulast%3DBronte%26aufirst%3DGiuseppe%26date%3D2021%26date%3D2021%26volume%3D10%26spage%3D1%26epage%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Simon  Doherty</span>, <span class="hlFld-ContribAuthor ">Julian G.  Knight</span>, <span class="hlFld-ContribAuthor ">Tina S. T.  Tran</span>, <span class="hlFld-ContribAuthor ">Hussam Y.  Alharbi</span>, <span class="hlFld-ContribAuthor ">Daniel O.  Perry</span>. </span><span class="cited-content_cbyCitation_article-title">The Synthesis of Biarylmonophosphonates via Palladium-Catalyzed Phosphonation, Iridium-Catalyzed C-H Borylation, Palladium-Catalyzed Suzuki–Miyaura Cross-Coupling. </span><span class="cited-content_cbyCitation_journal-name">Catalysis Letters</span><span> <strong>2021,</strong> <em>38 </em><a href="https://doi.org/10.1007/s10562-021-03643-3" title="DOI URL">https://doi.org/10.1007/s10562-021-03643-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10562-021-03643-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10562-021-03643-3%26sid%3Dliteratum%253Aachs%26jtitle%3DCatalysis%2520Letters%26atitle%3DThe%252BSynthesis%252Bof%252BBiarylmonophosphonates%252Bvia%252BPalladium-Catalyzed%252BPhosphonation%25252C%252BIridium-Catalyzed%252BC-H%252BBorylation%25252C%252BPalladium-Catalyzed%252BSuzuki%2525E2%252580%252593Miyaura%252BCross-Coupling%26aulast%3DDoherty%26aufirst%3DSimon%26date%3D2021%26date%3D2021%26volume%3D38" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zheng  Li</span>, <span class="hlFld-ContribAuthor ">Ming  Guo</span>, <span class="hlFld-ContribAuthor ">Meng  Cao</span>, <span class="hlFld-ContribAuthor ">Tianming  Zhao</span>, <span class="hlFld-ContribAuthor ">Mingzhu  Li</span>, <span class="hlFld-ContribAuthor ">Xin  Zhai</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and antitumor activity of Benzo[d]imidazol-containing 2,4-diarylaminopyrimidine analogues as ALK inhibitors with mutation-combating effects. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2021,</strong> <em>37 </em>, 116108. <a href="https://doi.org/10.1016/j.bmc.2021.116108" title="DOI URL">https://doi.org/10.1016/j.bmc.2021.116108</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2021.116108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2021.116108%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252Bantitumor%252Bactivity%252Bof%252BBenzo%25255Bd%25255Dimidazol-containing%252B2%25252C4-diarylaminopyrimidine%252Banalogues%252Bas%252BALK%252Binhibitors%252Bwith%252Bmutation-combating%252Beffects%26aulast%3DLi%26aufirst%3DZheng%26date%3D2021%26volume%3D37%26spage%3D116108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Edward S  Kim</span>, <span class="hlFld-ContribAuthor ">Fabrice  Barlesi</span>, <span class="hlFld-ContribAuthor ">Tony  Mok</span>, <span class="hlFld-ContribAuthor ">Myung-Ju  Ahn</span>, <span class="hlFld-ContribAuthor ">Junwu  Shen</span>, <span class="hlFld-ContribAuthor ">Pingkuan  Zhang</span>, <span class="hlFld-ContribAuthor ">Sai-Hong Ignatius  Ou</span>. </span><span class="cited-content_cbyCitation_article-title">ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib. </span><span class="cited-content_cbyCitation_journal-name">Future Oncology</span><span> <strong>2021,</strong> <em>17 </em>
                                    (14)
                                     , 1709-1719. <a href="https://doi.org/10.2217/fon-2020-1119" title="DOI URL">https://doi.org/10.2217/fon-2020-1119</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2217/fon-2020-1119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2217%2Ffon-2020-1119%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Oncology%26atitle%3DALTA-2%25253A%252BPhase%252BII%2525C2%2525A0study%252Bof%252Bbrigatinib%252Bin%252Bpatients%252Bwith%252BALK-positive%25252C%252Badvanced%252Bnon-small-cell%252Blung%252Bcancer%252Bwho%252Bprogressed%252Bon%252Balectinib%252Bor%252Bceritinib%26aulast%3DKim%26aufirst%3DEdward%2BS%26date%3D2021%26volume%3D17%26issue%3D14%26spage%3D1709%26epage%3D1719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sravani  Sana</span>, <span class="hlFld-ContribAuthor ">Velma Ganga  Reddy</span>, <span class="hlFld-ContribAuthor ">T.  Srinivasa Reddy</span>, <span class="hlFld-ContribAuthor ">Ramya  Tokala</span>, <span class="hlFld-ContribAuthor ">Rahul  Kumar</span>, <span class="hlFld-ContribAuthor ">Suresh K.  Bhargava</span>, <span class="hlFld-ContribAuthor ">Nagula  Shankaraiah</span>. </span><span class="cited-content_cbyCitation_article-title">Cinnamide derived pyrimidine-benzimidazole hybrids as tubulin inhibitors: Synthesis, in silico and cell growth inhibition studies. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>110 </em>, 104765. <a href="https://doi.org/10.1016/j.bioorg.2021.104765" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.104765</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.104765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.104765%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DCinnamide%252Bderived%252Bpyrimidine-benzimidazole%252Bhybrids%252Bas%252Btubulin%252Binhibitors%25253A%252BSynthesis%25252C%252Bin%252Bsilico%252Band%252Bcell%252Bgrowth%252Binhibition%252Bstudies%26aulast%3DSana%26aufirst%3DSravani%26date%3D2021%26volume%3D110%26spage%3D104765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Francesca  Spyrakis</span>, <span class="hlFld-ContribAuthor ">Aurijit  Sarkar</span>, <span class="hlFld-ContribAuthor ">Glen E.  Kellogg</span>. </span><span class="cited-content_cbyCitation_article-title">Docking, Scoring, and Virtual Screening in Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 1-102. <a href="https://doi.org/10.1002/0471266949.bmc301" title="DOI URL">https://doi.org/10.1002/0471266949.bmc301</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/0471266949.bmc301&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F0471266949.bmc301%26sid%3Dliteratum%253Aachs%26atitle%3DDocking%25252C%252BScoring%25252C%252Band%252BVirtual%252BScreening%252Bin%252BDrug%252BDiscovery%26aulast%3DSpyrakis%26aufirst%3DFrancesca%26date%3D2021%26date%3D2021%26spage%3D1%26epage%3D102%26pub%3DWiley%26atitle%3DBurger%252527s%252BMedicinal%252BChemistry%252Band%252BDrug%252BDiscovery%26aulast%3DAbraham%26aufirst%3DDonald%2BJ.%26date%3D2003%26date%3D2003%26volume%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Leonardo L.G.  Ferreira</span>, <span class="hlFld-ContribAuthor ">Adriano D.  Andricopulo</span>. </span><span class="cited-content_cbyCitation_article-title">Structure‐Based Drug Design. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 1-54. <a href="https://doi.org/10.1002/0471266949.bmc141.pub2" title="DOI URL">https://doi.org/10.1002/0471266949.bmc141.pub2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/0471266949.bmc141.pub2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F0471266949.bmc141.pub2%26sid%3Dliteratum%253Aachs%26atitle%3DStructure%2525E2%252580%252590Based%252BDrug%252BDesign%26aulast%3DFerreira%26aufirst%3DLeonardo%2BL.G.%26date%3D2021%26date%3D2021%26spage%3D1%26epage%3D54%26pub%3DWiley%26atitle%3DBurger%252527s%252BMedicinal%252BChemistry%252Band%252BDrug%252BDiscovery%26aulast%3DAbraham%26aufirst%3DDonald%2BJ.%26date%3D2003%26date%3D2003%26volume%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Neeraj  Gupta</span>, <span class="hlFld-ContribAuthor ">Michael J.  Hanley</span>, <span class="hlFld-ContribAuthor ">David  Kerstein</span>, <span class="hlFld-ContribAuthor ">Meera  Tugnait</span>, <span class="hlFld-ContribAuthor ">Narayana  Narasimhan</span>, <span class="hlFld-ContribAuthor ">Thomas C.  Marbury</span>, <span class="hlFld-ContribAuthor ">Karthik  Venkatakrishnan</span>. </span><span class="cited-content_cbyCitation_article-title">Effect of severe renal impairment on the pharmacokinetics of brigatinib. </span><span class="cited-content_cbyCitation_journal-name">Investigational New Drugs</span><span> <strong>2021,</strong> <em>108 </em><a href="https://doi.org/10.1007/s10637-021-01095-5" title="DOI URL">https://doi.org/10.1007/s10637-021-01095-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10637-021-01095-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10637-021-01095-5%26sid%3Dliteratum%253Aachs%26jtitle%3DInvestigational%2520New%2520Drugs%26atitle%3DEffect%252Bof%252Bsevere%252Brenal%252Bimpairment%252Bon%252Bthe%252Bpharmacokinetics%252Bof%252Bbrigatinib%26aulast%3DGupta%26aufirst%3DNeeraj%26date%3D2021%26date%3D2021%26volume%3D108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Laxmidhar  Rout</span>, <span class="hlFld-ContribAuthor ">Tharmalingam  Punniyamurthy</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in transition-metal-mediated Csp2-B and Csp2-P cross-coupling reactions. </span><span class="cited-content_cbyCitation_journal-name">Coordination Chemistry Reviews</span><span> <strong>2021,</strong> <em>431 </em>, 213675. <a href="https://doi.org/10.1016/j.ccr.2020.213675" title="DOI URL">https://doi.org/10.1016/j.ccr.2020.213675</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ccr.2020.213675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ccr.2020.213675%26sid%3Dliteratum%253Aachs%26jtitle%3DCoordination%2520Chemistry%2520Reviews%26atitle%3DRecent%252Badvances%252Bin%252Btransition-metal-mediated%252BCsp2-B%252Band%252BCsp2-P%252Bcross-coupling%252Breactions%26aulast%3DRout%26aufirst%3DLaxmidhar%26date%3D2021%26volume%3D431%26spage%3D213675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Makoto  Nishio</span>, <span class="hlFld-ContribAuthor ">Tatsuya  Yoshida</span>, <span class="hlFld-ContribAuthor ">Toru  Kumagai</span>, <span class="hlFld-ContribAuthor ">Toyoaki  Hida</span>, <span class="hlFld-ContribAuthor ">Ryo  Toyozawa</span>, <span class="hlFld-ContribAuthor ">Tadasuke  Shimokawaji</span>, <span class="hlFld-ContribAuthor ">Koichi  Goto</span>, <span class="hlFld-ContribAuthor ">Kazuhiko  Nakagawa</span>, <span class="hlFld-ContribAuthor ">Yuichiro  Ohe</span>, <span class="hlFld-ContribAuthor ">Takashi  Seto</span>, <span class="hlFld-ContribAuthor ">Kentarou  Kudou</span>, <span class="hlFld-ContribAuthor ">Takayuki  Asato</span>, <span class="hlFld-ContribAuthor ">Pingkuan  Zhang</span>, <span class="hlFld-ContribAuthor ">Nobuyuki  Yamamoto</span>. </span><span class="cited-content_cbyCitation_article-title">Brigatinib in Japanese Patients With ALK-Positive NSCLC Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial. </span><span class="cited-content_cbyCitation_journal-name">Journal of Thoracic Oncology</span><span> <strong>2021,</strong> <em>16 </em>
                                    (3)
                                     , 452-463. <a href="https://doi.org/10.1016/j.jtho.2020.11.004" title="DOI URL">https://doi.org/10.1016/j.jtho.2020.11.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jtho.2020.11.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jtho.2020.11.004%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Thoracic%2520Oncology%26atitle%3DBrigatinib%252Bin%252BJapanese%252BPatients%252BWith%252BALK-Positive%252BNSCLC%252BPreviously%252BTreated%252BWith%252BAlectinib%252Band%252BOther%252BTyrosine%252BKinase%252BInhibitors%25253A%252BOutcomes%252Bof%252Bthe%252BPhase%252B2%252BJ-ALTA%252BTrial%26aulast%3DNishio%26aufirst%3DMakoto%26date%3D2021%26volume%3D16%26issue%3D3%26spage%3D452%26epage%3D463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Halah S.  Almutairi</span>, <span class="hlFld-ContribAuthor ">Mona M.  AlShehri</span>, <span class="hlFld-ContribAuthor ">Mohammed M.  Alanazi</span>, <span class="hlFld-ContribAuthor ">Ibrahim A.  Darwish</span>, <span class="hlFld-ContribAuthor ">Hany W.  Darwish</span>. </span><span class="cited-content_cbyCitation_article-title">Novel spectrofluorimetric determination of brigatinib in bulk powder and human urine samples via ion-pair complex formation using eosin Y. </span><span class="cited-content_cbyCitation_journal-name">Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy</span><span> <strong>2021,</strong> <em>249 </em>, 119210. <a href="https://doi.org/10.1016/j.saa.2020.119210" title="DOI URL">https://doi.org/10.1016/j.saa.2020.119210</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.saa.2020.119210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.saa.2020.119210%26sid%3Dliteratum%253Aachs%26jtitle%3DSpectrochimica%2520Acta%2520Part%2520A%253A%2520Molecular%2520and%2520Biomolecular%2520Spectroscopy%26atitle%3DNovel%252Bspectrofluorimetric%252Bdetermination%252Bof%252Bbrigatinib%252Bin%252Bbulk%252Bpowder%252Band%252Bhuman%252Burine%252Bsamples%252Bvia%252Bion-pair%252Bcomplex%252Bformation%252Busing%252Beosin%252BY%26aulast%3DAlmutairi%26aufirst%3DHalah%2BS.%26date%3D2021%26volume%3D249%26spage%3D119210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Enric  Carcereny</span>, <span class="hlFld-ContribAuthor ">Alonso  Fernández-Nistal</span>, <span class="hlFld-ContribAuthor ">Araceli  López</span>, <span class="hlFld-ContribAuthor ">Carmen  Montoto</span>, <span class="hlFld-ContribAuthor ">Andrea  Naves</span>, <span class="hlFld-ContribAuthor ">Cristina  Segú-Vergés</span>, <span class="hlFld-ContribAuthor ">Mireia  Coma</span>, <span class="hlFld-ContribAuthor ">Guillem  Jorba</span>, <span class="hlFld-ContribAuthor ">Baldomero  Oliva</span>, <span class="hlFld-ContribAuthor ">Jose Manuel  Mas</span>. </span><span class="cited-content_cbyCitation_article-title">Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an
              in silico
              systems biology-based approach. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2021,</strong> <em>12 </em>
                                    (4)
                                     , 316-332. <a href="https://doi.org/10.18632/oncotarget.27875" title="DOI URL">https://doi.org/10.18632/oncotarget.27875</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.27875&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.27875%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DHead%252Bto%252Bhead%252Bevaluation%252Bof%252Bsecond%252Bgeneration%252BALK%252Binhibitors%252Bbrigatinib%252Band%252Balectinib%252Bas%252Bfirst-line%252Btreatment%252Bfor%252BALK%25252B%252BNSCLC%252Busing%252Ban%252Bin%252Bsilico%252Bsystems%252Bbiology-based%252Bapproach%26aulast%3DCarcereny%26aufirst%3DEnric%26date%3D2021%26volume%3D12%26issue%3D4%26spage%3D316%26epage%3D332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Neeraj  Gupta</span>, <span class="hlFld-ContribAuthor ">Xiaohui  Wang</span>, <span class="hlFld-ContribAuthor ">Elliot  Offman</span>, <span class="hlFld-ContribAuthor ">Marita  Prohn</span>, <span class="hlFld-ContribAuthor ">Narayana  Narasimhan</span>, <span class="hlFld-ContribAuthor ">David  Kerstein</span>, <span class="hlFld-ContribAuthor ">Michael J.  Hanley</span>, <span class="hlFld-ContribAuthor ">Karthik  Venkatakrishnan</span>. </span><span class="cited-content_cbyCitation_article-title">Population Pharmacokinetics of Brigatinib in Healthy Volunteers and Patients With Cancer. </span><span class="cited-content_cbyCitation_journal-name">Clinical Pharmacokinetics</span><span> <strong>2021,</strong> <em>60 </em>
                                    (2)
                                     , 235-247. <a href="https://doi.org/10.1007/s40262-020-00929-4" title="DOI URL">https://doi.org/10.1007/s40262-020-00929-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s40262-020-00929-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs40262-020-00929-4%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Pharmacokinetics%26atitle%3DPopulation%252BPharmacokinetics%252Bof%252BBrigatinib%252Bin%252BHealthy%252BVolunteers%252Band%252BPatients%252BWith%252BCancer%26aulast%3DGupta%26aufirst%3DNeeraj%26date%3D2021%26date%3D2020%26volume%3D60%26issue%3D2%26spage%3D235%26epage%3D247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mohammad Javed  Ansari</span>, <span class="hlFld-ContribAuthor ">Mohammed  Alnakhli</span>, <span class="hlFld-ContribAuthor ">Turki  Al-Otaibi</span>, <span class="hlFld-ContribAuthor ">Osaid Al  Meanazel</span>, <span class="hlFld-ContribAuthor ">Md Khalid  Anwer</span>, <span class="hlFld-ContribAuthor ">Mohammed Muqtader  Ahmed</span>, <span class="hlFld-ContribAuthor ">Saad M.  Alshahrani</span>, <span class="hlFld-ContribAuthor ">Abdullah  Alshetaili</span>, <span class="hlFld-ContribAuthor ">Mohammed F.  Aldawsari</span>, <span class="hlFld-ContribAuthor ">Ahmad S.  Alalaiwe</span>, <span class="hlFld-ContribAuthor ">Ahmed Z.  Alanazi</span>, <span class="hlFld-ContribAuthor ">Mohammed A.  Zahrani</span>, <span class="hlFld-ContribAuthor ">Niyaz  Ahmad</span>. </span><span class="cited-content_cbyCitation_article-title">Formulation and evaluation of self-nanoemulsifying drug delivery system of brigatinib: Improvement of solubility, in vitro release, ex-vivo permeation and anticancer activity. </span><span class="cited-content_cbyCitation_journal-name">Journal of Drug Delivery Science and Technology</span><span> <strong>2021,</strong> <em>61 </em>, 102204. <a href="https://doi.org/10.1016/j.jddst.2020.102204" title="DOI URL">https://doi.org/10.1016/j.jddst.2020.102204</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jddst.2020.102204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jddst.2020.102204%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Drug%2520Delivery%2520Science%2520and%2520Technology%26atitle%3DFormulation%252Band%252Bevaluation%252Bof%252Bself-nanoemulsifying%252Bdrug%252Bdelivery%252Bsystem%252Bof%252Bbrigatinib%25253A%252BImprovement%252Bof%252Bsolubility%25252C%252Bin%252Bvitro%252Brelease%25252C%252Bex-vivo%252Bpermeation%252Band%252Banticancer%252Bactivity%26aulast%3DAnsari%26aufirst%3DMohammad%2BJaved%26date%3D2021%26volume%3D61%26spage%3D102204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David  König</span>, <span class="hlFld-ContribAuthor ">Spasenija  Savic Prince</span>, <span class="hlFld-ContribAuthor ">Sacha I.  Rothschild</span>. </span><span class="cited-content_cbyCitation_article-title">Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (4)
                                     , 804. <a href="https://doi.org/10.3390/cancers13040804" title="DOI URL">https://doi.org/10.3390/cancers13040804</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13040804&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13040804%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DTargeted%252BTherapy%252Bin%252BAdvanced%252Band%252BMetastatic%252BNon-Small%252BCell%252BLung%252BCancer.%252BAn%252BUpdate%252Bon%252BTreatment%252Bof%252Bthe%252BMost%252BImportant%252BActionable%252BOncogenic%252BDriver%252BAlterations%26aulast%3DK%25C3%25B6nig%26aufirst%3DDavid%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D4%26spage%3D804" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ryohei  Katayama</span>. </span><span class="cited-content_cbyCitation_article-title">Resistance to anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) in patients with lung cancer: Single mutations, compound mutations, and other mechanisms of drug resistance. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 87-99. <a href="https://doi.org/10.1016/B978-0-12-821774-0.00015-2" title="DOI URL">https://doi.org/10.1016/B978-0-12-821774-0.00015-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-821774-0.00015-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-821774-0.00015-2%26sid%3Dliteratum%253Aachs%26atitle%3DResistance%252Bto%252Banaplastic%252Blymphoma%252Bkinase%252B%252528ALK%252529%252Btyrosine%252Bkinase%252Binhibitors%252B%252528TKIs%252529%252Bin%252Bpatients%252Bwith%252Blung%252Bcancer%25253A%252BSingle%252Bmutations%25252C%252Bcompound%252Bmutations%25252C%252Band%252Bother%252Bmechanisms%252Bof%252Bdrug%252Bresistance%26aulast%3DKatayama%26aufirst%3DRyohei%26date%3D2021%26spage%3D87%26epage%3D99%26pub%3DElsevier%26atitle%3DTherapeutic%252BStrategies%252Bto%252BOvercome%252BALK%252BResistance%252Bin%252BCancer%26date%3D2021%26volume%3D33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lyn H.  Jones</span>. </span><span class="cited-content_cbyCitation_article-title">Target Validation—Prosecuting the Target. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,<a href="https://doi.org/10.1016/B978-0-12-820472-6.00014-1" title="DOI URL">https://doi.org/10.1016/B978-0-12-820472-6.00014-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-820472-6.00014-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-820472-6.00014-1%26sid%3Dliteratum%253Aachs%26atitle%3DTarget%252BValidation%2525E2%252580%252594Prosecuting%252Bthe%252BTarget%26aulast%3DJones%26aufirst%3DLyn%2BH.%26date%3D2021%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BBiomedical%252BSciences%26date%3D2021%26volume%3D34" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tao  Fan</span>, <span class="hlFld-ContribAuthor ">Yan  Liu</span>, <span class="hlFld-ContribAuthor ">Caina  Jiang</span>, <span class="hlFld-ContribAuthor ">Yanli  Xu</span>, <span class="hlFld-ContribAuthor ">Yanyan  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">A metal-free radical cascade reaction of phosphine oxides with 2-aryloxy phenylacetylenes to synthesize diphosphonyl xanthene derivatives. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2021,</strong> <em>112 </em><a href="https://doi.org/10.1039/D1OB01045J" title="DOI URL">https://doi.org/10.1039/D1OB01045J</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1OB01045J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1OB01045J%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DA%252Bmetal-free%252Bradical%252Bcascade%252Breaction%252Bof%252Bphosphine%252Boxides%252Bwith%252B2-aryloxy%252Bphenylacetylenes%252Bto%252Bsynthesize%252Bdiphosphonyl%252Bxanthene%252Bderivatives%26aulast%3DFan%26aufirst%3DTao%26date%3D2021%26date%3D2021%26volume%3D112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nicole  L. Michmerhuizen</span>, <span class="hlFld-ContribAuthor ">Jiayu  Wang</span>, <span class="hlFld-ContribAuthor ">J. Chad  Brenner</span>. </span><span class="cited-content_cbyCitation_article-title">Integrated Molecular Profiling as an Approach to Identify PI3K Inhibitor Resistance Mechanisms. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,<a href="https://doi.org/10.5772/intechopen.92875" title="DOI URL">https://doi.org/10.5772/intechopen.92875</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.5772/intechopen.92875&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.5772%2Fintechopen.92875%26sid%3Dliteratum%253Aachs%26atitle%3DIntegrated%252BMolecular%252BProfiling%252Bas%252Ban%252BApproach%252Bto%252BIdentify%252BPI3K%252BInhibitor%252BResistance%252BMechanisms%26aulast%3DL.%2BMichmerhuizen%26aufirst%3DNicole%26date%3D2020%26date%3D2020%26pub%3DIntechOpen%26atitle%3DMolecular%252BPharmacology%26aulast%3DCatala%26aufirst%3DAngel%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Firdoos Ahmad  Sofi</span>, <span class="hlFld-ContribAuthor ">Prasad V.  Bharatam</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Drugs and Biorelevant N-heterocycles Employing Recent Advances in C-N Bond Formation. </span><span class="cited-content_cbyCitation_journal-name">Current Organic Chemistry</span><span> <strong>2020,</strong> <em>24 </em>
                                    (20)
                                     , 2293-2340. <a href="https://doi.org/10.2174/1385272824999200909114144" title="DOI URL">https://doi.org/10.2174/1385272824999200909114144</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1385272824999200909114144&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1385272824999200909114144%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Organic%2520Chemistry%26atitle%3DSynthesis%252Bof%252BDrugs%252Band%252BBiorelevant%252BN-heterocycles%252BEmploying%252BRecent%252BAdvances%252Bin%252BC-N%252BBond%252BFormation%26aulast%3DSofi%26aufirst%3DFirdoos%2BAhmad%26date%3D2020%26volume%3D24%26issue%3D20%26spage%3D2293%26epage%3D2340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Neeraj  Gupta</span>, <span class="hlFld-ContribAuthor ">Xiaohui  Wang</span>, <span class="hlFld-ContribAuthor ">Elliot  Offman</span>, <span class="hlFld-ContribAuthor ">Benjamin  Rich</span>, <span class="hlFld-ContribAuthor ">David  Kerstein</span>, <span class="hlFld-ContribAuthor ">Michael  Hanley</span>, <span class="hlFld-ContribAuthor ">Paul M.  Diderichsen</span>, <span class="hlFld-ContribAuthor ">Pingkuan  Zhang</span>, <span class="hlFld-ContribAuthor ">Karthik  Venkatakrishnan</span>. </span><span class="cited-content_cbyCitation_article-title">Brigatinib Dose Rationale in Anaplastic Lymphoma Kinase–Positive Non‐Small Cell Lung Cancer: Exposure–Response Analyses of Pivotal ALTA Study. </span><span class="cited-content_cbyCitation_journal-name">CPT: Pharmacometrics & Systems Pharmacology</span><span> <strong>2020,</strong> <em>9 </em>
                                    (12)
                                     , 718-730. <a href="https://doi.org/10.1002/psp4.12569" title="DOI URL">https://doi.org/10.1002/psp4.12569</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/psp4.12569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fpsp4.12569%26sid%3Dliteratum%253Aachs%26jtitle%3DCPT%253A%2520Pharmacometrics%2520%2526%2520Systems%2520Pharmacology%26atitle%3DBrigatinib%252BDose%252BRationale%252Bin%252BAnaplastic%252BLymphoma%252BKinase%2525E2%252580%252593Positive%252BNon%2525E2%252580%252590Small%252BCell%252BLung%252BCancer%25253A%252BExposure%2525E2%252580%252593Response%252BAnalyses%252Bof%252BPivotal%252BALTA%252BStudy%26aulast%3DGupta%26aufirst%3DNeeraj%26date%3D2020%26date%3D2020%26volume%3D9%26issue%3D12%26spage%3D718%26epage%3D730" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jianzhong  Chen</span>, <span class="hlFld-ContribAuthor ">Wei  Wang</span>, <span class="hlFld-ContribAuthor ">Haibo  Sun</span>, <span class="hlFld-ContribAuthor ">Laixue  Pang</span>, <span class="hlFld-ContribAuthor ">Baohua  Yin</span>. </span><span class="cited-content_cbyCitation_article-title">Mutation-mediated influences on binding of anaplastic lymphoma kinase to crizotinib decoded by multiple replica Gaussian accelerated molecular dynamics. </span><span class="cited-content_cbyCitation_journal-name">Journal of Computer-Aided Molecular Design</span><span> <strong>2020,</strong> <em>34 </em>
                                    (12)
                                     , 1289-1305. <a href="https://doi.org/10.1007/s10822-020-00355-5" title="DOI URL">https://doi.org/10.1007/s10822-020-00355-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10822-020-00355-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10822-020-00355-5%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Computer-Aided%2520Molecular%2520Design%26atitle%3DMutation-mediated%252Binfluences%252Bon%252Bbinding%252Bof%252Banaplastic%252Blymphoma%252Bkinase%252Bto%252Bcrizotinib%252Bdecoded%252Bby%252Bmultiple%252Breplica%252BGaussian%252Baccelerated%252Bmolecular%252Bdynamics%26aulast%3DChen%26aufirst%3DJianzhong%26date%3D2020%26date%3D2020%26volume%3D34%26issue%3D12%26spage%3D1289%26epage%3D1305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hanxiao  Yu</span>, <span class="hlFld-ContribAuthor ">He  Yang</span>, <span class="hlFld-ContribAuthor ">Enxue  Shi</span>, <span class="hlFld-ContribAuthor ">Wenjun  Tang</span>. </span><span class="cited-content_cbyCitation_article-title">Development and Clinical Application of Phosphorus-Containing Drugs. </span><span class="cited-content_cbyCitation_journal-name">Medicine in Drug Discovery</span><span> <strong>2020,</strong> <em>8 </em>, 100063. <a href="https://doi.org/10.1016/j.medidd.2020.100063" title="DOI URL">https://doi.org/10.1016/j.medidd.2020.100063</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.medidd.2020.100063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.medidd.2020.100063%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicine%2520in%2520Drug%2520Discovery%26atitle%3DDevelopment%252Band%252BClinical%252BApplication%252Bof%252BPhosphorus-Containing%252BDrugs%26aulast%3DYu%26aufirst%3DHanxiao%26date%3D2020%26volume%3D8%26spage%3D100063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhou  Deng</span>, <span class="hlFld-ContribAuthor ">Guyue  Chen</span>, <span class="hlFld-ContribAuthor ">Shuang  Liu</span>, <span class="hlFld-ContribAuthor ">Yunzhan  Li</span>, <span class="hlFld-ContribAuthor ">Jiaji  Zhong</span>, <span class="hlFld-ContribAuthor ">Baoding  Zhang</span>, <span class="hlFld-ContribAuthor ">Li  Li</span>, <span class="hlFld-ContribAuthor ">Huiying  Huang</span>, <span class="hlFld-ContribAuthor ">Zheng  Wang</span>, <span class="hlFld-ContribAuthor ">Qingyan  Xu</span>, <span class="hlFld-ContribAuthor ">Xianming  Deng</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of methyl 3-((2-((1-(dimethylglycyl)-5-methoxyindolin-6-yl)amino)-5-(trifluoro-methyl) pyrimidin-4-yl)amino)thiophene-2-carboxylate as a potent and selective polo-like kinase 1 (PLK1) inhibitor for combating hepatocellular carcinoma. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>206 </em>, 112697. <a href="https://doi.org/10.1016/j.ejmech.2020.112697" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112697</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112697%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bmethyl%252B3-%252528%2525282-%252528%2525281-%252528dimethylglycyl%252529-5-methoxyindolin-6-yl%252529amino%252529-5-%252528trifluoro-methyl%252529%252Bpyrimidin-4-yl%252529amino%252529thiophene-2-carboxylate%252Bas%252Ba%252Bpotent%252Band%252Bselective%252Bpolo-like%252Bkinase%252B1%252B%252528PLK1%252529%252Binhibitor%252Bfor%252Bcombating%252Bhepatocellular%252Bcarcinoma%26aulast%3DDeng%26aufirst%3DZhou%26date%3D2020%26volume%3D206%26spage%3D112697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">D. Ross  Camidge</span>, <span class="hlFld-ContribAuthor ">Hye Ryun  Kim</span>, <span class="hlFld-ContribAuthor ">Myung-Ju  Ahn</span>, <span class="hlFld-ContribAuthor ">James C. H.  Yang</span>, <span class="hlFld-ContribAuthor ">Ji-Youn  Han</span>, <span class="hlFld-ContribAuthor ">Maximilian J.  Hochmair</span>, <span class="hlFld-ContribAuthor ">Ki Hyeong  Lee</span>, <span class="hlFld-ContribAuthor ">Angelo  Delmonte</span>, <span class="hlFld-ContribAuthor ">Maria Rosario  García Campelo</span>, <span class="hlFld-ContribAuthor ">Dong-Wan  Kim</span>, <span class="hlFld-ContribAuthor ">Frank  Griesinger</span>, <span class="hlFld-ContribAuthor ">Enriqueta  Felip</span>, <span class="hlFld-ContribAuthor ">Raffaele  Califano</span>, <span class="hlFld-ContribAuthor ">Alexander  Spira</span>, <span class="hlFld-ContribAuthor ">Scott N.  Gettinger</span>, <span class="hlFld-ContribAuthor ">Marcello  Tiseo</span>, <span class="hlFld-ContribAuthor ">Huamao M.  Lin</span>, <span class="hlFld-ContribAuthor ">Neeraj  Gupta</span>, <span class="hlFld-ContribAuthor ">Michael J.  Hanley</span>, <span class="hlFld-ContribAuthor ">Quanhong  Ni</span>, <span class="hlFld-ContribAuthor ">Pingkuan  Zhang</span>, <span class="hlFld-ContribAuthor ">Sanjay  Popat</span>. </span><span class="cited-content_cbyCitation_article-title">Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial. </span><span class="cited-content_cbyCitation_journal-name">Journal of Clinical Oncology</span><span> <strong>2020,</strong> <em>38 </em>
                                    (31)
                                     , 3592-3603. <a href="https://doi.org/10.1200/JCO.20.00505" title="DOI URL">https://doi.org/10.1200/JCO.20.00505</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1200/JCO.20.00505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1200%2FJCO.20.00505%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Clinical%2520Oncology%26atitle%3DBrigatinib%252BVersus%252BCrizotinib%252Bin%252BAdvanced%252BALK%252BInhibitor%2525E2%252580%252593Naive%252BALK-Positive%252BNon%2525E2%252580%252593Small%252BCell%252BLung%252BCancer%25253A%252BSecond%252BInterim%252BAnalysis%252Bof%252Bthe%252BPhase%252BIII%252BALTA-1L%252BTrial%26aulast%3DCamidge%26aufirst%3DD.%2BRoss%26date%3D2020%26volume%3D38%26issue%3D31%26spage%3D3592%26epage%3D3603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jyoti  Singh</span>, <span class="hlFld-ContribAuthor ">Suaib  Luqman</span>, <span class="hlFld-ContribAuthor ">Abha  Meena</span>. </span><span class="cited-content_cbyCitation_article-title">Emerging role of phytochemicals in targeting predictive, prognostic, and diagnostic biomarkers of lung cancer. </span><span class="cited-content_cbyCitation_journal-name">Food and Chemical Toxicology</span><span> <strong>2020,</strong> <em>144 </em>, 111592. <a href="https://doi.org/10.1016/j.fct.2020.111592" title="DOI URL">https://doi.org/10.1016/j.fct.2020.111592</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.fct.2020.111592&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.fct.2020.111592%26sid%3Dliteratum%253Aachs%26jtitle%3DFood%2520and%2520Chemical%2520Toxicology%26atitle%3DEmerging%252Brole%252Bof%252Bphytochemicals%252Bin%252Btargeting%252Bpredictive%25252C%252Bprognostic%25252C%252Band%252Bdiagnostic%252Bbiomarkers%252Bof%252Blung%252Bcancer%26aulast%3DSingh%26aufirst%3DJyoti%26date%3D2020%26volume%3D144%26spage%3D111592" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sitanshu S.  Singh</span>, <span class="hlFld-ContribAuthor ">Achyut  Dahal</span>, <span class="hlFld-ContribAuthor ">Leeza  Shrestha</span>, <span class="hlFld-ContribAuthor ">Seetharama D.  Jois</span>. </span><span class="cited-content_cbyCitation_article-title">Genotype Driven Therapy for Non-Small Cell Lung Cancer: Resistance, Pan Inhibitors and Immunotherapy. </span><span class="cited-content_cbyCitation_journal-name">Current Medicinal Chemistry</span><span> <strong>2020,</strong> <em>27 </em>
                                    (32)
                                     , 5274-5316. <a href="https://doi.org/10.2174/0929867326666190222183219" title="DOI URL">https://doi.org/10.2174/0929867326666190222183219</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/0929867326666190222183219&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F0929867326666190222183219%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Medicinal%2520Chemistry%26atitle%3DGenotype%252BDriven%252BTherapy%252Bfor%252BNon-Small%252BCell%252BLung%252BCancer%25253A%252BResistance%25252C%252BPan%252BInhibitors%252Band%252BImmunotherapy%26aulast%3DSingh%26aufirst%3DSitanshu%2BS.%26date%3D2020%26volume%3D27%26issue%3D32%26spage%3D5274%26epage%3D5316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Luciana  Cicco</span>, <span class="hlFld-ContribAuthor ">Alba  Fombona‐Pascual</span>, <span class="hlFld-ContribAuthor ">Alba  Sánchez‐Condado</span>, <span class="hlFld-ContribAuthor ">Gabino A.  Carriedo</span>, <span class="hlFld-ContribAuthor ">Filippo M.  Perna</span>, <span class="hlFld-ContribAuthor ">Vito  Capriati</span>, <span class="hlFld-ContribAuthor ">Alejandro  Presa Soto</span>, <span class="hlFld-ContribAuthor ">Joaquín  García‐Álvarez</span>. </span><span class="cited-content_cbyCitation_article-title">Fast and Chemoselective Addition of Highly Polarized Lithium Phosphides Generated in Deep Eutectic Solvents to Aldehydes and Epoxides. </span><span class="cited-content_cbyCitation_journal-name">ChemSusChem</span><span> <strong>2020,</strong> <em>13 </em>
                                    (18)
                                     , 4967-4973. <a href="https://doi.org/10.1002/cssc.202001449" title="DOI URL">https://doi.org/10.1002/cssc.202001449</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cssc.202001449&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcssc.202001449%26sid%3Dliteratum%253Aachs%26jtitle%3DChemSusChem%26atitle%3DFast%252Band%252BChemoselective%252BAddition%252Bof%252BHighly%252BPolarized%252BLithium%252BPhosphides%252BGenerated%252Bin%252BDeep%252BEutectic%252BSolvents%252Bto%252BAldehydes%252Band%252BEpoxides%26aulast%3DCicco%26aufirst%3DLuciana%26date%3D2020%26date%3D2020%26volume%3D13%26issue%3D18%26spage%3D4967%26epage%3D4973" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Juliana F.  Vilachã</span>, <span class="hlFld-ContribAuthor ">Sarah C.  Mitchel</span>, <span class="hlFld-ContribAuthor ">Muluembet Z.  Akele</span>, <span class="hlFld-ContribAuthor ">Stephen  Evans</span>, <span class="hlFld-ContribAuthor ">Matthew R.  Groves</span>. </span><span class="cited-content_cbyCitation_article-title">Making NSCLC Crystal Clear: How Kinase Structures Revolutionized Lung Cancer Treatment. </span><span class="cited-content_cbyCitation_journal-name">Crystals</span><span> <strong>2020,</strong> <em>10 </em>
                                    (9)
                                     , 725. <a href="https://doi.org/10.3390/cryst10090725" title="DOI URL">https://doi.org/10.3390/cryst10090725</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cryst10090725&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcryst10090725%26sid%3Dliteratum%253Aachs%26jtitle%3DCrystals%26atitle%3DMaking%252BNSCLC%252BCrystal%252BClear%25253A%252BHow%252BKinase%252BStructures%252BRevolutionized%252BLung%252BCancer%252BTreatment%26aulast%3DVilach%25C3%25A3%26aufirst%3DJuliana%2BF.%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D9%26spage%3D725" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qian  Cai</span>, <span class="hlFld-ContribAuthor ">Wei  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Ullmann‐Ma
              Reaction: Development, Scope and Applications in Organic Synthesis
              †. </span><span class="cited-content_cbyCitation_journal-name">Chinese Journal of Chemistry</span><span> <strong>2020,</strong> <em>38 </em>
                                    (8)
                                     , 879-893. <a href="https://doi.org/10.1002/cjoc.202000075" title="DOI URL">https://doi.org/10.1002/cjoc.202000075</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cjoc.202000075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcjoc.202000075%26sid%3Dliteratum%253Aachs%26jtitle%3DChinese%2520Journal%2520of%2520Chemistry%26atitle%3DUllmann%2525E2%252580%252590Ma%252BReaction%25253A%252BDevelopment%25252C%252BScope%252Band%252BApplications%252Bin%252BOrganic%252BSynthesis%252B%2525E2%252580%2525A0%26aulast%3DCai%26aufirst%3DQian%26date%3D2020%26date%3D2020%26volume%3D38%26issue%3D8%26spage%3D879%26epage%3D893" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sravani  Sana</span>, <span class="hlFld-ContribAuthor ">Velma Ganga  Reddy</span>, <span class="hlFld-ContribAuthor ">Sonal  Bhandari</span>, <span class="hlFld-ContribAuthor ">T. Srinivasa  Reddy</span>, <span class="hlFld-ContribAuthor ">Ramya  Tokala</span>, <span class="hlFld-ContribAuthor ">Akash P.  Sakla</span>, <span class="hlFld-ContribAuthor ">Suresh K.  Bhargava</span>, <span class="hlFld-ContribAuthor ">Nagula  Shankaraiah</span>. </span><span class="cited-content_cbyCitation_article-title">Exploration of carbamide derived pyrimidine-thioindole conjugates as potential VEGFR-2 inhibitors with anti-angiogenesis effect. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>200 </em>, 112457. <a href="https://doi.org/10.1016/j.ejmech.2020.112457" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112457</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112457%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DExploration%252Bof%252Bcarbamide%252Bderived%252Bpyrimidine-thioindole%252Bconjugates%252Bas%252Bpotential%252BVEGFR-2%252Binhibitors%252Bwith%252Banti-angiogenesis%252Beffect%26aulast%3DSana%26aufirst%3DSravani%26date%3D2020%26volume%3D200%26spage%3D112457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bao-Li  Wang</span>, <span class="hlFld-ContribAuthor ">Song-Bo  Kou</span>, <span class="hlFld-ContribAuthor ">Zhen-Yi  Lin</span>, <span class="hlFld-ContribAuthor ">Jie-Hua  Shi</span>, <span class="hlFld-ContribAuthor ">Ying-Xin  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Insights on the interaction mechanism of brigatinib to human α-1-acid glycoprotein: Experimental and computational approaches. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Biological Macromolecules</span><span> <strong>2020,</strong> <em>157 </em>, 340-349. <a href="https://doi.org/10.1016/j.ijbiomac.2020.04.151" title="DOI URL">https://doi.org/10.1016/j.ijbiomac.2020.04.151</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ijbiomac.2020.04.151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ijbiomac.2020.04.151%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Biological%2520Macromolecules%26atitle%3DInsights%252Bon%252Bthe%252Binteraction%252Bmechanism%252Bof%252Bbrigatinib%252Bto%252Bhuman%252B%2525CE%2525B1-1-acid%252Bglycoprotein%25253A%252BExperimental%252Band%252Bcomputational%252Bapproaches%26aulast%3DWang%26aufirst%3DBao-Li%26date%3D2020%26volume%3D157%26spage%3D340%26epage%3D349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Herbert H.  Loong</span>, <span class="hlFld-ContribAuthor ">Molly S.C.  Li</span>, <span class="hlFld-ContribAuthor ">Gordon C.H.  Tang</span>, <span class="hlFld-ContribAuthor ">Yat-Ming  Lau</span>. </span><span class="cited-content_cbyCitation_article-title">Have We Revealed the Achilles’ Heel of Brigatinib? Implications on Clinical Practice. </span><span class="cited-content_cbyCitation_journal-name">Journal of Thoracic Oncology</span><span> <strong>2020,</strong> <em>15 </em>
                                    (7)
                                     , 1100-1102. <a href="https://doi.org/10.1016/j.jtho.2020.03.026" title="DOI URL">https://doi.org/10.1016/j.jtho.2020.03.026</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jtho.2020.03.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jtho.2020.03.026%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Thoracic%2520Oncology%26atitle%3DHave%252BWe%252BRevealed%252Bthe%252BAchilles%2525E2%252580%252599%252BHeel%252Bof%252BBrigatinib%25253F%252BImplications%252Bon%252BClinical%252BPractice%26aulast%3DLoong%26aufirst%3DHerbert%2BH.%26date%3D2020%26volume%3D15%26issue%3D7%26spage%3D1100%26epage%3D1102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dillon T.  Flood</span>, <span class="hlFld-ContribAuthor ">Xuejing  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiang  Fu</span>, <span class="hlFld-ContribAuthor ">Zhenxiang  Zhao</span>, <span class="hlFld-ContribAuthor ">Shota  Asai</span>, <span class="hlFld-ContribAuthor ">Brittany B.  Sanchez</span>, <span class="hlFld-ContribAuthor ">Emily J.  Sturgell</span>, <span class="hlFld-ContribAuthor ">Julien C.  Vantourout</span>, <span class="hlFld-ContribAuthor ">Paul  Richardson</span>, <span class="hlFld-ContribAuthor ">Mark E.  Flanagan</span>, <span class="hlFld-ContribAuthor ">David W.  Piotrowski</span>, <span class="hlFld-ContribAuthor ">Dominik K.  Kölmel</span>, <span class="hlFld-ContribAuthor ">Jinqiao  Wan</span>, <span class="hlFld-ContribAuthor ">Mei‐Hsuan  Tsai</span>, <span class="hlFld-ContribAuthor ">Jason S.  Chen</span>, <span class="hlFld-ContribAuthor ">Phil S.  Baran</span>, <span class="hlFld-ContribAuthor ">Philip E.  Dawson</span>. </span><span class="cited-content_cbyCitation_article-title">RASS‐Enabled S/P−C and S−N Bond Formation for DEL Synthesis. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2020,</strong> <em>132 </em>
                                    (19)
                                     , 7447-7453. <a href="https://doi.org/10.1002/ange.201915493" title="DOI URL">https://doi.org/10.1002/ange.201915493</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.201915493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.201915493%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DRASS%2525E2%252580%252590Enabled%252BS%25252FP%2525E2%252588%252592C%252Band%252BS%2525E2%252588%252592N%252BBond%252BFormation%252Bfor%252BDEL%252BSynthesis%26aulast%3DFlood%26aufirst%3DDillon%2BT.%26date%3D2020%26date%3D2020%26volume%3D132%26issue%3D19%26spage%3D7447%26epage%3D7453" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dillon T.  Flood</span>, <span class="hlFld-ContribAuthor ">Xuejing  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiang  Fu</span>, <span class="hlFld-ContribAuthor ">Zhenxiang  Zhao</span>, <span class="hlFld-ContribAuthor ">Shota  Asai</span>, <span class="hlFld-ContribAuthor ">Brittany B.  Sanchez</span>, <span class="hlFld-ContribAuthor ">Emily J.  Sturgell</span>, <span class="hlFld-ContribAuthor ">Julien C.  Vantourout</span>, <span class="hlFld-ContribAuthor ">Paul  Richardson</span>, <span class="hlFld-ContribAuthor ">Mark E.  Flanagan</span>, <span class="hlFld-ContribAuthor ">David W.  Piotrowski</span>, <span class="hlFld-ContribAuthor ">Dominik K.  Kölmel</span>, <span class="hlFld-ContribAuthor ">Jinqiao  Wan</span>, <span class="hlFld-ContribAuthor ">Mei‐Hsuan  Tsai</span>, <span class="hlFld-ContribAuthor ">Jason S.  Chen</span>, <span class="hlFld-ContribAuthor ">Phil S.  Baran</span>, <span class="hlFld-ContribAuthor ">Philip E.  Dawson</span>. </span><span class="cited-content_cbyCitation_article-title">RASS‐Enabled S/P−C and S−N Bond Formation for DEL Synthesis. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2020,</strong> <em>59 </em>
                                    (19)
                                     , 7377-7383. <a href="https://doi.org/10.1002/anie.201915493" title="DOI URL">https://doi.org/10.1002/anie.201915493</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.201915493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.201915493%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DRASS%2525E2%252580%252590Enabled%252BS%25252FP%2525E2%252588%252592C%252Band%252BS%2525E2%252588%252592N%252BBond%252BFormation%252Bfor%252BDEL%252BSynthesis%26aulast%3DFlood%26aufirst%3DDillon%2BT.%26date%3D2020%26date%3D2020%26volume%3D59%26issue%3D19%26spage%3D7377%26epage%3D7383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ning  Sun</span>, <span class="hlFld-ContribAuthor ">Chaowei  Ren</span>, <span class="hlFld-ContribAuthor ">Ying  Kong</span>, <span class="hlFld-ContribAuthor ">Hui  Zhong</span>, <span class="hlFld-ContribAuthor ">Jinju  Chen</span>, <span class="hlFld-ContribAuthor ">Yan  Li</span>, <span class="hlFld-ContribAuthor ">Jianshui  Zhang</span>, <span class="hlFld-ContribAuthor ">Yuedong  Zhou</span>, <span class="hlFld-ContribAuthor ">Xing  Qiu</span>, <span class="hlFld-ContribAuthor ">Haifan  Lin</span>, <span class="hlFld-ContribAuthor ">Xiaoling  Song</span>, <span class="hlFld-ContribAuthor ">Xiaobao  Yang</span>, <span class="hlFld-ContribAuthor ">Biao  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Development of a Brigatinib degrader (SIAIS117) as a potential treatment for ALK positive cancer resistance. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>193 </em>, 112190. <a href="https://doi.org/10.1016/j.ejmech.2020.112190" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112190</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112190&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112190%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDevelopment%252Bof%252Ba%252BBrigatinib%252Bdegrader%252B%252528SIAIS117%252529%252Bas%252Ba%252Bpotential%252Btreatment%252Bfor%252BALK%252Bpositive%252Bcancer%252Bresistance%26aulast%3DSun%26aufirst%3DNing%26date%3D2020%26volume%3D193%26spage%3D112190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">John D.  Westbrook</span>, <span class="hlFld-ContribAuthor ">Rose  Soskind</span>, <span class="hlFld-ContribAuthor ">Brian P.  Hudson</span>, <span class="hlFld-ContribAuthor ">Stephen K.  Burley</span>. </span><span class="cited-content_cbyCitation_article-title">Impact of the Protein Data Bank on antineoplastic approvals. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2020,</strong> <em>25 </em>
                                    (5)
                                     , 837-850. <a href="https://doi.org/10.1016/j.drudis.2020.02.002" title="DOI URL">https://doi.org/10.1016/j.drudis.2020.02.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2020.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2020.02.002%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DImpact%252Bof%252Bthe%252BProtein%252BData%252BBank%252Bon%252Bantineoplastic%252Bapprovals%26aulast%3DWestbrook%26aufirst%3DJohn%2BD.%26date%3D2020%26volume%3D25%26issue%3D5%26spage%3D837%26epage%3D850" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jie  Wang</span>, <span class="hlFld-ContribAuthor ">Shangfei  Wei</span>, <span class="hlFld-ContribAuthor ">Tong  Li</span>, <span class="hlFld-ContribAuthor ">Lingyun  Xing</span>, <span class="hlFld-ContribAuthor ">Meng  Cao</span>, <span class="hlFld-ContribAuthor ">Nan  Jiang</span>, <span class="hlFld-ContribAuthor ">Ming  Guo</span>, <span class="hlFld-ContribAuthor ">Daiying  Zuo</span>, <span class="hlFld-ContribAuthor ">Xin  Zhai</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-based design of 2,4-diaminopyrimidine derivatives bearing a pyrrolyl group as ALK and ROS1 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">New Journal of Chemistry</span><span> <strong>2020,</strong> <em>44 </em>
                                    (15)
                                     , 5850-5861. <a href="https://doi.org/10.1039/C9NJ05980F" title="DOI URL">https://doi.org/10.1039/C9NJ05980F</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9NJ05980F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9NJ05980F%26sid%3Dliteratum%253Aachs%26jtitle%3DNew%2520Journal%2520of%2520Chemistry%26atitle%3DStructure-based%252Bdesign%252Bof%252B2%25252C4-diaminopyrimidine%252Bderivatives%252Bbearing%252Ba%252Bpyrrolyl%252Bgroup%252Bas%252BALK%252Band%252BROS1%252Binhibitors%26aulast%3DWang%26aufirst%3DJie%26date%3D2020%26date%3D2020%26volume%3D44%26issue%3D15%26spage%3D5850%26epage%3D5861" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Koichi  Ando</span>, <span class="hlFld-ContribAuthor ">Kaho  Akimoto</span>, <span class="hlFld-ContribAuthor ">Hiroki  Sato</span>, <span class="hlFld-ContribAuthor ">Ryo  Manabe</span>, <span class="hlFld-ContribAuthor ">Yasunari  Kishino</span>, <span class="hlFld-ContribAuthor ">Tetsuya  Homma</span>, <span class="hlFld-ContribAuthor ">Sojiro  Kusumoto</span>, <span class="hlFld-ContribAuthor ">Toshimitsu  Yamaoka</span>, <span class="hlFld-ContribAuthor ">Akihiko  Tanaka</span>, <span class="hlFld-ContribAuthor ">Tohru  Ohmori</span>, <span class="hlFld-ContribAuthor ">Hironori  Sagara</span>. </span><span class="cited-content_cbyCitation_article-title">Brigatinib and Alectinib for ALK Rearrangement-Positive Advanced Non-Small Cell Lung Cancer with or without Central Nervous System Metastasis: A Systematic Review and Network Meta-Analysis. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2020,</strong> <em>12 </em>
                                    (4)
                                     , 942. <a href="https://doi.org/10.3390/cancers12040942" title="DOI URL">https://doi.org/10.3390/cancers12040942</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers12040942&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers12040942%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DBrigatinib%252Band%252BAlectinib%252Bfor%252BALK%252BRearrangement-Positive%252BAdvanced%252BNon-Small%252BCell%252BLung%252BCancer%252Bwith%252Bor%252Bwithout%252BCentral%252BNervous%252BSystem%252BMetastasis%25253A%252BA%252BSystematic%252BReview%252Band%252BNetwork%252BMeta-Analysis%26aulast%3DAndo%26aufirst%3DKoichi%26date%3D2020%26date%3D2020%26volume%3D12%26issue%3D4%26spage%3D942" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kader  SAHİN</span>, <span class="hlFld-ContribAuthor ">Serdar  DURDAGI</span>. </span><span class="cited-content_cbyCitation_article-title">Identifying the Novel Pyrimidine-Based CDK2 Inhibitors as Anticancer Agents Using Text-Mining and Combined Molecular Modeling Approaches. </span><span class="cited-content_cbyCitation_journal-name">Journal of the Turkish Chemical Society Section A: Chemistry</span><span> <strong>2020,</strong> <em> </em>, 383-404. <a href="https://doi.org/10.18596/jotcsa.701243" title="DOI URL">https://doi.org/10.18596/jotcsa.701243</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18596/jotcsa.701243&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18596%2Fjotcsa.701243%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520Turkish%2520Chemical%2520Society%2520Section%2520A%253A%2520Chemistry%26atitle%3DIdentifying%252Bthe%252BNovel%252BPyrimidine-Based%252BCDK2%252BInhibitors%252Bas%252BAnticancer%252BAgents%252BUsing%252BText-Mining%252Band%252BCombined%252BMolecular%252BModeling%252BApproaches%26aulast%3DSAH%25C4%25B0N%26aufirst%3DKader%26date%3D2020%26date%3D2020%26spage%3D383%26epage%3D404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ji-Shu  Zhang</span>, <span class="hlFld-ContribAuthor ">Tieqiao  Chen</span>, <span class="hlFld-ContribAuthor ">Li-Biao  Han</span>. </span><span class="cited-content_cbyCitation_article-title">Palladium-Catalyzed Direct Decarbonylative Phosphorylation of Benzoic Acids with P(O)-H Compounds. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>2020 </em>
                                    (9)
                                     , 1148-1153. <a href="https://doi.org/10.1002/ejoc.201901865" title="DOI URL">https://doi.org/10.1002/ejoc.201901865</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.201901865&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.201901865%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DPalladium-Catalyzed%252BDirect%252BDecarbonylative%252BPhosphorylation%252Bof%252BBenzoic%252BAcids%252Bwith%252BP%252528O%252529-H%252BCompounds%26aulast%3DZhang%26aufirst%3DJi-Shu%26date%3D2020%26date%3D2020%26volume%3D2020%26issue%3D9%26spage%3D1148%26epage%3D1153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brian J.  Groendyke</span>, <span class="hlFld-ContribAuthor ">Chelsea E.  Powell</span>, <span class="hlFld-ContribAuthor ">Frederic  Feru</span>, <span class="hlFld-ContribAuthor ">Thomas W.  Gero</span>, <span class="hlFld-ContribAuthor ">Zhengnian  Li</span>, <span class="hlFld-ContribAuthor ">Hilary  Szabo</span>, <span class="hlFld-ContribAuthor ">Kevin  Pang</span>, <span class="hlFld-ContribAuthor ">John  Feutrill</span>, <span class="hlFld-ContribAuthor ">Bailing  Chen</span>, <span class="hlFld-ContribAuthor ">Bin  Li</span>, <span class="hlFld-ContribAuthor ">Nathanael S.  Gray</span>, <span class="hlFld-ContribAuthor ">David A.  Scott</span>. </span><span class="cited-content_cbyCitation_article-title">Benzopyrimidodiazepinone inhibitors of TNK2. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>30 </em>
                                    (4)
                                     , 126948. <a href="https://doi.org/10.1016/j.bmcl.2020.126948" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.126948</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.126948&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.126948%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DBenzopyrimidodiazepinone%252Binhibitors%252Bof%252BTNK2%26aulast%3DGroendyke%26aufirst%3DBrian%2BJ.%26date%3D2020%26volume%3D30%26issue%3D4%26spage%3D126948" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shang-Zheng  Sun</span>, <span class="hlFld-ContribAuthor ">Ming  Shang</span>, <span class="hlFld-ContribAuthor ">Hui  Xu</span>, <span class="hlFld-ContribAuthor ">Tai-Jin  Cheng</span>, <span class="hlFld-ContribAuthor ">Ming-Hong  Li</span>, <span class="hlFld-ContribAuthor ">Hui-Xiong  Dai</span>. </span><span class="cited-content_cbyCitation_article-title">Copper mediated C(sp
              2
              )–H amination and hydroxylation of phosphinamides. </span><span class="cited-content_cbyCitation_journal-name">Chemical Communications</span><span> <strong>2020,</strong> <em>56 </em>
                                    (9)
                                     , 1444-1447. <a href="https://doi.org/10.1039/C9CC08879B" title="DOI URL">https://doi.org/10.1039/C9CC08879B</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9CC08879B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9CC08879B%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Communications%26atitle%3DCopper%252Bmediated%252BC%252528sp%252B2%252B%252529%2525E2%252580%252593H%252Bamination%252Band%252Bhydroxylation%252Bof%252Bphosphinamides%26aulast%3DSun%26aufirst%3DShang-Zheng%26date%3D2020%26date%3D2020%26volume%3D56%26issue%3D9%26spage%3D1444%26epage%3D1447" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Athina  Moschopoulou</span>, <span class="hlFld-ContribAuthor ">Stefan  Zwirner</span>, <span class="hlFld-ContribAuthor ">Lars  Zender</span>, <span class="hlFld-ContribAuthor ">Daniel  Dauch</span>. </span><span class="cited-content_cbyCitation_article-title">Exploiting Kinase Inhibitors for Cancer Treatment: An Overview of Clinical Results and Outlook. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 125-153. <a href="https://doi.org/10.1007/7355_2020_100" title="DOI URL">https://doi.org/10.1007/7355_2020_100</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7355_2020_100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7355_2020_100%26sid%3Dliteratum%253Aachs%26atitle%3DExploiting%252BKinase%252BInhibitors%252Bfor%252BCancer%252BTreatment%25253A%252BAn%252BOverview%252Bof%252BClinical%252BResults%252Band%252BOutlook%26aulast%3DMoschopoulou%26aufirst%3DAthina%26date%3D2020%26date%3D2020%26spage%3D125%26epage%3D153%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DProteinkinase%252BInhibitors%26aulast%3DLaufer%26aufirst%3DStefan%26date%3D2021%26volume%3D36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiuqi  Miao</span>, <span class="hlFld-ContribAuthor ">Lingyun  Xing</span>, <span class="hlFld-ContribAuthor ">Ming  Guo</span>, <span class="hlFld-ContribAuthor ">Hong  Zhang</span>, <span class="hlFld-ContribAuthor ">Sicong  Liu</span>, <span class="hlFld-ContribAuthor ">Shiliang  Yin</span>, <span class="hlFld-ContribAuthor ">Ping  Gong</span>, <span class="hlFld-ContribAuthor ">Dajun  Zhang</span>, <span class="hlFld-ContribAuthor ">Xin  Zhai</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of 2-arylaminopyrimidine derivatives bearing 1,3,8-triazaspiro[4,5]decan-4-one or piperidine-3-carboxamide moiety as novel Type-I1/2 ALK inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>94 </em>, 103456. <a href="https://doi.org/10.1016/j.bioorg.2019.103456" title="DOI URL">https://doi.org/10.1016/j.bioorg.2019.103456</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2019.103456&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2019.103456%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252B2-arylaminopyrimidine%252Bderivatives%252Bbearing%252B1%25252C3%25252C8-triazaspiro%25255B4%25252C5%25255Ddecan-4-one%252Bor%252Bpiperidine-3-carboxamide%252Bmoiety%252Bas%252Bnovel%252BType-I1%25252F2%252BALK%252Binhibitors%26aulast%3DMiao%26aufirst%3DXiuqi%26date%3D2020%26volume%3D94%26spage%3D103456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Abhay  Singh</span>, <span class="hlFld-ContribAuthor ">Hongbin  Chen</span>. </span><span class="cited-content_cbyCitation_article-title"><p>Optimal Care for Patients with Anaplastic Lymphoma Kinase (ALK)–Positive Non–Small Cell Lung Cancer: A Review on the Role and Utility of ALK Inhibitors</p>. </span><span class="cited-content_cbyCitation_journal-name">Cancer Management and Research</span><span> <strong>2020,</strong> <em>Volume 12 </em>, 6615-6628. <a href="https://doi.org/10.2147/CMAR.S260274" title="DOI URL">https://doi.org/10.2147/CMAR.S260274</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2147/CMAR.S260274&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2147%2FCMAR.S260274%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Management%2520and%2520Research%26atitle%3D%25253Cp%25253EOptimal%252BCare%252Bfor%252BPatients%252Bwith%252BAnaplastic%252BLymphoma%252BKinase%252B%252528ALK%252529%2525E2%252580%252593Positive%252BNon%2525E2%252580%252593Small%252BCell%252BLung%252BCancer%25253A%252BA%252BReview%252Bon%252Bthe%252BRole%252Band%252BUtility%252Bof%252BALK%252BInhibitors%25253C%25252Fp%25253E%26aulast%3DSingh%26aufirst%3DAbhay%26date%3D2020%26date%3D2020%26volume%3DVolume%252012%26spage%3D6615%26epage%3D6628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bo  Li</span>, <span class="hlFld-ContribAuthor ">Min  Lu</span>, <span class="hlFld-ContribAuthor ">Lei  Jin</span>, <span class="hlFld-ContribAuthor ">Maoen  Zheng</span>, <span class="hlFld-ContribAuthor ">Peilu  Sun</span>, <span class="hlFld-ContribAuthor ">Shanshan  Lei</span>, <span class="hlFld-ContribAuthor ">Shan  Xiong</span>, <span class="hlFld-ContribAuthor ">Suhong  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Simultaneous Quantification of Brigatinib and Brigatinib-Analog in Rat Plasma and Brain Homogenate by LC-MS/MS: Application to Comparative Pharmacokinetic and Brain Distribution Studies. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Analytical Chemistry</span><span> <strong>2019,</strong> <em>2019 </em>, 1-10. <a href="https://doi.org/10.1155/2019/9028309" title="DOI URL">https://doi.org/10.1155/2019/9028309</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1155/2019/9028309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1155%2F2019%2F9028309%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Analytical%2520Chemistry%26atitle%3DSimultaneous%252BQuantification%252Bof%252BBrigatinib%252Band%252BBrigatinib-Analog%252Bin%252BRat%252BPlasma%252Band%252BBrain%252BHomogenate%252Bby%252BLC-MS%25252FMS%25253A%252BApplication%252Bto%252BComparative%252BPharmacokinetic%252Band%252BBrain%252BDistribution%252BStudies%26aulast%3DLi%26aufirst%3DBo%26date%3D2019%26volume%3D2019%26spage%3D1%26epage%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Krishna Babu  Duggirala</span>, <span class="hlFld-ContribAuthor ">Hyeonjeong  Choe</span>, <span class="hlFld-ContribAuthor ">Byeong Uk  Jeon</span>, <span class="hlFld-ContribAuthor ">Myoung Eun  Jung</span>, <span class="hlFld-ContribAuthor ">Areum  Go</span>, <span class="hlFld-ContribAuthor ">Byungho  Lim</span>, <span class="hlFld-ContribAuthor ">Chaewon  Park</span>, <span class="hlFld-ContribAuthor ">Jiyeun  Yoon</span>, <span class="hlFld-ContribAuthor ">Chong Hak  Chae</span>, <span class="hlFld-ContribAuthor ">Byoung Chul  Cho</span>, <span class="hlFld-ContribAuthor ">Gildon  Choi</span>, <span class="hlFld-ContribAuthor ">Kwangho  Lee</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of TRE‐130 as Reversible Inhibitor of Pan‐EGFR Mutants while Sparing EGFR Wild‐Type Activity. </span><span class="cited-content_cbyCitation_journal-name">Bulletin of the Korean Chemical Society</span><span> <strong>2019,</strong> <em>40 </em>
                                    (12)
                                     , 1222-1225. <a href="https://doi.org/10.1002/bkcs.11886" title="DOI URL">https://doi.org/10.1002/bkcs.11886</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/bkcs.11886&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fbkcs.11886%26sid%3Dliteratum%253Aachs%26jtitle%3DBulletin%2520of%2520the%2520Korean%2520Chemical%2520Society%26atitle%3DIdentification%252Bof%252BTRE%2525E2%252580%252590130%252Bas%252BReversible%252BInhibitor%252Bof%252BPan%2525E2%252580%252590EGFR%252BMutants%252Bwhile%252BSparing%252BEGFR%252BWild%2525E2%252580%252590Type%252BActivity%26aulast%3DDuggirala%26aufirst%3DKrishna%2BBabu%26date%3D2019%26date%3D2019%26volume%3D40%26issue%3D12%26spage%3D1222%26epage%3D1225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ruifeng  Wang</span>, <span class="hlFld-ContribAuthor ">Yixuan  Chen</span>, <span class="hlFld-ContribAuthor ">Xiangxin  Zhao</span>, <span class="hlFld-ContribAuthor ">Sijia  Yu</span>, <span class="hlFld-ContribAuthor ">Bowen  Yang</span>, <span class="hlFld-ContribAuthor ">Tianxiao  Wu</span>, <span class="hlFld-ContribAuthor ">Jing  Guo</span>, <span class="hlFld-ContribAuthor ">Chenzhou  Hao</span>, <span class="hlFld-ContribAuthor ">Dongmei  Zhao</span>, <span class="hlFld-ContribAuthor ">Maosheng  Cheng</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of novel 7H-pyrrolo[2,3-d]pyrimidine derivatives as potential FAK inhibitors and anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>183 </em>, 111716. <a href="https://doi.org/10.1016/j.ejmech.2019.111716" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111716</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111716&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111716%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252B7H-pyrrolo%25255B2%25252C3-d%25255Dpyrimidine%252Bderivatives%252Bas%252Bpotential%252BFAK%252Binhibitors%252Band%252Banticancer%252Bagents%26aulast%3DWang%26aufirst%3DRuifeng%26date%3D2019%26volume%3D183%26spage%3D111716" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wenteng  Chen</span>, <span class="hlFld-ContribAuthor ">Xiao  Guo</span>, <span class="hlFld-ContribAuthor ">Can  Zhang</span>, <span class="hlFld-ContribAuthor ">Di  Ke</span>, <span class="hlFld-ContribAuthor ">Guolin  Zhang</span>, <span class="hlFld-ContribAuthor ">Yongping  Yu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 2-aminopyridines bearing a pyridone moiety as potent ALK inhibitors to overcome the crizotinib-resistant mutants. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>183 </em>, 111734. <a href="https://doi.org/10.1016/j.ejmech.2019.111734" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111734</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111734&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111734%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B2-aminopyridines%252Bbearing%252Ba%252Bpyridone%252Bmoiety%252Bas%252Bpotent%252BALK%252Binhibitors%252Bto%252Bovercome%252Bthe%252Bcrizotinib-resistant%252Bmutants%26aulast%3DChen%26aufirst%3DWenteng%26date%3D2019%26volume%3D183%26spage%3D111734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chao  Zhang</span>, <span class="hlFld-ContribAuthor ">Natasha B.  Leighl</span>, <span class="hlFld-ContribAuthor ">Yi-Long  Wu</span>, <span class="hlFld-ContribAuthor ">Wen-Zhao  Zhong</span>. </span><span class="cited-content_cbyCitation_article-title">Emerging therapies for non-small cell lung cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Hematology & Oncology</span><span> <strong>2019,</strong> <em>12 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s13045-019-0731-8" title="DOI URL">https://doi.org/10.1186/s13045-019-0731-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s13045-019-0731-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs13045-019-0731-8%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Hematology%2520%2526%2520Oncology%26atitle%3DEmerging%252Btherapies%252Bfor%252Bnon-small%252Bcell%252Blung%252Bcancer%26aulast%3DZhang%26aufirst%3DChao%26date%3D2019%26date%3D2019%26volume%3D12%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">G.  Hamilton</span>, <span class="hlFld-ContribAuthor ">M.J.  Hochmair</span>. </span><span class="cited-content_cbyCitation_article-title">An evaluation of brigatinib as a promising treatment option for non-small cell lung cancer. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Pharmacotherapy</span><span> <strong>2019,</strong> <em>20 </em>
                                    (13)
                                     , 1551-1561. <a href="https://doi.org/10.1080/14656566.2019.1643839" title="DOI URL">https://doi.org/10.1080/14656566.2019.1643839</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14656566.2019.1643839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14656566.2019.1643839%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Pharmacotherapy%26atitle%3DAn%252Bevaluation%252Bof%252Bbrigatinib%252Bas%252Ba%252Bpromising%252Btreatment%252Boption%252Bfor%252Bnon-small%252Bcell%252Blung%252Bcancer%26aulast%3DHamilton%26aufirst%3DG.%26date%3D2019%26date%3D2019%26volume%3D20%26issue%3D13%26spage%3D1551%26epage%3D1561" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Meera  Tugnait</span>, <span class="hlFld-ContribAuthor ">Neeraj  Gupta</span>, <span class="hlFld-ContribAuthor ">Michael J.  Hanley</span>, <span class="hlFld-ContribAuthor ">Karthik  Venkatakrishnan</span>, <span class="hlFld-ContribAuthor ">Daryl  Sonnichsen</span>, <span class="hlFld-ContribAuthor ">David  Kerstein</span>, <span class="hlFld-ContribAuthor ">David J.  Dorer</span>, <span class="hlFld-ContribAuthor ">Narayana  Narasimhan</span>. </span><span class="cited-content_cbyCitation_article-title">The Effect of a High‐Fat Meal on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers. </span><span class="cited-content_cbyCitation_journal-name">Clinical Pharmacology in Drug Development</span><span> <strong>2019,</strong> <em>8 </em>
                                    (6)
                                     , 734-741. <a href="https://doi.org/10.1002/cpdd.641" title="DOI URL">https://doi.org/10.1002/cpdd.641</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cpdd.641&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcpdd.641%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Pharmacology%2520in%2520Drug%2520Development%26atitle%3DThe%252BEffect%252Bof%252Ba%252BHigh%2525E2%252580%252590Fat%252BMeal%252Bon%252Bthe%252BPharmacokinetics%252Bof%252BBrigatinib%25252C%252Ban%252BOral%252BAnaplastic%252BLymphoma%252BKinase%252BInhibitor%25252C%252Bin%252BHealthy%252BVolunteers%26aulast%3DTugnait%26aufirst%3DMeera%26date%3D2019%26date%3D2018%26volume%3D8%26issue%3D6%26spage%3D734%26epage%3D741" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">William R  Lenderking</span>, <span class="hlFld-ContribAuthor ">Huamao  Lin</span>, <span class="hlFld-ContribAuthor ">Rebecca M  Speck</span>, <span class="hlFld-ContribAuthor ">Yanyan  Zhu</span>, <span class="hlFld-ContribAuthor ">Hui  Huang</span>, <span class="hlFld-ContribAuthor ">Joice  Huang</span>, <span class="hlFld-ContribAuthor ">David  Kerstein</span>, <span class="hlFld-ContribAuthor ">Corey J  Langer</span>. </span><span class="cited-content_cbyCitation_article-title">Patient-reported outcomes and quality of life in advanced ALK+ non-small-cell lung cancer trial of brigatinib (ALTA). </span><span class="cited-content_cbyCitation_journal-name">Future Oncology</span><span> <strong>2019,</strong> <em>15 </em>
                                    (24)
                                     , 2841-2855. <a href="https://doi.org/10.2217/fon-2019-0185" title="DOI URL">https://doi.org/10.2217/fon-2019-0185</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2217/fon-2019-0185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2217%2Ffon-2019-0185%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Oncology%26atitle%3DPatient-reported%252Boutcomes%252Band%252Bquality%252Bof%252Blife%252Bin%252Badvanced%252BALK%25252B%252Bnon-small-cell%252Blung%252Bcancer%252Btrial%252Bof%252Bbrigatinib%252B%252528ALTA%252529%26aulast%3DLenderking%26aufirst%3DWilliam%2BR%26date%3D2019%26volume%3D15%26issue%3D24%26spage%3D2841%26epage%3D2855" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Debasis  Das</span>, <span class="hlFld-ContribAuthor ">Jingbing  Wang</span>, <span class="hlFld-ContribAuthor ">Yong  Li</span>, <span class="hlFld-ContribAuthor ">Jingli  Shi</span>, <span class="hlFld-ContribAuthor ">Jian  Hong</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis of orally bioavailable novel anaplastic lymphoma kinase (ALK) inhibitor diphenylaminopyrimidine analogs and efficacy study on NCI-H2228 xenografts mice model. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (12)
                                     , 1514-1517. <a href="https://doi.org/10.1016/j.bmcl.2019.04.012" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.04.012</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.04.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.04.012%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%25252C%252Bsynthesis%252Bof%252Borally%252Bbioavailable%252Bnovel%252Banaplastic%252Blymphoma%252Bkinase%252B%252528ALK%252529%252Binhibitor%252Bdiphenylaminopyrimidine%252Banalogs%252Band%252Befficacy%252Bstudy%252Bon%252BNCI-H2228%252Bxenografts%252Bmice%252Bmodel%26aulast%3DDas%26aufirst%3DDebasis%26date%3D2019%26volume%3D29%26issue%3D12%26spage%3D1514%26epage%3D1517" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hongrui  Lei</span>, <span class="hlFld-ContribAuthor ">Nan  Jiang</span>, <span class="hlFld-ContribAuthor ">Xiuqi  Miao</span>, <span class="hlFld-ContribAuthor ">Lingyun  Xing</span>, <span class="hlFld-ContribAuthor ">Ming  Guo</span>, <span class="hlFld-ContribAuthor ">Yang  Liu</span>, <span class="hlFld-ContribAuthor ">Haowen  Xu</span>, <span class="hlFld-ContribAuthor ">Ping  Gong</span>, <span class="hlFld-ContribAuthor ">Daiying  Zuo</span>, <span class="hlFld-ContribAuthor ">Xin  Zhai</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel mutant-combating ALK and ROS1 dual inhibitors bearing imidazolidin-2-one moiety with reasonable PK properties. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>171 </em>, 297-309. <a href="https://doi.org/10.1016/j.ejmech.2019.03.038" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.03.038</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.03.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.03.038%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252Bmutant-combating%252BALK%252Band%252BROS1%252Bdual%252Binhibitors%252Bbearing%252Bimidazolidin-2-one%252Bmoiety%252Bwith%252Breasonable%252BPK%252Bproperties%26aulast%3DLei%26aufirst%3DHongrui%26date%3D2019%26volume%3D171%26spage%3D297%26epage%3D309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sara A.  Spencer</span>, <span class="hlFld-ContribAuthor ">Angela C.  Riley</span>, <span class="hlFld-ContribAuthor ">Adia  Matthew</span>, <span class="hlFld-ContribAuthor ">Anthony J.  Di Pasqua</span>. </span><span class="cited-content_cbyCitation_article-title">Brigatinib: Novel ALK Inhibitor for Non–Small-Cell Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">Annals of Pharmacotherapy</span><span> <strong>2019,</strong> <em>53 </em>
                                    (6)
                                     , 621-626. <a href="https://doi.org/10.1177/1060028018824578" title="DOI URL">https://doi.org/10.1177/1060028018824578</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/1060028018824578&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F1060028018824578%26sid%3Dliteratum%253Aachs%26jtitle%3DAnnals%2520of%2520Pharmacotherapy%26atitle%3DBrigatinib%25253A%252BNovel%252BALK%252BInhibitor%252Bfor%252BNon%2525E2%252580%252593Small-Cell%252BLung%252BCancer%26aulast%3DSpencer%26aufirst%3DSara%2BA.%26date%3D2019%26date%3D2019%26volume%3D53%26issue%3D6%26spage%3D621%26epage%3D626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christoph A.  Bauer</span>, <span class="hlFld-ContribAuthor ">Gisbert  Schneider</span>, <span class="hlFld-ContribAuthor ">Andreas H.  Göller</span>. </span><span class="cited-content_cbyCitation_article-title">Gaussian Process Regression Models for the Prediction of Hydrogen Bond Acceptor Strengths. </span><span class="cited-content_cbyCitation_journal-name">Molecular Informatics</span><span> <strong>2019,</strong> <em>38 </em>
                                    (4)
                                     , 1800115. <a href="https://doi.org/10.1002/minf.201800115" title="DOI URL">https://doi.org/10.1002/minf.201800115</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/minf.201800115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fminf.201800115%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Informatics%26atitle%3DGaussian%252BProcess%252BRegression%252BModels%252Bfor%252Bthe%252BPrediction%252Bof%252BHydrogen%252BBond%252BAcceptor%252BStrengths%26aulast%3DBauer%26aufirst%3DChristoph%2BA.%26date%3D2019%26date%3D2018%26volume%3D38%26issue%3D4%26spage%3D1800115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kazuhiko  Iikubo</span>, <span class="hlFld-ContribAuthor ">Kazuo  Kurosawa</span>, <span class="hlFld-ContribAuthor ">Takahiro  Matsuya</span>, <span class="hlFld-ContribAuthor ">Yutaka  Kondoh</span>, <span class="hlFld-ContribAuthor ">Akio  Kamikawa</span>, <span class="hlFld-ContribAuthor ">Ayako  Moritomo</span>, <span class="hlFld-ContribAuthor ">Yoshinori  Iwai</span>, <span class="hlFld-ContribAuthor ">Hiroshi  Tomiyama</span>, <span class="hlFld-ContribAuthor ">Itsuro  Shimada</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and structure–activity relationships of pyrazine-2-carboxamide derivatives as novel echinoderm microtubule-associated protein-like 4 (EML4)–anaplastic lymphoma kinase (ALK) inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2019,</strong> <em>27 </em>
                                    (8)
                                     , 1683-1692. <a href="https://doi.org/10.1016/j.bmc.2019.03.018" title="DOI URL">https://doi.org/10.1016/j.bmc.2019.03.018</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2019.03.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2019.03.018%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bstructure%2525E2%252580%252593activity%252Brelationships%252Bof%252Bpyrazine-2-carboxamide%252Bderivatives%252Bas%252Bnovel%252Bechinoderm%252Bmicrotubule-associated%252Bprotein-like%252B4%252B%252528EML4%252529%2525E2%252580%252593anaplastic%252Blymphoma%252Bkinase%252B%252528ALK%252529%252Binhibitors%26aulast%3DIikubo%26aufirst%3DKazuhiko%26date%3D2019%26volume%3D27%26issue%3D8%26spage%3D1683%26epage%3D1692" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Changwei  Chen</span>, <span class="hlFld-ContribAuthor ">Peichen  Pan</span>, <span class="hlFld-ContribAuthor ">Ziyang  Deng</span>, <span class="hlFld-ContribAuthor ">Dahai  Wang</span>, <span class="hlFld-ContribAuthor ">Qifan  Wu</span>, <span class="hlFld-ContribAuthor ">Lei  Xu</span>, <span class="hlFld-ContribAuthor ">Tingjun  Hou</span>, <span class="hlFld-ContribAuthor ">Sunliang  Cui</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 3,6-diaryl-1H-pyrazolo[3,4-b]pyridines as potent anaplastic lymphoma kinase (ALK) inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (7)
                                     , 912-916. <a href="https://doi.org/10.1016/j.bmcl.2019.01.037" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.01.037</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.01.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.01.037%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252B3%25252C6-diaryl-1H-pyrazolo%25255B3%25252C4-b%25255Dpyridines%252Bas%252Bpotent%252Banaplastic%252Blymphoma%252Bkinase%252B%252528ALK%252529%252Binhibitors%26aulast%3DChen%26aufirst%3DChangwei%26date%3D2019%26volume%3D29%26issue%3D7%26spage%3D912%26epage%3D916" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rong  Wang</span>, <span class="hlFld-ContribAuthor ">Liang  Li</span>, <span class="hlFld-ContribAuthor ">Aijun  Duan</span>, <span class="hlFld-ContribAuthor ">Yi  Li</span>, <span class="hlFld-ContribAuthor ">Xiujun  Liu</span>, <span class="hlFld-ContribAuthor ">Qingfang  Miao</span>, <span class="hlFld-ContribAuthor ">Jianhua  Gong</span>, <span class="hlFld-ContribAuthor ">Yongsu  Zhen</span>. </span><span class="cited-content_cbyCitation_article-title">Crizotinib enhances anti-CD30-LDM induced antitumor efficacy in NPM-ALK positive anaplastic large cell lymphoma. </span><span class="cited-content_cbyCitation_journal-name">Cancer Letters</span><span> <strong>2019,</strong> <em>448 </em>, 84-93. <a href="https://doi.org/10.1016/j.canlet.2019.02.002" title="DOI URL">https://doi.org/10.1016/j.canlet.2019.02.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.canlet.2019.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.canlet.2019.02.002%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Letters%26atitle%3DCrizotinib%252Benhances%252Banti-CD30-LDM%252Binduced%252Bantitumor%252Befficacy%252Bin%252BNPM-ALK%252Bpositive%252Banaplastic%252Blarge%252Bcell%252Blymphoma%26aulast%3DWang%26aufirst%3DRong%26date%3D2019%26volume%3D448%26spage%3D84%26epage%3D93" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Koutaroh  Okada</span>, <span class="hlFld-ContribAuthor ">Mitsugu  Araki</span>, <span class="hlFld-ContribAuthor ">Takuya  Sakashita</span>, <span class="hlFld-ContribAuthor ">Biao  Ma</span>, <span class="hlFld-ContribAuthor ">Ryo  Kanada</span>, <span class="hlFld-ContribAuthor ">Noriko  Yanagitani</span>, <span class="hlFld-ContribAuthor ">Atsushi  Horiike</span>, <span class="hlFld-ContribAuthor ">Sumie  Koike</span>, <span class="hlFld-ContribAuthor ">Tomoko  Oh-hara</span>, <span class="hlFld-ContribAuthor ">Kana  Watanabe</span>, <span class="hlFld-ContribAuthor ">Keiichi  Tamai</span>, <span class="hlFld-ContribAuthor ">Makoto  Maemondo</span>, <span class="hlFld-ContribAuthor ">Makoto  Nishio</span>, <span class="hlFld-ContribAuthor ">Takeshi  Ishikawa</span>, <span class="hlFld-ContribAuthor ">Yasushi  Okuno</span>, <span class="hlFld-ContribAuthor ">Naoya  Fujita</span>, <span class="hlFld-ContribAuthor ">Ryohei  Katayama</span>. </span><span class="cited-content_cbyCitation_article-title">Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance. </span><span class="cited-content_cbyCitation_journal-name">EBioMedicine</span><span> <strong>2019,</strong> <em>41 </em>, 105-119. <a href="https://doi.org/10.1016/j.ebiom.2019.01.019" title="DOI URL">https://doi.org/10.1016/j.ebiom.2019.01.019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ebiom.2019.01.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ebiom.2019.01.019%26sid%3Dliteratum%253Aachs%26jtitle%3DEBioMedicine%26atitle%3DPrediction%252Bof%252BALK%252Bmutations%252Bmediating%252BALK-TKIs%252Bresistance%252Band%252Bdrug%252Bre-purposing%252Bto%252Bovercome%252Bthe%252Bresistance%26aulast%3DOkada%26aufirst%3DKoutaroh%26date%3D2019%26volume%3D41%26spage%3D105%26epage%3D119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">You-Lu  Pan</span>, <span class="hlFld-ContribAuthor ">Yan-Ling  Liu</span>, <span class="hlFld-ContribAuthor ">Jian-Zhong  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular simulation studies on the binding activity and selectivity of 3-amino-phenyl-5-chloro-pyrimidine-2, 4-diamine derivatives in complexes with kinases
              c
              -Met and ALK. </span><span class="cited-content_cbyCitation_journal-name">Molecular Simulation</span><span> <strong>2019,</strong> <em>45 </em>
                                    (1)
                                     , 1-14. <a href="https://doi.org/10.1080/08927022.2018.1515486" title="DOI URL">https://doi.org/10.1080/08927022.2018.1515486</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/08927022.2018.1515486&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F08927022.2018.1515486%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Simulation%26atitle%3DMolecular%252Bsimulation%252Bstudies%252Bon%252Bthe%252Bbinding%252Bactivity%252Band%252Bselectivity%252Bof%252B3-amino-phenyl-5-chloro-pyrimidine-2%25252C%252B4-diamine%252Bderivatives%252Bin%252Bcomplexes%252Bwith%252Bkinases%252Bc%252B-Met%252Band%252BALK%26aulast%3DPan%26aufirst%3DYou-Lu%26date%3D2019%26date%3D2018%26volume%3D45%26issue%3D1%26spage%3D1%26epage%3D14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zorawar S.  Noor</span>, <span class="hlFld-ContribAuthor ">Jonathan W.  Goldman</span>. </span><span class="cited-content_cbyCitation_article-title">EGFR Targeted Therapy. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 1-30. <a href="https://doi.org/10.1007/978-3-030-17832-1_1" title="DOI URL">https://doi.org/10.1007/978-3-030-17832-1_1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-030-17832-1_1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-030-17832-1_1%26sid%3Dliteratum%253Aachs%26atitle%3DEGFR%252BTargeted%252BTherapy%26aulast%3DNoor%26aufirst%3DZorawar%2BS.%26date%3D2019%26date%3D2019%26spage%3D1%26epage%3D30%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DTargeted%252BTherapies%252Bfor%252BLung%252BCancer%26aulast%3DSalgia%26aufirst%3DRavi%26date%3D2019%26volume%3D17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Harun M.  Patel</span>, <span class="hlFld-ContribAuthor ">Rahul  Pawara</span>, <span class="hlFld-ContribAuthor ">Sanjay J.  Surana</span>. </span><span class="cited-content_cbyCitation_article-title">Approved and Clinical Trial Third-Generation EGFR Inhibitors. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 25-43. <a href="https://doi.org/10.1016/B978-0-08-102661-8.00002-0" title="DOI URL">https://doi.org/10.1016/B978-0-08-102661-8.00002-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-08-102661-8.00002-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-08-102661-8.00002-0%26sid%3Dliteratum%253Aachs%26atitle%3DApproved%252Band%252BClinical%252BTrial%252BThird-Generation%252BEGFR%252BInhibitors%26aulast%3DPatel%26aufirst%3DHarun%2BM.%26date%3D2019%26spage%3D25%26epage%3D43%26pub%3DElsevier%26atitle%3DThird%252BGeneration%252BEGFR%252BInhibitors%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div><a href="#" data-source="/pb/widgets/cited-by?doi=10.1021%2Facs.jmedchem.6b00306&amp;widgetId=9cf770f4-a9a2-46e0-bd29-3da15bcf4ae0&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b00306%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2016.59.issue-10%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text&amp;citedByCount=155&amp;pagesCount=2&amp;pageNumber=-1" title="Load all citations" class="button_primary float-right cited-by__see-more mb-5"><i aria-hidden="”true”" class="icon-angle-double-down"></i><span>Load all citations</span></a></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.6b00306/20160520/images/medium/jm-2016-00306u_0005.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.6b00306/20160520/images/large/jm-2016-00306u_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00306&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.6b00306/20160520/images/medium/jm-2016-00306u_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.6b00306/20160520/images/large/jm-2016-00306u_0007.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of select ALK inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.6b00306/20160520/images/large/jm-2016-00306u_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00306&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.6b00306/20160520/images/medium/jm-2016-00306u_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.6b00306/20160520/images/large/jm-2016-00306u_0008.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Chemical structures of SRC inhibitor <b>6</b> and ALK inhibitors <b>10a</b>–<b>g</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.6b00306/20160520/images/large/jm-2016-00306u_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00306&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.6b00306/20160520/images/medium/jm-2016-00306u_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.6b00306/20160520/images/large/jm-2016-00306u_0009.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Homology model of <b>10f</b> bound to ALK. Dotted lines indicate hydrogen bond interactions.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.6b00306/20160520/images/large/jm-2016-00306u_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00306&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.6b00306/20160520/images/medium/jm-2016-00306u_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.6b00306/20160520/images/large/jm-2016-00306u_0010.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) X-ray crystal structure of ALK in complex with investigational brigatinib. Dotted lines indicate hydrogen bond interactions. (B) Comparison of brigatinib (pink) and compound <b>7</b> (orange) bound to wild-type ALK. Certain residues in the brigatinib–ALK complex are shown in gray; residue L1256 (green) in the <b>7</b>–ALK complex is also displayed.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.6b00306/20160520/images/large/jm-2016-00306u_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00306&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.6b00306/20160520/images/medium/jm-2016-00306u_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.6b00306/20160520/images/large/jm-2016-00306u_0011.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. <i>In vivo</i> efficacy of <b>11q</b> (brigatinib) in a H3122 NSCLC model.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.6b00306/20160520/images/large/jm-2016-00306u_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00306&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.6b00306/20160520/images/medium/jm-2016-00306u_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.6b00306/20160520/images/large/jm-2016-00306u_0012.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.6b00306/20160520/images/large/jm-2016-00306u_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00306&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) K<sub>2</sub>CO<sub>3</sub>, NaH or LiHMDS, DMF, 65 °C; (ii) for <b>11t</b> and <b>11u</b>, Pd(OAc)<sub>2</sub>, Xantphos, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 110 °C; for other inhibitors, 2.5 M HCl in EtOH, dioxane, 2-methoxyethanol, or 2-butanol.</p></p></figure><figure data-id="sch2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.6b00306/20160520/images/medium/jm-2016-00306u_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.6b00306/20160520/images/large/jm-2016-00306u_0013.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.6b00306/20160520/images/large/jm-2016-00306u_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00306&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) Pd(OAc)<sub>2</sub>, xantphos, K<sub>3</sub>PO<sub>4</sub>, DMF, 120 °C; (ii) Pd on carbon, 30 psi H<sub>2</sub>, EtOH, rt; (iii) K<sub>2</sub>CO<sub>3</sub>, MeCN, 80 °C; (iv) 2.5 M HCl in EtOH, 2-methoxyethanol, 120 °C; (v) Pd(OAc)<sub>2</sub>, PPh<sub>3</sub>, K<sub>2</sub>CO<sub>3</sub>, DMF/H<sub>2</sub>O, reflux; (vi) lithium aluminum hydride, THF, reflux.</p></p></figure><figure data-id="sch3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.6b00306/20160520/images/medium/jm-2016-00306u_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.6b00306/20160520/images/large/jm-2016-00306u_0014.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.6b00306/20160520/images/large/jm-2016-00306u_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00306&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) dimethylphosphine oxide, Pd(OAc)<sub>2</sub>, xantphos, K<sub>3</sub>PO<sub>4</sub>, DMF, 120 °C; (ii) 2,4,5-trichloropyrimidine, K<sub>2</sub>CO<sub>3</sub>, <i>n</i>-Bu<sub>4</sub>NHSO<sub>4</sub>, DMF, 65 °C; (iii) 2.5 M HCl in EtOH, 2-methoxyethanol, 120 °C; (iv) 1-methyl-4-(piperidin-4-yl)piperazine, CuI, <span class="smallcaps smallerCapital">l</span>-proline, K<sub>3</sub>PO<sub>4</sub>, DMSO, 100 °C; (v) trimethylsilylacetylene, Pd(PPh<sub>3</sub>)<sub>4</sub>, CuI, Et<sub>3</sub>N, DMF, 50 °C.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i86">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70287" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70287" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 59 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Morris, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirstein, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valentine, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dittmer, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saltman, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Look, A. T.</span><span> </span><span class="NLM_article-title">Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">263</span><span class="NLM_x">, </span> <span class="NLM_fpage">1281</span><span class="NLM_x">–</span> <span class="NLM_lpage">1284</span><span class="refDoi"> DOI: 10.1126/science.8122112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1126%2Fscience.8122112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=8122112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADyaK2cXis1aks7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=263&publication_year=1994&pages=1281-1284&author=S.+W.+Morrisauthor=M.+N.+Kirsteinauthor=M.+B.+Valentineauthor=K.+G.+Dittmerauthor=D.+N.+Shapiroauthor=D.+L.+Saltmanauthor=A.+T.+Look&title=Fusion+of+a+kinase+gene%2C+ALK%2C+to+a+nucleolar+protein+gene%2C+NPM%2C+in+non-Hodgkin%E2%80%99s+lymphoma&doi=10.1126%2Fscience.8122112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma</span></div><div class="casAuthors">Morris, Stephan, W.; Kirstein, Mark, N.; Valentine, Marcus B.; Dittmer, Kristopher G.; Shapiro, David N.; Saltman, David L.; Look, A. Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">263</span>
        (<span class="NLM_cas:issue">5151</span>),
    <span class="NLM_cas:pages">1281-4</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">The 2;5 chromosomal translocation occurs in most anaplastic large-cell non-Hodgkin's lymphomas arising from activated T lymphocytes.  This rearrangement was shown to fuse the NPM nucleolar phosphoprotein gene on chromosome 5q35 to a previously unidentified protein tyrosine kinase gene, ALK, on chromosome 2p23.  In the predicted hybrid protein, the amino terminus of nucleophosmin (NPM) is linked to the catalytic domain of anaplastic lymphoma kinase (ALK).  Expressed in the small intestine, testis, and brain but not in normal lymphoid cells, ALK shows greatest sequence similarity to the insulin receptor subfamily of kinases.  Unscheduled expression of the truncated ALK may contribute to malignant transformation in these lymphomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGox3KZnxLYaerVg90H21EOLACvtfcHk0lhgYbXI6boqNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXis1aks7Y%253D&md5=219ee9615e613be456a05f8f1ded6066</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1126%2Fscience.8122112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.8122112%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DS.%2BW.%26aulast%3DKirstein%26aufirst%3DM.%2BN.%26aulast%3DValentine%26aufirst%3DM.%2BB.%26aulast%3DDittmer%26aufirst%3DK.%2BG.%26aulast%3DShapiro%26aufirst%3DD.%2BN.%26aulast%3DSaltman%26aufirst%3DD.%2BL.%26aulast%3DLook%26aufirst%3DA.%2BT.%26atitle%3DFusion%2520of%2520a%2520kinase%2520gene%252C%2520ALK%252C%2520to%2520a%2520nucleolar%2520protein%2520gene%252C%2520NPM%252C%2520in%2520non-Hodgkin%25E2%2580%2599s%2520lymphoma%26jtitle%3DScience%26date%3D1994%26volume%3D263%26spage%3D1281%26epage%3D1284%26doi%3D10.1126%2Fscience.8122112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Chiarle, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voena, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ambrogio, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piva, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inghirami, G.</span><span> </span><span class="NLM_article-title">The anaplastic lymphoma kinase in the pathogenesis of cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">11</span><span class="NLM_x">–</span> <span class="NLM_lpage">23</span><span class="refDoi"> DOI: 10.1038/nrc2291</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1038%2Fnrc2291" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=18097461" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVKku73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=11-23&author=R.+Chiarleauthor=C.+Voenaauthor=C.+Ambrogioauthor=R.+Pivaauthor=G.+Inghirami&title=The+anaplastic+lymphoma+kinase+in+the+pathogenesis+of+cancer&doi=10.1038%2Fnrc2291"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The anaplastic lymphoma kinase in the pathogenesis of cancer</span></div><div class="casAuthors">Chiarle, Roberto; Voena, Claudia; Ambrogio, Chiara; Piva, Roberto; Inghirami, Giorgio</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-23</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The receptor tyrosine kinase anaplastic lymphoma kinase (ALK) was first identified as part of a chromosomal translocation assocd. with some anaplastic large cell lymphomas (ALCLs).  Now data are emerging that indicate that ALK might be a valid therapeutic target in ALCL and that it could also be involved in other cancers.  Tyrosine kinases are involved in the pathogenesis of most cancers.  However, few tyrosine kinases have been shown to have a well-defined pathogenetic role in lymphomas.  The anaplastic lymphoma kinase (ALK) is the oncogene of most anaplastic large cell lymphomas (ALCL), driving transformation through many mol. mechanisms.  In this review, we will analyze how translocations or deregulated expression of ALK contribute to oncogenesis and how recent genetic or pharmacol. tools, aimed at neutralizing its activity, can represent the basis for the design of powerful combination therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5HoaZPQUiUrVg90H21EOLACvtfcHk0lgVfkbtTBaUhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVKku73P&md5=a57d7ab61be51664ca9f5b804c3e2910</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrc2291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2291%26sid%3Dliteratum%253Aachs%26aulast%3DChiarle%26aufirst%3DR.%26aulast%3DVoena%26aufirst%3DC.%26aulast%3DAmbrogio%26aufirst%3DC.%26aulast%3DPiva%26aufirst%3DR.%26aulast%3DInghirami%26aufirst%3DG.%26atitle%3DThe%2520anaplastic%2520lymphoma%2520kinase%2520in%2520the%2520pathogenesis%2520of%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2008%26volume%3D8%26spage%3D11%26epage%3D23%26doi%3D10.1038%2Fnrc2291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Griffin, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawkins, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dvorak, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henkle, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellingham, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perlman, E. J.</span><span> </span><span class="NLM_article-title">Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">2776</span><span class="NLM_x">–</span> <span class="NLM_lpage">2780</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10383129" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADyaK1MXktVOktbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1999&pages=2776-2780&author=C.+A.+Griffinauthor=A.+L.+Hawkinsauthor=C.+Dvorakauthor=C.+Henkleauthor=T.+Ellinghamauthor=E.+J.+Perlman&title=Recurrent+involvement+of+2p23+in+inflammatory+myofibroblastic+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors</span></div><div class="casAuthors">Griffin, Constance A.; Hawkins, Anita L.; Dvorak, Cecily; Henkle, Carol; Ellingham, Tara; Perlman, Elizabeth J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2776-2780</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">AACR Subscription Office</span>)
        </div><div class="casAbstract">Inflammatory myofibroblastic tumor (IMT) is a relatively rare soft tissue tumor.  The reactive vs. neoplastic pathogenesis of this tumor is unresolved.  We found clonal chromosome aberrations involving 2p23 upon metaphase anal. of two IMTs.  Fluorescence in situ hybridization with a probe flanking the ALK gene at 2p23 demonstrated rearrangement of the probe in both of these cases and in a third case, and immunohistochem. revealed ALK expression in all three cases.  A 2p22-24 involvement has been reported previously in four addnl. cases of IMT.  We suggest that chromosomal rearrangements involving 2p23 near or within ALK are recurrent alterations in IMT and that ALK may have a novel role outside its previously recognized realm of lymphoid neoplasms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocvXV2ukz3crVg90H21EOLACvtfcHk0lgVfkbtTBaUhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXktVOktbk%253D&md5=8054eeaaf0cb85ee85afff461797c84c</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGriffin%26aufirst%3DC.%2BA.%26aulast%3DHawkins%26aufirst%3DA.%2BL.%26aulast%3DDvorak%26aufirst%3DC.%26aulast%3DHenkle%26aufirst%3DC.%26aulast%3DEllingham%26aufirst%3DT.%26aulast%3DPerlman%26aufirst%3DE.%2BJ.%26atitle%3DRecurrent%2520involvement%2520of%25202p23%2520in%2520inflammatory%2520myofibroblastic%2520tumors%26jtitle%3DCancer%2520Res.%26date%3D1999%26volume%3D59%26spage%3D2776%26epage%3D2780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Gascoyne, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamant, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin-Subero, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lestou, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, N. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller-Hermelink, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seymour, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horsman, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Auvigne, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Espinos, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siebert, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delsol, G.</span><span> </span><span class="NLM_article-title">ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">2568</span><span class="NLM_x">–</span> <span class="NLM_lpage">2573</span><span class="refDoi"> DOI: 10.1182/blood-2003-03-0786</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1182%2Fblood-2003-03-0786" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=12763927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnslykurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2003&pages=2568-2573&author=R.+D.+Gascoyneauthor=L.+Lamantauthor=J.+I.+Martin-Suberoauthor=V.+S.+Lestouauthor=N.+L.+Harrisauthor=H.+K.+Muller-Hermelinkauthor=J.+F.+Seymourauthor=L.+J.+Campbellauthor=D.+E.+Horsmanauthor=I.+Auvigneauthor=E.+Espinosauthor=R.+Siebertauthor=G.+Delsol&title=ALK-positive+diffuse+large+B-cell+lymphoma+is+associated+with+Clathrin-ALK+rearrangements%3A+report+of+6+cases&doi=10.1182%2Fblood-2003-03-0786"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">ALK-positive diffuse large B-cell lymphoma is associated with clathrin-ALK rearrangements: Report of 6 cases</span></div><div class="casAuthors">Gascoyne, Randy D.; Lamant, Laurence; Martin-Subero, Jose I.; Lestou, Valia S.; Harris, Nancy Lee; Mueller-Hermelink, Hans-Konrad; Seymour, John F.; Campbell, Lynda J.; Horsman, Douglas E.; Auvigne, Isabelle; Espinos, Estelle; Siebert, Reiner; Delsol, Georges</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2568-2573</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Expression of ALK protein by lymphoid cells and the description of variant anaplastic lymphoma kinase (ALK) translocations have typically been restricted to cases of T-cell and null anaplastic large-cell lymphoma (ALCL).  All such cases result from a novel fusion created by the ALK gene on chromosome 2p23 and NPM on 5q35 or other variant translocation partners.  A rare variant of diffuse large B-cell lymphoma (DLBCL), originally described in 1997, was thought to overexpress full-length ALK in contrast to a chimeric protein characteristic of ALCL.  However, full-length ALK protein lacks tyrosine kinase activity and thus the mechanism of oncogenesis has remained elusive.  We describe 6 cases of ALK+ DLBCL characterized by a simple or complex t(2;17)(p23;q23) involving the clathrin gene (CLTC) at chromosome band 17q23 and the ALK gene at chromosome band 2p23.  All cases were studied using fluorescence in situ hybridization (FISH), complemented in one case with std. cytogenetic anal., multicolor karyotyping (M-FISH), and reverse transcriptase-polymerase chain reaction.  These results clearly demonstrate that most cases of ALK+ DLBCL share the same mechanism of deregulated ALK expression.  Moreover, these results demonstrate the presence of CLTC-ALK fusions in these tumors and extend the list of diseases assocd. with this genetic abnormality to include classical T-cell or null ALCL, ALK+ DLBCL, and inflammatory myofibroblastic tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3UcmsuahiXLVg90H21EOLACvtfcHk0ljMeyOok10tJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnslykurw%253D&md5=9eedc8c22c580dbadee982b4d3da35a8</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1182%2Fblood-2003-03-0786&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2003-03-0786%26sid%3Dliteratum%253Aachs%26aulast%3DGascoyne%26aufirst%3DR.%2BD.%26aulast%3DLamant%26aufirst%3DL.%26aulast%3DMartin-Subero%26aufirst%3DJ.%2BI.%26aulast%3DLestou%26aufirst%3DV.%2BS.%26aulast%3DHarris%26aufirst%3DN.%2BL.%26aulast%3DMuller-Hermelink%26aufirst%3DH.%2BK.%26aulast%3DSeymour%26aufirst%3DJ.%2BF.%26aulast%3DCampbell%26aufirst%3DL.%2BJ.%26aulast%3DHorsman%26aufirst%3DD.%2BE.%26aulast%3DAuvigne%26aufirst%3DI.%26aulast%3DEspinos%26aufirst%3DE.%26aulast%3DSiebert%26aufirst%3DR.%26aulast%3DDelsol%26aufirst%3DG.%26atitle%3DALK-positive%2520diffuse%2520large%2520B-cell%2520lymphoma%2520is%2520associated%2520with%2520Clathrin-ALK%2520rearrangements%253A%2520report%2520of%25206%2520cases%26jtitle%3DBlood%26date%3D2003%26volume%3D102%26spage%3D2568%26epage%3D2573%26doi%3D10.1182%2Fblood-2003-03-0786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Soda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Enomoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takada, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamashita, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujiwara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurashina, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatanaka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bando, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohno, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aburatani, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sohara, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugiyama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mano, H.</span><span> </span><span class="NLM_article-title">Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">448</span><span class="NLM_x">, </span> <span class="NLM_fpage">561</span><span class="NLM_x">–</span> <span class="NLM_lpage">566</span><span class="refDoi"> DOI: 10.1038/nature05945</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1038%2Fnature05945" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=17625570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BD2sXosVSrtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=448&publication_year=2007&pages=561-566&author=M.+Sodaauthor=Y.+L.+Choiauthor=M.+Enomotoauthor=S.+Takadaauthor=Y.+Yamashitaauthor=S.+Ishikawaauthor=S.+Fujiwaraauthor=H.+Watanabeauthor=K.+Kurashinaauthor=H.+Hatanakaauthor=M.+Bandoauthor=S.+Ohnoauthor=Y.+Ishikawaauthor=H.+Aburataniauthor=T.+Nikiauthor=Y.+Soharaauthor=Y.+Sugiyamaauthor=H.+Mano&title=Identification+of+the+transforming+EML4-ALK+fusion+gene+in+non-small-cell+lung+cancer&doi=10.1038%2Fnature05945"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer</span></div><div class="casAuthors">Soda, Manabu; Choi, Young Lim; Enomoto, Munehiro; Takada, Shuji; Yamashita, Yoshihiro; Ishikawa, Shunpei; Fujiwara, Shin-ichiro; Watanabe, Hideki; Kurashina, Kentaro; Hatanaka, Hisashi; Bando, Masashi; Ohno, Shoji; Ishikawa, Yuichi; Aburatani, Hiroyuki; Niki, Toshiro; Sohara, Yasunori; Sugiyama, Yukihiko; Mano, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">448</span>
        (<span class="NLM_cas:issue">7153</span>),
    <span class="NLM_cas:pages">561-566</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Improvement in the clin. outcome of lung cancer is likely to be achieved by identification of the mol. events that underlie its pathogenesis.  Here we show that a small inversion within chromosome 2p results in the formation of a fusion gene comprising portions of the echinoderm microtubule-assocd. protein-like 4 (EML4) gene and the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer (NSCLC) cells.  Mouse 3T3 fibroblasts forced to express this human fusion tyrosine kinase generated transformed foci in culture and s.c. tumors in nude mice.  The EML4-ALK fusion transcript was detected in 6.7% (5 out of 75) of NSCLC patients examd.; these individuals were distinct from those harboring mutations in the epidermal growth factor receptor gene.  Our data demonstrate that a subset of NSCLC patients may express a transforming fusion kinase that is a promising candidate for a therapeutic target as well as for a diagnostic mol. marker in NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomhAXuLtrJ6rVg90H21EOLACvtfcHk0ljMeyOok10tJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXosVSrtrs%253D&md5=7f567e80814b9ccc87e5bceeebb467a7</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnature05945&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature05945%26sid%3Dliteratum%253Aachs%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DEnomoto%26aufirst%3DM.%26aulast%3DTakada%26aufirst%3DS.%26aulast%3DYamashita%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DS.%26aulast%3DFujiwara%26aufirst%3DS.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DKurashina%26aufirst%3DK.%26aulast%3DHatanaka%26aufirst%3DH.%26aulast%3DBando%26aufirst%3DM.%26aulast%3DOhno%26aufirst%3DS.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DAburatani%26aufirst%3DH.%26aulast%3DNiki%26aufirst%3DT.%26aulast%3DSohara%26aufirst%3DY.%26aulast%3DSugiyama%26aufirst%3DY.%26aulast%3DMano%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520the%2520transforming%2520EML4-ALK%2520fusion%2520gene%2520in%2520non-small-cell%2520lung%2520cancer%26jtitle%3DNature%26date%3D2007%26volume%3D448%26spage%3D561%26epage%3D566%26doi%3D10.1038%2Fnature05945" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Gainor, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varghese, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kabraji, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Awad, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katayama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawlak, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mino-Kenudson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeap, B. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arcila, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladanyi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dias-Santagata, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span> </span><span class="NLM_article-title">ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">4273</span><span class="NLM_x">–</span> <span class="NLM_lpage">4281</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-0318</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1158%2F1078-0432.CCR-13-0318" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=23729361" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1amt7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=4273-4281&author=J.+F.+Gainorauthor=A.+M.+Vargheseauthor=S.+H.+Ouauthor=S.+Kabrajiauthor=M.+M.+Awadauthor=R.+Katayamaauthor=A.+Pawlakauthor=M.+Mino-Kenudsonauthor=B.+Y.+Yeapauthor=G.+J.+Rielyauthor=A.+J.+Iafrateauthor=M.+E.+Arcilaauthor=M.+Ladanyiauthor=J.+A.+Engelmanauthor=D.+Dias-Santagataauthor=A.+T.+Shaw&title=ALK+rearrangements+are+mutually+exclusive+with+mutations+in+EGFR+or+KRAS%3A+an+analysis+of+1%2C683+patients+with+non-small+cell+lung+cancer&doi=10.1158%2F1078-0432.CCR-13-0318"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Gainor, Justin F.; Varghese, Anna M.; Ou, Sai-Hong Ignatius; Kabraji, Sheheryar; Awad, Mark M.; Katayama, Ryohei; Pawlak, Amanda; Mino-Kenudson, Mari; Yeap, Beow Y.; Riely, Gregory J.; Iafrate, A. John; Arcila, Maria E.; Ladanyi, Marc; Engelman, Jeffrey A.; Dias-Santagata, Dora; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4273-4281</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Anaplastic lymphoma kinase (ALK) gene rearrangements define a distinct mol. subset of non-small cell lung cancer (NSCLC).  Recently, several case reports and small series have reported that ALK rearrangements can overlap with other oncogenic drivers in NSCLC in crizotinib-naive and crizotinib-resistant cancers.  Exptl. Design: We reviewed clin. genotyping data from 1,683 patients with NSCLC and investigated the prevalence of concomitant EGFR or KRAS mutations among patients with ALK-pos. NSCLC.  We also examd. biopsy specimens from 34 patients with ALK-pos. NSCLC after the development of resistance to crizotinib.  Results: Screening identified 301 (17.8%) EGFR mutations, 465 (27.6%) KRAS mutations, and 75 (4.4%) ALK rearrangements.  EGFR mutations and ALK rearrangements were mutually exclusive.  Four patients with KRAS mutations were found to have abnormal ALK FISH patterns, most commonly involving isolated 5' green probes.  Sufficient tissue was available for confirmatory ALK immunohistochem. in 3 cases, all of which were neg. for ALK expression.  Among patients with ALK-pos. NSCLC who acquired resistance to crizotinib, repeat biopsy specimens were ALK FISH pos. in 29 of 29 (100%) cases.  Secondary mutations in the ALK kinase domain and ALK gene amplification were obsd. in 7 of 34 (20.6%) and 3 of 29 (10.3%) cases, resp.  No EGFR or KRAS mutations were identified among any of the 25 crizotinib-resistant, ALK-pos. patients with sufficient tissue for testing.  Conclusions: Functional ALK rearrangements were mutually exclusive with EGFR and KRAS mutations in a large Western patient population.  This lack of overlap was also obsd. in ALK-pos. cancers with acquired resistance to crizotinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnuDecyNaYQrVg90H21EOLACvtfcHk0ljMeyOok10tJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1amt7zI&md5=6355f3f634ef5b7ba06a497d0bf71a1a</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-0318&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-0318%26sid%3Dliteratum%253Aachs%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DVarghese%26aufirst%3DA.%2BM.%26aulast%3DOu%26aufirst%3DS.%2BH.%26aulast%3DKabraji%26aufirst%3DS.%26aulast%3DAwad%26aufirst%3DM.%2BM.%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DPawlak%26aufirst%3DA.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DYeap%26aufirst%3DB.%2BY.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DDias-Santagata%26aufirst%3DD.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DALK%2520rearrangements%2520are%2520mutually%2520exclusive%2520with%2520mutations%2520in%2520EGFR%2520or%2520KRAS%253A%2520an%2520analysis%2520of%25201%252C683%2520patients%2520with%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D4273%26epage%3D4281%26doi%3D10.1158%2F1078-0432.CCR-13-0318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Mosse, Y. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laudenslager, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Longo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Attiyeh, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laquaglia, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sennett, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laureys, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Speleman, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hakonarson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torkamani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schork, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brodeur, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonini, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rappaport, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maris, J. M.</span><span> </span><span class="NLM_article-title">Identification of ALK as a major familial neuroblastoma predisposition gene</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">455</span><span class="NLM_x">, </span> <span class="NLM_fpage">930</span><span class="NLM_x">–</span> <span class="NLM_lpage">935</span><span class="refDoi"> DOI: 10.1038/nature07261</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1038%2Fnature07261" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=18724359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Ggur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=930-935&author=Y.+P.+Mosseauthor=M.+Laudenslagerauthor=L.+Longoauthor=K.+A.+Coleauthor=A.+Woodauthor=E.+F.+Attiyehauthor=M.+J.+Laquagliaauthor=R.+Sennettauthor=J.+E.+Lynchauthor=P.+Perriauthor=G.+Laureysauthor=F.+Spelemanauthor=C.+Kimauthor=C.+Houauthor=H.+Hakonarsonauthor=A.+Torkamaniauthor=N.+J.+Schorkauthor=G.+M.+Brodeurauthor=G.+P.+Toniniauthor=E.+Rappaportauthor=M.+Devotoauthor=J.+M.+Maris&title=Identification+of+ALK+as+a+major+familial+neuroblastoma+predisposition+gene&doi=10.1038%2Fnature07261"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of ALK as a major familial neuroblastoma predisposition gene</span></div><div class="casAuthors">Mosse, Yael P.; Laudenslager, Marci; Longo, Luca; Cole, Kristina A.; Wood, Andrew; Attiyeh, Edward F.; Laquaglia, Michael J.; Sennett, Rachel; Lynch, Jill E.; Perri, Patrizia; Laureys, Genevieve; Speleman, Frank; Kim, Cecilia; Hou, Cuiping; Hakonarson, Hakon; Torkamani, Ali; Schork, Nicholas J.; Brodeur, Garrett M.; Tonini, Gian P.; Rappaport, Eric; Devoto, Marcella; Maris, John M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">455</span>
        (<span class="NLM_cas:issue">7215</span>),
    <span class="NLM_cas:pages">930-935</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Neuroblastoma is a childhood cancer that can be inherited, but the genetic etiol. is largely unknown.  Here we show that germline mutations in the anaplastic lymphoma kinase (ALK) gene explain most hereditary neuroblastomas, and that activating mutations can also be somatically acquired.  We first identified a significant linkage signal at chromosome bands 2p23-24 using a whole-genome scan in neuroblastoma pedigrees.  Re-sequencing of regional candidate genes identified three sep. germline missense mutations in the tyrosine kinase domain of ALK that segregated with the disease in eight sep. families.  Re-sequencing in 194 high-risk neuroblastoma samples showed somatically acquired mutations in the tyrosine kinase domain in 12.4% of samples.  Nine of the ten mutations map to crit. regions of the kinase domain and were predicted, with high probability, to be oncogenic drivers.  Mutations resulted in constitutive phosphorylation, and targeted knockdown of ALK mRNA resulted in profound inhibition of growth in all cell lines harboring mutant or amplified ALK, as well as in two out of six wild-type cell lines for ALK.  Our results demonstrate that heritable mutations of ALK are the main cause of familial neuroblastoma, and that germline or acquired activation of this cell-surface kinase is a tractable therapeutic target for this lethal pediatric malignancy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMNOcIFf5xjbVg90H21EOLACvtfcHk0lhr5b-cn6uOMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Ggur%252FP&md5=bb998ef8f6bfbd85f928263e13954ce4</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnature07261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07261%26sid%3Dliteratum%253Aachs%26aulast%3DMosse%26aufirst%3DY.%2BP.%26aulast%3DLaudenslager%26aufirst%3DM.%26aulast%3DLongo%26aufirst%3DL.%26aulast%3DCole%26aufirst%3DK.%2BA.%26aulast%3DWood%26aufirst%3DA.%26aulast%3DAttiyeh%26aufirst%3DE.%2BF.%26aulast%3DLaquaglia%26aufirst%3DM.%2BJ.%26aulast%3DSennett%26aufirst%3DR.%26aulast%3DLynch%26aufirst%3DJ.%2BE.%26aulast%3DPerri%26aufirst%3DP.%26aulast%3DLaureys%26aufirst%3DG.%26aulast%3DSpeleman%26aufirst%3DF.%26aulast%3DKim%26aufirst%3DC.%26aulast%3DHou%26aufirst%3DC.%26aulast%3DHakonarson%26aufirst%3DH.%26aulast%3DTorkamani%26aufirst%3DA.%26aulast%3DSchork%26aufirst%3DN.%2BJ.%26aulast%3DBrodeur%26aufirst%3DG.%2BM.%26aulast%3DTonini%26aufirst%3DG.%2BP.%26aulast%3DRappaport%26aufirst%3DE.%26aulast%3DDevoto%26aufirst%3DM.%26aulast%3DMaris%26aufirst%3DJ.%2BM.%26atitle%3DIdentification%2520of%2520ALK%2520as%2520a%2520major%2520familial%2520neuroblastoma%2520predisposition%2520gene%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D930%26epage%3D935%26doi%3D10.1038%2Fnature07261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Murugan, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xing, M.</span><span> </span><span class="NLM_article-title">Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">4403</span><span class="NLM_x">–</span> <span class="NLM_lpage">4411</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-4041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1158%2F0008-5472.CAN-10-4041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=21596819" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotlersb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=4403-4411&author=A.+K.+Muruganauthor=M.+Xing&title=Anaplastic+thyroid+cancers+harbor+novel+oncogenic+mutations+of+the+ALK+gene&doi=10.1158%2F0008-5472.CAN-10-4041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic Thyroid Cancers Harbor Novel Oncogenic Mutations of the ALK Gene</span></div><div class="casAuthors">Murugan, Avaniyapuram Kannan; Xing, Mingzhao</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4403-4411</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Thyroid cancer is the most common endocrine cancer, and targeted approaches to treat it pose considerable interest.  In this study, the authors report the discovery of ALK gene mutations in thyroid cancer that may rationalize clin. evaluation of anaplastic lymphoma kinase (ALK) inhibitors in this setting.  In undifferentiated anaplastic thyroid cancer (ATC), the authors identified 2 novel point mutations, C3592T and G3602A, in exon 23 of the ALK gene, with a prevalence of 11.11%, but found no mutations in the matched normal tissues or in well-differentiated thyroid cancers.  These 2 mutations, resulting in L1198F and G1201E amino acid changes, resp., both reside within the ALK tyrosine kinase domain where they dramatically increased tyrosine kinase activities.  Similarly, these mutations heightened the ability of ALK to activate the phosphatidylinositol 3-kinase (PI3K)/Akt and mitogen-activated protein (MAP) kinase pathways in established mouse cells.  Further investigations showed that these 2 ALK mutants strongly promoted cell focus formation, anchorage-independent growth, and cell invasion.  Similar oncogenic properties were obsd. in the neuroblastoma-assocd. ALK mutants K1062M and F1174L but not in wild-type ALK.  Overall, the authors' results reveal 2 novel gain-of-function mutations of ALK in certain ATCs, and they suggest efforts to clin. evaluate the use of ALK kinase inhibitors to treat patients who harbor ATCs with these mutations.  Cancer Res; 71(13); 4403-11.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLyuBgJ52gn7Vg90H21EOLACvtfcHk0lhr5b-cn6uOMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotlersb4%253D&md5=0316be9945baab3a8d08b6c75e2cd90f</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-4041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-4041%26sid%3Dliteratum%253Aachs%26aulast%3DMurugan%26aufirst%3DA.%2BK.%26aulast%3DXing%26aufirst%3DM.%26atitle%3DAnaplastic%2520thyroid%2520cancers%2520harbor%2520novel%2520oncogenic%2520mutations%2520of%2520the%2520ALK%2520gene%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D4403%26epage%3D4411%26doi%3D10.1158%2F0008-5472.CAN-10-4041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Ren, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, Z. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crosby, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haack, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beausoleil, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moritz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Innocenti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rush, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, X. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comb, M. J.</span><span> </span><span class="NLM_article-title">Identification of anaplastic lymphoma kinase as a potential therapeutic target in ovarian cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">3312</span><span class="NLM_x">–</span> <span class="NLM_lpage">3323</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-11-3931</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1158%2F0008-5472.CAN-11-3931" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=22570254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsFKku7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=3312-3323&author=H.+Renauthor=Z.+P.+Tanauthor=X.+Zhuauthor=K.+Crosbyauthor=H.+Haackauthor=J.+M.+Renauthor=S.+Beausoleilauthor=A.+Moritzauthor=G.+Innocentiauthor=J.+Rushauthor=Y.+Zhangauthor=X.+M.+Zhouauthor=T.+L.+Guauthor=Y.+F.+Yangauthor=M.+J.+Comb&title=Identification+of+anaplastic+lymphoma+kinase+as+a+potential+therapeutic+target+in+ovarian+cancer&doi=10.1158%2F0008-5472.CAN-11-3931"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Anaplastic Lymphoma Kinase as a Potential Therapeutic Target in Ovarian Cancer</span></div><div class="casAuthors">Ren, Hong; Tan, Zhi-Ping; Zhu, Xin; Crosby, Katherine; Haack, Herbert; Ren, Jian-Min; Beausoleil, Sean; Moritz, Albrecht; Innocenti, Gregory; Rush, John; Zhang, Yi; Zhou, Xin-Min; Gu, Ting-Lei; Yang, Yi-Feng; Comb, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3312-3323</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Findings suggest the use of ALK kinase inhibitors now in clin. development as potential agents for treatment of some patients with serous ovarian carcinoma or stromal sarcoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoi924EZXGeJ7Vg90H21EOLACvtfcHk0lhr5b-cn6uOMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsFKku7w%253D&md5=a263a135244b307b864c098769d10a7a</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-3931&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-3931%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DH.%26aulast%3DTan%26aufirst%3DZ.%2BP.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DCrosby%26aufirst%3DK.%26aulast%3DHaack%26aufirst%3DH.%26aulast%3DRen%26aufirst%3DJ.%2BM.%26aulast%3DBeausoleil%26aufirst%3DS.%26aulast%3DMoritz%26aufirst%3DA.%26aulast%3DInnocenti%26aufirst%3DG.%26aulast%3DRush%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DX.%2BM.%26aulast%3DGu%26aufirst%3DT.%2BL.%26aulast%3DYang%26aufirst%3DY.%2BF.%26aulast%3DComb%26aufirst%3DM.%2BJ.%26atitle%3DIdentification%2520of%2520anaplastic%2520lymphoma%2520kinase%2520as%2520a%2520potential%2520therapeutic%2520target%2520in%2520ovarian%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D3312%26epage%3D3323%26doi%3D10.1158%2F0008-5472.CAN-11-3931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran-Dube, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pairish, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funk, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botrous, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grodsky, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padrique, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timofeevski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mroczkowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kania, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. P.</span><span> </span><span class="NLM_article-title">Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">6342</span><span class="NLM_x">–</span> <span class="NLM_lpage">6363</span><span class="refDoi"> DOI: 10.1021/jm2007613</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2007613" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVegtLrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6342-6363&author=J.+J.+Cuiauthor=M.+Tran-Dubeauthor=H.+Shenauthor=M.+Nambuauthor=P.+P.+Kungauthor=M.+Pairishauthor=L.+Jiaauthor=J.+Mengauthor=L.+Funkauthor=I.+Botrousauthor=M.+McTigueauthor=N.+Grodskyauthor=K.+Ryanauthor=E.+Padriqueauthor=G.+Altonauthor=S.+Timofeevskiauthor=S.+Yamazakiauthor=Q.+Liauthor=H.+Zouauthor=J.+Christensenauthor=B.+Mroczkowskiauthor=S.+Benderauthor=R.+S.+Kaniaauthor=M.+P.+Edwards&title=Structure+based+drug+design+of+crizotinib+%28PF-02341066%29%2C+a+potent+and+selective+dual+inhibitor+of+mesenchymal-epithelial+transition+factor+%28c-MET%29+kinase+and+anaplastic+lymphoma+kinase+%28ALK%29&doi=10.1021%2Fjm2007613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)</span></div><div class="casAuthors">Cui, J. Jean; Tran-Dube, Michelle; Shen, Hong; Nambu, Mitchell; Kung, Pei-Pei; Pairish, Mason; Jia, Lei; Meng, Jerry; Funk, Lee; Botrous, Iriny; McTigue, Michele; Grodsky, Neil; Ryan, Kevin; Padrique, Ellen; Alton, Gordon; Timofeevski, Sergei; Yamazaki, Shinji; Li, Qiuhua; Zou, Helen; Christensen, James; Mroczkowski, Barbara; Bender, Steve; Kania, Robert S.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6342-6363</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Because of the crit. roles of aberrant signaling in cancer, both c-MET and ALK receptor tyrosine kinases are attractive oncol. targets for therapeutic intervention.  The cocrystal structure of 3 (PHA-665752), bound to c-MET kinase domain, revealed a novel ATP site environment, which served as the target to guide parallel, multiattribute drug design.  A novel 2-amino-5-aryl-3-benzyloxypyridine series was created to more effectively make the key interactions achieved with 3.  In the novel series, the 2-aminopyridine core allowed a 3-benzyloxy group to reach into the same pocket as the 2,6-dichlorophenyl group of 3 via a more direct vector and thus with a better ligand efficiency (LE).  Further optimization of the lead series generated the clin. candidate crizotinib (PF-02341066), which demonstrated potent in vitro and in vivo c-MET kinase and ALK inhibition, effective tumor growth inhibition, and good pharmaceutical properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHs_cKJ-U3t7Vg90H21EOLACvtfcHk0lg28YcjJoz_rA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVegtLrN&md5=dbab4c1b3e7c76180dbad04be2b6a474</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fjm2007613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2007613%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DTran-Dube%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DNambu%26aufirst%3DM.%26aulast%3DKung%26aufirst%3DP.%2BP.%26aulast%3DPairish%26aufirst%3DM.%26aulast%3DJia%26aufirst%3DL.%26aulast%3DMeng%26aufirst%3DJ.%26aulast%3DFunk%26aufirst%3DL.%26aulast%3DBotrous%26aufirst%3DI.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DGrodsky%26aufirst%3DN.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DPadrique%26aufirst%3DE.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DStructure%2520based%2520drug%2520design%2520of%2520crizotinib%2520%2528PF-02341066%2529%252C%2520a%2520potent%2520and%2520selective%2520dual%2520inhibitor%2520of%2520mesenchymal-epithelial%2520transition%2520factor%2520%2528c-MET%2529%2520kinase%2520and%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6342%26epage%3D6363%26doi%3D10.1021%2Fjm2007613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arango, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonnell, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koudriakova, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambu, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Los, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mroczkowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span> </span><span class="NLM_article-title">An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">4408</span><span class="NLM_x">–</span> <span class="NLM_lpage">4417</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-06-4443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1158%2F0008-5472.CAN-06-4443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=17483355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltVyrsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=4408-4417&author=H.+Y.+Zouauthor=Q.+Liauthor=J.+H.+Leeauthor=M.+E.+Arangoauthor=S.+R.+McDonnellauthor=S.+Yamazakiauthor=T.+B.+Koudriakovaauthor=G.+Altonauthor=J.+J.+Cuiauthor=P.+P.+Kungauthor=M.+D.+Nambuauthor=G.+Losauthor=S.+L.+Benderauthor=B.+Mroczkowskiauthor=J.+G.+Christensen&title=An+orally+available+small-molecule+inhibitor+of+c-Met%2C+PF-2341066%2C+exhibits+cytoreductive+antitumor+efficacy+through+antiproliferative+and+antiangiogenic+mechanisms&doi=10.1158%2F0008-5472.CAN-06-4443"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms</span></div><div class="casAuthors">Zou, Helen Y.; Li, Qiuhua; Lee, Joseph H.; Arango, Maria E.; McDonnell, Scott R.; Yamazaki, Shinji; Koudriakova, Tatiana B.; Alton, Gordon; Cui, Jingrong J.; Kung, Pei-Pei; Nambu, Mitchell D.; Los, Gerrit; Bender, Steven L.; Mroczkowski, Barbara; Christensen, James G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4408-4417</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The c-Met receptor tyrosine kinase and its ligand, hepatocyte growth factor (HGF), have been implicated in the progression of several human cancers and are attractive therapeutic targets.  PF-2341066 was identified as a potent, orally bioavailable, ATP-competitive small-mol. inhibitor of the catalytic activity of c-Met kinase.  PF-2341066 was selective for c-Met (and anaplastic lymphoma kinase) compared with a panel of >120 diverse tyrosine and serine-threonine kinases.  PF-2341066 potently inhibited c-Met phosphorylation and c-Met-dependent proliferation, migration, or invasion of human tumor cells in vitro (IC50 values, 5-20 nmol/L).  In addn., PF-2341066 potently inhibited HGF-stimulated endothelial cell survival or invasion and serum-stimulated tubulogenesis in vitro, suggesting that this agent also exhibits antiangiogenic properties.  PF-2341066 showed efficacy at well-tolerated doses, including marked cytoreductive antitumor activity, in several tumor models that expressed activated c-Met.  The antitumor efficacy of PF-2341066 was dose dependent and showed a strong correlation to inhibition of c-Met phosphorylation in vivo.  Near-maximal inhibition of c-Met activity for the full dosing interval was necessary to maximize the efficacy of PF-2341066.  Addnl. mechanism-of-action studies showed dose-dependent inhibition of c-Met-dependent signal transduction, tumor cell proliferation (Ki67), induction of apoptosis (caspase-3), and redn. of microvessel d. (CD31).  These results indicated that the antitumor activity of PF-2341066 may be mediated by direct effects on tumor cell growth or survival as well as antiangiogenic mechanisms.  Collectively, these results show the therapeutic potential of targeting c-Met with selective small-mol. inhibitors for the treatment of human cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEAWtGPOBHC7Vg90H21EOLACvtfcHk0lg28YcjJoz_rA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltVyrsbg%253D&md5=798bf93e6cf8d5e9897e27485cba9002</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-4443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-4443%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DArango%26aufirst%3DM.%2BE.%26aulast%3DMcDonnell%26aufirst%3DS.%2BR.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DKoudriakova%26aufirst%3DT.%2BB.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DKung%26aufirst%3DP.%2BP.%26aulast%3DNambu%26aufirst%3DM.%2BD.%26aulast%3DLos%26aufirst%3DG.%26aulast%3DBender%26aufirst%3DS.%2BL.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26atitle%3DAn%2520orally%2520available%2520small-molecule%2520inhibitor%2520of%2520c-Met%252C%2520PF-2341066%252C%2520exhibits%2520cytoreductive%2520antitumor%2520efficacy%2520through%2520antiproliferative%2520and%2520antiangiogenic%2520mechanisms%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D4408%26epage%3D4417%26doi%3D10.1158%2F0008-5472.CAN-06-4443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crino, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Pas, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besse, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackhall, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Byrne, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moro-Sibilot, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mok, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsh, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iyer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tassell, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span> </span><span class="NLM_article-title">Crizotinib versus chemotherapy in advanced ALK-positive lung cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">368</span><span class="NLM_x">, </span> <span class="NLM_fpage">2385</span><span class="NLM_x">–</span> <span class="NLM_lpage">2394</span><span class="refDoi"> DOI: 10.1056/NEJMoa1214886</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1056%2FNEJMoa1214886" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=23724913" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVSnu7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2013&pages=2385-2394&author=A.+T.+Shawauthor=D.+W.+Kimauthor=K.+Nakagawaauthor=T.+Setoauthor=L.+Crinoauthor=M.+J.+Ahnauthor=T.+De+Pasauthor=B.+Besseauthor=B.+J.+Solomonauthor=F.+Blackhallauthor=Y.+L.+Wuauthor=M.+Thomasauthor=K.+J.+O%E2%80%99Byrneauthor=D.+Moro-Sibilotauthor=D.+R.+Camidgeauthor=T.+Mokauthor=V.+Hirshauthor=G.+J.+Rielyauthor=S.+Iyerauthor=V.+Tassellauthor=A.+Polliauthor=K.+D.+Wilnerauthor=P.+A.+Janne&title=Crizotinib+versus+chemotherapy+in+advanced+ALK-positive+lung+cancer&doi=10.1056%2FNEJMoa1214886"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Crizotinib versus chemotherapy in advanced ALK-positive lung cancer</span></div><div class="casAuthors">Shaw, Alice T.; Kim, Dong-Wan; Nakagawa, Kazuhiko; Seto, Takashi; Crino, Lucio; Ahn, Myung-Ju; De Pas, Tommaso; Besse, Benjamin; Solomon, Benjamin J.; Blackhall, Fiona; Wu, Yi-Long; Thomas, Michael; O'Byrne, Kenneth J.; Moro-Sibilot, Denis; Camidge, D. Ross; Mok, Tony; Hirsh, Vera; Riely, Gregory J.; Iyer, Shrividya; Tassell, Vanessa; Polli, Anna; Wilner, Keith D.; Janne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">368</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2385-2394</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">In single-group studies, chromosomal rearrangements of the anaplastic lymphoma kinase gene (ALK) have been assocd. with marked clin. responses to crizotinib, an oral tyrosine kinase inhibitor targeting ALK.  Whether crizotinib is superior to std. chemotherapy with respect to efficacy is unknown.  We conducted a phase 3, open-label trial comparing crizotinib with chemotherapy in 347 patients with locally advanced or metastatic ALK-pos. lung cancer who had received one prior platinum-based regimen.  Patients were randomly assigned to receive oral treatment with crizotinib (250 mg) twice daily or i.v. chemotherapy with either pemetrexed (500 mg per square meter of body-surface area) or docetaxel (75 mg per square meter) every 3 wk.  Patients in the chemotherapy group who had disease progression were permitted to cross over to crizotinib as part of a sep. study.  The primary end point was progression-free survival.  The median progression-free survival was 7.7 mo in the crizotinib group and 3.0 mo in the chemotherapy group (hazard ratio for progression or death with crizotinib, 0.49; 95% confidence interval [CI], 0.37 to 0.64; P<0.001).  The response rates were 65% (95% CI, 58 to 72) with crizotinib, as compared with 20% (95% CI, 14 to 26) with chemotherapy (P<0.001).  An interim anal. of overall survival showed no significant improvement with crizotinib as compared with chemotherapy (hazard ratio for death in the crizotinib group, 1.02; 95% CI, 0.68 to 1.54; P = 0.54).  Common adverse events assocd. with crizotinib were visual disorder, gastrointestinal side effects, and elevated liver aminotransferase levels, whereas common adverse events with chemotherapy were fatigue, alopecia, and dyspnea.  Patients reported greater redns. in symptoms of lung cancer and greater improvement in global quality of life with crizotinib than with chemotherapy.  Crizotinib is superior to std. chemotherapy in patients with previously treated, advanced non-small-cell lung cancer with ALK rearrangement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrk62MsVCiljLVg90H21EOLACvtfcHk0lh_RL3IZw7tGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVSnu7%252FM&md5=8c6f1a73472f87fa9a19ceac6fdbb132</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1214886&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1214886%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DNakagawa%26aufirst%3DK.%26aulast%3DSeto%26aufirst%3DT.%26aulast%3DCrino%26aufirst%3DL.%26aulast%3DAhn%26aufirst%3DM.%2BJ.%26aulast%3DDe%2BPas%26aufirst%3DT.%26aulast%3DBesse%26aufirst%3DB.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DBlackhall%26aufirst%3DF.%26aulast%3DWu%26aufirst%3DY.%2BL.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Byrne%26aufirst%3DK.%2BJ.%26aulast%3DMoro-Sibilot%26aufirst%3DD.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DMok%26aufirst%3DT.%26aulast%3DHirsh%26aufirst%3DV.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DIyer%26aufirst%3DS.%26aulast%3DTassell%26aufirst%3DV.%26aulast%3DPolli%26aufirst%3DA.%26aulast%3DWilner%26aufirst%3DK.%2BD.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DCrizotinib%2520versus%2520chemotherapy%2520in%2520advanced%2520ALK-positive%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D368%26spage%3D2385%26epage%3D2394%26doi%3D10.1056%2FNEJMoa1214886" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Solomon, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mok, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mekhail, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felip, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cappuzzo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paolini, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Usari, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iyer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reisman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tursi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackhall, F.</span><span> </span><span class="NLM_article-title">First-line crizotinib versus chemotherapy in ALK-positive lung cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">371</span><span class="NLM_x">, </span> <span class="NLM_fpage">2167</span><span class="NLM_x">–</span> <span class="NLM_lpage">2177</span><span class="refDoi"> DOI: 10.1056/NEJMoa1408440</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1056%2FNEJMoa1408440" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=25470694" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1ekt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2014&pages=2167-2177&author=B.+J.+Solomonauthor=T.+Mokauthor=D.+W.+Kimauthor=Y.+L.+Wuauthor=K.+Nakagawaauthor=T.+Mekhailauthor=E.+Felipauthor=F.+Cappuzzoauthor=J.+Paoliniauthor=T.+Usariauthor=S.+Iyerauthor=A.+Reismanauthor=K.+D.+Wilnerauthor=J.+Tursiauthor=F.+Blackhall&title=First-line+crizotinib+versus+chemotherapy+in+ALK-positive+lung+cancer&doi=10.1056%2FNEJMoa1408440"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">First-line crizotinib versus chemotherapy in ALK-positive lung cancer</span></div><div class="casAuthors">Solomon, Benjamin J.; Mok, Tony; Kim, Dong-Wan; Wu, Yi-Long; Nakagawa, Kazuhiko; Mekhail, Tarek; Felip, Enriqueta; Cappuzzo, Federico; Paolini, Jolanda; Usari, Tiziana; Iyer, Shrividya; Reisman, Arlene; Wilner, Keith D.; Tursi, Jennifer; Blackhall, Fiona</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2167-2177/1-2167-2177/11, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND The efficacy of the ALK inhibitor crizotinib as compared with std. chemotherapy as first-line treatment for advanced ALK-pos. non-small-cell lung cancer (NSCLC) is unknown.  METHODS We conducted an open-label, phase 3 trial comparing crizotinib with chemotherapy in 343 patients with advanced ALK-pos. nonsquamous NSCLC who had received no previous systemic treatment for advanced disease.  Patients were randomly assigned to receive oral crizotinib at a dose of 250 mg twice daily or to receive i.v. chemotherapy (pemetrexed, 500 mg per square meter of bodysurface area, plus either cisplatin, 75 mg per square meter, or carboplatin, target area under the curve of 5 to 6 mg per mL per min) every 3 wk for up to six cycles.  Crossover to crizotinib treatment after disease progression was permitted for patients receiving chemotherapy.  The primary end point was progression-free survival as assessed by independent radiol. review.  RESULTS Progression-free survival was significantly longer with crizotinib than with chemotherapy (median, 10.9 mo vs. 7.0 mo; hazard ratio for progression or death with crizotinib, 0.45; 95% confidence interval [CI], 0.35 to 0.60; P<0.001).  Objective response rates were 74% and 45 %, resp. (P<0.001).  Median overall survival was not reached in either group (hazard ratio for death with crizotinib, 0.82; 95% CI, 0.54 to 1.26; P = 0.36); the probability of 1-yr survival was 84% with crizotinib and 79% with chemotherapy.  The most common adverse events with crizotinib were vision disorders, diarrhea, nausea, and edema, and the most common events with chemotherapy were nausea, fatigue, vomiting, and decreased appetite.  As compared with chemotherapy, crizotinib was assocd. with greater redn. in lung cancer symptoms and greater improvement in quality of life.  CONCLUSIONS Crizotinib was superior to std. first-line pemetrexed-plus-platinum chemotherapy in patients with previously untreated advanced ALK-pos. NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoV7N7XM7ywBLVg90H21EOLACvtfcHk0lh_RL3IZw7tGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1ekt74%253D&md5=afd3c75ef95aff5c0fa12b6b7e22b46a</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1408440&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1408440%26sid%3Dliteratum%253Aachs%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DMok%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DWu%26aufirst%3DY.%2BL.%26aulast%3DNakagawa%26aufirst%3DK.%26aulast%3DMekhail%26aufirst%3DT.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DCappuzzo%26aufirst%3DF.%26aulast%3DPaolini%26aufirst%3DJ.%26aulast%3DUsari%26aufirst%3DT.%26aulast%3DIyer%26aufirst%3DS.%26aulast%3DReisman%26aufirst%3DA.%26aulast%3DWilner%26aufirst%3DK.%2BD.%26aulast%3DTursi%26aufirst%3DJ.%26aulast%3DBlackhall%26aufirst%3DF.%26atitle%3DFirst-line%2520crizotinib%2520versus%2520chemotherapy%2520in%2520ALK-positive%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D371%26spage%3D2167%26epage%3D2177%26doi%3D10.1056%2FNEJMoa1408440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Steuer, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramalingam, S. S.</span><span> </span><span class="NLM_article-title">ALK-positive non-small cell lung cancer: mechanisms of resistance and emerging treatment options</span> <span class="citation_source-journal">Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">120</span><span class="NLM_x">, </span> <span class="NLM_fpage">2392</span><span class="NLM_x">–</span> <span class="NLM_lpage">2402</span><span class="refDoi"> DOI: 10.1002/cncr.28597</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1002%2Fcncr.28597" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2014&pages=2392-2402&author=C.+E.+Steuerauthor=S.+S.+Ramalingam&title=ALK-positive+non-small+cell+lung+cancer%3A+mechanisms+of+resistance+and+emerging+treatment+options&doi=10.1002%2Fcncr.28597"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1002%2Fcncr.28597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.28597%26sid%3Dliteratum%253Aachs%26aulast%3DSteuer%26aufirst%3DC.%2BE.%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26atitle%3DALK-positive%2520non-small%2520cell%2520lung%2520cancer%253A%2520mechanisms%2520of%2520resistance%2520and%2520emerging%2520treatment%2520options%26jtitle%3DCancer%26date%3D2014%26volume%3D120%26spage%3D2392%26epage%3D2402%26doi%3D10.1002%2Fcncr.28597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Toyokawa, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seto, T.</span><span> </span><span class="NLM_article-title">Updated evidence on the mechanisms of resistance to ALK inhibitors and strategies to overcome such resistance: clinical and preclinical data</span> <span class="citation_source-journal">Oncol. Res. Treat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">291</span><span class="NLM_x">–</span> <span class="NLM_lpage">298</span><span class="refDoi"> DOI: 10.1159/000430852</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1159%2F000430852" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=26045026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpvVKit7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2015&pages=291-298&author=G.+Toyokawaauthor=T.+Seto&title=Updated+evidence+on+the+mechanisms+of+resistance+to+ALK+inhibitors+and+strategies+to+overcome+such+resistance%3A+clinical+and+preclinical+data&doi=10.1159%2F000430852"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Updated Evidence on the Mechanisms of Resistance to ALK Inhibitors and Strategies to Overcome Such Resistance: Clinical and Preclinical Data</span></div><div class="casAuthors">Toyokawa, Gouji; Seto, Takashi</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Research and Treatment</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">291-298</span>CODEN:
                <span class="NLM_cas:coden">ORTNB2</span>;
        ISSN:<span class="NLM_cas:issn">2296-5270</span>.
    
            (<span class="NLM_cas:orgname">S. Karger GmbH</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase(ALK) rearrangement is one of the oncogenes in non-small cell lung cancer (NSCLC) identified in 2007.  The PROFILE trials demonstrated that patients with ALK-rearranged NSCLC can be successfully treated with crizotinib, and that crizotinib is superior to chemotherapy in both first- and second-line settings.  Furthermore, next-generation ALK inhibitors, such as alectinib and ceritinib, have been shown to harbor excellent efficacy for NSCLC patients with ALK rearrangement.  However, it is known that many cases ultimately acquire resistance to ALK inhibitors.  Some potential mechanisms of resistance to ALK inhibitors are as follows: ALK dominant resistance, such as secondary mutations and copy no. gain in the ALK gene; activation of the bypass tracks, including EGFR, KRAS, KIT, MET, and IGF-1R.  Furthermore, treatment strategies to overcome these resistance mechanisms have been proposed, and next-generation ALK inhibitors, agents which inhibit the bypass tracks, and heat shock protein 90 inhibitors are thought to be promising.  Thus, clin. and pre-clin. evidence on the resistance mechanisms to ALK inhibitors and treatment strategies to overcome the resistance have been gradually obtained.  Herein, we concisely review the current clin. and pre-clin. data regarding the mechanisms of resistance to ALK inhibitors and treatments to overcome such resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodLzrCSGMfxbVg90H21EOLACvtfcHk0lh_RL3IZw7tGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpvVKit7g%253D&md5=2cc77bae5e32bd39cee710ecfbbc205d</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1159%2F000430852&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000430852%26sid%3Dliteratum%253Aachs%26aulast%3DToyokawa%26aufirst%3DG.%26aulast%3DSeto%26aufirst%3DT.%26atitle%3DUpdated%2520evidence%2520on%2520the%2520mechanisms%2520of%2520resistance%2520to%2520ALK%2520inhibitors%2520and%2520strategies%2520to%2520overcome%2520such%2520resistance%253A%2520clinical%2520and%2520preclinical%2520data%26jtitle%3DOncol.%2520Res.%2520Treat.%26date%3D2015%26volume%3D38%26spage%3D291%26epage%3D298%26doi%3D10.1159%2F000430852" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Awad, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span> </span><span class="NLM_article-title">ALK inhibitors in non-small cell lung cancer: crizotinib and beyond</span> <span class="citation_source-journal">Clin. Adv. Hematol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">429</span><span class="NLM_x">–</span> <span class="NLM_lpage">439</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=25322323" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A280%3ADC%252BC2M3htl2qug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2014&pages=429-439&author=M.+M.+Awadauthor=A.+T.+Shaw&title=ALK+inhibitors+in+non-small+cell+lung+cancer%3A+crizotinib+and+beyond"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">ALK inhibitors in non-small cell lung cancer: crizotinib and beyond</span></div><div class="casAuthors">Awad Mark M; Shaw Alice T</div><div class="citationInfo"><span class="NLM_cas:title">Clinical advances in hematology & oncology : H&O</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">429-39</span>
        ISSN:<span class="NLM_cas:issn">1543-0790</span>.
    </div><div class="casAbstract">The treatment of patients with advanced non-small cell lung cancer (NSCLC) harboring chromosomal rearrangements of anaplastic lymphoma kinase (ALK) has been revolutionized by the development of crizotinib, a small molecule inhibitor of the tyrosine kinases ALK, ROS1, and MET.  Resistance to crizotinib invariably develops, however, through a variety of mechanisms.  In the last few years, a flurry of new and more potent ALK inhibitors has emerged for the treatment of ALK-positive NSCLC, including ceritinib (LDK378), alectinib (RO5424802/CH5424802), AP26113, ASP3026, TSR-011, PF-06463922, RXDX-101, X-396, and CEP-37440.  Cancers harboring ALK rearrangements may also be susceptible to treatment with heat shock protein 90 inhibitors.  This review focuses on the pharmacologic and clinical properties of these compounds, either as monotherapies or in combination with other drugs.  With so many ALK inhibitors in development, the challenges of how these agents should be studied and ultimately prescribed are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSTc4MrEK-FRv9pSBfyDvp7fW6udTcc2eZ445GpYsjwULntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M3htl2qug%253D%253D&md5=ae4655774258c9265a283749559ac393</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAwad%26aufirst%3DM.%2BM.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DALK%2520inhibitors%2520in%2520non-small%2520cell%2520lung%2520cancer%253A%2520crizotinib%2520and%2520beyond%26jtitle%3DClin.%2520Adv.%2520Hematol.%2520Oncol.%26date%3D2014%26volume%3D12%26spage%3D429%26epage%3D439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Marsilje, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pei, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uno, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warmuth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarkisova, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steffy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pferdekamper, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joseph, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuntland, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steensma, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chopiuk, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richmond, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groessl, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phimister, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aycinena, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bursulaya, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karanewsky, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seidel, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michellys, P. Y.</span><span> </span><span class="NLM_article-title">Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N<sup>2</sup>-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N<sup>4</sup>-(2-(isopropylsulf onyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">5675</span><span class="NLM_x">–</span> <span class="NLM_lpage">5690</span><span class="refDoi"> DOI: 10.1021/jm400402q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400402q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptVWjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=5675-5690&author=T.+H.+Marsiljeauthor=W.+Peiauthor=B.+Chenauthor=W.+Luauthor=T.+Unoauthor=Y.+Jinauthor=T.+Jiangauthor=S.+Kimauthor=N.+Liauthor=M.+Warmuthauthor=Y.+Sarkisovaauthor=F.+Sunauthor=A.+Steffyauthor=A.+C.+Pferdekamperauthor=A.+G.+Liauthor=S.+B.+Josephauthor=Y.+Kimauthor=B.+Liuauthor=T.+Tuntlandauthor=X.+Cuiauthor=N.+S.+Grayauthor=R.+Steensmaauthor=Y.+Wanauthor=J.+Jiangauthor=G.+Chopiukauthor=J.+Liauthor=W.+P.+Gordonauthor=W.+Richmondauthor=K.+Johnsonauthor=J.+Changauthor=T.+Groesslauthor=Y.+Q.+Heauthor=A.+Phimisterauthor=A.+Aycinenaauthor=C.+C.+Leeauthor=B.+Bursulayaauthor=D.+S.+Karanewskyauthor=H.+M.+Seidelauthor=J.+L.+Harrisauthor=P.+Y.+Michellys&title=Synthesis%2C+structure-activity+relationships%2C+and+in+vivo+efficacy+of+the+novel+potent+and+selective+anaplastic+lymphoma+kinase+%28ALK%29+inhibitor+5-chloro-N2-%282-isopropoxy-5-methyl-4-%28piperidin-4-yl%29phenyl%29-N4-%282-%28isopropylsulf+onyl%29phenyl%29pyrimidine-2%2C4-diamine+%28LDK378%29+currently+in+phase+1+and+phase+2+clinical+trials&doi=10.1021%2Fjm400402q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Structure-Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials</span></div><div class="casAuthors">Marsilje, Thomas H.; Pei, Wei; Chen, Bei; Lu, Wenshuo; Uno, Tetsuo; Jin, Yunho; Jiang, Tao; Kim, Sungjoon; Li, Nanxin; Warmuth, Markus; Sarkisova, Yelena; Sun, Frank; Steffy, Auzon; Pferdekamper, AnneMarie C.; Li, Allen G.; Joseph, Sean B.; Kim, Young; Liu, Bo; Tuntland, Tove; Cui, Xiaoming; Gray, Nathanael S.; Steensma, Ruo; Wan, Yongqin; Jiang, Jiqing; Chopiuk, Greg; Li, Jie; Gordon, W. Perry; Richmond, Wendy; Johnson, Kevin; Chang, Jonathan; Groessl, Todd; He, You-Qun; Phimister, Andrew; Aycinena, Alex; Lee, Christian C.; Bursulaya, Badry; Karanewsky, Donald S.; Seidel, H. Martin; Harris, Jennifer L.; Michellys, Pierre-Yves</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5675-5690</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis, preclin. profile, and in vivo efficacy in rat xenograft models of the novel and selective anaplastic lymphoma kinase inhibitor (I; LDK378) are described.  In this initial report, preliminary structure-activity relationships (SARs) are described as well as the rational design strategy employed to overcome the development deficiencies of the first generation ALK inhibitor (II; TAE684).  Compd. I is currently in phase 1 and phase 2 clin. trials with substantial antitumor activity being obsd. in ALK-pos. cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZ-y7ZuX2XLLVg90H21EOLACvtfcHk0liC447-EruckA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptVWjs7g%253D&md5=4b8f66e4acb27efe814956d7d0016068</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm400402q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400402q%26sid%3Dliteratum%253Aachs%26aulast%3DMarsilje%26aufirst%3DT.%2BH.%26aulast%3DPei%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DUno%26aufirst%3DT.%26aulast%3DJin%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DSarkisova%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DSteffy%26aufirst%3DA.%26aulast%3DPferdekamper%26aufirst%3DA.%2BC.%26aulast%3DLi%26aufirst%3DA.%2BG.%26aulast%3DJoseph%26aufirst%3DS.%2BB.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DSteensma%26aufirst%3DR.%26aulast%3DWan%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DChopiuk%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DGordon%26aufirst%3DW.%2BP.%26aulast%3DRichmond%26aufirst%3DW.%26aulast%3DJohnson%26aufirst%3DK.%26aulast%3DChang%26aufirst%3DJ.%26aulast%3DGroessl%26aufirst%3DT.%26aulast%3DHe%26aufirst%3DY.%2BQ.%26aulast%3DPhimister%26aufirst%3DA.%26aulast%3DAycinena%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DC.%2BC.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DKaranewsky%26aufirst%3DD.%2BS.%26aulast%3DSeidel%26aufirst%3DH.%2BM.%26aulast%3DHarris%26aufirst%3DJ.%2BL.%26aulast%3DMichellys%26aufirst%3DP.%2BY.%26atitle%3DSynthesis%252C%2520structure-activity%2520relationships%252C%2520and%2520in%2520vivo%2520efficacy%2520of%2520the%2520novel%2520potent%2520and%2520selective%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520inhibitor%25205-chloro-N2-%25282-isopropoxy-5-methyl-4-%2528piperidin-4-yl%2529phenyl%2529-N4-%25282-%2528isopropylsulf%2520onyl%2529phenyl%2529pyrimidine-2%252C4-diamine%2520%2528LDK378%2529%2520currently%2520in%2520phase%25201%2520and%2520phase%25202%2520clinical%2520trials%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D5675%26epage%3D5690%26doi%3D10.1021%2Fjm400402q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Friboulet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katayama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gainor, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crystal, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michellys, P. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Awad, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yanagitani, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pferdekamper, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasibhatla, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hua, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahmood, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockerman, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujita, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span> </span><span class="NLM_article-title">The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">662</span><span class="NLM_x">–</span> <span class="NLM_lpage">673</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-13-0846</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1158%2F2159-8290.CD-13-0846" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=24675041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpsVGgs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=662-673&author=L.+Fribouletauthor=N.+Liauthor=R.+Katayamaauthor=C.+C.+Leeauthor=J.+F.+Gainorauthor=A.+S.+Crystalauthor=P.+Y.+Michellysauthor=M.+M.+Awadauthor=N.+Yanagitaniauthor=S.+Kimauthor=A.+C.+Pferdekamperauthor=J.+Liauthor=S.+Kasibhatlaauthor=F.+Sunauthor=X.+Sunauthor=S.+Huaauthor=P.+McNamaraauthor=S.+Mahmoodauthor=E.+L.+Lockermanauthor=N.+Fujitaauthor=M.+Nishioauthor=J.+L.+Harrisauthor=A.+T.+Shawauthor=J.+A.+Engelman&title=The+ALK+inhibitor+ceritinib+overcomes+crizotinib+resistance+in+non-small+cell+lung+cancer&doi=10.1158%2F2159-8290.CD-13-0846"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Friboulet, Luc; Li, Nanxin; Katayama, Ryohei; Lee, Christian C.; Gainor, Justin F.; Crystal, Adam S.; Michellys, Pierre-Yves; Awad, Mark M.; Yanagitani, Noriko; Kim, Sungjoon; Pferdekamper, AnneMarie C.; Li, Jie; Kasibhatla, Shailaja; Sun, Frank; Sun, Xiuying; Hua, Su; McNamara, Peter; Mahmood, Sidra; Lockerman, Elizabeth L.; Fujita, Naoya; Nishio, Makoto; Harris, Jennifer L.; Shaw, Alice T.; Engelman, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">662-673</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Non-small cell lung cancers (NSCLC) harboring anaplastic lymphoma kinase (ALK) gene rearrangements invariably develop resistance to the ALK tyrosine kinase inhibitor (TKI) crizotinib.  Herein, we report the first preclin. evaluation of the next-generation ALK TKI, ceritinib (LDKB78), in the setting of crizotinib resistance.  An interrogation of in vitro and in vivo models of acquired resistance to crizotinib, including cell lines established from biopsies of patients with crizotinib-resistant NSCLC, revealed that ceritinib potently overcomes crizotinib-resistant mutations.  In particular, ceritinib effectively inhibits ALK harboring L1196M, G1269A, 11171T1 and S1206Y mutations, and a cocrystal structure of ceritinib bound to ALK provides structural bases for this increased potency.  However, we obsd. that ceritinib did not overcome two crizotinib-resistant ALK mutations, G1202R and F1174C, and one of these mutations was identified in 5 of 11 biopsies from patients with acquired resistance to ceritinib.  Altogether, our results demonstrate that ceritinib can overcome crizotinib resistance, consistent with clin. data showing marked efficacy of ceritinib in patients with crizotinib-resistant disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRf8PgZpJ60bVg90H21EOLACvtfcHk0lgDOetIxqeuAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpsVGgs78%253D&md5=f60c45d0debfa6e86ff10c758c95da8d</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0846&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0846%26sid%3Dliteratum%253Aachs%26aulast%3DFriboulet%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DC.%2BC.%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DCrystal%26aufirst%3DA.%2BS.%26aulast%3DMichellys%26aufirst%3DP.%2BY.%26aulast%3DAwad%26aufirst%3DM.%2BM.%26aulast%3DYanagitani%26aufirst%3DN.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DPferdekamper%26aufirst%3DA.%2BC.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DKasibhatla%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DSun%26aufirst%3DX.%26aulast%3DHua%26aufirst%3DS.%26aulast%3DMcNamara%26aufirst%3DP.%26aulast%3DMahmood%26aufirst%3DS.%26aulast%3DLockerman%26aufirst%3DE.%2BL.%26aulast%3DFujita%26aufirst%3DN.%26aulast%3DNishio%26aufirst%3DM.%26aulast%3DHarris%26aufirst%3DJ.%2BL.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520ALK%2520inhibitor%2520ceritinib%2520overcomes%2520crizotinib%2520resistance%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26spage%3D662%26epage%3D673%26doi%3D10.1158%2F2159-8290.CD-13-0846" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Kinoshita, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asoh, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furuichi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawada, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohwada, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyagi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takanashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukaguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukuda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oikawa, N.</span><span> </span><span class="NLM_article-title">Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802)</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1271</span><span class="NLM_x">–</span> <span class="NLM_lpage">1280</span><span class="refDoi"> DOI: 10.1016/j.bmc.2011.12.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1016%2Fj.bmc.2011.12.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=22225917" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFSmu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=1271-1280&author=K.+Kinoshitaauthor=K.+Asohauthor=N.+Furuichiauthor=T.+Itoauthor=H.+Kawadaauthor=S.+Haraauthor=J.+Ohwadaauthor=T.+Miyagiauthor=T.+Kobayashiauthor=K.+Takanashiauthor=T.+Tsukaguchiauthor=H.+Sakamotoauthor=T.+Tsukudaauthor=N.+Oikawa&title=Design+and+synthesis+of+a+highly+selective%2C+orally+active+and+potent+anaplastic+lymphoma+kinase+inhibitor+%28CH5424802%29&doi=10.1016%2Fj.bmc.2011.12.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802)</span></div><div class="casAuthors">Kinoshita, Kazutomo; Asoh, Kohsuke; Furuichi, Noriyuki; Ito, Toshiya; Kawada, Hatsuo; Hara, Sousuke; Ohwada, Jun; Miyagi, Takuho; Kobayashi, Takamitsu; Takanashi, Kenji; Tsukaguchi, Toshiyuki; Sakamoto, Hiroshi; Tsukuda, Takuo; Oikawa, Nobuhiro</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1271-1280</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) receptor tyrosine kinase is considered an attractive therapeutic target for human cancers, esp. non-small cell lung cancer (NSCLC).  Our previous study revealed that 8,9-side-chains of 6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazole scaffold crucially affected kinase selectivity, cellular activity, and metabolic stability.  In this work, we optimized the side-chains and identified highly selective, orally active and potent ALK inhibitor CH5424802 (18a) as the clin. candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpG6Im56-4v17Vg90H21EOLACvtfcHk0lgDOetIxqeuAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFSmu70%253D&md5=cff263d2dd8c66de9fd687530fdadb06</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2011.12.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2011.12.021%26sid%3Dliteratum%253Aachs%26aulast%3DKinoshita%26aufirst%3DK.%26aulast%3DAsoh%26aufirst%3DK.%26aulast%3DFuruichi%26aufirst%3DN.%26aulast%3DIto%26aufirst%3DT.%26aulast%3DKawada%26aufirst%3DH.%26aulast%3DHara%26aufirst%3DS.%26aulast%3DOhwada%26aufirst%3DJ.%26aulast%3DMiyagi%26aufirst%3DT.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DTakanashi%26aufirst%3DK.%26aulast%3DTsukaguchi%26aufirst%3DT.%26aulast%3DSakamoto%26aufirst%3DH.%26aulast%3DTsukuda%26aufirst%3DT.%26aulast%3DOikawa%26aufirst%3DN.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520a%2520highly%2520selective%252C%2520orally%2520active%2520and%2520potent%2520anaplastic%2520lymphoma%2520kinase%2520inhibitor%2520%2528CH5424802%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26spage%3D1271%26epage%3D1280%26doi%3D10.1016%2Fj.bmc.2011.12.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Sakamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukaguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiroshima, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kodama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukami, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oikawa, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukuda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishii, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoki, Y.</span><span> </span><span class="NLM_article-title">CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">679</span><span class="NLM_x">–</span> <span class="NLM_lpage">690</span><span class="refDoi"> DOI: 10.1016/j.ccr.2011.04.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1016%2Fj.ccr.2011.04.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=21575866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtFGlsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=679-690&author=H.+Sakamotoauthor=T.+Tsukaguchiauthor=S.+Hiroshimaauthor=T.+Kodamaauthor=T.+Kobayashiauthor=T.+A.+Fukamiauthor=N.+Oikawaauthor=T.+Tsukudaauthor=N.+Ishiiauthor=Y.+Aoki&title=CH5424802%2C+a+selective+ALK+inhibitor+capable+of+blocking+the+resistant+gatekeeper+mutant&doi=10.1016%2Fj.ccr.2011.04.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant</span></div><div class="casAuthors">Sakamoto, Hiroshi; Tsukaguchi, Toshiyuki; Hiroshima, Sayuri; Kodama, Tatsushi; Kobayashi, Takamitsu; Fukami, Takaaki A.; Oikawa, Nobuhiro; Tsukuda, Takuo; Ishii, Nobuya; Aoki, Yuko</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">679-690</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is a tyrosine kinase that is constitutively activated in certain cancers, following gene alterations such as chromosomal translocation, amplification, or point mutation.  Here, the authors identified CH5424802, a potent, selective, and orally available ALK inhibitor with a unique chem. scaffold, showing preferential antitumor activity against cancers with gene alterations of ALK, such as non-small cell lung cancer (NSCLC) cells expressing EML4-ALK fusion and anaplastic large-cell lymphoma (ALCL) cells expressing NPM-ALK fusion in vitro and in vivo.  CH5424802 inhibited ALK L1196M, which corresponds to the gatekeeper mutation conferring common resistance to kinase inhibitors, and blocked EML4-ALK L1196M-driven cell growth.  The authors' results support the potential for clin. evaluation of CH5424802 for the treatment of patients with ALK-driven tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrk3zvzF9p67Vg90H21EOLACvtfcHk0lgDOetIxqeuAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtFGlsL8%253D&md5=cae32f3a3647926ba835293b68e776f8</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2011.04.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2011.04.004%26sid%3Dliteratum%253Aachs%26aulast%3DSakamoto%26aufirst%3DH.%26aulast%3DTsukaguchi%26aufirst%3DT.%26aulast%3DHiroshima%26aufirst%3DS.%26aulast%3DKodama%26aufirst%3DT.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DFukami%26aufirst%3DT.%2BA.%26aulast%3DOikawa%26aufirst%3DN.%26aulast%3DTsukuda%26aufirst%3DT.%26aulast%3DIshii%26aufirst%3DN.%26aulast%3DAoki%26aufirst%3DY.%26atitle%3DCH5424802%252C%2520a%2520selective%2520ALK%2520inhibitor%2520capable%2520of%2520blocking%2520the%2520resistant%2520gatekeeper%2520mutant%26jtitle%3DCancer%2520Cell%26date%3D2011%26volume%3D19%26spage%3D679%26epage%3D690%26doi%3D10.1016%2Fj.ccr.2011.04.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Ou, S.-H. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsiang, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herman, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kain, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siwak-Tapp, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casey, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klempner, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span> </span><span class="NLM_article-title">Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib</span> <span class="citation_source-journal">J. Thorac. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">549</span><span class="NLM_x">–</span> <span class="NLM_lpage">553</span><span class="refDoi"> DOI: 10.1097/JTO.0000000000000094</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1097%2FJTO.0000000000000094" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=24736079" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=549-553&author=S.-H.+I.+Ouauthor=M.+Azadaauthor=D.+J.+Hsiangauthor=J.+M.+Hermanauthor=T.+S.+Kainauthor=C.+Siwak-Tappauthor=C.+Caseyauthor=J.+Heauthor=S.+M.+Aliauthor=S.+J.+Klempnerauthor=V.+A.+Miller&title=Next-generation+sequencing+reveals+a+Novel+NSCLC+ALK+F1174V+mutation+and+confirms+ALK+G1202R+mutation+confers+high-level+resistance+to+alectinib+%28CH5424802%2FRO5424802%29+in+ALK-rearranged+NSCLC+patients+who+progressed+on+crizotinib&doi=10.1097%2FJTO.0000000000000094"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1097%2FJTO.0000000000000094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJTO.0000000000000094%26sid%3Dliteratum%253Aachs%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26aulast%3DAzada%26aufirst%3DM.%26aulast%3DHsiang%26aufirst%3DD.%2BJ.%26aulast%3DHerman%26aufirst%3DJ.%2BM.%26aulast%3DKain%26aufirst%3DT.%2BS.%26aulast%3DSiwak-Tapp%26aufirst%3DC.%26aulast%3DCasey%26aufirst%3DC.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DAli%26aufirst%3DS.%2BM.%26aulast%3DKlempner%26aufirst%3DS.%2BJ.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26atitle%3DNext-generation%2520sequencing%2520reveals%2520a%2520Novel%2520NSCLC%2520ALK%2520F1174V%2520mutation%2520and%2520confirms%2520ALK%2520G1202R%2520mutation%2520confers%2520high-level%2520resistance%2520to%2520alectinib%2520%2528CH5424802%252FRO5424802%2529%2520in%2520ALK-rearranged%2520NSCLC%2520patients%2520who%2520progressed%2520on%2520crizotinib%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2014%26volume%3D9%26spage%3D549%26epage%3D553%26doi%3D10.1097%2FJTO.0000000000000094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Katayama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friboulet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koike, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockerman, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gainor, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeuchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taiji, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okuno, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujita, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span> </span><span class="NLM_article-title">Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">5686</span><span class="NLM_x">–</span> <span class="NLM_lpage">5696</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-1511</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1158%2F1078-0432.CCR-14-1511" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=25228534" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFGgs7fJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=5686-5696&author=R.+Katayamaauthor=L.+Fribouletauthor=S.+Koikeauthor=E.+L.+Lockermanauthor=T.+M.+Khanauthor=J.+F.+Gainorauthor=A.+J.+Iafrateauthor=K.+Takeuchiauthor=M.+Taijiauthor=Y.+Okunoauthor=N.+Fujitaauthor=J.+A.+Engelmanauthor=A.+T.+Shaw&title=Two+novel+ALK+mutations+mediate+acquired+resistance+to+the+next-generation+ALK+inhibitor+alectinib&doi=10.1158%2F1078-0432.CCR-14-1511"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib</span></div><div class="casAuthors">Katayama, Ryohei; Friboulet, Luc; Koike, Sumie; Lockerman, Elizabeth L.; Khan, Tahsin M.; Gainor, Justin F.; Iafrate, A. John; Takeuchi, Kengo; Taiji, Makoto; Okuno, Yasushi; Fujita, Naoya; Engelman, Jeffrey A.; Shaw, Alice T.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5686-5696</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The first-generation ALK tyrosine kinase inhibitor (TKI) crizotinib is a std. therapy for patients with ALK-rearranged non-small cell lung cancer (NSCLC).  Several next-generation ALK-TKIs have entered the clinic and have shown promising activity in crizotinib-resistant patients.  As patients still relapse even on these next-generation ALK-TKIs, we examd. mechanisms of resistance to the next-generation ALK-TKI alectinib and potential strategies to overcome this resistance.  Exptl. Design: We established a cell line model of alectinib resistance, and analyzed a resistant tumor specimen from a patient who had relapsed on alectinib.  We developed Ba/F3 models harboring alectinib-resistant ALK mutations and evaluated the potency of other next-generation ALK-TKIs in these models.  We tested the antitumor activity of the next-generation ALK-TKI ceritinib in the patient with acquired resistance to alectinib.  To elucidate structure-activity relationships of ALK mutations, we performed computational thermodn. simulation with MP-CAFEE.  Results: We identified a novel V1180L gatekeeper mutation from the cell line model and a second novel I1171T mutation from the patient who developed resistance to alectinib.  Both ALK mutations conferred resistance to alectinib as well as to crizotinib, but were sensitive to ceritinib and other next-generation ALK-TKIs.  Treatment of the patient with ceritinib led to a marked response.  Thermodn. simulation suggests that both mutations lead to distinct structural alterations that decrease the binding affinity with alectinib.  Conclusions: We have identified two novel ALK mutations arising after alectinib exposure that are sensitive to other next-generation ALK-TKIs.  The ability of ceritinib to overcome alectinib-resistance mutations suggests a potential role for sequential therapy with multiple next-generation ALK-TKIs.  Clin Cancer Res; 20(22); 5686-96. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnIA7-P96QUrVg90H21EOLACvtfcHk0lgk83vrb2HAZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFGgs7fJ&md5=b95f2f96f90fa09b48c82e0baf1b6525</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-1511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-1511%26sid%3Dliteratum%253Aachs%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DFriboulet%26aufirst%3DL.%26aulast%3DKoike%26aufirst%3DS.%26aulast%3DLockerman%26aufirst%3DE.%2BL.%26aulast%3DKhan%26aufirst%3DT.%2BM.%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DTakeuchi%26aufirst%3DK.%26aulast%3DTaiji%26aufirst%3DM.%26aulast%3DOkuno%26aufirst%3DY.%26aulast%3DFujita%26aufirst%3DN.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DTwo%2520novel%2520ALK%2520mutations%2520mediate%2520acquired%2520resistance%2520to%2520the%2520next-generation%2520ALK%2520inhibitor%2520alectinib%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D5686%26epage%3D5696%26doi%3D10.1158%2F1078-0432.CCR-14-1511" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Mori, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueno, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konagai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fushiki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimada, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondoh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saito, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shindou, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soga, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakagami, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furutani, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doihara, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kudoh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuromitsu, S.</span><span> </span><span class="NLM_article-title">The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">329</span><span class="NLM_x">–</span> <span class="NLM_lpage">340</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0395</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1158%2F1535-7163.MCT-13-0395" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=24419060" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFWmsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=329-340&author=M.+Moriauthor=Y.+Uenoauthor=S.+Konagaiauthor=H.+Fushikiauthor=I.+Shimadaauthor=Y.+Kondohauthor=R.+Saitoauthor=K.+Moriauthor=N.+Shindouauthor=T.+Sogaauthor=H.+Sakagamiauthor=T.+Furutaniauthor=H.+Doiharaauthor=M.+Kudohauthor=S.+Kuromitsu&title=The+selective+anaplastic+lymphoma+receptor+tyrosine+kinase+inhibitor+ASP3026+induces+tumor+regression+and+prolongs+survival+in+non-small+cell+lung+cancer+model+mice&doi=10.1158%2F1535-7163.MCT-13-0395"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">The Selective Anaplastic Lymphoma Receptor Tyrosine Kinase Inhibitor ASP3026 Induces Tumor Regression and Prolongs Survival in Non-Small Cell Lung Cancer Model Mice</span></div><div class="casAuthors">Mori, Masamichi; Ueno, Yoko; Konagai, Satoshi; Fushiki, Hiroshi; Shimada, Itsuro; Kondoh, Yutaka; Saito, Rika; Mori, Kenichi; Shindou, Nobuaki; Soga, Takatoshi; Sakagami, Hideki; Furutani, Takashi; Doihara, Hitoshi; Kudoh, Masafumi; Kuromitsu, Sadao</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">329-340</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Activation of anaplastic lymphoma receptor tyrosine kinase (ALK) is involved in the pathogenesis of several carcinomas, including non-small cell lung cancer (NSCLC).  Echinoderm microtubule-assocd. protein like 4 (EML4)-ALK, which is derived from the rearrangement of ALK and EML4 genes, has been validated as a therapeutic target in a subset of patients with NSCLC.  Here, we investigated the effects of ASP3026, a novel small-mol. ALK inhibitor, against ALK-driven NSCLC.  ASP3026 inhibited ALK activity in an ATP-competitive manner and had an inhibitory spectrum that differed from that of crizotinib, a dual ALK/MET inhibitor.  In mice xenografted with NCI-H2228 cells expressing EML4-ALK, orally administered ASP3026 was well absorbed in tumor tissues, reaching concns. >10-fold higher than those in plasma, and induced tumor regression with a wide therapeutic margin between efficacious and toxic doses.  In the same mouse model, ASP3026 enhanced the antitumor activities of paclitaxel and pemetrexed without affecting body wt.  ASP3026 also showed potent antitumor activities, including tumor shrinkage to a nondetectable level, in hEML4-ALK transgenic mice and prolonged survival in mice with intrapleural NCI-H2228 xenografts.  In an intrahepatic xenograft model using NCI-H2228 cells, ASP3026 induced continuous tumor regression, whereas mice treated with crizotinib showed tumor relapse after an initial response.  Finally, ASP3026 exhibited potent antitumor activity against cells expressing EML4-ALK with a mutation in the gatekeeper position (L1196M) that confers crizotinib resistance.  Taken together, these findings indicate that ASP3026 has potential efficacy for NSCLC and is expected to improve the therapeutic outcomes of patients with cancer with ALK abnormality.  Mol Cancer Ther; 13(2); 329-40. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpU-kqfwbUJrLVg90H21EOLACvtfcHk0lgk83vrb2HAZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFWmsb8%253D&md5=4d8de3814f3f8fa198f2d3acb5d3860a</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0395%26sid%3Dliteratum%253Aachs%26aulast%3DMori%26aufirst%3DM.%26aulast%3DUeno%26aufirst%3DY.%26aulast%3DKonagai%26aufirst%3DS.%26aulast%3DFushiki%26aufirst%3DH.%26aulast%3DShimada%26aufirst%3DI.%26aulast%3DKondoh%26aufirst%3DY.%26aulast%3DSaito%26aufirst%3DR.%26aulast%3DMori%26aufirst%3DK.%26aulast%3DShindou%26aufirst%3DN.%26aulast%3DSoga%26aufirst%3DT.%26aulast%3DSakagami%26aufirst%3DH.%26aulast%3DFurutani%26aufirst%3DT.%26aulast%3DDoihara%26aufirst%3DH.%26aulast%3DKudoh%26aufirst%3DM.%26aulast%3DKuromitsu%26aufirst%3DS.%26atitle%3DThe%2520selective%2520anaplastic%2520lymphoma%2520receptor%2520tyrosine%2520kinase%2520inhibitor%2520ASP3026%2520induces%2520tumor%2520regression%2520and%2520prolongs%2520survival%2520in%2520non-small%2520cell%2520lung%2520cancer%2520model%2520mice%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D329%26epage%3D340%26doi%3D10.1158%2F1535-7163.MCT-13-0395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Lovly, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Infante, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumenschein, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reckamp, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakelee, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waqar, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gockerman, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dukart, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrow, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horn, L.</span><span> </span><span class="NLM_article-title">Phase I/II trial of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor, in patients with ALK+ non-small cell lung cancer (NSCLC)</span> <span class="citation_source-journal">AACR Annu. Meet. Proc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span><span class="NLM_elocation-id">CT088</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=C.+M.+Lovlyauthor=J.+R.+Infanteauthor=G.+R.+Blumenscheinauthor=K.+Reckampauthor=H.+Wakeleeauthor=C.+A.+Carterauthor=S.+N.+Waqarauthor=J.+Nealauthor=J.+P.+Gockermanauthor=G.+Dukartauthor=K.+Harrowauthor=C.+Liangauthor=J.+J.+Gibbonsauthor=L.+Horn&title=Phase+I%2FII+trial+of+X-396%2C+a+novel+anaplastic+lymphoma+kinase+%28ALK%29+inhibitor%2C+in+patients+with+ALK%2B+non-small+cell+lung+cancer+%28NSCLC%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLovly%26aufirst%3DC.%2BM.%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26aulast%3DBlumenschein%26aufirst%3DG.%2BR.%26aulast%3DReckamp%26aufirst%3DK.%26aulast%3DWakelee%26aufirst%3DH.%26aulast%3DCarter%26aufirst%3DC.%2BA.%26aulast%3DWaqar%26aufirst%3DS.%2BN.%26aulast%3DNeal%26aufirst%3DJ.%26aulast%3DGockerman%26aufirst%3DJ.%2BP.%26aulast%3DDukart%26aufirst%3DG.%26aulast%3DHarrow%26aufirst%3DK.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DGibbons%26aufirst%3DJ.%2BJ.%26aulast%3DHorn%26aufirst%3DL.%26atitle%3DPhase%2520I%252FII%2520trial%2520of%2520X-396%252C%2520a%2520novel%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520inhibitor%252C%2520in%2520patients%2520with%2520ALK%252B%2520non-small%2520cell%2520lung%2520cancer%2520%2528NSCLC%2529%26jtitle%3DAACR%2520Annu.%2520Meet.%2520Proc.%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Jacobs, M. J.; Ott, G. R.</span><span> </span><span class="NLM_article-title">Preparation of fused bicyclic 2, 4- diaminopyrimidine derivatives as a dual ALK and FAK inhibitor</span>. PCT Int. Appl. WO 2013134353,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=M.+J.+Jacobs&author=G.+R.+Ott&title=Preparation+of+fused+bicyclic+2%2C+4-+diaminopyrimidine+derivatives+as+a+dual+ALK+and+FAK+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJacobs%26aufirst%3DM.%2BJ.%26atitle%3DPreparation%2520of%2520fused%2520bicyclic%25202%252C%25204-%2520diaminopyrimidine%2520derivatives%2520as%2520a%2520dual%2520ALK%2520and%2520FAK%2520inhibitor%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Wiess, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sachdev, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Infante, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mita, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Natale, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arkenau, H.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilcoxen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kansra, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laken, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooks, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martell, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anthony, S. P.</span><span> </span><span class="NLM_article-title">Phase (Ph) 1/2 study of TSR-011, a potent inhibitor of ALK and TRK, including crizotinib-resistant ALK mutations</span> <span class="citation_source-journal">ASCO Annu. Meet. Proc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_elocation-id">e19005</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&author=G.+J.+Wiessauthor=J.+C.+Sachdevauthor=J.+R.+Infanteauthor=M.+M.+Mitaauthor=R.+B.+Nataleauthor=H.-T.+Arkenauauthor=K.+Wilcoxenauthor=V.+Kansraauthor=H.+Lakenauthor=L.+Hughesauthor=D.+G.+Brooksauthor=R.+E.+Martellauthor=S.+P.+Anthony&title=Phase+%28Ph%29+1%2F2+study+of+TSR-011%2C+a+potent+inhibitor+of+ALK+and+TRK%2C+including+crizotinib-resistant+ALK+mutations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWiess%26aufirst%3DG.%2BJ.%26aulast%3DSachdev%26aufirst%3DJ.%2BC.%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26aulast%3DMita%26aufirst%3DM.%2BM.%26aulast%3DNatale%26aufirst%3DR.%2BB.%26aulast%3DArkenau%26aufirst%3DH.-T.%26aulast%3DWilcoxen%26aufirst%3DK.%26aulast%3DKansra%26aufirst%3DV.%26aulast%3DLaken%26aufirst%3DH.%26aulast%3DHughes%26aufirst%3DL.%26aulast%3DBrooks%26aufirst%3DD.%2BG.%26aulast%3DMartell%26aufirst%3DR.%2BE.%26aulast%3DAnthony%26aufirst%3DS.%2BP.%26atitle%3DPhase%2520%2528Ph%2529%25201%252F2%2520study%2520of%2520TSR-011%252C%2520a%2520potent%2520inhibitor%2520of%2520ALK%2520and%2520TRK%252C%2520including%2520crizotinib-resistant%2520ALK%2520mutations%26jtitle%3DASCO%2520Annu.%2520Meet.%2520Proc.%26date%3D2014%26volume%3D32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friboulet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kodack, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engstrom, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsaparikos, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timofeevski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katayama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinh, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bezwada, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frias, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lifshits, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahmood, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gainor, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Affolter, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lappin, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gukasyan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jain, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fantin, V. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smeal, T.</span><span> </span><span class="NLM_article-title">PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">70</span><span class="NLM_x">–</span> <span class="NLM_lpage">81</span><span class="refDoi"> DOI: 10.1016/j.ccell.2015.05.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1016%2Fj.ccell.2015.05.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=26144315" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFahsr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2015&pages=70-81&author=H.+Y.+Zouauthor=L.+Fribouletauthor=D.+P.+Kodackauthor=L.+D.+Engstromauthor=Q.+Liauthor=M.+Westauthor=R.+W.+Tangauthor=H.+Wangauthor=K.+Tsaparikosauthor=J.+Wangauthor=S.+Timofeevskiauthor=R.+Katayamaauthor=D.+M.+Dinhauthor=H.+Lamauthor=J.+L.+Lamauthor=S.+Yamazakiauthor=W.+Huauthor=B.+Patelauthor=D.+Bezwadaauthor=R.+L.+Friasauthor=E.+Lifshitsauthor=S.+Mahmoodauthor=J.+F.+Gainorauthor=T.+Affolterauthor=P.+B.+Lappinauthor=H.+Gukasyanauthor=N.+Leeauthor=S.+Dengauthor=R.+K.+Jainauthor=T.+W.+Johnsonauthor=A.+T.+Shawauthor=V.+R.+Fantinauthor=T.+Smeal&title=PF-06463922%2C+an+ALK%2FROS1+inhibitor%2C+overcomes+resistance+to+first+and+second+generation+ALK+inhibitors+in+preclinical+models&doi=10.1016%2Fj.ccell.2015.05.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models</span></div><div class="casAuthors">Zou, Helen Y.; Friboulet, Luc; Kodack, David P.; Engstrom, Lars D.; Li, Qiuhua; West, Melissa; Tang, Ruth W.; Wang, Hui; Tsaparikos, Konstantinos; Wang, Jinwei; Timofeevski, Sergei; Katayama, Ryohei; Dinh, Dac M.; Lam, Hieu; Lam, Justine L.; Yamazaki, Shinji; Hu, Wenyue; Patel, Bhushankumar; Bezwada, Divya; Frias, Rosa L.; Lifshits, Eugene; Mahmood, Sidra; Gainor, Justin F.; Affolter, Timothy; Lappin, Patrick B.; Gukasyan, Hovhannes; Lee, Nathan; Deng, Shibing; Jain, Rakesh K.; Johnson, Ted W.; Shaw, Alice T.; Fantin, Valeria R.; Smeal, Tod</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">70-81</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">We report the preclin. evaluation of PF-06463922, a potent and brain-penetrant ALK/ROS1 inhibitor.  Compared with other clin. available ALK inhibitors, PF-06463922 displayed superior potency against all known clin. acquired ALK mutations, including the highly resistant G1202R mutant.  Furthermore, PF-06463922 treatment led to regression of EML4-ALK-driven brain metastases, leading to prolonged mouse survival, in a superior manner.  Finally, PF-06463922 demonstrated high selectivity and safety margins in a variety of preclin. studies.  These results suggest that PF-06463922 will be highly effective for the treatment of patients with ALK-driven lung cancers, including those who relapsed on clin. available ALK inhibitors because of secondary ALK kinase domain mutations and/or brain metastases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3jseXrLwlSLVg90H21EOLACvtfcHk0ljvw6t8-CaKkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFahsr7E&md5=5bd2b7be6086f607b33b2255ad350486</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2015.05.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2015.05.010%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DFriboulet%26aufirst%3DL.%26aulast%3DKodack%26aufirst%3DD.%2BP.%26aulast%3DEngstrom%26aufirst%3DL.%2BD.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DWest%26aufirst%3DM.%26aulast%3DTang%26aufirst%3DR.%2BW.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DTsaparikos%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DDinh%26aufirst%3DD.%2BM.%26aulast%3DLam%26aufirst%3DH.%26aulast%3DLam%26aufirst%3DJ.%2BL.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DPatel%26aufirst%3DB.%26aulast%3DBezwada%26aufirst%3DD.%26aulast%3DFrias%26aufirst%3DR.%2BL.%26aulast%3DLifshits%26aufirst%3DE.%26aulast%3DMahmood%26aufirst%3DS.%26aulast%3DGainor%26aufirst%3DJ.%2BF.%26aulast%3DAffolter%26aufirst%3DT.%26aulast%3DLappin%26aufirst%3DP.%2BB.%26aulast%3DGukasyan%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DN.%26aulast%3DDeng%26aufirst%3DS.%26aulast%3DJain%26aufirst%3DR.%2BK.%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DFantin%26aufirst%3DV.%2BR.%26aulast%3DSmeal%26aufirst%3DT.%26atitle%3DPF-06463922%252C%2520an%2520ALK%252FROS1%2520inhibitor%252C%2520overcomes%2520resistance%2520to%2520first%2520and%2520second%2520generation%2520ALK%2520inhibitors%2520in%2520preclinical%2520models%26jtitle%3DCancer%2520Cell%26date%3D2015%26volume%3D28%26spage%3D70%26epage%3D81%26doi%3D10.1016%2Fj.ccell.2015.05.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Johnson, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooun, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deal, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engstrom, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kania, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kath, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lingardo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sach, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smeal, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timofeevski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. P.</span><span> </span><span class="NLM_article-title">Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(m etheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">4720</span><span class="NLM_x">–</span> <span class="NLM_lpage">4744</span><span class="refDoi"> DOI: 10.1021/jm500261q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500261q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnvVSgtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4720-4744&author=T.+W.+Johnsonauthor=P.+F.+Richardsonauthor=S.+Baileyauthor=A.+Broounauthor=B.+J.+Burkeauthor=M.+R.+Collinsauthor=J.+J.+Cuiauthor=J.+G.+Dealauthor=Y.+L.+Dengauthor=D.+Dinhauthor=L.+D.+Engstromauthor=M.+Heauthor=J.+Hoffmanauthor=R.+L.+Hoffmanauthor=Q.+Huangauthor=R.+S.+Kaniaauthor=J.+C.+Kathauthor=H.+Lamauthor=J.+L.+Lamauthor=P.+T.+Leauthor=L.+Lingardoauthor=W.+Liuauthor=M.+McTigueauthor=C.+L.+Palmerauthor=N.+W.+Sachauthor=T.+Smealauthor=G.+L.+Smithauthor=A.+E.+Stewartauthor=S.+Timofeevskiauthor=H.+Zhuauthor=J.+Zhuauthor=H.+Y.+Zouauthor=M.+P.+Edwards&title=Discovery+of+%2810R%29-7-amino-12-fluoro-2%2C10%2C16-trimethyl-15-oxo-10%2C15%2C16%2C17-tetrahydro-2H-8%2C4-%28m+etheno%29pyrazolo%5B4%2C3-h%5D%5B2%2C5%2C11%5D-benzoxadiazacyclotetradecine-3-carbonitrile+%28PF-06463922%29%2C+a+macrocyclic+inhibitor+of+anaplastic+lymphoma+kinase+%28ALK%29+and+c-ros+oncogene+1+%28ROS1%29+with+preclinical+brain+exposure+and+broad-spectrum+potency+against+ALK-resistant+mutations&doi=10.1021%2Fjm500261q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations</span></div><div class="casAuthors">Johnson, Ted W.; Richardson, Paul F.; Bailey, Simon; Brooun, Alexei; Burke, Benjamin J.; Collins, Michael R.; Cui, J. Jean; Deal, Judith G.; Deng, Ya-Li; Dinh, Dac; Engstrom, Lars D.; He, Mingying; Hoffman, Jacqui; Hoffman, Robert L.; Huang, Qinhua; Kania, Robert S.; Kath, John C.; Lam, Hieu; Lam, Justine L.; Le, Phuong T.; Lingardo, Laura; Liu, Wei; McTigue, Michele; Palmer, Cynthia L.; Sach, Neal W.; Smeal, Tod; Smith, Graham L.; Stewart, Albert E.; Timofeevski, Sergei; Zhu, Huichun; Zhu, Jinjiang; Zou, Helen Y.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4720-4744</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Although crizotinib demonstrates robust efficacy in anaplastic lymphoma kinase (ALK)-pos. non-small-cell lung carcinoma patients, progression during treatment eventually develops.  Resistant patient samples revealed a variety of point mutations in the kinase domain of ALK, including the L1196M gatekeeper mutation.  In addn., some patients progress due to cancer metastasis in the brain.  Using structure-based drug design, lipophilic efficiency, and phys.-property-based optimization, highly potent macrocyclic ALK inhibitors were prepd. with good absorption, distribution, metab., and excretion (ADME), low propensity for p-glycoprotein 1-mediated efflux, and good passive permeability.  These structurally unusual macrocyclic inhibitors were potent against wild-type ALK and clin. reported ALK kinase domain mutations.  Significant synthetic challenges were overcome, utilizing novel transformations to enable the use of these macrocycles in drug discovery paradigms.  This work led to the discovery of 8k (PF-06463922), combining broad-spectrum potency, central nervous system ADME, and a high degree of kinase selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqXkb49ad31bVg90H21EOLACvtfcHk0lhkrVXCjole6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnvVSgtL4%253D&md5=db21844f8e9a2f9ca5953bca56ad7b1c</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm500261q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500261q%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DRichardson%26aufirst%3DP.%2BF.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DBrooun%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DB.%2BJ.%26aulast%3DCollins%26aufirst%3DM.%2BR.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DDeal%26aufirst%3DJ.%2BG.%26aulast%3DDeng%26aufirst%3DY.%2BL.%26aulast%3DDinh%26aufirst%3DD.%26aulast%3DEngstrom%26aufirst%3DL.%2BD.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DHoffman%26aufirst%3DJ.%26aulast%3DHoffman%26aufirst%3DR.%2BL.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DLam%26aufirst%3DH.%26aulast%3DLam%26aufirst%3DJ.%2BL.%26aulast%3DLe%26aufirst%3DP.%2BT.%26aulast%3DLingardo%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DPalmer%26aufirst%3DC.%2BL.%26aulast%3DSach%26aufirst%3DN.%2BW.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DG.%2BL.%26aulast%3DStewart%26aufirst%3DA.%2BE.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DDiscovery%2520of%2520%252810R%2529-7-amino-12-fluoro-2%252C10%252C16-trimethyl-15-oxo-10%252C15%252C16%252C17-tetrahydro-2H-8%252C4-%2528m%2520etheno%2529pyrazolo%255B4%252C3-h%255D%255B2%252C5%252C11%255D-benzoxadiazacyclotetradecine-3-carbonitrile%2520%2528PF-06463922%2529%252C%2520a%2520macrocyclic%2520inhibitor%2520of%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520and%2520c-ros%2520oncogene%25201%2520%2528ROS1%2529%2520with%2520preclinical%2520brain%2520exposure%2520and%2520broad-spectrum%2520potency%2520against%2520ALK-resistant%2520mutations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4720%26epage%3D4744%26doi%3D10.1021%2Fjm500261q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Infarinato, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krytska, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryles, H. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sano, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szigety, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, N. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smeal, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemmon, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosse, Y. P.</span><span> </span><span class="NLM_article-title">The ALK/ROS1 inhibitor PF-06463922 overcomes primary resistance to crizotinib in ALK-driven neuroblastoma</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">96</span><span class="NLM_x">–</span> <span class="NLM_lpage">107</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-15-1056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1158%2F2159-8290.CD-15-1056" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=96-107&author=N.+R.+Infarinatoauthor=J.+H.+Parkauthor=K.+Krytskaauthor=H.+T.+Rylesauthor=R.+Sanoauthor=K.+M.+Szigetyauthor=Y.+Liauthor=H.+Y.+Zouauthor=N.+V.+Leeauthor=T.+Smealauthor=M.+A.+Lemmonauthor=Y.+P.+Mosse&title=The+ALK%2FROS1+inhibitor+PF-06463922+overcomes+primary+resistance+to+crizotinib+in+ALK-driven+neuroblastoma&doi=10.1158%2F2159-8290.CD-15-1056"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-15-1056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-15-1056%26sid%3Dliteratum%253Aachs%26aulast%3DInfarinato%26aufirst%3DN.%2BR.%26aulast%3DPark%26aufirst%3DJ.%2BH.%26aulast%3DKrytska%26aufirst%3DK.%26aulast%3DRyles%26aufirst%3DH.%2BT.%26aulast%3DSano%26aufirst%3DR.%26aulast%3DSzigety%26aufirst%3DK.%2BM.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DLee%26aufirst%3DN.%2BV.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DLemmon%26aufirst%3DM.%2BA.%26aulast%3DMosse%26aufirst%3DY.%2BP.%26atitle%3DThe%2520ALK%252FROS1%2520inhibitor%2520PF-06463922%2520overcomes%2520primary%2520resistance%2520to%2520crizotinib%2520in%2520ALK-driven%2520neuroblastoma%26jtitle%3DCancer%2520Discovery%26date%3D2016%26volume%3D6%26spage%3D96%26epage%3D107%26doi%3D10.1158%2F2159-8290.CD-15-1056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Ardini, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menichincheri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banfi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bosotti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Ponti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pulci, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballinari, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciomei, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Texido, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Degrassi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avanzi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amboldi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saccardo, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casero, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orsini, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bandiera, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mologni, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vernier, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felder, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donati, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isacchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesenti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnaghi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galvani, A.</span><span> </span><span class="NLM_article-title">Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">628</span><span class="NLM_x">–</span> <span class="NLM_lpage">639</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-15-0758</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1158%2F1535-7163.MCT-15-0758" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=26939704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsVSqtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=628-639&author=E.+Ardiniauthor=M.+Menichincheriauthor=P.+Banfiauthor=R.+Bosottiauthor=C.+De+Pontiauthor=R.+Pulciauthor=D.+Ballinariauthor=M.+Ciomeiauthor=G.+Texidoauthor=A.+Degrassiauthor=N.+Avanziauthor=N.+Amboldiauthor=M.+B.+Saccardoauthor=D.+Caseroauthor=P.+Orsiniauthor=T.+Bandieraauthor=L.+Mologniauthor=D.+Andersonauthor=G.+Weiauthor=J.+Harrisauthor=J.+M.+Vernierauthor=G.+Liauthor=E.+Felderauthor=D.+Donatiauthor=A.+Isacchiauthor=E.+Pesentiauthor=P.+Magnaghiauthor=A.+Galvani&title=Entrectinib%2C+a+Pan-TRK%2C+ROS1%2C+and+ALK+Inhibitor+with+Activity+in+Multiple+Molecularly+Defined+Cancer+Indications&doi=10.1158%2F1535-7163.MCT-15-0758"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications</span></div><div class="casAuthors">Ardini, Elena; Menichincheri, Maria; Banfi, Patrizia; Bosotti, Roberta; De Ponti, Cristina; Pulci, Romana; Ballinari, Dario; Ciomei, Marina; Texido, Gemma; Degrassi, Anna; Avanzi, Nilla; Amboldi, Nadia; Saccardo, Maria Beatrice; Casero, Daniele; Orsini, Paolo; Bandiera, Tiziano; Mologni, Luca; Anderson, David; Wei, Ge; Harris, Jason; Vernier, Jean-Michel; Li, Gang; Felder, Eduard; Donati, Daniele; Isacchi, Antonella; Pesenti, Enrico; Magnaghi, Paola; Galvani, Arturo</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">628-639</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Activated ALK and ROS1 tyrosine kinases, resulting from chromosomal rearrangements, occur in a subset of non-small cell lung cancers (NSCLC) as well as other tumor types and their oncogenic relevance as actionable targets has been demonstrated by the efficacy of selective kinase inhibitors such as crizotinib, ceritinib, and alectinib.  More recently, low-frequency rearrangements of TRK kinases have been described in NSCLC, colorectal carcinoma, glioblastoma, and Spitzoid melanoma.  Entrectinib, whose discovery and preclin. characterization are reported herein, is a novel, potent inhibitor of ALK, ROS1, and, importantly, of TRK family kinases, which shows promise for therapy of tumors bearing oncogenic forms of these proteins.  Proliferation profiling against over 200 human tumor cell lines revealed that entrectinib is exquisitely potent in vitro against lines that are dependent on the drug's pharmacol. targets.  Oral administration of entrectinib to tumor-bearing mice induced regression in relevant human xenograft tumors, including the TRKA-dependent colorectal carcinoma KM12, ROS1-driven tumors, and several ALK-dependent models of different tissue origins, including a model of brain-localized lung cancer metastasis.  Entrectinib is currently showing great promise in phase I/II clin. trials, including the first documented objective responses to a TRK inhibitor in colorectal carcinoma and in NSCLC.  The drug is, thus, potentially suited to the therapy of several molecularly defined cancer settings, esp. that of TRK-dependent tumors, for which no approved drugs are currently available.  Mol Cancer Ther; 15(4); 628-39. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOaNX-kFz2qbVg90H21EOLACvtfcHk0lhkrVXCjole6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsVSqtL4%253D&md5=dd75115cb344f0e3a6d299781043d7d6</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-15-0758&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-15-0758%26sid%3Dliteratum%253Aachs%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DMenichincheri%26aufirst%3DM.%26aulast%3DBanfi%26aufirst%3DP.%26aulast%3DBosotti%26aufirst%3DR.%26aulast%3DDe%2BPonti%26aufirst%3DC.%26aulast%3DPulci%26aufirst%3DR.%26aulast%3DBallinari%26aufirst%3DD.%26aulast%3DCiomei%26aufirst%3DM.%26aulast%3DTexido%26aufirst%3DG.%26aulast%3DDegrassi%26aufirst%3DA.%26aulast%3DAvanzi%26aufirst%3DN.%26aulast%3DAmboldi%26aufirst%3DN.%26aulast%3DSaccardo%26aufirst%3DM.%2BB.%26aulast%3DCasero%26aufirst%3DD.%26aulast%3DOrsini%26aufirst%3DP.%26aulast%3DBandiera%26aufirst%3DT.%26aulast%3DMologni%26aufirst%3DL.%26aulast%3DAnderson%26aufirst%3DD.%26aulast%3DWei%26aufirst%3DG.%26aulast%3DHarris%26aufirst%3DJ.%26aulast%3DVernier%26aufirst%3DJ.%2BM.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DFelder%26aufirst%3DE.%26aulast%3DDonati%26aufirst%3DD.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DMagnaghi%26aufirst%3DP.%26aulast%3DGalvani%26aufirst%3DA.%26atitle%3DEntrectinib%252C%2520a%2520Pan-TRK%252C%2520ROS1%252C%2520and%2520ALK%2520Inhibitor%2520with%2520Activity%2520in%2520Multiple%2520Molecularly%2520Defined%2520Cancer%2520Indications%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26spage%3D628%26epage%3D639%26doi%3D10.1158%2F1535-7163.MCT-15-0758" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Menichincheri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ardini, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnaghi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avanzi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banfi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bossi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buffa, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canevari, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ceriani, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colombo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corti, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donati, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fasolini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felder, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiorelli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiorentini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galvani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isacchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borgia, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marchionni, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nesi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orrenius, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panzeri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesenti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusconi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saccardo, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanotti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perrone, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orsini, P.</span><span> </span><span class="NLM_article-title">Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">3392</span><span class="NLM_x">–</span> <span class="NLM_lpage">3408</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00064</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00064" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BC28Xks1eitL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=3392-3408&author=M.+Menichincheriauthor=E.+Ardiniauthor=P.+Magnaghiauthor=N.+Avanziauthor=P.+Banfiauthor=R.+Bossiauthor=L.+Buffaauthor=G.+Canevariauthor=L.+Cerianiauthor=M.+Colomboauthor=L.+Cortiauthor=D.+Donatiauthor=M.+Fasoliniauthor=E.+Felderauthor=C.+Fiorelliauthor=F.+Fiorentiniauthor=A.+Galvaniauthor=A.+Isacchiauthor=A.+L.+Borgiaauthor=C.+Marchionniauthor=M.+Nesiauthor=C.+Orreniusauthor=A.+Panzeriauthor=E.+Pesentiauthor=L.+Rusconiauthor=M.+B.+Saccardoauthor=E.+Vanottiauthor=E.+Perroneauthor=P.+Orsini&title=Discovery+of+Entrectinib%3A+A+New+3-Aminoindazole+As+a+Potent+Anaplastic+Lymphoma+Kinase+%28ALK%29%2C+c-ros+Oncogene+1+Kinase+%28ROS1%29%2C+and+Pan-Tropomyosin+Receptor+Kinases+%28Pan-TRKs%29+inhibitor&doi=10.1021%2Facs.jmedchem.6b00064"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor</span></div><div class="casAuthors">Menichincheri, Maria; Ardini, Elena; Magnaghi, Paola; Avanzi, Nilla; Banfi, Patrizia; Bossi, Roberto; Buffa, Laura; Canevari, Giulia; Ceriani, Lucio; Colombo, Maristella; Corti, Luca; Donati, Daniele; Fasolini, Marina; Felder, Eduard; Fiorelli, Claudio; Fiorentini, Francesco; Galvani, Arturo; Isacchi, Antonella; Borgia, Andrea Lombardi; Marchionni, Chiara; Nesi, Marcella; Orrenius, Christian; Panzeri, Achille; Pesenti, Enrico; Rusconi, Luisa; Saccardo, Maria Beatrice; Vanotti, Ermes; Perrone, Ettore; Orsini, Paolo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3392-3408</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase responsible for the development of different tumor types.  Despite the remarkable clin. activity of crizotinib (Xalkori), the first ALK inhibitor approved in 2011, the emergence of resistance mutations and of brain metastases frequently causes relapse in patients.  Within the ALK drug discovery program, the authors identified compd. I, a novel 3-aminoindazole active on ALK in biochem. and in cellular assays.  Its optimization led to compd. II (entrectinib), a potent orally available ALK inhibitor active on ALK-dependent cell lines, efficiently penetrant the blood-brain barrier (BBB) in different animal species and highly efficacious in in vivo xenograft models.  Moreover, entrectinib resulted to be strictly potent on the closely related tyrosine kinases ROS1 and TRKs recently found constitutively activated in several tumor types.  Entrectinib is currently undergoing phase I/II clin. trial for the treatment of patients affected by ALK-, ROS1-, and TRK-pos. tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpU_xyLC5-GabVg90H21EOLACvtfcHk0liIZpNjppWnhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xks1eitL8%253D&md5=140217fba2ac81d71600f7344f2d8a3e</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00064%26sid%3Dliteratum%253Aachs%26aulast%3DMenichincheri%26aufirst%3DM.%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DMagnaghi%26aufirst%3DP.%26aulast%3DAvanzi%26aufirst%3DN.%26aulast%3DBanfi%26aufirst%3DP.%26aulast%3DBossi%26aufirst%3DR.%26aulast%3DBuffa%26aufirst%3DL.%26aulast%3DCanevari%26aufirst%3DG.%26aulast%3DCeriani%26aufirst%3DL.%26aulast%3DColombo%26aufirst%3DM.%26aulast%3DCorti%26aufirst%3DL.%26aulast%3DDonati%26aufirst%3DD.%26aulast%3DFasolini%26aufirst%3DM.%26aulast%3DFelder%26aufirst%3DE.%26aulast%3DFiorelli%26aufirst%3DC.%26aulast%3DFiorentini%26aufirst%3DF.%26aulast%3DGalvani%26aufirst%3DA.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DBorgia%26aufirst%3DA.%2BL.%26aulast%3DMarchionni%26aufirst%3DC.%26aulast%3DNesi%26aufirst%3DM.%26aulast%3DOrrenius%26aufirst%3DC.%26aulast%3DPanzeri%26aufirst%3DA.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DRusconi%26aufirst%3DL.%26aulast%3DSaccardo%26aufirst%3DM.%2BB.%26aulast%3DVanotti%26aufirst%3DE.%26aulast%3DPerrone%26aufirst%3DE.%26aulast%3DOrsini%26aufirst%3DP.%26atitle%3DDiscovery%2520of%2520Entrectinib%253A%2520A%2520New%25203-Aminoindazole%2520As%2520a%2520Potent%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%252C%2520c-ros%2520Oncogene%25201%2520Kinase%2520%2528ROS1%2529%252C%2520and%2520Pan-Tropomyosin%2520Receptor%2520Kinases%2520%2528Pan-TRKs%2529%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D3392%26epage%3D3408%26doi%3D10.1021%2Facs.jmedchem.6b00064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Song, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, A.</span><span> </span><span class="NLM_article-title">Discovery of novel 2,4-diarylaminopyrimidine analogues (DAAPalogues) showing potent inhibitory activities against both wild-type and mutant ALK kinases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">197</span><span class="NLM_x">–</span> <span class="NLM_lpage">211</span><span class="refDoi"> DOI: 10.1021/jm5005144</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5005144" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=197-211&author=Z.+Songauthor=Y.+Yangauthor=Z.+Liuauthor=X.+Pengauthor=J.+Guoauthor=X.+Yangauthor=K.+Wuauthor=J.+Aiauthor=J.+Dingauthor=M.+Gengauthor=A.+Zhang&title=Discovery+of+novel+2%2C4-diarylaminopyrimidine+analogues+%28DAAPalogues%29+showing+potent+inhibitory+activities+against+both+wild-type+and+mutant+ALK+kinases&doi=10.1021%2Fjm5005144"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm5005144&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5005144%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DPeng%26aufirst%3DX.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DK.%26aulast%3DAi%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520novel%25202%252C4-diarylaminopyrimidine%2520analogues%2520%2528DAAPalogues%2529%2520showing%2520potent%2520inhibitory%2520activities%2520against%2520both%2520wild-type%2520and%2520mutant%2520ALK%2520kinases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D197%26epage%3D211%26doi%3D10.1021%2Fjm5005144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Liu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, A.</span><span> </span><span class="NLM_article-title">Novel 2,4-diarylaminopyrimidine analogues (DAAPalogues) showing potent c-Met/ALK multikinase inhibitory activities</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">304</span><span class="NLM_x">–</span> <span class="NLM_lpage">308</span><span class="refDoi"> DOI: 10.1021/ml400373j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml400373j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=304-308&author=Z.+Liuauthor=J.+Aiauthor=X.+Pengauthor=Z.+Songauthor=K.+Wuauthor=J.+Zhangauthor=Q.+Yaoauthor=Y.+Chenauthor=Y.+Jiauthor=Y.+Yangauthor=M.+Gengauthor=A.+Zhang&title=Novel+2%2C4-diarylaminopyrimidine+analogues+%28DAAPalogues%29+showing+potent+c-Met%2FALK+multikinase+inhibitory+activities&doi=10.1021%2Fml400373j"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fml400373j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml400373j%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DAi%26aufirst%3DJ.%26aulast%3DPeng%26aufirst%3DX.%26aulast%3DSong%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYao%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DJi%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DA.%26atitle%3DNovel%25202%252C4-diarylaminopyrimidine%2520analogues%2520%2528DAAPalogues%2529%2520showing%2520potent%2520c-Met%252FALK%2520multikinase%2520inhibitory%2520activities%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26spage%3D304%26epage%3D308%26doi%3D10.1021%2Fml400373j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Lewis, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bode, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choquette, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potashman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stellwagen, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teffera, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittington, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Epstein, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emkey, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrews, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saffran, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drew, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merkel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szilvassy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brake, R. L.</span><span> </span><span class="NLM_article-title">The discovery and optimization of a novel class of potent, selective, and orally bioavailable anaplastic lymphoma kinase (ALK) inhibitors with potential utility for the treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">6523</span><span class="NLM_x">–</span> <span class="NLM_lpage">6540</span><span class="refDoi"> DOI: 10.1021/jm3005866</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3005866" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BC38XptF2hsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6523-6540&author=R.+T.+Lewisauthor=C.+M.+Bodeauthor=D.+M.+Choquetteauthor=M.+Potashmanauthor=K.+Romeroauthor=J.+C.+Stellwagenauthor=Y.+Tefferaauthor=E.+Mooreauthor=D.+A.+Whittingtonauthor=H.+Chenauthor=L.+F.+Epsteinauthor=R.+Emkeyauthor=P.+S.+Andrewsauthor=V.+L.+Yuauthor=D.+C.+Saffranauthor=M.+Xuauthor=A.+Drewauthor=P.+Merkelauthor=S.+Szilvassyauthor=R.+L.+Brake&title=The+discovery+and+optimization+of+a+novel+class+of+potent%2C+selective%2C+and+orally+bioavailable+anaplastic+lymphoma+kinase+%28ALK%29+inhibitors+with+potential+utility+for+the+treatment+of+cancer&doi=10.1021%2Fjm3005866"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">The Discovery and Optimization of a Novel Class of Potent, Selective, and Orally Bioavailable Anaplastic Lymphoma Kinase (ALK) Inhibitors with Potential Utility for the Treatment of Cancer</span></div><div class="casAuthors">Lewis, Richard T.; Bode, Christiane M.; Choquette, Deborah M.; Potashman, Michele; Romero, Karina; Stellwagen, John C.; Teffera, Yohannes; Moore, Earl; Whittington, Douglas A.; Chen, Hao; Epstein, Linda F.; Emkey, Renee; Andrews, Paul S.; Yu, Violeta L.; Saffran, Douglas C.; Xu, Man; Drew, Allison; Merkel, Patricia; Szilvassy, Steven; Brake, Rachael L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6523-6540</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A class of 2-acyliminobenzimidazoles has been developed as potent and selective inhibitors of anaplastic lymphoma kinase (ALK).  Structure based design facilitated the rapid development of structure-activity relationships (SAR) and the optimization of kinase selectivity.  Introduction of an optimally placed polar substituent was key to solving issues of metabolic stability and led to the development of potent, selective, orally bioavailable ALK inhibitors.  Compd. I [Ar = 3,5-F2Ph] achieved substantial tumor regression in an NPM-ALK driven murine tumor xenograft model when dosed qd.  Compd. I [Ar = 3,5-F2Ph, 4-FPh] show favorable potency and PK characteristics in preclin. species indicative of suitability for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDAwmBMVhyL7Vg90H21EOLACvtfcHk0lhIqaVphP7SUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XptF2hsbo%253D&md5=a3c2f9e8dbf7d73319657e456bd45076</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjm3005866&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3005866%26sid%3Dliteratum%253Aachs%26aulast%3DLewis%26aufirst%3DR.%2BT.%26aulast%3DBode%26aufirst%3DC.%2BM.%26aulast%3DChoquette%26aufirst%3DD.%2BM.%26aulast%3DPotashman%26aufirst%3DM.%26aulast%3DRomero%26aufirst%3DK.%26aulast%3DStellwagen%26aufirst%3DJ.%2BC.%26aulast%3DTeffera%26aufirst%3DY.%26aulast%3DMoore%26aufirst%3DE.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DEpstein%26aufirst%3DL.%2BF.%26aulast%3DEmkey%26aufirst%3DR.%26aulast%3DAndrews%26aufirst%3DP.%2BS.%26aulast%3DYu%26aufirst%3DV.%2BL.%26aulast%3DSaffran%26aufirst%3DD.%2BC.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DDrew%26aufirst%3DA.%26aulast%3DMerkel%26aufirst%3DP.%26aulast%3DSzilvassy%26aufirst%3DS.%26aulast%3DBrake%26aufirst%3DR.%2BL.%26atitle%3DThe%2520discovery%2520and%2520optimization%2520of%2520a%2520novel%2520class%2520of%2520potent%252C%2520selective%252C%2520and%2520orally%2520bioavailable%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520inhibitors%2520with%2520potential%2520utility%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6523%26epage%3D6540%26doi%3D10.1021%2Fjm3005866" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Ott, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thieu, T. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quail, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lisko, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mesaros, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gingrich, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghose, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albom, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsey, B. D.</span><span> </span><span class="NLM_article-title">2,7-disubstituted-pyrrolo[2,1-f][1,2,4]triazines: new variant of an old template and application to the discovery of anaplastic lymphoma kinase (ALK) inhibitors with in vivo antitumor activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">6328</span><span class="NLM_x">–</span> <span class="NLM_lpage">6341</span><span class="refDoi"> DOI: 10.1021/jm200758k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200758k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVGmsr%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6328-6341&author=G.+R.+Ottauthor=G.+J.+Wellsauthor=T.+V.+Thieuauthor=M.+R.+Quailauthor=J.+G.+Liskoauthor=E.+F.+Mesarosauthor=D.+E.+Gingrichauthor=A.+K.+Ghoseauthor=W.+Wanauthor=L.+Luauthor=M.+Chengauthor=M.+S.+Albomauthor=T.+S.+Angelesauthor=Z.+Huangauthor=L.+D.+Aimoneauthor=M.+A.+Atorauthor=B.+A.+Ruggeriauthor=B.+D.+Dorsey&title=2%2C7-disubstituted-pyrrolo%5B2%2C1-f%5D%5B1%2C2%2C4%5Dtriazines%3A+new+variant+of+an+old+template+and+application+to+the+discovery+of+anaplastic+lymphoma+kinase+%28ALK%29+inhibitors+with+in+vivo+antitumor+activity&doi=10.1021%2Fjm200758k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">2,7-Disubstituted-pyrrolo[2,1-f][1,2,4]triazines: New Variant of an Old Template and Application to the Discovery of Anaplastic Lymphoma Kinase (ALK) Inhibitors with in Vivo Antitumor Activity</span></div><div class="casAuthors">Ott, Gregory R.; Wells, Gregory J.; Thieu, Tho-V.; Quail, Matthew R.; Lisko, Joseph G.; Mesaros, Eugen F.; Gingrich, Diane E.; Ghose, Arup K.; Wan, Wei-Hua; Lu, Li-Hui; Cheng, Man-Geng; Albom, Mark S.; Angeles, Thelma S.; Huang, Ze-Qi; Aimone, Lisa D.; Ator, Mark A.; Ruggeri, Bruce A.; Dorsey, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6328-6341</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel 2,7-disubstituted-pyrrolo[2,1-f][1,2,4]triazine scaffold has been designed as a new kinase inhibitor platform mimicking the bioactive conformation of the well-known diaminopyrimidine motif.  Herein the design, synthesis, and validation of this new pyrrolo[2,1-f][1,2,4]triazine scaffold is described for inhibitors of anaplastic lymphoma kinase (ALK).  Importantly, incorporation of appropriate potency and selectivity determinants has led to the discovery of several advanced leads that were orally efficacious in animal models of anaplastic large cell lymphoma (ALCL).  A lead inhibitor I displaying superior efficacy was identified.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQP33sAtk5w7Vg90H21EOLACvtfcHk0lhIqaVphP7SUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVGmsr%252FK&md5=a591238a89465683c709e6a965108212</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm200758k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200758k%26sid%3Dliteratum%253Aachs%26aulast%3DOtt%26aufirst%3DG.%2BR.%26aulast%3DWells%26aufirst%3DG.%2BJ.%26aulast%3DThieu%26aufirst%3DT.%2BV.%26aulast%3DQuail%26aufirst%3DM.%2BR.%26aulast%3DLisko%26aufirst%3DJ.%2BG.%26aulast%3DMesaros%26aufirst%3DE.%2BF.%26aulast%3DGingrich%26aufirst%3DD.%2BE.%26aulast%3DGhose%26aufirst%3DA.%2BK.%26aulast%3DWan%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26atitle%3D2%252C7-disubstituted-pyrrolo%255B2%252C1-f%255D%255B1%252C2%252C4%255Dtriazines%253A%2520new%2520variant%2520of%2520an%2520old%2520template%2520and%2520application%2520to%2520the%2520discovery%2520of%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520inhibitors%2520with%2520in%2520vivo%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6328%26epage%3D6341%26doi%3D10.1021%2Fjm200758k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Deng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sim, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luther, W.,  2nd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Discovery of 3,5-diamino-1,2,4-triazole ureas as potent anaplastic lymphoma kinase inhibitors</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">379</span><span class="NLM_x">–</span> <span class="NLM_lpage">384</span><span class="refDoi"> DOI: 10.1021/ml200002a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200002a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjtFersrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=379-384&author=X.+Dengauthor=J.+Wangauthor=J.+Zhangauthor=T.+Simauthor=N.+D.+Kimauthor=T.+Sasakiauthor=W.+Lutherauthor=R.+E.+Georgeauthor=P.+A.+Janneauthor=N.+S.+Gray&title=Discovery+of+3%2C5-diamino-1%2C2%2C4-triazole+ureas+as+potent+anaplastic+lymphoma+kinase+inhibitors&doi=10.1021%2Fml200002a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 3,5-Diamino-1,2,4-triazole Ureas as Potent Anaplastic Lymphoma Kinase Inhibitors</span></div><div class="casAuthors">Deng, Xianming; Wang, Jinhua; Zhang, Jianming; Sim, Taebo; Kim, Nam Doo; Sasaki, Takaaki; Luther, William, II; George, Rani E.; Janne, Pasi A.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">379-384</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of novel 3,5-diamino-1,2,4-triazole benzyl ureas was identified as having potent anaplastic lymphoma kinase (ALK) inhibition exemplified by I (X = O), II, and I (X = S), which exhibited antiproliferative IC50 values of 70, 40, and 20 nM in Tel-ALK transformed Ba/F3 cells, resp.  Moreover, I (X = O, S) potently inhibited the growth and survival of NPM-ALK pos. anaplastic large cell lymphoma cell (SU-DHL-1) and neuroblastoma cell lines (KELLY, SH-SY5Y) contg. the F1174L ALK mutation.  These compds. provide novel leads for the development of small-mol. ALK inhibitors for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_KXj1NxtfHLVg90H21EOLACvtfcHk0lhIqaVphP7SUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjtFersrc%253D&md5=cd4a0e5eefcf0b1b6e3c5dab5dc87d81</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fml200002a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200002a%26sid%3Dliteratum%253Aachs%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DN.%2BD.%26aulast%3DSasaki%26aufirst%3DT.%26aulast%3DLuther%26aufirst%3DW.%26aulast%3DGeorge%26aufirst%3DR.%2BE.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520of%25203%252C5-diamino-1%252C2%252C4-triazole%2520ureas%2520as%2520potent%2520anaplastic%2520lymphoma%2520kinase%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D379%26epage%3D384%26doi%3D10.1021%2Fml200002a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Ott, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tripathy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHugh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anzalone, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Underiner, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curry, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quail, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albom, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsey, B. D.</span><span> </span><span class="NLM_article-title">Discovery of a potent inhibitor of anaplastic lymphoma kinase with in vivo antitumor activity</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">493</span><span class="NLM_x">–</span> <span class="NLM_lpage">498</span><span class="refDoi"> DOI: 10.1021/ml100158s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml100158s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtV2jtrrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=493-498&author=G.+R.+Ottauthor=R.+Tripathyauthor=M.+Chengauthor=R.+McHughauthor=A.+V.+Anzaloneauthor=T.+L.+Underinerauthor=M.+A.+Curryauthor=M.+R.+Quailauthor=L.+Luauthor=W.+Wanauthor=T.+S.+Angelesauthor=M.+S.+Albomauthor=L.+D.+Aimoneauthor=M.+A.+Atorauthor=B.+A.+Ruggeriauthor=B.+D.+Dorsey&title=Discovery+of+a+potent+inhibitor+of+anaplastic+lymphoma+kinase+with+in+vivo+antitumor+activity&doi=10.1021%2Fml100158s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent Inhibitor of Anaplastic Lymphoma Kinase with in Vivo Antitumor Activity</span></div><div class="casAuthors">Ott, Gregory R.; Tripathy, Rabindranath; Cheng, Mangeng; McHugh, Robert; Anzalone, Andrew V.; Underiner, Ted L.; Curry, Matthew A.; Quail, Matthew R.; Lu, Lihui; Wan, Weihua; Angeles, Thelma S.; Albom, Mark S.; Aimone, Lisa D.; Ator, Mark A.; Ruggeri, Bruce A.; Dorsey, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">493-498</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of novel 7-amino-1,3,4,5-tetrahydrobenzo[b]azepin-2-one derivs. within the diaminopyrimidine class of kinase inhibitors were identified that target anaplastic lymphoma kinase (ALK).  These inhibitors are potent against ALK in an isolated enzyme assay and inhibit autophosphorylation of the oncogenic fusion protein NPM-ALK in anaplastic large cell lymphoma (ALCL) cell lines.  The lead inhibitor 15 (I), which incorporates a bicyclo[2.2.1]hept-5-ene ring system in place of an aryl moiety, activates the pro-apoptotic caspases (3 and 7) and displays selective cytotoxicity against ALK-pos. ALCL cells.  Furthermore, 15 provides more than 40-fold selectivity against the structurally related insulin receptor, is orally bioavailable in multiple species, and displays in vivo antitumor efficacy when dosed orally in ALK-pos. ALCL tumor xenografts in Scid mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGof0qilbcAbZ7Vg90H21EOLACvtfcHk0lgL7Od4rChUBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtV2jtrrJ&md5=15d4f7aea64f212338d8c9cd88a36c64</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fml100158s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml100158s%26sid%3Dliteratum%253Aachs%26aulast%3DOtt%26aufirst%3DG.%2BR.%26aulast%3DTripathy%26aufirst%3DR.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DMcHugh%26aufirst%3DR.%26aulast%3DAnzalone%26aufirst%3DA.%2BV.%26aulast%3DUnderiner%26aufirst%3DT.%2BL.%26aulast%3DCurry%26aufirst%3DM.%2BA.%26aulast%3DQuail%26aufirst%3DM.%2BR.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DWan%26aufirst%3DW.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26atitle%3DDiscovery%2520of%2520a%2520potent%2520inhibitor%2520of%2520anaplastic%2520lymphoma%2520kinase%2520with%2520in%2520vivo%2520antitumor%2520activity%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D1%26spage%3D493%26epage%3D498%26doi%3D10.1021%2Fml100158s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Cheng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ott, G. R.</span><span> </span><span class="NLM_article-title">Anaplastic lymphoma kinase as a therapeutic target in anaplastic large cell lymphoma, non-small cell lung cancer and neuroblastoma</span> <span class="citation_source-journal">Anti-Cancer Agents Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">236</span><span class="NLM_x">–</span> <span class="NLM_lpage">249</span><span class="refDoi"> DOI: 10.2174/1871520611009030236</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.2174%2F1871520611009030236" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=236-249&author=M.+Chengauthor=G.+R.+Ott&title=Anaplastic+lymphoma+kinase+as+a+therapeutic+target+in+anaplastic+large+cell+lymphoma%2C+non-small+cell+lung+cancer+and+neuroblastoma&doi=10.2174%2F1871520611009030236"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.2174%2F1871520611009030236&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1871520611009030236%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DOtt%26aufirst%3DG.%2BR.%26atitle%3DAnaplastic%2520lymphoma%2520kinase%2520as%2520a%2520therapeutic%2520target%2520in%2520anaplastic%2520large%2520cell%2520lymphoma%252C%2520non-small%2520cell%2520lung%2520cancer%2520and%2520neuroblastoma%26jtitle%3DAnti-Cancer%2520Agents%2520Med.%2520Chem.%26date%3D2010%26volume%3D10%26spage%3D236%26epage%3D249%26doi%3D10.2174%2F1871520611009030236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Webb, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slavish, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Look, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rentrop, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, S. W.</span><span> </span><span class="NLM_article-title">Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy</span> <span class="citation_source-journal">Expert Rev. Anticancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">331</span><span class="NLM_x">–</span> <span class="NLM_lpage">356</span><span class="refDoi"> DOI: 10.1586/14737140.9.3.331</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1586%2F14737140.9.3.331" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=19275511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtFaltrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=331-356&author=T.+R.+Webbauthor=J.+Slavishauthor=R.+E.+Georgeauthor=A.+T.+Lookauthor=L.+Xueauthor=Q.+Jiangauthor=X.+Cuiauthor=W.+B.+Rentropauthor=S.+W.+Morris&title=Anaplastic+lymphoma+kinase%3A+role+in+cancer+pathogenesis+and+small-molecule+inhibitor+development+for+therapy&doi=10.1586%2F14737140.9.3.331"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy</span></div><div class="casAuthors">Webb, Thomas R.; Slavish, Jake; George, Rani E.; Look, A. Thomas; Xue, Liquan; Jiang, Qin; Cui, Xiaoli; Rentrop, Walter B.; Morris, Stephan W.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anticancer Therapy</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">331-356</span>CODEN:
                <span class="NLM_cas:coden">ERATBJ</span>;
        ISSN:<span class="NLM_cas:issn">1473-7140</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  Anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase in the insulin receptor superfamily, was initially identified in constitutively activated oncogenic fusion forms - the most common being nucleophosmin-ALK - in anaplastic large-cell lymphomas, and subsequent studies have identified ALK fusions in diffuse large B-cell lymphomas, systemic histiocytosis, inflammatory myofibroblastic tumors, esophageal squamous cell carcinomas and non-small-cell lung carcinomas.  More recently, genomic DNA amplification and protein overexpression, as well as activating point mutations, of ALK have been described in neuroblastomas.  In addn. to those cancers for which a causative role for aberrant ALK activity is well validated, more circumstantial links implicate the full-length, normal ALK receptor in the genesis of other malignancies - including glioblastoma and breast cancer - via a mechanism of receptor activation involving autocrine and/or paracrine growth loops with the reported ALK ligands, pleiotrophin and midkine.  This review summarizes normal ALK biol., the confirmed and putative roles of ALK in the development of human cancers and efforts to target ALK using small-mol. kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoERzbvlik_c7Vg90H21EOLACvtfcHk0lgL7Od4rChUBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtFaltrc%253D&md5=a980ef18ac316bd3894b72ddd2748c17</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1586%2F14737140.9.3.331&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14737140.9.3.331%26sid%3Dliteratum%253Aachs%26aulast%3DWebb%26aufirst%3DT.%2BR.%26aulast%3DSlavish%26aufirst%3DJ.%26aulast%3DGeorge%26aufirst%3DR.%2BE.%26aulast%3DLook%26aufirst%3DA.%2BT.%26aulast%3DXue%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DQ.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DRentrop%26aufirst%3DW.%2BB.%26aulast%3DMorris%26aufirst%3DS.%2BW.%26atitle%3DAnaplastic%2520lymphoma%2520kinase%253A%2520role%2520in%2520cancer%2520pathogenesis%2520and%2520small-molecule%2520inhibitor%2520development%2520for%2520therapy%26jtitle%3DExpert%2520Rev.%2520Anticancer%2520Ther.%26date%3D2009%26volume%3D9%26spage%3D331%26epage%3D356%26doi%3D10.1586%2F14737140.9.3.331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Smith, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eastman, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Njardarson, J. T.</span><span> </span><span class="NLM_article-title">Beyond C, H, O, and N. Analysis of the elemental composition of U.S. FDA approved drug architectures</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">9764</span><span class="NLM_x">–</span> <span class="NLM_lpage">9773</span><span class="refDoi"> DOI: 10.1021/jm501105n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501105n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=9764-9773&author=B.+R.+Smithauthor=C.+M.+Eastmanauthor=J.+T.+Njardarson&title=Beyond+C%2C+H%2C+O%2C+and+N.+Analysis+of+the+elemental+composition+of+U.S.+FDA+approved+drug+architectures&doi=10.1021%2Fjm501105n"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm501105n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501105n%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DB.%2BR.%26aulast%3DEastman%26aufirst%3DC.%2BM.%26aulast%3DNjardarson%26aufirst%3DJ.%2BT.%26atitle%3DBeyond%2520C%252C%2520H%252C%2520O%252C%2520and%2520N.%2520Analysis%2520of%2520the%2520elemental%2520composition%2520of%2520U.S.%2520FDA%2520approved%2520drug%2520architectures%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D9764%26epage%3D9773%26doi%3D10.1021%2Fjm501105n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Rivera, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Squillace, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berk, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardwell, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ning, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollock, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narasimhan, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iuliucci, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span> </span><span class="NLM_article-title">Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1059</span><span class="NLM_x">–</span> <span class="NLM_lpage">1071</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-10-0792</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1158%2F1535-7163.MCT-10-0792" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=21482695" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnt1anurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=1059-1071&author=V.+M.+Riveraauthor=R.+M.+Squillaceauthor=D.+Millerauthor=L.+Berkauthor=S.+D.+Wardwellauthor=Y.+Ningauthor=R.+Pollockauthor=N.+I.+Narasimhanauthor=J.+D.+Iuliucciauthor=F.+Wangauthor=T.+Clackson&title=Ridaforolimus+%28AP23573%3B+MK-8669%29%2C+a+potent+mTOR+inhibitor%2C+has+broad+antitumor+activity+and+can+be+optimally+administered+using+intermittent+dosing+regimens&doi=10.1158%2F1535-7163.MCT-10-0792"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens</span></div><div class="casAuthors">Rivera, Victor M.; Squillace, Rachel M.; Miller, David; Berk, Lori; Wardwell, Scott D.; Ning, Yaoyu; Pollock, Roy; Narasimhan, Narayana I.; Iuliucci, John D.; Wang, Frank; Clackson, Tim</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1059-1071</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The mTOR pathway is hyperactivated through oncogenic transformation in many human malignancies.  Ridaforolimus (AP23573; MK-8669) is a novel rapamycin analog that selectively targets mTOR and is currently under clin. evaluation.  In this study, we investigated the mechanistic basis for the antitumor activity of ridaforolimus in a range of human tumor types, exploring potential markers of response, and detg. optimal dosing regimens to guide clin. studies.  Administration of ridaforolimus to tumor cells in vitro elicited dose-dependent inhibition of mTOR activity with concomitant effects on cell growth and division.  We showed that ridaforolimus exhibits a predominantly cytostatic mode of action, consistent with the findings for other mTOR inhibitors.  Potent inhibitory effects on vascular endothelial growth factor secretion, endothelial cell growth, and glucose metab. were also obsd.  Although PTEN and/or phosphorylated AKT status have been proposed as potential mTOR pathway biomarkers, neither was predictive for ridaforolimus responsiveness in the heterogeneous panel of cancer cell lines examd.  In mouse models, robust antitumor activity was obsd. in human tumor xenografts using a series of intermittent dosing schedules, consistent with pharmacodynamic observations of mTOR pathway inhibition for at least 72 h following dosing.  Parallel skin-graft rejection studies established that intermittent dosing schedules lack the immunosuppressive effects seen with daily dosing.  Overall these findings show the broad inhibitory effects of ridaforolimus on cell growth, division, metab., and angiogenesis, and support the use of intermittent dosing as a means to optimize antitumor activity while minimizing systemic effects.  Mol Cancer Ther; 10(6); 1059-71.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHghCGdAPjCrVg90H21EOLACvtfcHk0lj4xOTNGDsZRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnt1anurs%253D&md5=a23835227e1a0b27332ca973c87f202a</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-10-0792&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-10-0792%26sid%3Dliteratum%253Aachs%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DSquillace%26aufirst%3DR.%2BM.%26aulast%3DMiller%26aufirst%3DD.%26aulast%3DBerk%26aufirst%3DL.%26aulast%3DWardwell%26aufirst%3DS.%2BD.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DPollock%26aufirst%3DR.%26aulast%3DNarasimhan%26aufirst%3DN.%2BI.%26aulast%3DIuliucci%26aufirst%3DJ.%2BD.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DClackson%26aufirst%3DT.%26atitle%3DRidaforolimus%2520%2528AP23573%253B%2520MK-8669%2529%252C%2520a%2520potent%2520mTOR%2520inhibitor%252C%2520has%2520broad%2520antitumor%2520activity%2520and%2520can%2520be%2520optimally%2520administered%2520using%2520intermittent%2520dosing%2520regimens%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26spage%3D1059%26epage%3D1071%26doi%3D10.1158%2F1535-7163.MCT-10-0792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bohacek, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keenan, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundaramoorthi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, C.,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dilauro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roeloffzen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saltmarsh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paramanathan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narula, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pradeepan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Schravendijk, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ram, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liou, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardwell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bogus, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iuliucci, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weigele, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xing, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyce, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, T. K.</span><span> </span><span class="NLM_article-title">SAR of carbon-linked, 2-substituted purines: synthesis and characterization of AP23451 as a novel bone-targeted inhibitor of Src tyrosine kinase with in vivo anti-resorptive activity</span> <span class="citation_source-journal">Chem. Biol. Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">97</span><span class="NLM_x">–</span> <span class="NLM_lpage">105</span><span class="refDoi"> DOI: 10.1111/j.1747-0285.2007.00615.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1111%2Fj.1747-0285.2007.00615.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=18179464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFSntbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2008&pages=97-105&author=W.+C.+Shakespeareauthor=Y.+Wangauthor=R.+Bohacekauthor=T.+Keenanauthor=R.+Sundaramoorthiauthor=C.+Metcalfauthor=A.+Dilauroauthor=S.+Roeloffzenauthor=S.+Liuauthor=J.+Saltmarshauthor=G.+Paramanathanauthor=D.+Dalgarnoauthor=S.+Narulaauthor=S.+Pradeepanauthor=M.+R.+van+Schravendijkauthor=J.+Keatsauthor=M.+Ramauthor=S.+Liouauthor=S.+Adamsauthor=S.+Wardwellauthor=J.+Bogusauthor=J.+Iuliucciauthor=M.+Weigeleauthor=L.+Xingauthor=B.+Boyceauthor=T.+K.+Sawyer&title=SAR+of+carbon-linked%2C+2-substituted+purines%3A+synthesis+and+characterization+of+AP23451+as+a+novel+bone-targeted+inhibitor+of+Src+tyrosine+kinase+with+in+vivo+anti-resorptive+activity&doi=10.1111%2Fj.1747-0285.2007.00615.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">SAR of carbon-linked, 2-substituted purines: synthesis and characterization of AP23451 as a novel bone-targeted inhibitor of Src tyrosine kinase with in vivo anti-resorptive activity</span></div><div class="casAuthors">Shakespeare, William C.; Wang, Yihan; Bohacek, Regine; Keenan, Terry; Sundaramoorthi, Raji; Metcalf, Chet, III; Dilauro, Anne; Roeloffzen, Sonya; Liu, Shuangying; Saltmarsh, Jennifer; Paramanathan, Guru; Dalgarno, David; Narula, Surinder; Pradeepan, Selvi; van Schravendijk, Marie Rose; Keats, Jeff; Ram, Mary; Liou, Shuenn; Adams, Susan; Wardwell, Scott; Bogus, Julie; Iuliucci, John; Weigele, Manfred; Xing, Lianping; Boyce, Brendan; Sawyer, Tomi K.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">97-105</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Targeted disruption of the pp60src (Src) gene has implicated this tyrosine kinase in osteoclast-mediated bone resorption and as a therapeutic target for the treatment of osteoporosis and other bone-related diseases.  Here, we describe structure activity relationships of a novel series of carbon-linked, 2-substituted purines that led to the identification of AP23451 as a potent inhibitor of Src tyrosine kinase with antiresorptive activity in vivo.  AP23451 features the use of an arylphosphinylmethylphosphinic acid moiety which confers bone-targeting properties to the mol., thereby increasing local concns. of the inhibitor to actively resorbing osteoclasts at the bone interface.  AP23451 exhibited an IC50 = 68 nM against Src kinase; an x-ray crystal structure of the mol. complexed with Src detailed the mol. interactions responsible for its Src inhibition.  In vivo, AP23451 demonstrated a dose-dependent decrease in PTH-induced hypercalcemia.  Moreover, AP23517, a structurally and biochem. similar mol. with comparable activity (IC50 = 73 nM) except devoid of the bone-targeting element, demonstrated significantly reduced in vivo efficacy, suggesting that Src activity was necessary but not sufficient for in vivo activity in this series of compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMOkUhcT4xFrVg90H21EOLACvtfcHk0lj4xOTNGDsZRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFSntbs%253D&md5=256b265a9c89d3702881efdd357c31f9</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2007.00615.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2007.00615.x%26sid%3Dliteratum%253Aachs%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DBohacek%26aufirst%3DR.%26aulast%3DKeenan%26aufirst%3DT.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DMetcalf%26aufirst%3DC.%26aulast%3DDilauro%26aufirst%3DA.%26aulast%3DRoeloffzen%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DSaltmarsh%26aufirst%3DJ.%26aulast%3DParamanathan%26aufirst%3DG.%26aulast%3DDalgarno%26aufirst%3DD.%26aulast%3DNarula%26aufirst%3DS.%26aulast%3DPradeepan%26aufirst%3DS.%26aulast%3Dvan%2BSchravendijk%26aufirst%3DM.%2BR.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DRam%26aufirst%3DM.%26aulast%3DLiou%26aufirst%3DS.%26aulast%3DAdams%26aufirst%3DS.%26aulast%3DWardwell%26aufirst%3DS.%26aulast%3DBogus%26aufirst%3DJ.%26aulast%3DIuliucci%26aufirst%3DJ.%26aulast%3DWeigele%26aufirst%3DM.%26aulast%3DXing%26aufirst%3DL.%26aulast%3DBoyce%26aufirst%3DB.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26atitle%3DSAR%2520of%2520carbon-linked%252C%25202-substituted%2520purines%253A%2520synthesis%2520and%2520characterization%2520of%2520AP23451%2520as%2520a%2520novel%2520bone-targeted%2520inhibitor%2520of%2520Src%2520tyrosine%2520kinase%2520with%2520in%2520vivo%2520anti-resorptive%2520activity%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2008%26volume%3D71%26spage%3D97%26epage%3D105%26doi%3D10.1111%2Fj.1747-0285.2007.00615.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">O’Hare, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollock, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoffregen, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abdullah, O. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moseson, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, C. A.,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bohacek, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundaramoorthi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span> </span><span class="NLM_article-title">Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">2532</span><span class="NLM_x">–</span> <span class="NLM_lpage">2539</span><span class="refDoi"> DOI: 10.1182/blood-2004-05-1851</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1182%2Fblood-2004-05-1851" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2004&pages=2532-2539&author=T.+O%E2%80%99Hareauthor=R.+Pollockauthor=E.+P.+Stoffregenauthor=J.+A.+Keatsauthor=O.+M.+Abdullahauthor=E.+M.+Mosesonauthor=V.+M.+Riveraauthor=H.+Tangauthor=C.+A.+Metcalfauthor=R.+S.+Bohacekauthor=Y.+Wangauthor=R.+Sundaramoorthiauthor=W.+C.+Shakespeareauthor=D.+Dalgarnoauthor=T.+Clacksonauthor=T.+K.+Sawyerauthor=M.+W.+Deiningerauthor=B.+J.+Druker&title=Inhibition+of+wild-type+and+mutant+Bcr-Abl+by+AP23464%2C+a+potent+ATP-based+oncogenic+protein+kinase+inhibitor%3A+implications+for+CML&doi=10.1182%2Fblood-2004-05-1851"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1182%2Fblood-2004-05-1851&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2004-05-1851%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DPollock%26aufirst%3DR.%26aulast%3DStoffregen%26aufirst%3DE.%2BP.%26aulast%3DKeats%26aufirst%3DJ.%2BA.%26aulast%3DAbdullah%26aufirst%3DO.%2BM.%26aulast%3DMoseson%26aufirst%3DE.%2BM.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DTang%26aufirst%3DH.%26aulast%3DMetcalf%26aufirst%3DC.%2BA.%26aulast%3DBohacek%26aufirst%3DR.%2BS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DDalgarno%26aufirst%3DD.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26atitle%3DInhibition%2520of%2520wild-type%2520and%2520mutant%2520Bcr-Abl%2520by%2520AP23464%252C%2520a%2520potent%2520ATP-based%2520oncogenic%2520protein%2520kinase%2520inhibitor%253A%2520implications%2520for%2520CML%26jtitle%3DBlood%26date%3D2004%26volume%3D104%26spage%3D2532%26epage%3D2539%26doi%3D10.1182%2Fblood-2004-05-1851" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Dalgarno, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stehle, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narula, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schelling, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Schravendijk, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrade, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ram, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grossman, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacNeil, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, C.,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keenan, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundaramoorthi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bohacek, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weigele, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, T.</span><span> </span><span class="NLM_article-title">Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds</span> <span class="citation_source-journal">Chem. Biol. Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">46</span><span class="NLM_x">–</span> <span class="NLM_lpage">57</span><span class="refDoi"> DOI: 10.1111/j.1747-0285.2005.00316.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1111%2Fj.1747-0285.2005.00316.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=16492148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BD28XhsVSjt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2006&pages=46-57&author=D.+Dalgarnoauthor=T.+Stehleauthor=S.+Narulaauthor=P.+Schellingauthor=M.+R.+van+Schravendijkauthor=S.+Adamsauthor=L.+Andradeauthor=J.+Keatsauthor=M.+Ramauthor=L.+Jinauthor=T.+Grossmanauthor=I.+MacNeilauthor=C.+Metcalfauthor=W.+Shakespeareauthor=Y.+Wangauthor=T.+Keenanauthor=R.+Sundaramoorthiauthor=R.+Bohacekauthor=M.+Weigeleauthor=T.+Sawyer&title=Structural+basis+of+Src+tyrosine+kinase+inhibition+with+a+new+class+of+potent+and+selective+trisubstituted+purine-based+compounds&doi=10.1111%2Fj.1747-0285.2005.00316.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds</span></div><div class="casAuthors">Dalgarno, David; Stehle, Thilo; Narula, Surinder; Schelling, Pierre; van Schravendijk, Marie Rose; Adams, Susan; Andrade, Lawrence; Keats, Jeff; Ram, Mary; Jin, Lei; Grossman, Trudy; MacNeil, Ian; Metcalf, Chester, III; Shakespeare, William; Wang, Yihan; Keenan, Terry; Sundaramoorthi, Raji; Bohacek, Regine; Weigele, Manfred; Sawyer, Tomi</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">46-57</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">The tyrosine kinase pp60src (Src) is the prototypical member of a family of proteins that participate in a broad array of cellular signal transduction processes, including cell growth, differentiation, survival, adhesion, and migration.  Abnormal Src family kinase (SFK) signaling has been linked to several disease states, including osteoporosis and cancer metastases.  Src has thus emerged as a mol. target for the discovery of small-mol. inhibitors that regulate Src kinase activity by binding to the ATP pocket within the catalytic domain.  Here, we present crystal structures of the kinase domain of Src in complex with two purine-based inhibitors: AP23451, a small-mol. inhibitor designed to inhibit Src-dependent bone resorption, and AP23464, a small-mol. inhibitor designed to inhibit the Src-dependent metastatic spread of cancer.  In each case, a trisubstituted purine template core was elaborated using structure-based drug design to yield a potent Src kinase inhibitor.  These structures represent early examples of high affinity purine-based Src family kinase-inhibitor complexes, and they provide a detailed view of the specific protein-ligand interactions that lead to potent inhibition of Src.  In particular, the 3-hydroxyphenethyl N9 substituent of AP23464 forms unique interactions with the protein that are crit. to the picomolar affinity of this compd. for Src.  The comparison of these new structures with two relevant kinase-inhibitor complexes provides a structural basis for the obsd. kinase inhibitory selectivity.  Further comparisons reveal a concerted induced-fit movement between the N- and C-terminal lobes of the kinase that correlates with the affinity of the ligand.  Binding of the most potent inhibitor, AP23464, results in the largest induced-fit movement, which can be directly linked to interactions of the hydrophenethyl N9 substituent with a region at the interface between the two lobes.  A less pronounced induced-fit movement is also obsd. in the Src-AP23451 complex.  These new structures illustrate how the combination of structural, computational, and medicinal chem. can be used to rationalize the process of developing high affinity, selective tyrosine kinase inhibitors as potential therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqAcWZyLy8JrVg90H21EOLACvtfcHk0ljwMyIfBddCMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhsVSjt7Y%253D&md5=5a89de976e29e65aec0553c84e2e0b92</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2005.00316.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2005.00316.x%26sid%3Dliteratum%253Aachs%26aulast%3DDalgarno%26aufirst%3DD.%26aulast%3DStehle%26aufirst%3DT.%26aulast%3DNarula%26aufirst%3DS.%26aulast%3DSchelling%26aufirst%3DP.%26aulast%3Dvan%2BSchravendijk%26aufirst%3DM.%2BR.%26aulast%3DAdams%26aufirst%3DS.%26aulast%3DAndrade%26aufirst%3DL.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DRam%26aufirst%3DM.%26aulast%3DJin%26aufirst%3DL.%26aulast%3DGrossman%26aufirst%3DT.%26aulast%3DMacNeil%26aufirst%3DI.%26aulast%3DMetcalf%26aufirst%3DC.%26aulast%3DShakespeare%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DKeenan%26aufirst%3DT.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DBohacek%26aufirst%3DR.%26aulast%3DWeigele%26aufirst%3DM.%26aulast%3DSawyer%26aufirst%3DT.%26atitle%3DStructural%2520basis%2520of%2520Src%2520tyrosine%2520kinase%2520inhibition%2520with%2520a%2520new%2520class%2520of%2520potent%2520and%2520selective%2520trisubstituted%2520purine-based%2520compounds%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2006%26volume%3D67%26spage%3D46%26epage%3D57%26doi%3D10.1111%2Fj.1747-0285.2005.00316.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Zhang, S.; Anjum, R.; Squillace, R.; Nadworny, S.; Zhou, T.; Keats, J.; Ning, Y.; Wardwell, S. D.; Miller, D.; Song, Y.; Eichinger, L.; Moran, L.; Huang, W.-S.; Liu, S.; Zou, D.; Wang, Y.; Mohemmad, Q.; Jang, H. G.; Ye, E.; Narasimhan, N.; Wang, F.; Miret, J.; Zhu, X.; Clackson, T.; Dalgarno, D.; Shakespeare, W.; Rivera, V. M.</span><span> </span><span class="NLM_article-title">The potent ALK inhibitor brigatinib (AP26113) overcomes mechanisms of resistance to first- and second-generation ALK inhibitors in preclinical models</span>. Clin. Cancer Res.<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">, </span>submitted for publication</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=S.+Zhang&author=R.+Anjum&author=R.+Squillace&author=S.+Nadworny&author=T.+Zhou&author=J.+Keats&author=Y.+Ning&author=S.+D.+Wardwell&author=D.+Miller&author=Y.+Song&author=L.+Eichinger&author=L.+Moran&author=W.-S.+Huang&author=S.+Liu&author=D.+Zou&author=Y.+Wang&author=Q.+Mohemmad&author=H.+G.+Jang&author=E.+Ye&author=N.+Narasimhan&author=F.+Wang&author=J.+Miret&author=X.+Zhu&author=T.+Clackson&author=D.+Dalgarno&author=W.+Shakespeare&author=V.+M.+Rivera&title=The+potent+ALK+inhibitor+brigatinib+%28AP26113%29+overcomes+mechanisms+of+resistance+to+first-+and+second-generation+ALK+inhibitors+in+preclinical+models"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DS.%26atitle%3DThe%2520potent%2520ALK%2520inhibitor%2520brigatinib%2520%2528AP26113%2529%2520overcomes%2520mechanisms%2520of%2520resistance%2520to%2520first-%2520and%2520second-generation%2520ALK%2520inhibitors%2520in%2520preclinical%2520models%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Huang, W.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardwell, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ning, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohlmann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, E. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narasimhan, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C. .</span><span> </span><span class="NLM_article-title">Discovery of AP26113, a potent, orally active inhibitor of anaplastic lymphoma kinase and clinically relevant mutants</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x"> (</span><span class="NLM_issue">15 suppl</span><span class="NLM_x">) </span> <span class="NLM_fpage">No. 2827</span><span class="refDoi"> DOI: 10.1158/1538-7445.AM2015-2827</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1158%2F1538-7445.AM2015-2827" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=No.+2827&issue=15+suppl&author=W.-S.+Huangauthor=F.+Liauthor=L.+Caiauthor=Y.+Xuauthor=S.+Zhangauthor=S.+D.+Wardwellauthor=Y.+Ningauthor=A.+Kohlmannauthor=T.+Zhouauthor=E.+Y.+Yeauthor=X.+Zhuauthor=N.+I.+Narasimhanauthor=T.+Clacksonauthor=V.+M.+Riveraauthor=D.+Dalgarnoauthor=W.+C.+.+Shakespeare&title=Discovery+of+AP26113%2C+a+potent%2C+orally+active+inhibitor+of+anaplastic+lymphoma+kinase+and+clinically+relevant+mutants&doi=10.1158%2F1538-7445.AM2015-2827"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2015-2827&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2015-2827%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.-S.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DCai%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DWardwell%26aufirst%3DS.%2BD.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DKohlmann%26aufirst%3DA.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DYe%26aufirst%3DE.%2BY.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DNarasimhan%26aufirst%3DN.%2BI.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DDalgarno%26aufirst%3DD.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%2B.%26atitle%3DDiscovery%2520of%2520AP26113%252C%2520a%2520potent%252C%2520orally%2520active%2520inhibitor%2520of%2520anaplastic%2520lymphoma%2520kinase%2520and%2520clinically%2520relevant%2520mutants%26jtitle%3DCancer%2520Res.%26date%3D2015%26volume%3D75%26issue%3D15%2520suppl%26spage%3DNo.%25202827%26doi%3D10.1158%2F1538-7445.AM2015-2827" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Li, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, S. W.</span><span> </span><span class="NLM_article-title">Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy</span> <span class="citation_source-journal">Med. Res. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">372</span><span class="NLM_x">–</span> <span class="NLM_lpage">412</span><span class="refDoi"> DOI: 10.1002/med.20109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1002%2Fmed.20109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=17694547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsVyltLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2008&pages=372-412&author=R.+Liauthor=S.+W.+Morris&title=Development+of+anaplastic+lymphoma+kinase+%28ALK%29+small-molecule+inhibitors+for+cancer+therapy&doi=10.1002%2Fmed.20109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy</span></div><div class="casAuthors">Li, Rongshi; Morris, Stephan W.</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">372-412</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase (RTK) involved in the genesis of several human cancers; indeed, ALK was initially identified in constitutively activated and oncogenic fusion forms-the most common being nucleophosmin (NPM)-ALK-in a nonHodgkin's lymphoma (NHL) known as anaplastic large-cell lymphoma (ALCL) and subsequent studies identified ALK fusions in the human sarcomas called inflammatory myofibroblastic tumors (IMTs).  In addn., two recent reports have suggested that the ALK fusion, TPM4-ALK, may be involved in the genesis of a subset of esophageal squamous cell carcinomas.  While the cause-effect relationship between ALK fusions and malignancies such as ALCL and IMT is very well established, more circumstantial links implicate the involvement of the full-length, normal ALK receptor in the genesis of addnl. malignancies including glioblastoma, neuroblastoma, breast cancer, and others; in these instances, ALK is believed to foster tumorigenesis following activation by autocrine and/or paracrine growth loops involving the reported ALK ligands, pleiotrophin (PTN) and midkine (MK).  There are no currently available ALK small-mol. inhibitors approved for clin. cancer therapy; however, recognition of the variety of malignancies in which ALK may play a causative role has recently begun to prompt developmental efforts in this area.  This review provides a succinct summary of normal ALK biol., the confirmed and putative roles of ALK fusions and the full-length ALK receptor in the development of human cancers, and efforts to target ALK using small-mol. kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoB3B7c_OpT2LVg90H21EOLACvtfcHk0lgnYXHsEB1M1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsVyltLs%253D&md5=d8521d00232b6b3d1c807fb65645ac67</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1002%2Fmed.20109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.20109%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DR.%26aulast%3DMorris%26aufirst%3DS.%2BW.%26atitle%3DDevelopment%2520of%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520small-molecule%2520inhibitors%2520for%2520cancer%2520therapy%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2008%26volume%3D28%26spage%3D372%26epage%3D412%26doi%3D10.1002%2Fmed.20109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Galkin, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melnick, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hood, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steensma, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chopiuk, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warmuth, M.</span><span> </span><span class="NLM_article-title">Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">270</span><span class="NLM_x">–</span> <span class="NLM_lpage">275</span><span class="refDoi"> DOI: 10.1073/pnas.0609412103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1073%2Fpnas.0609412103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=17185414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjt12jsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=270-275&author=A.+V.+Galkinauthor=J.+S.+Melnickauthor=S.+Kimauthor=T.+L.+Hoodauthor=N.+Liauthor=L.+Liauthor=G.+Xiaauthor=R.+Steensmaauthor=G.+Chopiukauthor=J.+Jiangauthor=Y.+Wanauthor=P.+Dingauthor=Y.+Liuauthor=F.+Sunauthor=P.+G.+Schultzauthor=N.+S.+Grayauthor=M.+Warmuth&title=Identification+of+NVP-TAE684%2C+a+potent%2C+selective%2C+and+efficacious+inhibitor+of+NPM-ALK&doi=10.1073%2Fpnas.0609412103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK</span></div><div class="casAuthors">Galkin, Anna V.; Melnick, Jonathon S.; Kim, Sunjoon; Hood, Tami L.; Li, Nanxin; Li, Lintong; Xia, Gang; Steensma, Ruo; Chopiuk, Greg; Wan, Yongqin; Ding, Peter; Liu, Yi; Sun, Fangxian; Schultz, Peter G.; Gray, Nathanael S.; Warmuth, Markus</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">270-275</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Constitutive overexpression and activation of NPM-ALK fusion protein [t(2:5)(p23;q35)] is a key oncogenic event that drives the survival and proliferation of anaplastic large cell lymphomas (ALCLs).  We have identified a highly potent and selective small-mol. ALK inhibitor, NVP-TAE684, which blocked the growth of ALCL-derived and ALK-dependent cell lines with IC50 values between 2 and 10 nM.  NVP-TAE684 treatment resulted in a rapid and sustained inhibition of phosphorylation of NPM-ALK and its downstream effectors and subsequent induction of apoptosis and cell cycle arrest.  In vivo, NVP-TAE684 suppressed lymphomagenesis in two independent models of ALK-pos. ALCL and induced regression of established Karpas-299 lymphomas.  NVP-TAE684 also induced down-regulation of CD30 expression, suggesting that CD30 may be used as a biomarker of therapeutic NPM-ALK kinase activity inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLbZwqZzPX-bVg90H21EOLACvtfcHk0lgnYXHsEB1M1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjt12jsQ%253D%253D&md5=4a3441ee637a67dc496c80730bd0e184</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0609412103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0609412103%26sid%3Dliteratum%253Aachs%26aulast%3DGalkin%26aufirst%3DA.%2BV.%26aulast%3DMelnick%26aufirst%3DJ.%2BS.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DHood%26aufirst%3DT.%2BL.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DXia%26aufirst%3DG.%26aulast%3DSteensma%26aufirst%3DR.%26aulast%3DChopiuk%26aufirst%3DG.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DWan%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DWarmuth%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520NVP-TAE684%252C%2520a%2520potent%252C%2520selective%252C%2520and%2520efficacious%2520inhibitor%2520of%2520NPM-ALK%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2007%26volume%3D104%26spage%3D270%26epage%3D275%26doi%3D10.1073%2Fpnas.0609412103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Huang, W.-S.; Thomas, R. M.</span><span> </span><span class="NLM_article-title">Pyrazinopyrazine derivatives as kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of cancer</span>. PCT Int. Appl. WO 2010056311,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=W.-S.+Huang&author=R.+M.+Thomas&title=Pyrazinopyrazine+derivatives+as+kinase+inhibitors+and+their+preparation%2C+pharmaceutical+compositions+and+use+in+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.-S.%26atitle%3DPyrazinopyrazine%2520derivatives%2520as%2520kinase%2520inhibitors%2520and%2520their%2520preparation%252C%2520pharmaceutical%2520compositions%2520and%2520use%2520in%2520the%2520treatment%2520of%2520cancer%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Kothe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohls, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Low, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rennie, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feru, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhn, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, Y. H.</span><span> </span><span class="NLM_article-title">Selectivity-determining residues in Plk1</span> <span class="citation_source-journal">Chem. Biol. Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">540</span><span class="NLM_x">–</span> <span class="NLM_lpage">546</span><span class="refDoi"> DOI: 10.1111/j.1747-0285.2007.00594.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1111%2Fj.1747-0285.2007.00594.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=18005335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVGhsbrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2007&pages=540-546&author=M.+Kotheauthor=D.+Kohlsauthor=S.+Lowauthor=R.+Coliauthor=G.+R.+Rennieauthor=F.+Feruauthor=C.+Kuhnauthor=Y.+H.+Ding&title=Selectivity-determining+residues+in+Plk1&doi=10.1111%2Fj.1747-0285.2007.00594.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Selectivity-determining residues in Plk1</span></div><div class="casAuthors">Kothe, Michael; Kohls, Darcy; Low, Simon; Coli, Rocco; Rennie, Glen R.; Feru, Frederic; Kuhn, Cyrille; Ding, Yuan-Hua</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">540-546</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Polo-like kinase 1 is an important regulator of cell cycle progression whose over-expression is often assocd. with oncogenesis.  Polo-like kinase 1 hence represents an attractive target for cancer intervention.  BI 2536 (Boehringer Ingelheim, Ingelheim, Germany), a Polo-like kinase 1 inhibitor currently in clin. trials, exhibits nanomolar potency against Polo-like kinase isoforms and high selectivity against other kinases.  The authors have previously published the crystal structures of the Polo-like kinase 1 domain in complex with AMPPNP and an Aurora A inhibitor.  In this work, the authors present the cocrystal structure of Polo-like kinase 1 with BI 2536.  The structure, in combination with selectivity data for BI 2536 and related compds., illustrates important features for potency and selectivity.  In particular, the authors show that the methoxy group of BI 2536 is an important specificity determinant against non-Polo-like kinases by taking advantage of a small pocket generated by Leu 132 in the hinge region of Polo-like kinase 1.  The work presented here provides a framework for structure-based drug design of Polo-like kinase 1-specific inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjA3mwWD7K0bVg90H21EOLACvtfcHk0ljt84QgVdajkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVGhsbrJ&md5=0f976bb98fe7d0413e8d2314abc68e2b</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2007.00594.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2007.00594.x%26sid%3Dliteratum%253Aachs%26aulast%3DKothe%26aufirst%3DM.%26aulast%3DKohls%26aufirst%3DD.%26aulast%3DLow%26aufirst%3DS.%26aulast%3DColi%26aufirst%3DR.%26aulast%3DRennie%26aufirst%3DG.%2BR.%26aulast%3DFeru%26aufirst%3DF.%26aulast%3DKuhn%26aufirst%3DC.%26aulast%3DDing%26aufirst%3DY.%2BH.%26atitle%3DSelectivity-determining%2520residues%2520in%2520Plk1%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2007%26volume%3D70%26spage%3D540%26epage%3D546%26doi%3D10.1111%2Fj.1747-0285.2007.00594.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Laurence, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brameld, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graton, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Questel, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renault, E.</span><span> </span><span class="NLM_article-title">The pK(BHX) Database: toward a better understanding of hydrogen-bond basicity for medicinal chemists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">4073</span><span class="NLM_x">–</span> <span class="NLM_lpage">4086</span><span class="refDoi"> DOI: 10.1021/jm801331y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801331y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnsFKns7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=4073-4086&author=C.+Laurenceauthor=K.+A.+Brameldauthor=J.+Gratonauthor=J.+Y.+Le+Questelauthor=E.+Renault&title=The+pK%28BHX%29+Database%3A+toward+a+better+understanding+of+hydrogen-bond+basicity+for+medicinal+chemists&doi=10.1021%2Fjm801331y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">The pKBHX Database: Toward a Better Understanding of Hydrogen-Bond Basicity for Medicinal Chemists</span></div><div class="casAuthors">Laurence, Christian; Brameld, Ken A.; Graton, Jerome; Le Questel, Jean-Yves; Renault, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4073-4086</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The pKBHX database is presented, which corresponds to three main fields of data: hydrogen bond donor identification, thermodn. data and spectroscopic data.  The pKBHX scale of hydrogen donor basicity differs considerable from the pKBH+ scale of proton transfer basicity.  The hydrogen bond basicities of functional groups relevant to medicinal chem. and drug design is reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGql9OhmMu2VILVg90H21EOLACvtfcHk0ljt84QgVdajkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnsFKns7w%253D&md5=9ce4bea3e810752baba6ea5784b55ea0</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fjm801331y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801331y%26sid%3Dliteratum%253Aachs%26aulast%3DLaurence%26aufirst%3DC.%26aulast%3DBrameld%26aufirst%3DK.%2BA.%26aulast%3DGraton%26aufirst%3DJ.%26aulast%3DLe%2BQuestel%26aufirst%3DJ.%2BY.%26aulast%3DRenault%26aufirst%3DE.%26atitle%3DThe%2520pK%2528BHX%2529%2520Database%253A%2520toward%2520a%2520better%2520understanding%2520of%2520hydrogen-bond%2520basicity%2520for%2520medicinal%2520chemists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D4073%26epage%3D4086%26doi%3D10.1021%2Fjm801331y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Rai, U. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Symons, M. C. R.</span><span> </span><span class="NLM_article-title">EPR data do not support the P═O representation for trialkyl phosphates and phosphine oxides or sulfides</span> <span class="citation_source-journal">J. Chem. Soc., Faraday Trans.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">90</span><span class="NLM_x">, </span> <span class="NLM_fpage">2649</span><span class="NLM_x">–</span> <span class="NLM_lpage">2652</span><span class="refDoi"> DOI: 10.1039/FT9949002649</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1039%2FFT9949002649" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=1994&pages=2649-2652&author=U.+S.+Raiauthor=M.+C.+R.+Symons&title=EPR+data+do+not+support+the+P%E2%95%90O+representation+for+trialkyl+phosphates+and+phosphine+oxides+or+sulfides&doi=10.1039%2FFT9949002649"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1039%2FFT9949002649&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FFT9949002649%26sid%3Dliteratum%253Aachs%26aulast%3DRai%26aufirst%3DU.%2BS.%26aulast%3DSymons%26aufirst%3DM.%2BC.%2BR.%26atitle%3DEPR%2520data%2520do%2520not%2520support%2520the%2520P%25E2%2595%2590O%2520representation%2520for%2520trialkyl%2520phosphates%2520and%2520phosphine%2520oxides%2520or%2520sulfides%26jtitle%3DJ.%2520Chem.%2520Soc.%252C%2520Faraday%2520Trans.%26date%3D1994%26volume%3D90%26spage%3D2649%26epage%3D2652%26doi%3D10.1039%2FFT9949002649" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Power, W. P.</span><span> </span><span class="NLM_article-title">P-31 solid-state NMR of a phosphine borane adduct - phosphorus chemical shielding trends in the isoelectronic series R(3)PX, where X = BH3, CH2, NH, O</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">117</span><span class="NLM_x">, </span> <span class="NLM_fpage">1800</span><span class="NLM_x">–</span> <span class="NLM_lpage">1806</span><span class="refDoi"> DOI: 10.1021/ja00111a019</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja00111a019" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=1995&pages=1800-1806&author=W.+P.+Power&title=P-31+solid-state+NMR+of+a+phosphine+borane+adduct+-+phosphorus+chemical+shielding+trends+in+the+isoelectronic+series+R%283%29PX%2C+where+X+%3D+BH3%2C+CH2%2C+NH%2C+O&doi=10.1021%2Fja00111a019"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Fja00111a019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00111a019%26sid%3Dliteratum%253Aachs%26aulast%3DPower%26aufirst%3DW.%2BP.%26atitle%3DP-31%2520solid-state%2520NMR%2520of%2520a%2520phosphine%2520borane%2520adduct%2520-%2520phosphorus%2520chemical%2520shielding%2520trends%2520in%2520the%2520isoelectronic%2520series%2520R%25283%2529PX%252C%2520where%2520X%2520%253D%2520BH3%252C%2520CH2%252C%2520NH%252C%2520O%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1995%26volume%3D117%26spage%3D1800%26epage%3D1806%26doi%3D10.1021%2Fja00111a019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Chesnut, D. B.</span><span> </span><span class="NLM_article-title">An ab initio nuclear magnetic resonance and atoms-in-molecules study of the PO bond in phosphine oxides</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">120</span><span class="NLM_x">, </span> <span class="NLM_fpage">10504</span><span class="NLM_x">–</span> <span class="NLM_lpage">10510</span><span class="refDoi"> DOI: 10.1021/ja9822198</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja9822198" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=1998&pages=10504-10510&author=D.+B.+Chesnut&title=An+ab+initio+nuclear+magnetic+resonance+and+atoms-in-molecules+study+of+the+PO+bond+in+phosphine+oxides&doi=10.1021%2Fja9822198"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Fja9822198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja9822198%26sid%3Dliteratum%253Aachs%26aulast%3DChesnut%26aufirst%3DD.%2BB.%26atitle%3DAn%2520ab%2520initio%2520nuclear%2520magnetic%2520resonance%2520and%2520atoms-in-molecules%2520study%2520of%2520the%2520PO%2520bond%2520in%2520phosphine%2520oxides%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1998%26volume%3D120%26spage%3D10504%26epage%3D10510%26doi%3D10.1021%2Fja9822198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Dobado, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez-Garcia, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molina, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundberg, M. R.</span><span> </span><span class="NLM_article-title">Chemical bonding in hypervalent molecules revised. Application of the atoms in molecules theory to Y-3 X and Y-3 XZ (Y = H or CH3; X = N, P or As; Z = O or S) compounds</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">120</span><span class="NLM_x">, </span> <span class="NLM_fpage">8461</span><span class="NLM_x">–</span> <span class="NLM_lpage">8471</span><span class="refDoi"> DOI: 10.1021/ja980141p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja980141p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=1998&pages=8461-8471&author=J.+A.+Dobadoauthor=H.+Martinez-Garciaauthor=J.+M.+Molinaauthor=M.+R.+Sundberg&title=Chemical+bonding+in+hypervalent+molecules+revised.+Application+of+the+atoms+in+molecules+theory+to+Y-3+X+and+Y-3+XZ+%28Y+%3D+H+or+CH3%3B+X+%3D+N%2C+P+or+As%3B+Z+%3D+O+or+S%29+compounds&doi=10.1021%2Fja980141p"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fja980141p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja980141p%26sid%3Dliteratum%253Aachs%26aulast%3DDobado%26aufirst%3DJ.%2BA.%26aulast%3DMartinez-Garcia%26aufirst%3DH.%26aulast%3DMolina%26aufirst%3DJ.%2BM.%26aulast%3DSundberg%26aufirst%3DM.%2BR.%26atitle%3DChemical%2520bonding%2520in%2520hypervalent%2520molecules%2520revised.%2520Application%2520of%2520the%2520atoms%2520in%2520molecules%2520theory%2520to%2520Y-3%2520X%2520and%2520Y-3%2520XZ%2520%2528Y%2520%253D%2520H%2520or%2520CH3%253B%2520X%2520%253D%2520N%252C%2520P%2520or%2520As%253B%2520Z%2520%253D%2520O%2520or%2520S%2529%2520compounds%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1998%26volume%3D120%26spage%3D8461%26epage%3D8471%26doi%3D10.1021%2Fja980141p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Alkorta, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elguero, J.</span><span> </span><span class="NLM_article-title">Theoretical study of strong hydrogen bonds between neutral molecules: the case of amine oxides and phosphine oxides as hydrogen bond acceptors</span> <span class="citation_source-journal">J. Phys. Chem. A</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">272</span><span class="NLM_x">–</span> <span class="NLM_lpage">279</span><span class="refDoi"> DOI: 10.1021/jp982644n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jp982644n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADyaK1cXotVOmtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=1999&pages=272-279&author=I.+Alkortaauthor=J.+Elguero&title=Theoretical+study+of+strong+hydrogen+bonds+between+neutral+molecules%3A+the+case+of+amine+oxides+and+phosphine+oxides+as+hydrogen+bond+acceptors&doi=10.1021%2Fjp982644n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Theoretical Study of Strong Hydrogen Bonds between Neutral Molecules: The Case of Amine Oxides and Phosphine Oxides as Hydrogen Bond Acceptors</span></div><div class="casAuthors">Alkorta, Ibon; Elguero, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physical Chemistry A</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">272-279</span>CODEN:
                <span class="NLM_cas:coden">JPCAFH</span>;
        ISSN:<span class="NLM_cas:issn">1089-5639</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A theor. study of the ability of amine oxides and phosphine oxides as hydrogen bond (HB) acceptors has been carried out using ammonium oxide, trimethylamine oxide, and phosphine oxide as model systems.  The anal. of the energetic results indicate that only small spatial preferences are obsd. in the HB interaction.  The value of the interaction energies are in several cases within the range of strong HB (>12 kcal/mol), and in complexes between amine oxides and strong acids in the gas phase, a spontaneous proton transfer is obtained.  A logarithmic correlation between the electron d. at the HB crit. points and the HB distance that is able to fit not only calcd. data but also exptl. ones has been obtained. Finally, a linear relationship has been found between the no. of HBs and the 31P NMR shielding in the H3PO···(HF)n series, in good agreement with exptl. reports.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC_Hcc8nS0z7Vg90H21EOLACvtfcHk0liJQiW1Yn321A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXotVOmtL0%253D&md5=75c0da9fa02cf656f817f5b3f04ea94d</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Fjp982644n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjp982644n%26sid%3Dliteratum%253Aachs%26aulast%3DAlkorta%26aufirst%3DI.%26aulast%3DElguero%26aufirst%3DJ.%26atitle%3DTheoretical%2520study%2520of%2520strong%2520hydrogen%2520bonds%2520between%2520neutral%2520molecules%253A%2520the%2520case%2520of%2520amine%2520oxides%2520and%2520phosphine%2520oxides%2520as%2520hydrogen%2520bond%2520acceptors%26jtitle%3DJ.%2520Phys.%2520Chem.%2520A%26date%3D1999%26volume%3D103%26spage%3D272%26epage%3D279%26doi%3D10.1021%2Fjp982644n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Xu, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, J. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Y. Z.</span><span> </span><span class="NLM_article-title">Palladium-catalyzed synthesis of alkylarylphenylphosphine oxides</span> <span class="citation_source-journal">Synthesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1984</span><span class="NLM_x">, </span> <span class="NLM_volume">1984</span><span class="NLM_x">, </span> <span class="NLM_fpage">781</span><span class="NLM_x">–</span> <span class="NLM_lpage">782</span><span class="refDoi"> DOI: 10.1055/s-1984-30972</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1055%2Fs-1984-30972" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1984&publication_year=1984&pages=781-782&author=Y.+Y.+Xuauthor=Z.+Liauthor=J.+Z.+Xiaauthor=H.+J.+Guoauthor=Y.+Z.+Huang&title=Palladium-catalyzed+synthesis+of+alkylarylphenylphosphine+oxides&doi=10.1055%2Fs-1984-30972"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1055%2Fs-1984-30972&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-1984-30972%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DY.%2BY.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DXia%26aufirst%3DJ.%2BZ.%26aulast%3DGuo%26aufirst%3DH.%2BJ.%26aulast%3DHuang%26aufirst%3DY.%2BZ.%26atitle%3DPalladium-catalyzed%2520synthesis%2520of%2520alkylarylphenylphosphine%2520oxides%26jtitle%3DSynthesis%26date%3D1984%26volume%3D1984%26spage%3D781%26epage%3D782%26doi%3D10.1055%2Fs-1984-30972" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Kim, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harden, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyer, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubyak, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burnstock, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, K. A.</span><span> </span><span class="NLM_article-title">Structure-activity relationships of pyridoxal phosphate derivatives as potent and selective antagonists of P2 × 1 receptors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">340</span><span class="NLM_x">–</span> <span class="NLM_lpage">349</span><span class="refDoi"> DOI: 10.1021/jm9904203</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9904203" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=340-349&author=Y.+C.+Kimauthor=S.+G.+Brownauthor=T.+K.+Hardenauthor=J.+L.+Boyerauthor=G.+Dubyakauthor=B.+F.+Kingauthor=G.+Burnstockauthor=K.+A.+Jacobson&title=Structure-activity+relationships+of+pyridoxal+phosphate+derivatives+as+potent+and+selective+antagonists+of+P2+%C3%97+1+receptors&doi=10.1021%2Fjm9904203"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Fjm9904203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9904203%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DY.%2BC.%26aulast%3DBrown%26aufirst%3DS.%2BG.%26aulast%3DHarden%26aufirst%3DT.%2BK.%26aulast%3DBoyer%26aufirst%3DJ.%2BL.%26aulast%3DDubyak%26aufirst%3DG.%26aulast%3DKing%26aufirst%3DB.%2BF.%26aulast%3DBurnstock%26aufirst%3DG.%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26atitle%3DStructure-activity%2520relationships%2520of%2520pyridoxal%2520phosphate%2520derivatives%2520as%2520potent%2520and%2520selective%2520antagonists%2520of%2520P2%2520%25C3%2597%25201%2520receptors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D340%26epage%3D349%26doi%3D10.1021%2Fjm9904203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group">Xuan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, L. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, W. J.</span><span> </span><span class="NLM_article-title">Room temperature C-P bond formation enabled by merging nickel catalysis and visible-light-induced photoredox catalysis</span> <span class="citation_source-journal">Chem. - Eur. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">4962</span><span class="NLM_x">–</span> <span class="NLM_lpage">4965</span><span class="refDoi"> DOI: 10.1002/chem.201500227</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=10.1002%2Fchem.201500227" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=25688851" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsl2qs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=4962-4965&author=J.+Xuanauthor=T.+T.+Zengauthor=J.+R.+Chenauthor=L.+Q.+Luauthor=W.+J.+Xiao&title=Room+temperature+C-P+bond+formation+enabled+by+merging+nickel+catalysis+and+visible-light-induced+photoredox+catalysis&doi=10.1002%2Fchem.201500227"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Room temperature C-P bond formation enabled by merging nickel catalysis and visible-light-induced photoredox catalysis</span></div><div class="casAuthors">Xuan, Jun; Zeng, Ting-Ting; Chen, Jia-Rong; Lu, Liang-Qiu; Xiao, Wen-Jing</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4962-4965</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A novel and efficient C-P bond formation reaction of diarylphosphine oxides with aryl iodides was achieved by combining nickel catalysis and visible-light-induced photoredox catalysis.  Reaction of secondary phosphine oxide, Ph2P(O)H with aryl iodides ArI, catalyzed by a combination of 2 mol% of a Ni(0) source, Ni(cod)2, 2 mol% of the nitrogen ligand, 4,4'-di-tert-butyl-2,2'-bipyridine (dtbbpy) and 5 mol% of [Ru(bpy)3]Cl2·6H2O as a photoredox catalyst, gave the triarylphosphine oxides Ph2ArPO (3a-n, Ar = Ph, MeOC6H4, FC6H4, ClC6H4, BrC6H4, HOC6H4, H2NC6H4, 1-naphthyl, 2-pyridyl) with 71-91% yields.  This dual-catalytic reaction showed a broad substrate scope, excellent functional group tolerance, and afforded the corresponding products in good to excellent yields.  Compared with the previously reported use of photoredox/nickel dual catalysis in the construction of C-C bonds, the methodol. described herein was obsd. to be the first to allow for C-heteroatom bond formation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHg41nsc7WZrVg90H21EOLACvtfcHk0liJQiW1Yn321A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsl2qs7o%253D&md5=ae1d0b928d31e7cffad1cbc3d9dc8030</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1002%2Fchem.201500227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.201500227%26sid%3Dliteratum%253Aachs%26aulast%3DXuan%26aufirst%3DJ.%26aulast%3DZeng%26aufirst%3DT.%2BT.%26aulast%3DChen%26aufirst%3DJ.%2BR.%26aulast%3DLu%26aufirst%3DL.%2BQ.%26aulast%3DXiao%26aufirst%3DW.%2BJ.%26atitle%3DRoom%2520temperature%2520C-P%2520bond%2520formation%2520enabled%2520by%2520merging%2520nickel%2520catalysis%2520and%2520visible-light-induced%2520photoredox%2520catalysis%26jtitle%3DChem.%2520-%2520Eur.%2520J.%26date%3D2015%26volume%3D21%26spage%3D4962%26epage%3D4965%26doi%3D10.1002%2Fchem.201500227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5J7H" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5J7H','PDB','5J7H'); return false;">PDB: 5J7H</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1ir3" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1ir3','PDB','1ir3'); return false;">PDB: 1ir3</a></li></ul></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.6b00306&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b00306%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2016.59.issue-10%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.6b00306" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799a3325db13cfa","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
